croi-2013-pocket-program

Pocket 

Program 

CR I 

2O13 

20th Conference on Retroviruses 

and Opportunistic Infections 

March 3-6, 2013 

Georgia World Congress Center 

Atlanta, GA, US

CROI 2013 General Information 

OVERVIEW 

The 20 th Conference on Retroviruses and Opportunistic Infections (CROI) 

is a research meeting created to provide a forum for basic scientists, clinical 

investigators, and global health researchers to present, discuss, and critique 

their investigations into the epidemiology and biology of human retroviruses 

and the diseases they produce with the ultimate goal of translating laboratory 

and clinical research into progress against the AIDS epidemic. 

To support the goals of the meeting and the preferences of the scientific 

community the conference serves, the Scientific Program Committee has 

limited registration to researchers actively participating as investigators in 

basic science or clinical studies of retroviral diseases and their complications 

and clinician-teachers (full-time academic faculty members responsible for 

HIV/AIDS training and research programs). Preference will be accorded to 

doctoral and professional degree level researchers/clinicians. In addition, a 

limited number of slots have been reserved for: 1) media, 2) AIDS treatment 

and prevention community educators, and 3) senior clinical development 

personnel from industry who have product development planning 

responsibilities. 

At the conclusion of CROI 2013, attendees will again be polled 

to determine their programmatic and logistical preferences for future 

conferences. CME Claims and/or Conference Survey should be completed 

(online at www.retroconference.org) no later than April 6, 2013. The Scientific 

Program Committee welcomes your opinions on how to continue to improve 

the conference. The committee will use the survey results to determine the 

venue and policies for future meetings, so your feedback is important. 

OBJECTIVES 

At the completion of this activity, the participants should be able to: 

1) appraise and critique their individual efforts in light of the most current 

knowledge and information about HIV/AIDS and its complications; 

2) integrate into their respective professional medical endeavors those best 

practices emerging from laboratory, clinical, and epidemiological research; 

and 3) translate the latest laboratory and clinical research into making progress 

against the AIDS epidemic. 

NEEDS ASSESSMENT 

More than 30 million people worldwide are infected with HIV, with 

millions of new infections each year. The research efforts of tens of thousands 

of scientists and clinicians have had considerable success in diagnosing and 

treating infection. Nevertheless, we still do not have either a curative treatment 

or a preventive vaccine, without which most of those presently infected will die 

of AIDS, and new infections will continue unabated. The need for continued 

research on HIV/AIDS is clear. Timely communication of the results of such 

research among scientists and clinicians working on this subject is critical to 

advancing the field as rapidly as possible. CROI fills this need by bringing 

about 4,000 of the leaders in disparate, but interrelated areas of AIDS research 

to interact with and educate one another in the very latest results, treatment 

methods, and state-of-the-art technological advances. 

v

vi 

General Information CROI 2013 

ABBREVIATIONS AND ICONS USED IN THE PROGRAM 

International Scholarship Awardee 

(a listing of the 34 International Scholarship Awardees appears in the Program 

& Abstracts book) 

Young Investigator Awardee 

(a listing of the 278 Young Investigator Awardees appears in the Program & Abstracts book) 

LB Late Breaker Abstract Presentation 

Workshop Oral Abstracts 

Plenary Themed Discussion 

Symposium Poster Abstracts 

Session will be Webcast 

Session will be Podcast 

Session is eligible for CME credit 

AMERICANS WITH DISABILITIES ACT 

Each participating hotel is in compliance to some degree with the Americans 

with Disabilities Act. Special services (e.g., wheelchair-accessible 

transportation and sign interpreters for the hearing impaired) are available if 

requested in advance. Should you require assistance onsite, please visit the 

Meeting Headquarters. 

BADGES 

All registered meeting attendees, after showing photo identification, will 

be issued a meeting badge when they pick up their registration materials 

onsite and will be required to wear their badge at all official functions. Due 

to enhanced security measures, attendees will need to present their badges 

for admittance into the convention center at all times. In the event of a lost 

badge, the attendee will be required to pay another registration fee, in order 

for their badge to be reissued. 

CHILD CARE 

Due to the professional nature of this meeting, children are not allowed 

in sessions, the poster hall, or the Welcome Reception, so please plan 

accordingly. Child care arrangements can usually be made through the hotel 

concierge. Alternatively, the Atlanta Convention and Visitors Bureau has 

suggested: TLC Sitters of Atlanta (770-410-4774 / tlcatl@bellsouth.net / 

tlcsittersofatlanta.com). 

CONFERENCE COURTESIES 

In consideration of all meeting attendees: 

�� 

vibrate mode) in session rooms; kindly step out of the room prior to 

answering or initiating a cell phone call. 

�� 

sessions will be available online). 

�� 

productive meeting experience, no disruptions and/or protests are allowed. 

�� 

who wish to smoke should do so outside of the building.


CONTINUING MEDICAL EDUCATION (CME) 

This activity has been planned and implemented in accordance with the 

Essential Areas and policies of the Accreditation Council for Continuing 

Medical Education through the joint sponsorship of the University 

of California, San Diego School of Medicine and the Conference on 

Retroviruses and Opportunistic Infections. The University of California, 

San Diego School of Medicine is accredited by the ACCME to provide 

continuing medical education for physicians. 

The University of California, San Diego School of Medicine designates 

this live activity for a maximum of 27.25 AMA PRA Category 1 Credits . 

Physicians should claim only the credit commensurate with the extent of their 

participation in the activity. 

To claim credit for this conference, registrants must complete the CME 

Claims and Conference Survey (online at www.retroconference.org) no 

later than April 6, 2013. Your badge number will be required to access the 

forms. CME certificates will be mailed after June 1, 2013. 

California Assembly Bill 1195 requires continuing medical education 

activities with patient care components to include curriculum in the subjects 

of cultural and linguistic competency. It is the intent of the bill, which 

went into effect on July 1, 2006, to encourage physicians and surgeons, 

CME providers in the state of California, and the Accreditation Council 

for Continuing Medical Education to meet the cultural and linguistic 

concerns of a diverse patient population through appropriate professional 

development. The planners, speakers and authors of this CME activity have 

been encouraged to address issues relevant in their topic area. In addition, 

a variety of resources are available that address cultural and linguistic 

competency, some of which are included in your syllabus or handout 

materials. Additional resources and information about AB1195 can be found 

on our website at http://cme.ucsd.edu. 

MEALS 

Complimentary continental breakfast, morning coffee breaks, and afternoon 

snack breaks will be available to conference registrants in the Poster Hall. 

Attendees are on their own for lunch during the hours of 12 noon to 

1:30 pm each day. Below is a list of food service options located in the 

Convention Center or within a short walking distance. 

At the Convention Center 

�� 

�� 

�� 

At the CNN Center (across the street from the main entrance of the Convention Center) 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

�� 

Within 4 blocks of the Convention Center 

�� 

�� 

�� 

�� 

�� 

�� 

vii

viii 

General Information CROI 2013 

MOBILE APPLICATION 

To download the CROI 2013 mobile app, scan the QR code or go to 

www.retroconference.org/mobile. 

OVERFLOW ACCOMMODATIONS FOR SESSION ROOMS 

Most session rooms will have designated overflow areas. Should any session 

draw significantly higher attendance than can be accommodated, a nearby 

space will be available to show the live audio/video feed. 

WEBCASTS AND PODCASTS 

www.retroconference.org 

Plenaries, symposia, scientific overviews, oral abstract sessions, and themed 

discussions will be webcast and podcast. Webcasts are also available as 

streaming video on the Apple iPad and iPhone. In addition, abstracts and 

posters from CROI 2013 as well as webcasts, abstracts, and posters from 

previous meetings (CROI 1994-2012) will be available online. 

WELCOME RECEPTION 

Sunday, March 3, 7-10 pm 

Georgia Aquarium 

�� 

�� 

aquatic animals. It combines entertainment, education 

and science through exhibits and programs which 

provide engaging and exciting guest experiences, while 

promoting the conservation of aquatic biodiversity 

throughout the world. 

WIFI ACCESS 

�� 

World Congress Center. Coverage in the facility includes CROI general 

session and breakout rooms, poster hall, and registration area. No additional 

equipment is required beyond the wireless access card already installed in a 

�� 

is CROI; the password is CROI2013.


Offices 

& Services 

Atlanta 

Information 

& Restaurant 

Reservations 

Coat & 

Baggage 

Check 

CyberCafe Hall B2 

Level One 

Media Center 

404-222-5808 

Meeting 

Headquarters 

404-222-5804 

Message 

Center 

404-222-5800 

Registration 

& Housing 

404-222-5801 

Speaker 

Services 

& Poster 

Drop-off 

404-222-5807 

Location Hours of Operation Information 

Lobby Saturday 12 n-5 pm 

Sunday 11 am-7 pm 

Monday 10 am-6 pm 

Tuesday 10 am-6 pm 

Wednesday 10 am-6 pm 

Lobby Sunday 7 am-7:30 pm 

Monday 7 am-7:15 pm 

Tuesday 7 am-7:15 pm 

Wednesday 7 am-6:30 pm 

B202 

Level Two 

B211 

Level Two 

Saturday 12 n-5 pm 






Monday 8 am-6:30 pm 

Tuesday 8 am-6:30 pm 

Wednesday 8 am-6:30 pm 
















B208 

Level Two 






For maps, information on 

local attractions and 

restaurant reservations. 

Coat & Baggage Check 

service is complimentary. 

Computers will be available 

to view webcasts, search 

the abstracts and posters, 

and check email. In 

addition, WiFi service will 

be available throughout 

the convention center. 

Computers in the 

CyberCafe will also provide 

Message Center functions. 

Voice and text messages 

may be left for attendees 

here and at the Message 

Center. 

Pre-registered journalists 

should pick up press kits 

and convene for daily 

press conferences in the 

Media Center. There is no 

onsite press registration. 

To contact staff or for lostand-found 

items, please 

go to the Meeting 

Headquarters. 

Voice and text messages 

may be left for attendees at 

the Message Center. 

Computers in the 

CyberCafe will also provide 

Message Center functions. 

Pre-registered attendees 

should pick up conference 

materials including 

badges, Program & 

Abstracts, and Addenda 

during registration hours. 

There is no on-site 

registration. 

Speakers should bring 

their presentation (in MS 

PowerPoint or Apple 

Keynote only) to the 

Speaker Services Room 

on a disk or drive at least 

4 hours prior to 

presentation. CROI 

supports both MacIntosh 

and PC platforms. The 

Speaker Services Room 

will be equipped with 

workstations, and an art 

director and AV 

technicians will be 

available to assist 

speakers. This is also 

where poster presenters 

should submit an 

electronic version of their 

poster for placement on 

the CROI website. 

ix

x 

Hotel Information CROI 2013 

Map 

Key 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

5 

8 

3 

8 

Hotel Rate 

Atlanta Marriott Downtown 

160 Spring St, NW, Atlanta, GA 30303 

phone: 404-688-8600 / fax: 678-686-3327 

Atlanta Marriott Marquis 

�� 

phone: 404-521-0000 / fax: 404-586-6299 

Embassy Suites Atlanta 

at Centennial Olympic Park 

267 Marietta St, Atlanta, GA 30313 

phone: 404-223-2300 / fax: 404-223-0925 

Hilton Atlanta 

�� 

phone: 404-659-2000 / fax: 404-221-6368 

Hilton Garden Inn Downtown 

�� 

phone: 404-577-2001 / fax: 404-577-2002 

Holiday Inn Atlanta Downtown 

�� 

phone: 404-524-5555 / fax: 404-221-0702 

Hyatt Regency Atlanta 

�� 

phone: 404-577-1234 / fax: 404-588-4137 

Omni Hotel at CNN Center 

�� 

phone: 404-659-0000 / fax: 404-525-5050 

The Ritz Carlton Atlanta 

�� 

phone: 404-659-0400 / fax: 404-688-0400 

Sheraton Atlanta Hotel 

�� 

phone: 404-659-6500 / fax: 404-524-1259 

W Atlanta Downtown 

�� 

phone: 404-582-5800 / fax: 404-582-5805 

Westin Peachtree Plaza 

�� 

phone: 404-659-1400 / fax: 404-589-7424 

6 

1 

11 

12 

9 

7 

2 

# of blocks to 

Convention Center 

$133 � � �� 

$133 � � �� 

$159 � � �� 

$123 � � �� 

$149 � � �� 

$123 � � �� 

$128 � � �� 

$159 � �� 

$165 � � �� 

$123 � � �� 

$149 � � �� 

$133 � � �� 

10 

4

CROI 2013 Ground Transportation Information 

GROUND TRANSPORTATION 

From Hartsfield-Jackson Atlanta International Airport 

Taxi Service 

Travel time from airport to downtown is approximately 10 miles and can 

take up to 30 minutes depending on traffic. Taxi fare from the airport is 

approximately $34. 

Shuttle Service 

Travel time from the airport to downtown can take up to 45 minutes. 

Discounts have been arranged with Atlanta Airport Shuttle Service for $5 

off round trip. Pre-pay for shuttle service at http://www.taass.net/index-4. 

�� 

a fare of $27 or Downtown One-Way under Single Rates for a fare of 

$16.50. Reservations must be made 24 hours in advance. 

Public Transit 

MARTA is easily accessible at the airport and takes you directly downtown. 

The station is located between the two terminals at the end of the baggage 

claim area. 

MARTA runs from 4:45 am-1 am on weekdays and 6 am-1 am on weekends. 

Trains arrive and depart every 15-20 minutes, depending on the time of day. 

Travel time is approximately 20 minutes. Transit fare is $2.50 one way + a 

�� 

Local Travel 

�� 

�� 

CROI will be held) is through the atrium, between Buildings A and B, off 

of Andrew Young International Boulevard. Their website offers detailed 

directions on driving and taking public transportation to, as well as parking 

at and around, the Convention Center. 

xi

CROI 2013 Session 2 

j Sunday, 9 am-1:30 pm; B406 

Session 1–Workshop 

New Investigators and Trainees 

The purpose of this workshop is to educate and engage new 

investigators and trainees, to spark interest in the field, to provide 

opportunities for interaction among trainees and faculty, and to 

orient trainees to the science being presented at the conference. 

Presentations will be geared toward new trainees (e.g.,undergraduate 

students, graduate students, postdoctoral fellows, and physician 

fellows) and new investigators (both international and domestic) 

who have been conducting active research in the field for less 

than 3 years. Priority will be given to awardees from the young 

investigator, international scholar, and community educator 

programs. Other CROI registrants may attend the workshop (on a 

space available basis). Boxed lunches will be available for awardees 

only. No pre-registration is required. 

The format is designed to be interactive. Each presenter will provide 

a state-of-the-art summary of a major area of HIV investigation 

being covered at the conference and end by outlining the top 3 to 5 

research questions in the field from his/her perspective. The floor 

will then be open for audience questions and discussion. 

9:00-9:15 am 

Opening Remarks 

Conveners: 

Scott Hammer, Columbia Univ, Coll of 

Physicians & Surgeons, New York, NY, US 

John Mellors, Univ of Pittsburgh, PA, US 

9:15-9:45 am 

1 

Transmission/Founder Viruses and Their 

Phenotypic Properties 

Beatrice Hahn 

Univ of Pennsylvania, Philadelphia, US 

9:45-10:15 am 

2 

Research on Viral Reservoirs, Persistence, 

and Cure 

Mario Stevenson 

Univ of Miami Miller Sch of Med, FL, US 

10:15-10:45 am 

3 

Recent Advances in HIV and SIV Pathogenesis 

Guido Silvestri 

Emory Univ Sch of Med and Yerkes Natl Primate Res Ctr, 

Atlanta, GA, US 

10:45-11:15 am 

Coffee Break 

11:15-11:45 am 

4 

HIV Prevention Research: What’s Next? 

Susan Buchbinder 

San Francisco Dept of Publ Hlth, CA, US 

12:15-12:30 pm 

Closing Remarks 

11:45 am-12:15 pm 

5 

Hepatitis C Virus Research and Treatment 

Robert Schooley 

Univ of California, San Diego, US 

12:30-12:45 pm 

Box Lunch Distribution to Young Investigators, International 

Scholars, and Community Educators 

12:45-1:30 pm 

6 

Martin Delaney Lecture 

The Challenge of Marginalization in the Fight 

against HIV, and the Resiliency of Individuals 

and Communities 

Paul Semugoma 

African Men for Sexual Hlth and Rights, ANOVA Hlth, 

South Africa 

c Sunday, 2:30-4:30 pm; B308 


Frontiers in Laboratory Science 

The purpose of this workshop is to present the main technological 

and conceptual developments in life sciences that are influencing 

HIV research or that hold a significant potential for research. The 

presentations should educate and engage investigators and clinicians, 

and spark interest in emerging technologies.CROI registrants may 

attend the workshop. No pre-registration is required. 

Convener: 

Amalio Telenti, Univ of Lausanne, Switzerland 

7 

In Vivo Imaging of Viral and Cellular 

Dynamics in HIV Infection 

T Murooka 1,2 , M Deruaz 1,2 , F Marangoni 1,2 , E Seung 1,2 , 

V Vrbanac 1 , U von Andrian 2 , A Tager 1,2 , A Luster 1,2 , 

and Thorsten Mempel* 1,2 

1 Ctr for Immunology and Inflammatory Diseases, 

Massachusetts Gen Hosp, Boston, US and 2 Harvard Med Sch, 

Boston, MA, US 

8 

Systems Vaccinology: Its Promise and 

Challenge for HIV Vaccine Development 

Helder Nakaya 

Emory Univ Sch of Med, Atlanta, GA, US 

9 

Crowd-sourcing, Social Networks, and Twitter 

Research in Infectious Diseases 

Marcel Salathe 

Ctr for Infectious Disease Dynamics, Pennsylvania State Univ, 

University Park, US 

10 

Using Viral Meta-genomics to Identify 

“Novel” Human and Animal Viruses 

Eric Delwart 

Blood Systems Res Inst and Univ of California, San Francisco, US 

Program � 1 

Sunday 

March 3 Oral Sessions

Sunday 

March 3 Oral Sessions 

Session 3 CROI 2013 

c Sunday, 2:30-4:30 pm; B313 


Clinical Trials Design 

This workshop is designed to address several current issues in HIV 

clinical trial design and interpretation. These talks are intended for 

a general audience and will explore issues such as how to integrate 

data from clinical trials with mathematical models, what you need 

to know about adaptive trial designs, and alternatives to randomized 

clinical trials. These lectures will use examples from recent HIV 

treatment and prevention trials and will include time for Q&A. 

CROI registrants may attend the workshop. No pre-registration is 

required. 

Conveners: 

Susan Buchbinder, San Francisco Dept 

of Publ Hlth, CA, US 

Richard Chaisson, Johns Hopkins Univ 

Sch of Med, Baltimore, MD, US 

2:35-3:10 pm 

11 

Adaptive Methods: What You Really Need to 

Know 

Michael Proschan 

Biostatistics Res Branch, NIAID, NIH, Bethesda, MD, US 

3:10-3:45 pm 

12 

Alternatives to Randomized Controlled Trials: 

When and How to Use 

Caroline Sabin 

Univ Coll London, UK 

3:45-4:20 pm 

13 

The Symbiotic Relationship between Trials 

and Mathematical Models 

Timothy Hallett 

Imperial Coll London, UK 

2 � 20th Conference on Retroviruses and Opportunistic Infections 

f Sunday, 5-7 pm; Hall B1 

Session 4–Opening 

Greetings from the Program Committee 

Kevin De Cock 

CDC Kenya, Nairobi 

Remarks from the Director of the US Centers 

for Disease Control and Prevention 

Thomas Frieden 

CDC, Atlanta, GA, US 

18 th Bernard Fields Lecture 

The Bernard Fields lectureship recognizes a scientist whose body of 

work has significantly contributed to the understanding of virology 

and viral pathogenesis as exemplified by the career of Bernard Fields. 

14 

ARV Drug Discovery: HIV-1 Integrase 

Inhibitors and Beyond 

Daria Hazuda 

Merck Res Labs, West Point, PA, US 

Objectives: This session is directed to clinicians and scientists 

interested in ART and novel targets for drug discovery. It is assumed 

that participants have a basic understanding of retroviral biology 

and are familiar with HIV therapeutics. At the completion of the 

session, participants will have a deeper understanding the biology 

of integrase and the development of integrase inhibitors as well as 

increased knowledge of the drug discovery process as it applies to 

future therapeutics. 

7 th N’Galy-Mann Lecture 

The N’Galy-Mann lectureship was established in 2006 to recognize 

an individual researcher or team who has made important and timely 

contributions in epidemiology and clinical research as exemplified 

by the collaborative careers of Bosenge N’Galy and Jonathan Mann. 

15 

MTCT: From Epidemic to Elimination 

Lynne Mofenson 

Natl Inst of Child Hlth and Human Devt, NIH, Rockville, MD, US 


interested in the evolution of interventions for PMTCT in the US 

and globally, and lessons learned. It is assumed that participants are 

familiar with mechanisms of MTCT and interventions to prevent it. 

At the completion of the session, participants will be knowledgeable 

about clinical trials and implementation science related to PMTCT, 

lessons learned from the US, and implications globally 

Welcome Reception 

7-10 pm 

Georgia Aquarium 

The Georgia Aquarium is a short walk (3 blocks) from the Convention Center.


i Monday, 8:30-9 am; Hall B1 

Session 5–Plenary 

HIV-1 Eradication Strategies: Design, 

Assessment, and Clinical Consequences 

16 

Robert Siliciano 

Johns Hopkins Univ Sch of Med, Baltimore, MD, US 


interested in HIV-1 eradication studies. It is assumed participants 

are familiar with fundamental aspects of HIV-1 treatment such as 

the response to HAART, and the need for additional interventions 

to eliminate the residual virus that persists despite HAART. At the 

completion of the session, participants will be knowledgeable about 

assays to measure viral reservoirs and the clinical consequences of 

reductions in reservoir size induced by eradication strategies. 

j Monday, 9-9:30 am; Hall B1 


Reality Check: Is the End of AIDS in Sight? 

17 

Francois Dabis 

Bordeaux Sch of Publ Hlth and INSERM U897, Univ Bordeaux, 

Segalen, France 


interested in the global perspective of the fight against HIV/AIDS. 

It is assumed that participants are familiar with the concepts of 

prevention and care and the programmatic differences between 

resource-rich and -limited settings. At the completion of the session, 

participants will be knowledgeable about the most recent advances 

in biomedical prevention and the foreseeable scenarios for the 

coming years. 

k Monday, 10-11:30 am; B406 

Session 7–Oral Abstracts 

Neurocognitive Disorders: New Developments and 

Therapies 

Moderators: 

Christina Marra, Univ of Washington Sch of Med, Seattle, US 

Ann Ragin, Northwestern Univ Feinberg Sch of Med, Chicago, IL, US 

10:00 18 Very Early Viral Infection of the Central 

Nervous System without Evidence of 

Compartmentalization during Acute HIV-1 

Infection (RV254) 

Serena Spudich* 1 , G Kijak 2,3 , J Ananworanich 4,5 , M Bose 2,3 , 

V Assawadarachai 5 , S Rattamanee 4,5 , E Sanders-Buell 2,3 , V Valcour 6 , 

J Kim 2 , S Tovanabutra 2,3 , and RV254/SEARCH 010 Study Group 

1 Yale Univ, New Haven, CT, US;; 2 US Military HIV Res Prgm, 

Walter Reed Army Inst of Res, Silver Spring, MD;; 3 Henry M Jackson 

Fndn for the Advancement of Military Med, Bethesda, MD, US;; 

4 SEARCH, The Thai Red Cross AIDS Res Ctr, HIVNAT, Bangkok;; 

5 Armed Forces Res Inst for Med Sci, Bangkok, Thailand;; and 6 Univ 

of California, San Francisco, US 

10:15 19 Neuropsychological Performance in Acute HIV: 

Determinants of Baseline Performance and 

Effects of Immediate ART 

Idil Kore* 1 , J Ananworanich 2,3,4 , V Valcour 5 , J Fletcher 2 , 

D Suttichom 2 , P Mangum 2 , L Jagodzinski 6 , J Kim 6 , S Spudich 1 , 

and RV254/SEARCH 010 Study Group 

1 Yale Univ Sch of Med, New Haven, CT, US;; 2 SEARCH, The Thai 

Red Cross AIDS Res Ctr, Bangkok;; 3 HIVNAT, Bangkok, Thailand;; 

4 Faculty of Med, Chulalongkorn Univ, Bangkok, Thailand;; 5 Univ 

of California, San Francisco, US;; and 6 US Military HIV Res Prgm, 

Silver Spring, MD 

10:30 20 A Randomized, Controlled Trial of a Central 

Nervous System-targeted ART Strategy for 

HIV-associated Neurocognitive Disorders 

Ronald Ellis* 1 , F Vaida 1 , S Letendre 1 , R Haubrich 1 , R Heaton 1 , 

A McCutchan 1 , M Cherner 1 , A Umlauf 1 , N Sacktor 2 , and D Clifford 3 

1 Univ of California, San Diego, US;; 2 Johns Hopkins Univ, 

Baltimore, MD, US;; and 3 Washington Univ, St Louis, MO, US 

10:45 21 Regional Brain Atrophy Is Associated with 

Mitochondrial Dysfunction and Elevated 

Mitochondrial Oxidative Stress in HIV + Individuals 

K Kallianpur, M Gerschenson, T Umaki, D Chow, B Nakamoto, 

D Libutti, M Lopez, J Taylor, L Marotz, and Cecilia Shikuma* 

Univ of Hawaii, Honolulu, US 

11:00 22 VLA-4 Treatment Blocks Virus Traffic to the 

Gut and Brain Early, and Stabilizes CNS Injury 

Late in Infection 

Jennifer Campbell* 1 , P Autissier 1 , A MacLean 2 , T Burdo 1 , 

S Westmoreland 3 , G Gonzalez 4,5 , E-M Ratai 4,5 , and K Williams 1 

1 Boston Coll, Chestnut Hill, MA, US;; 2 Tulane Natl Primate Res 

Ctr, Covington, LA, US;; 3 New England Regional Primate Res Ctr, 

Southborough, MA, US;; 4 Harvard Med Sch, Boston, MA, US;; and 

5 Athinoula A Martinos Ctr for Biomed Imaging, Massachusetts Gen 

Hosp, Boston, US 

11:15 23 Central Nervous System Compartmentalization 

of HIV-1 Subtype C Variants Early and Late in 

Infection in Young Children 

Christa Buckheit Sturdevant* 1 , A Dow 1 , C Jabara 1 , S Joseph 1 , 

G Schnell 2 , N Takamune 3 , M Mallewa 4 , R Heyderman 4 , A Van Rie 1 , 

and R Swanstrom 1 

1 Univ of North Carolina at Chapel Hill, US;; 2 Univ of Washington, 

Seattle, US;; 3 Kumamoto Univ, Japan;; and 4 Univ of Malawi Coll of 

Med, Blantyre 

k Monday, 10 am-12:15 pm; Ballroom 3-4 


HIV Prevention: ARV, Counseling, 

Contraception, and Condoms 

Moderators: 

Monica Gandhi, Univ of California, San Francisco, Sch of Med, US 

James McIntyre, Anova Hlth Inst, Johannesburg, South Africa 

10:00 24LB Long-acting Parenteral Formulation of 

GSK1265744 Protects Macaques against 

Repeated Intrarectal Challenges with SHIV 

Chasity Andrews* 1 , A Gettie 1 , K Russell-Lodrigue 2 , L Moss 3 , 

H Mohri 1 , W Spreen 3 , C Cheng-Mayer 1 , Z Hong 3 , M Markowitz 1 , 

and D Ho 1 

1 Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, 

NY, US;; 2 Tulane Natl Primate Res Ctr, Covington, LA, US;; and 

3 GlaxoSmithKline, Research Triangle Park, NC, US 

10:15 25LB A Tenofovir Disoproxil Fumarate Intravaginal 

Ring Completely Protects against Repeated 

SHIV Vaginal Challenge in Nonhuman Primates 

James Smith* 1 , R Rastogi 2 , R Teller 2 , P Srinivasan 1 , J Mitchell 1 , 

J McNicholl 1 , M Hendry 1 , P Mesquita 3 , P Kiser 2 , and B Herold 3 

1 CDC, Atlanta, GA, US;; 2 Univ of Utah, Salt Lake City, US;; and 

3 Albert Einstein Coll of Med, Bronx, NY, US 

10:30 26LB Pre-exposure Prophylaxis for HIV in Women: 

Daily Oral Tenofovir, Oral Tenofovir/ 

Emtricitabine, or Vaginal Tenofovir Gel 

in the VOICE Study (MTN 003) 

Jeanne Marrazzo* 1 , G Ramjee 2 , G Nair 3 , T Palanee 4 , B Mkhize 5 , 

C Nakabiito 6 , M Taljaard 7 , J Piper 8 , K Gomez Feliciano 9 , 

M Chirenje 10 , and VOICE Study Team 

1 Univ of Washington, Seattle, US;; 2 HIV Prevention Res Unit, 

Durban, South Africa;; 3 CAPRISA-eThekwini CRS, Duban, South 

Africa;; 4 Witwatersrand Reproductive Hlth & HIV Inst;; 5 Perinatal 

HIV Res Unit, Johannesburg, South Africa;; 6 Makerere-Johns 

Hopkins Univ Res Collaboration, Kampala, Uganda;; 7 Aurum 

Inst, Klerksdorp, South Africa;; 8 Division of AIDS, NIH, Bethesda, 

MD, US;; 9 FHI360, Research Triangle Park, NC, US;; and 10 Univ of 

Zimbabwe-UCSF CTU, Harare 

10:45 27 No Excess in HIV Incidence after Stopping 

Oral Emtricitabine/Tenofovir Pre-exposure 

Prophylaxis: The iPrEx Trial 

Robert Grant* 1,2 , J Guanira 3 , S Buchbinder 2,4 , C Mosquera 3 , V Veloso 5 , 

E Kallas 6 , M Mehrotra 1 , V McMahan 1 , R Amico 7 , D Glidden 2 , and iPrEx 

Study Team 

1 Gladstone Inst, San Francisco, CA, US;; 2 Univ of California, San 

Francisco, US;; 3 INMENSA, Lima, Peru;; 4 San Francisco Dept of 

Publ Hlth, CA, US;; 5 FIOCRUZ, Rio de Janeiro, Brazil;; 6 Univ of Sao 

Paulo, Brazil;; and 7 Univ of Connecticut, Storrs, US 

Program � 3 

Monday 


Monday 



11:00 28 Hormonal Contraception and Risk of HIV: 

An Analysis of Data from the Microbicides 

Development Programme Trial 

Angela Crook* 1 , H Rees 2 , G Ramjee 3 , A Kamali 4 , S Kapiga 5 , 

M Chisembele 6 , M Gafos 1 , A Nunn 1 , R Hayes 7 , and S McCormack 1 

1 MRC Clin Trials Unit, London, UK;; 2 Univ of the Witwatersrand, 

Johannesburg, South Africa;; 3 MRC HIV Prevention Res Unit, 

Durban, South Africa;; 4 MRC/UVRI Uganda Res Unit, Entebbe;; 

5 Mwanza Intervention Trials Unit, Tanzania;; 6 Univ Teaching Hosp, 

Lusaka, Zambia;; and 7 London Sch of Hygiene and Tropical Med, UK 

11:15 29 Is Depot Medroxyprogesterone Acetate 

Likely to Increase Infectivity in HIV-1 + 

Women Receiving ART? 

Summer Day* 1 , S Graham 1,2 , L Masese 1,2 , B Richardson 1,3 , 

J Kiarie 2 , W Jaoko 2 , B Estambale 2 , V Chohan 1,3 , J Overbaugh 3 , 

and S McClelland 1,2 

1 Univ of Washington, Seattle, US;; 2 Inst of Tropical and Infectious 

Diseases, Univ of Nairobi, Kenya;; and 3 Fred Hutchison Cancer Res 

Ctr, Seattle, WA, US 

11:30 30 Community-level Reductions in Estimated HIV 

Incidence: HIV Prevention Trials Network 043, 

Project Accept 

Thomas Coates* 1 , S Eshleman 2 , S Chariyalertsak 3 , A Chingono 4 , 

G Gray 5 , J Mbwambo 6 , L Richter 7 , D Donnell 8 , E Piwowar-Manning 2 , 

M Kulich 9 , and the HPTN 043 Project Accept Study Team 

1 Univ of California, Los Angeles, US;; 2 Johns Hopkins Univ Sch 

of Med, Baltimore, MD, US;; 3 Chiang Mai Univ, Thailand;; 4 Univ 

of Zimbabwe, Harare;; 5 Univ of the Witwatersrand, Soweto, South 

Africa;; 6 Muhimbili Univ, Dar es Salaam, Tanzania;; 7 Human Sci Res 

Council, Vulindlela, South Africa;; 8 Statistical Ctr for HIV/AIDS Res 

and Prevention, Fred Hutchinson Cancer Res Ctr, Seattle, WA, US;; 

and 9 Charles Univ, Prague, Czech Repulic 

11:45 31 Which HIV Testing and Counseling Model 

Works Best in African Outpatient Departments? 

Results from the Strengthening HIV Test Access 

and Treatment Uptake Study 

AD McNaghten* 1 , A Schilsky Mneimneh 2 , T Farirai 3 , N Wamai 4 , 

M Ntiro 5 , J Sabatier 2 , N Makhunga-Ramfolo 6 , S Mwanasalli 7 , 

A Awor 4 , J Moore 2 , and Project STATUS Study Team 

1 Emory Univ, Atlanta, GA, US;; 2 CDC, Atlanta, GA, US;; 3 CDC, 

Pretoria, South Africa;; 4 CDC, Entebbe, Uganda;; 5 Ministry of Hlth 

and Social Welfare, Dar es Salaam, Tanzania;; 6 Univ Res Co, LLC, 

Pretoria, South Africa;; and 7 CDC, Dar es Salaam, Tanzania 

12:00 32 Condom Efficacy by Consistency of Use 

among MSM: US 

Dawn Smith*, J Herbst, X Zhang, and C Rose 


k Monday, 10 am-12:15 pm; Ballroom 1-2 


Advances in Hepatitis Therapy 

Moderators: 

Juergen Rockstroh, Univ of Bonn, Germany 

Kimberly Workowski, Emory Univ Sch of Med, Atlanta, GA, US 

10:00 33 Protective Effect of Hepatitis B Virus-active cART 

against Primary Hepatitis B Virus Infection 

M Heuft, G van den Berk, T Smissaert, W Blok, R Regez, L Dijksman, 

and Kees Brinkman* 

Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands 

10:15 34 Increased Plasma and Intracellular Ribavirin 

Concentrations Associated with Telaprevir Use 

Kyle Hammond* 1 , L Jimmerson 1 , C MacBrayne 1 , M Ray 1 , 

L Bushman 1 , J Burton 1 , F Baouchi-Mokrane 2 , G Everson 1 , 

P Anderson 1 , and J Kiser 1 

1 Univ of Colorado Denver, Aurora, US and 2 Denver Hlth Med Ctr, 

CO, US 

10:30 35 Pharmacokinetic Interactions of Darunavir/ 

ritonavir, Efavirenz, and Tenofovir with the 

Hepatitis C Virus Protease Inhibitor Faldaprevir 

in Healthy Volunteers 

J Sabo 1 , Jens Kort* 1 , M Haschke 2 , C Ballow 3 , B Girlich 4 , U Feifel 5 , 

B Lang 6 , M Schobelock 1 , and M Elgadi 7 

1 Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, 

US;; 2 Univ Hosp Basel, Switzerland;; 3 Buffalo Clin Res Ctr, NY, 

US;; 4 Boehringer Ingelheim Schweiz GmbH, Basel, Switzerland;; 

5 Boehringer Ingelheim Pharmaceuticals GmbH & Co KG, 

Ingelheim, Germany;; 6 Boehringer Ingelheim Pharmaceuticals 

GmbH & Co KG, Biberach, Germany;; and 7 Boehringer Ingelheim 

Canada Ltd, Burlington 


10:45 36 High Early Virological Response with 

Telaprevir-Pegylated-Interferon-Ribavirin 

in Treatment-experienced Hepatitis C Virus 

Genotype 1/HIV Co-infected Patients: 

ANRS HC26 TelapreVIH Study 

Laurent Cotte* 1 , J Braun 2 , C Lascoux-Combe 3,4 , C Vincent 2 , 

S Pol 3,5 , M-A Valentin 3,6 , K Lacombe 3 , D Nau 7 , J-P Aboulker 2 , 

J-M Molina 3,4 , and ANRS HC26 Study Group 

1 INSERM U1052, Hospices Civils de Lyon, France;; 2 INSERM 

SC10-US019, Villejuif, France;; 3 Assistance Publ Hosp de Paris, 

France;; 4 Univ Paris VII Denis Diderot, Paris, France;; 5 Univ Paris 

Descartes, Paris, France;; 6 INSERM UMR-S 943, Paris, France;; 

and 7 Hosp Pellegrin, Bordeaux, France 

11:00 37 ANRS-HC27 BocepreVIH Interim Analysis: 

High Early Virologic Response with Boceprevir 

+ Pegylated Interferon + Ribivirin in Hepatitis 

C Virus/HIV Co-infected Patients with Previous 

Failure to Pegylated Interferon + Ribivirin 

Isabelle Poizot-Martin* 1 , E Bellissant 2 , L Piroth 3 , A Renault 2 , 

Y Quertainmont 4 , E Rosenthal 5 , L Alric 6 , D Guyader 2 , M Bourliere 7 , 

J-M Molina 8 , and ANRS-HC27 BOCEPREVIH Study Group 

1 Hosp Ste Marguerite, Marseille, France;; 2 Hosp de Pontchaillou, 

Rennes, France;; 3 Hosp du Bocage, Dijon, France;; 4 Hosp de 

Kremlin-Bicetre, Paris, France;; 5 Hosp de LArchet, Nice, France;; 

6 Hosp de Purpan, Toulouse, France;; 7 Hosp St-Joseph, Marseille, 

France;; and 8 Hosp St-Louis, Paris, France 

11:15 38 12 Weeks of ABT-450/Ritonavir, Non-nucleoside 

Inhibitor and Ribavirin Achieved SVR24 in 

>90% of Treatment-naïve Hepatitis C Virus GT1 

Patients and 47% of Prior Non-responders 

Eric Lawitz* 1 , D Cohen 2 , F Poordad 1 , K Kowdley 3 , G Everson 4 , 

B Freilich 5 , D Jensen 6 , M Heckaman 2 , T Pilot-Matias 2 , and B Bernstein 2 

1 Alamo Med Res, San Antonio, TX, US;; 2 Abbott, Abbott Park, IL, US;; 

3 Digestive Disease Inst, Virginia Mason Med Ctr, Seattle, WA, US;; 

4 Univ of Colorado Denver and Univ of Colorado Hosp, Aurora, US;; 

5 Kansas City Gastroenterology and Hepatology, MO, US;; and 6 Ctr 

for Liver Diseases, Univ of Chicago Med Ctr, IL, US 

11:30 39 Risk of Virologic Relapse in Hepatitis C Virus 

GT1-infected Subjects after 8, 12, and 24 Weeks 

of ABT-450/r+ABT-267+ABT-333+Ribavirin: 

Identifying Optimal Treatment Duration 

Martin King*, W Xie, L Larsen, D Cohen, T Podsadecki, 

and B Bernstein 

AbbVie, North Chicago, IL, US 

11:45 40LB STARTVerso 4: High Rates of Early Virologic 

Response in Hepatitis C Virus Genotype 1/HIV 

Co-infected Patients Treated with Faldaprevir + 

Pegylated Interferon and Ribavirin 

Douglas Dieterich* 1 , V Soriano 2 , M Nelson 3 , J Rockstroh 4 , 

K Arasteh 5 , S Bhagani 6 , A Talal 7 , C Tural 8 , R Vinisko 9 , and J Kort 9 

1 Mt Sinai Sch of Med, New York, NY, US;; 2 Hosp Carlos III, Madrid, 

Spain;; 3 Chelsea and Westminster Hosp, London, UK;; 4 Univ of Bonn, 

Germany;; 5 EPIMED, Vivantes Auguste-Viktoria Hosp, Berlin, 

Germany;; 6 Royal Free Hosp, London, UK;; 7 State Univ of New York, 

Buffalo, US;; 8 Hosp Univ Germans Trias i Pujol, Barcelona, Spain;; 

and 9 Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, US 

12:00 41LB ELECTRON: 100% Suppression of Viral Load 

through 4 Weeks Post-treatment for Sofosbuvir 

+ Ledipasvir (GS-5885) + Ribavirin for 12 Weeks 

in Treatment-naïve and -experienced Hepatitis C 

Virus GT1 Patients 

Edward Gane* 1 , R Hyland 2 , X Ding 2 , P Pang 2 , 

J McHutchison 2 , W Symonds 2 , and C Stedman 3 

1 Auckland Clin Studies, New Zealand;; 2 Gilead Sci, Foster City, CA, 

US;; and 3 Christchurch Hosp, New Zealand


k Monday, 10 am-12:15 pm; Hall B1 


Is There Hope for HIV Eradication? 

Moderators: 

Kersten Koelsch, Univ of New South Wales, Kirby Inst for Infection and 

Immunity in Society, Sydney, Australia 

Ronald Swanstrom, Ctr for AIDS Res, Univ of North Carolina at Chapel 

Hill, US 

10:00 42 Increase in 2-LTR Circles after Raltegravir 

Intensification in HAART-suppressed Patients 

with High CD4 + T Cell Counts: A Randomized, 

Controlled Trial 

Hiroyu Hatano* 1 , M Strain 2 , R Scherzer 1 , E Sinclair 1 , S Palmer 3 , 

M Busch 1,4 , P Bacchetti 1 , P Hsue 1 , D Richman 2 , and S Deeks 1 

1 Univ of California, San Francisco, US;; 2 Univ of California, San 

Diego and VA San Diego Hlthcare System, US;; 3 Karolinska Inst, 

Solna, Sweden;; and 4 Blood Systems Res Inst, San Francisco, CA, US 

10:15 43 Characterization of Non-induced HIV-1 Proviruses 

Dampens the Hope for HIV-1 Eradication 

Ya-Chi Ho* 1 , L Shan 1 , J Wang 2 , N Hosmane 1 , J Blankson 1 , 

and R Siliciano 1,3 

1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Louisiana 

State Univ Hlth Sci Ctr Sch of Med, New Orleans, US;; and 3 Howard 

Hughes Med Inst, Chevy Chase, MD, US 

10:30 44 T Memory Stem Cells Are a Long-term Reservoir 

for HIV-1 

Maria Buzon* 1 , H Sun 1 , C Li 1 , E Martin-Gayo 1 , K Seiss 1 , 

A Shaw 1 , E Rosenberg 2 , F Pareyra 1,3 , X Yu 1 , and M Lichterfeld 2 

1 Ragon Inst of MGH, MIT and Harvard, Boston, MA, US;; 

2 Massachusetts Gen Hosp, Boston, US;; and 3 Brigham and Women�s 

Hosp, Boston, MA, US 

10:45 45 High Levels of CD2 Expression Identify HIV-1 

Latently Infected Resting Memory CD4 + T Cells 

in Virally Suppressed Subjects 

M Iglesias-Ussel 1 , C Vandergeeten 2 , L Marchionni 3 , N Chomont 2 , 

and Fabio Romerio* 1 

1 Inst of Human Virology, Baltimore, MD, US;; 2 VGTI Florida, Port St 

Lucie, US;; and 3 Johns Hopkins Univ, Baltimore, MD, US 

11:00 46 Study of Transitional Memory CD4 + T Cells 

�� 

Replication Competent HIV-1 

Natalia Soriano-Sarabia*, N Archin, and D Margolis 

Univ of North Carolina at Chapel Hill, US 

11:15 47 Early ART Intervention Restricts the Seeding 

of the HIV Reservoir in Long-lived Central 

Memory CD4 T Cells 

Jintanat Ananworanich* 1,2,3,4 , C Vandergeeten 5 , N Chomchey 1,2 , 

N Phanuphak 1,2 , V Ngauy 6 , R-P Sekaly 5 , M Robb 7 , N Michael 7 , 

J Kim 1,7 , N Chomont 5 , and RV254/SEARCH 010 Study Group 

1 SEARCH, Bangkok, Thailand;; 2 The Thai Red Cross AIDS Res 

Ctr, Bangkok;; 3 HIVNAT, Bangkok, Thailand;; 4 Faculty of Med, 

Chulalongkorn Univ, Bangkok, Thailand;; 5 Vaccine and Gene 

Therapy Inst, Port St Lucie, FL, US;; 6 Armed Forces Res Inst of Med 

Sci, Bangkok, Thailand;; and 7 US Military HIV Res Prgm, Silver 

Spring, MD 

11:30 48LB Functional HIV Cure after Very Early ART 

of an Infected Infant 

Deborah Persaud* 1 , H Gay 2 , C Ziemniak 1 , YH Chen 1 , M Piatak 3 , 

T-W Chun 4 , M Strain 5 , D Richman 5 , and K Luzuriaga 6 

1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Univ of 

Mississippi Med Ctr, Jackson, US;; 3 Frederick Natl Lab for Cancer 

Res, MD,US;; 4 NIAID, NIH, Bethesda, MD, US;; 5 Univ of California 

San Diego, La Jolla and VA San Diego Hlthcare System, US;; and 

6 Univ of Massachusetts Med Sch, Worcester, US 

11:45 49 Novel Approaches for the Assessment of the 

in vivo Residual Virus Pool and Viral Eradication 

Strategies in SIV + Rhesus Macaques 

Gregory Del Prete* 1 , X Wu 2 , C Trubey 1 , R Kiser 1 , V Coalter 1 , 

J Smedley 3 , J Hesselgesser 4 , M Piatak 1 , R Geleziunas 4 , and J Lifson 1 

1 AIDS and Cancer Virus Prgm, SAIC-Frederick, Inc, Frederick 

Natl Lab for Cancer Res, MD, US;; 2 Advanced Tech Prgm, SAIC- 

Frederick, Inc, Frederick Natl Lab for Cancer Res, MD, US;; 3 Lab 

Animal Sci Prgm, SAIC-Frederick, Inc, Frederick Natl Lab for 

Cancer Res, MD, US;; and 4 Gilead Sci, Foster City, CA, US 

12:00 50LB The Safety and Effect of Multiple Doses of 

Vorinostat on HIV Transcription in HIV + 

Patients Receiving cART 

J Elliott 1,2,3 , A Solomon 2,3 , F Wightman 2,3 , M Smith 2,3 , S Palmer 4 , 

M Prince 5 , J Watson 6 , J Hoy 1,2 , J McMahon 1 , and Sharon Lewin* 1,2,3 

1 Alfred Hosp, Melbourne, Australia;; 2 Monash Univ, Melbourne, 

Australia;; 3 Burnet Inst, Melbourne, Australia;; 4 Karolinska Inst, 

Stockholm, Sweden;; 5 Peter MacCallum Cancer Ctr, Melbourne, 

Australia;; and 6 Natl Assoc of People Living with HIV, Sydney, 

Australia 

b Monday, 1:30-2:30 pm; B402 

Session 11–Themed Discussion 

(see Session 94 on Tuesday for corresponding Poster Abstracts) 

Simian Viral Reservoirs 

Discussants: 

Cristian Apetrei, Univ of Pittsburgh Ctr for Vaccine Res, PA, US 

Mirko Paiardini, Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US 

482 Discovery of Novel and Highly Divergent SIV in Three 

Wild Monkey Species in Kibale National Park, Uganda 

William Switzer* 1 , M Lauck 2 , A Shankar 1 , D Hyeroba 3,4 , A Tumukunde 4 , 

C Chapman 4,5,6 , N Ting 7 , T Friedrich 2,8 , D O’Connor 2,8 , and T Goldberg 2,4,6,8 

1 CDC, Atlanta, GA, US;; 2 Univ of Wisconsin-Madison, US;; 3 Jane Goodall 

Inst, Entebbe, Uganda;; 4 Kibale EcoHlth Project, Makerere Univ Bio Field 

Station, Kanyawara, Uganda;; 5 McGill Univ, Montreal, Canada;; 6 Makerere 

Univ, Kampala, Uganda;; 7 Univ of Oregon, Eugene, US;; and 8 Wisconsin 

Natl Primate Res Ctr, Madison, US 

483 Full-length Genome Analyses of Two Highly 

Divergent SIV mus Strains Isolated in Mustached 

Monkeys (C. cephus) Hunted for Bushmeat in Gabon 

Florian Liegeois* 1,2 , V Boue 1,2 , C Butel 1 , P Ngari 2 , F Mouacha 1 , B Mve 

Ondo 2 , L Eric 2 , M Peeters 1 , and F Rouet 2 

1 UMI 233, Inst de Recherche pour le Devt and Univ of Montpellier, France 

and 2 Ctr Intl de Recherches Med de Franceville, Gabon 

484 Gorillas in Southwest Cameroon Are the Reservoir 

of HIV-1 Group P Ancestors 

Mirela D’arc* 1,2 , A Ayouba 1 , A Esteban 1 , L Etienne 1 , S Locatelli 1 , 

A Aghokeng 1,3 , E Delaporte 1 , EM Ngole 3 , and M Peeters 1 

1 UMI 233, IRD and Univ of Montpellier 1, France;; 2 Univ Federal do Rio 

de Janeiro, Brazil;; and 3 Projet PRESICA and IMPM/CREMER, Yaounde, 

Cameroon 

485 Non-Invasive Follow-up of SIV cpzPtt Infection in Wildliving 

Chimpanzees in Northeast Gabon 

Vanina Boue* 1,2 , F Liegeois 1,2 , AP Okouga 2 , S Locatelli 1 , C Butel 1 , 

P Ngari 2 , E Delaporte 1 , M Peeters 1 , and F Rouet 2 

1 UMI 233, Inst de Recherche pour le Devt and Univ of Montpellier, France 

and 2 Ctr Intl de Recherches Med de Franceville, Gabon 

486 Expanded Screening for Simian Foamy Virus in New 

World Primates Identifies 2 Novel Simian Foamy 

Virus in Tamarin and Uakari Monkeys from Brazil 

Claudia Muniz* 1 , A Santos 1 , H Jia 2 , L Troncoso 1 , L Faria 1 , A Augusto 3 , 

L Fedullo 3 , A Pissinatti 4 , M Soares 1,5 , and W Switzer 2 

1 Univ Federal do Rio de Janeiro, Brazil;; 2 CDC, Atlanta, GA, US;; 3 Fndn 

Rio-Zoo, Rio de Janeiro, Brazil;; 4 Ctr de Primatologia do Rio de Janeiro, 

Brazil;; and 5 Prgm de Oncovirologia, Inst Nacional de Cancer, Rio de 

Janeiro, Brazil 

487 Co-infection of Wild African Primates with SIV and 

Simian Hemorrhagic Fever Viruses 

Tony Goldberg* 1,2,3 , M Lauck 2 , W Switzer 4 , D Hyeroba 3 , A Tumukunde 3 , 

J Kuhn 5 , C Chapman 6 , N Ting 7 , T Friedrich 1,2 , and D O’Connor 1,2 

1 Univ of Wisconsin-Madison, US;; 2 Wisconsin Natl Primate Res Ctr, 

Madison, US;; 3 Kibale EcoHlth Project, Makerere Univ Bio Field Station, 

Kanyawara, Uganda;; 4 CDC, Atlanta, GA, US;; 5 IRF-Frederick, NIH, Fort 

Detrick, MD, US;; 6 Sch of Environment, McGill Univ, Montreal, Canada;; 

and 7 Univ of Oregon, Eugene, US 

b Monday, 1:30-2:30 pm; B406 

Session 12–Themed Discussion & Scientific Overview 

(see Session 179 on Wednesday for corresponding Poster Abstracts) 

Tenofovir in Children 

Program � 5 

Monday 


Discussants: 

Peter Havens, Med Coll of Wisconsin, Children’s Hosp of Wisconsin, 

Children’s Res Inst, Milwaukee, US 

Cristina Hofer, Federal Univ of Rio de Janeiro, Brazil 

971 

Tenofovir Disoproxil Fumarate Use in 

Children and Youth 

Peter Havens* 1 and R Hazra 2 

1 Med Coll of Wisconsin, Children�s Hosp of Wisconsin, 

Children�s Res Inst, Milwaukee, US and 2 Natl Inst of Child Hlth 

and Human Devt, NIH, Bethesda, MD, US 

972 48-Week Safety of Tenofovir when Administered 

According to Weight-band Dosing in HIV + Children 

�� 

L Aurpibul 1 , T Narkbunnam 2 , Virat Sirisanthana* 1 , O Wittawatmongkol 2 , 

W Phongsamart 2 , T Sudjaritruk 1 , T Cressey 1,3,4 , and K Chokephaibulkit 2 

1 Chiang Mai Univ, Thailand;; 2 Mahidol Univ, Bangkok, Thailand;; 3 Harvard 

Sch of Publ Hlth, Boston, MA, US;; and 4 Inst de Recherche pour le Devt, 

Marseille, France

Monday 



973 Pharmacokinetics of Tenofovir in Thai Adolescents 

Using Ritonavir-boosted Protease Inhibitor-based 

Regimens 

Wasana Prasitsuebsai* 1 , S Kerr 1,2 , N Thammajaruk 1 , A Colbers 3 , 

S Keadpudsa 1 , T Chuanjaroen 1 , M Gorowara 1 , D Burger 3 , A Sohn 4 , 

and J Ananworanich 1,5 

1 HIV-NAT Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok;; 

2 Kirby Inst, Univ of New South Wales, Sydney, Australia;; 3 Radboud Univ 

Nijmegen Med Ctr, The Netherlands;; 4 TREAT Asia/amfAR-Fndn for AIDS 

Res, Bangkok, Thailand;; and 5 SEARCH, Thai Red Cross AIDS Res Ctr, 

Bangkok 

b Monday, 1:30-2:30 pm; B308 

Session 13–Themed Discussion & Scientific Overview 


New Approaches to ARV Drug Delivery 

Discussants: 

Marta Boffito, Chelsea and Westminster Hosp, London, UK 

Kimberly Struble, FDA, Silver Spring, MD, US 

511 

Challenges and Opportunities for the 

Development of Long-acting ARVs 

�� 

Chelsea and Westminster Hosp, London, UK 

512a Improved Biodistribution, Pharmacokinetics, and 

ARV Responses for Folate-targeted Nanoformulated 

ART 

Pavan Puligujja*, H Gendelman, L Kendrick, N Smith, S Balkundi, 

U Roy, R Veerubhotla, J McMillan, and X Liu 

Univ of Nebraska Med Ctr, Omaha, US 

512b Development of Small Magnetite ARV Nanoparticles 

for Targeted Drug Delivery to Viral Reservoirs 

Dongwei Guo*, T Li, J McMillan, M Boska, X Liu, and H Gendelman 


513 Enhanced Pharmacological Properties of Efavirenz 

Formulated as Solid Drug Nanoparticles 

P Martin 1 , Neill Liptrott* 1 , T McDonald 1 , M Giardiello 1 , P Roberts 1 , 

P Curley 1 , D Smith 2 , M Siccardi 1 , S Rannard 1 , and A Owen 1 

1 Univ of Liverpool, UK and 2 Univ of Northumbria, Newcastle Upon Tyne, UK 

Concluding Comments: The Regulatory Pathway for 

Development of Long-acting ARVs 

Kimberly Struble FDA, Silver Spring, MD, US 

b Monday, 1:30-2:30 pm; B313 



Implementation and Cost-effectiveness of Male 

Circumcision 

Discussants: 

Connie Celum, Univ of Washington, Seattle, US 

Kenneth Freedberg, Massachusetts Gen Hosp, Boston, US (invited) 

1007 Shang Ring vs Forceps-guided Adult Male Circumcision, 

a Randomized Controlled Effectiveness Study: Western 

Uganda 

Samuel Kanyago* 1,2 , D Riding 1,3 , E Mutakooha 1 , A Lopez 1 , and M Siedner 4 

1 Mbarara Univ of Sci and Tech, Uganda;; 2 Good Shepherd Hosp, Siteki, 

Swaziland;; 3 Northwest Deanery, Manchester, UK;; and 4 Massachusetts Gen 

Hosp Ctr for Global Hlth, Boston, US 

1008 Factors Associated with Voluntary Medical Male 

Circumcision Adverse Events: Nyanza Province, Kenya 

Kipruto Chesang* 1 , Z Mwandi 1 , S Mwalili 1 , P Cherutich 2 , A Ochieng 2 , 

P Oyaro 3 , G Otieno 4 , K Serrem 5 , D Odera 6 , and A Kim 1 

1 CDC, Ctr for Global Hlth, Nairobi, Kenya;; 2 Natl AIDS and STD Control 

Prgm, Kenya Ministry of Publ Hlth and Sanitation, Nairobi;; 3 Kenya Med 

Res Inst, Nairobi;; 4 Nyanza Reproductive Hlth Society, Kisumu, Kenya;; 

5 Catholic Med Mission Board, Nairobi, Kenya;; and 6 Impact Res and Devt 

Org, Kisumu, Kenya 

1009 Male Circumcision Coverage by Risk Profiles: 

Rakai, Uganda 

Xiangrong Kong* 1 , A Ndyanabo 2 , G Kigozi 2 , F Nalugoda 2 , D Serwadda 3 , 

M Wawer 1 , R Gray 1 , and Rakai Hlth Sci Prgm 

1 Johns Hopkins Univ, Baltimore, MD, US;; 2 Rakai Hlth Sci Prgm, Kalisizo, 

Uganda;; and 3 Makerere Univ, Kampala, Uganda 


1010 Costs and Effectiveness of Male Circumcision 

Scale-up for the Prevention of HIV and Other 

Sexually Transmitted Infections: Sub-Saharan Africa 

Seema Kacker* 1 , K Frick 2 , T Quinn 1,3 , R Gray 2 , and A Tobian 1 

1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Johns Hopkins 

Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; and 3 NIAID, NIH, 

Bethesda, MD, US 

1011 Uptake of Neonatal Male Circumcision as Part of HIV 

Prevention Efforts in Botswana: Maternal Motivators 

and Barriers 

Rebeca Plank* 1,2,3 , K Wirth 2,3 , N Ndubuka 3 , P Kebaabetswe 4 , C Lesetedi 5 , 

J Makhema 3 , D Halperin 6 , R Shapiro 2,3,7 , M Mmalane 3 , and S Lockman 1,2,3 

1 Brigham and Women�s Hosp;; 2 Harvard Sch of Publ Hlth;; 3 Botswana- 

Harvard Partnership;; 4 Univ of Botswana, Sch of Med;; 5 Botswana 

Ministry of Hlth;; 6 Univ of North Carolina at Chapel Hill;; and 7 Beth Israel 

Deaconess Med Ctr 

b Monday, 1:30-2:30 pm; Ballroom 3-4 



What Is Latency and What Can We Do about It? 

Discussants: 

Mary Kearney, Ctr for Cancer Res, NCI, NIH, Frederick, MD, US 

Robert Siliciano, Johns Hopkins Univ Sch of Med, Baltimore, MD, US 

371 Only a Small Fraction of HIV-1 Proviruses in Resting 

CD4 + T Cells Can Be Induced to Produce Virions 

ex vivo with Anti-CD3/CD28 or Vorinostat 

Anthony Cillo* 1 , M Sobolewski1 , J Coffin2 , and J Mellors1 1 2 Univ of Pittsburgh, PA, US and Tufts Univ, Boston, MA, US 

372 A Comparison of Methods Used to Measure Rectal 

HIV Levels Suggests that HIV DNA Resides in Cells 

Other than CD4 + T Cells, Including CD45 + CD13 + Cells 

Steven Yukl* 1,2 , H Hatano2,3 , L Epling2,3 , P Hunt2,3 , P Li1,2 , D Havlir2,3 , 

M Somsouk2,3 , E Sinclair2,3 , S Deeks2,3 , J Wong1,2 , and DARE 

1 2 San Francisco VAMC, CA, US;; Univ of California, San Francisco, US;; 

and 3San Francisco Gen Hosp, CA, US 

373 Integrated HIV DNA and Associated Histiocyte 

Marker mRNA in Autopsy Samples of Non-lymphoid 

Tissue Including the Central Nervous System 

Benjamin Gelman* 1 , T Chen1 , J Lisinicchia1 , and A Rice2 1 2 Univ of Texas Med Branch, Galveston, US and Baylor Coll of Med, 

Houston, TX, US 

374 HIV Preferentially Infects Hematopoietic Progenitor 

Cells with High CD4 and Can Be Found in CD133 + 

Hematopoietic Progenitor Cells in a Subset of 

Optimally Treated People with Long-term Viral 

Suppression 

Lucy McNamara*, N Sebastian, A Onafuwa-Nuga, J Riddell, 

D Bixby, and K Collins 

Univ of Michigan, Ann Arbor, US 

375 Differences in Integration Site Distributions for 

Latent and Expressed HIV-1 Proviruses 

Scott Sherrill-Mix*, K Ocwieja, N Malani, U O’Doherty, 

and F Bushman 


376 Histone Deacetylase Inhibitor Romidepsin Induces 

HIV in CD4 + T Cells from ART-suppressed Subjects 

at Concentrations Achieved by Clinical Dosing 

George Wei* 1 , V Chiang1 , E Fyne2 , M Balakrishnan1 , G Stepan1 , A Tsai1 , 

J Lalezari3 , J Mellors2 , R Geleziunas1 , and T Cihlar1 1 2 Gilead Sci Inc, Foster City, CA, US;; Univ of Pittsburgh Sch of Med, PA, 

US;; and 3Quest Clin Res, San Francisco, CA, US


b Monday, 1:30-2:30 pm; Ballroom 1-2 



Statin Use and HIV: How Sweet Is It? 

Discussants: 

Steven Grinspoon, Massachusetts Gen Hosp, Boston, US 

Priscilla Hsue, Univ of California, San Francisco, US 

764 Statin Therapy and Mortality in HIV + Individuals: 

A Danish Nationwide Population-based Cohort Study 

Line Rasmussen* 1 , G Kronborg 2 , C Larsen 3 , C Pedersen 1 , J Gerstoft 4 , 

and N Obel 4 

1 Odense Univ Hosp, Denmark;; 2 Copenhagen Univ Hosp, Hvidovre, 

Denmark;; 3 Aarhus Univ Hosp, Skejby, Denmark;; and 4 Copenhagen Univ 

Hosp, Rigshospitalet, Denmark 

765 Impact of Statin Exposure on Mortality and 

Non-AIDS Complications in HIV Patients on HAART 

Henning Drechsler* 1,2 , S Zhang 2 , N Maalouf 2 , J Cutrell 2 , P Tebas 3 , 

and R Bedimo 1,2 

1 VA North Texas Hlth Care System, Dallas, US;; 2 Univ of Texas Southwestern 

Med Ctr, Dallas, US;; and 3 Univ of Pennsylvania, Philadelphia, US 

766 Association between Statin Use and Type-2 Diabetes 

Mellitus Occurrence among HIV-1 + Patients 

Receiving ART 

Vincenzo Spagnuolo* 1 , L Galli 1 , A Poli 1 , S Salpietro 1 , N Gianotti 1 , 

P Piatti 1 , C Vinci 1 , E Carini 1 , A Lazzarin 1,2 , and A Castagna 1 

1 San Raffaele Sci Inst, Milan, Italy and 2 Univ Vita-Salute San Raffaele, 

Milan, Italy 

767 Statin Use Is Associated with Incident Diabetes 

Mellitus among Patients in the HIV Outpatient 

Study 

Kenneth Lichtenstein* 1 , R Debes 2 , K Wood 2 , S Bozzette 2,3 , K Buchacz 4 , 

J Brooks 4 , and HIV Outpatient Study Investigators 

1 Natl Jewish Hlth, Denver, CO, US;; 2 Cerner Corp, Kansas City, MO, US;; 

3 Univ of California, San Diego, US;; and 4 CDC, Atlanta, GA, US 

C Monday, 2:30-4 pm; Hall B2 

Poster Abstracts 

(see full session listings starting on page 24) 

Session 53. HIV Persistence, Reservoirs, and Viremic Control 

Session 55. Envelope/Entry/Tropism/Transmission 

Session 58. Assembly–Putting It All Together 

Session 59. Restriction Factors: Old and New 

Session 64. HIV Compartments 

Session 67. HIV Infection Models 

Session 71. Immune Restoration 

Session 73. Immune Activation/Function in HIV Infection 

Session 74. Immune Activation, T Cell Homeostasis, and Therapy 

Session 75. Mucosal Factors in HIV Transmission and Infection 

Session 77. HIV Compartmentalization and Evolution on Therapy 

Session 84. Progressive Multifocal Leukoencephalopathy and Other 

Central Nervous System Infections 

Session 85. Central Nervous System Penetration, ART Intensification, 

and Cerebrospinal Fluid Escape 

Session 86. ART, Neurocognitive Outcomes, and New Central Nervous 

System-targeted Therapies 

Session 87. Central Nervous System Viral Evolution and 

Compartmentalization 

Session 95. Mining Sequence Data to Understand Transmission and 

Disease 

Session 96. Transmission Clusters 

Session 98. Within-patient Diversity Compartmentalization, Dual 

Infection, and Recombination 

Session 100. ARV Pharmacogenetics: Metabolism, Drug Interactions, 

and Response 

Session 101. ARV Drug Exposure, Safety, and Efficacy 

Session 105. New ARV Agents 

Session 106. Randomized Trials of ART: A Potpourri 

Session 118. Hepatic Injury and Fibrosis 

Session 119. Laboratory Assessment and Imaging of Hepatic Injury 

Session 120. Hepatitis E Virus 

Session 121. Hepatitis B Virus 

Session 128. HIV-associated Malignancies: Miscellaneous 

Session 130. Cardiovascular Disease: Predicting Risk and Monitoring 

Outcomes 

Session 131. Endothelial Dysfunction in HIV Infection 

Session 132. Vascular Imaging and Subclinical Atherosclerosis 

Session 141. Diabetes, Metabolic Syndrome, and Vitamin D Deficiency 

Session 143. Bone Loss: Risk Factors and Pathogenesis 

Session 144. ART and Bone Disease 

Session 150. Cryptococcal Infections 

Session 151. Herpes Zoster 

Session 152. Cytomegalovirus–Host Pathogen Interactions 

Session 153. Syphilis: Not Gone, Not Forgotten 

Session 154. Opportunistic Infections and Other Novel Pathogens 

Session 155. Vaccines: TB, Pneumococcus, and Influenza 

Session 156. HIV Shedding and Impact of Infection on Immune Cells in 

Women 

Session 161. HIV Testing and ARV Drug Resistance during Pregnancy 

Session 162. ART, Viral Suppression, and MTCT 

Session 170. Incidence and Prevention of PMTCT-associated Drug 

Resistance 

Session 171. New HIV Infections among Children in the US 

Session 172. ART Initiation and Immune Reconstitution Inflammatory 

Syndrome among Infants and Children 

Session 173. ART Strategies and Outcomes among Children 

Session 174. Cost and Cost-effectiveness of ART and Monitoring 

Strategies in Children 

Session 178. Characteristics of Youth with HIV 

Session 180. ARV Pharmacokinetics in Children 

Session 183. Preclinical Studies of Topical ARV for Prevention 

Session 187. Voluntary Medical Male Circumcision 

Session 190. The Cascade of Care 

Session 191. Engagement and Retention in Care 

Session 197. Performance and Innovation in ART Programs in RLS 

Program � 7 

Monday 


Monday 



e Monday, 4-6 pm; B406 

Session 17–Symposium 

Is Something Bugging You? 

Conveners: 

Giulia Marchetti, San Paolo Hosp, 

Univ of Milan, Italy 

John Zaunders, St Vincent’s Hosp, 

Sydney, Australia 

51 

The Human Microbiome in Health and 

Immunodeficient States 

Frederic Bushman*, G Wu, J Lewis, H Li, K Bittinger, 

E Charlson, C Hoffmann, and R Collman 

Univ of Pennsylvania Perleman Sch of Med, Philadelphia, US 

52 

HIV and SIV Pathogenesis at the Interface of 

Gut Mucosal Immune Defense and Microbiota 

I Grishina, L Hirao, L Nagy, S Sankaran, A Baumler, M Marco, 

H Cheng, and Satya Dandekar* 

Univ of California, Davis, US 

53 

Treating Microbial Translocation in 

Progressive HIV/SIV Infections 

N Klatt 1 , Z Klase 1 , M Quinones 2 , D Hazuda 3 , M Miller 4 , J Segre 5 , 

J Lifson 6 , E Haddad 7 , J Estes 6 , and Jason Brenchley* 1 

1 Prgm in Barrier Immunity and Repair, NIAID, NIH, Bethesda, 

MD, US;; 2 Bioinformatics and Computational Biosci Branch 

OCICB, OSMO, OD, NIAID, NIH, Bethesda, MD, US;; 3 Merck 

Res Labs, West Point, PA, US;; 4 Gilead Sci, Inc., Foster City, CA, 

US;; 5 Genetics and Molecular Microbio Branch, NHGRI, NIH, 

Bethesda, MD, US;; 6 ACVP, SAIC-Frederick, Inc, Frederick Natl 

Lab for Cancer Res, MD, US;; and 7 Vaccine and Gene Therapy 

Inst-Florida, Port St Lucie, US 

54 

The Enteric Virome in AIDS 

S Handley 1 , L Thackray 1 , G Zhao 1 , R Presti 1 , J Brenchley 2 , 

R Veazey 3 , T Stappenbeck 1 , D Wang 1 , D Barouch 4,5 , 

and Herbert Virgin* 1 

1 Washington Univ Sch of Med, St Louis, MO, US;; 2 Lab of 

Molecular Microbio, NIAID, NIH, Bethesda, MD, US;; 3 Tulane 

Natl Primate Res Ctr, Tulane Univ Sch of Med, Covington, LA, 

US;; 4 Ctr for Virology and Vaccine Res, Beth Israel Deaconess 

Med Ctr, Boston, MA, US;; and 5 Ragon Inst of MGH, MIT, and 

Harvard Med Sch, Boston, MA, US 

5:30-6 pm 

Panel Discussion 


interested in understanding the roles of the microbiome and the 

virome in the pathogenesis of HIV infection and AIDS. Recent 

discoveries in these areas will be discussed. It is assumed that 

participants are familiar with the general concept of microbiomes 

and have some understanding of the molecular mechanisms used 

for its investigation. At the completion of the session, participants 

will be knowledgeable about the gut and lung microbiomes, the 

alterations in the gut virome associated with lentiviral infections, 

and their influence in pathogenesis. 


e Monday, 4-6 pm; Ballroom 3-4 


Preventing HIV/AIDS in the US: Can We Do Better? 

Conveners: 

Wayne Duffus, CDC, Atlanta, GA, US 

Monica Sweeney, New York City Dept 

of Hlth, NY, US 

55 

Drivers of the HIV Epidemic in the Southern 

US 

Adaora Adimora 


56 

What Do Sexual Networks Tell Us about How 

to Block Transmission? 

Steven Goodreau 

Univ of Washington, Seattle, US 

57 

How Should We Spend Our Prevention 

Dollars? 

Carlos del Rio 

Emory Univ Ctr for AIDS Res, Atlanta, GA, US 

58 

Addressing the Cascade of Care 

Alan Greenberg 

George Washington Univ and District of Columbia Devt Ctr for 

AIDS Res, US 

5:30-6 pm 



interested in HIV prevention, treatment, and policy. It is assumed 

participants are familiar with basic knowledge of HIV epidemiology 

in the US, and HIV prevention and treatment modalities. At the 

completion of the session, participants will be knowledgeable about 

which populations in the US are not being reached adequately, 

factors that may be driving these failures to prevent HIV infection 

and diagnose and adequately treat HIV infected persons, and some 

proposed solutions for addressing the HIV/AIDS epidemic in the US.


e Monday, 4-6 pm; Ballroom 1-2 


Cardiovascular Disease and Other Non-AIDS 

Events: Epidemiology and Pathogenesis 

Moderators: 

Matthew Freiberg, Ctr for Res on Hlth Care, Univ of Pittsburgh, PA, US 

Peter Reiss, Academic Med Ctr, Univ of Amsterdam, The Netherlands 

4:00 59 HIV + Adults Are at Greater Risk for Myocardial 

Infarction, Non-AIDS Cancer, and End-stage 

Renal Disease, but Events Occur at Similar Ages 

Compared to HIV – Adults 

Keri Althoff* 1 , C Wyatt2 , C Gibert1 , KA Oursler3 , D Rimland4 , 

M Rodriguez-Barradas5 , K McGinnis6 , M Skanderson6 , K Gebo7 , 

A Justice6 , for Veterans Aging Cohort Study 

1VAMC and George Washington Univ Med Ctr, Washington, DC, 

US;; 2Mt Sinai Sch of Med, New York, NY, US;; 3Univ of Maryland 

and VA Maryland Hlth Care System, Baltimore, US;; 4Atlanta VAMC 

and Emory Univ Sch of Med, GA, US;; 5Baylor Coll of Med and 

the Michael E DeBakey VAMC, Houston, TX, US;; 6Yale Univ and 

the VA Connecticut Hlthcare System, New Haven, US;; and 7Johns Hopkins Univ, Baltimore, MD, US 

4:15 60 Combined Effect of Interleukin-6 and D-dimer 

on the Risk of Serious Non-AIDS Conditions: 

Data from 3 Prospective Cohorts 

Birgit Grund* 1 , J Baker2 , S Deeks3 , J Wolfson1 , D Wentworth1 , 

A Cozzi-Lepri4 , C Cohen5 , A Phillips4 , J Lundgren6 , J Neaton1 , 

and INSIGHT SMART/ESPRIT/SILCAAT Study Group 

1 2 Univ of Minnesota, Minneapolis, US;; Hennepin County Med 

Ctr, Minneapolis, MN, US;; 3San Francisco Gen Hosp and Univ of 

California, San Francisco, US;; 4Univ Coll London, UK;; 5Univ of 

California, San Francisco, US;; and 6Copenhagen Univ Hosp and 

Univ of Copenhagen, Denmark 

4:30 61 Increased Risk of Cardiovascular Disease with 

Age in Men: A Comparison of D:A:D with HIV – 

Cardiovascular Disease Risk Equations 

Kathy Petoumenos* 1 , W El-Sadr2 , A d’Arminio Monforte3 , 

C Sabin4 , P Reiss5 , L Ryom6 , S De Wit7 , M Rickenbach8 , J Lundgren6 , 

M Law1 , for D:A:D Study Group 

1 2 The Kirby Inst, Univ of New South Wales, Sydney, Australia;; Intl 

Ctr for AIDS Care and Treatment Prgms, Columbia Univ and 

Harlem Hosp, New York, NY, US;; 3Azienda Ospedaliera-Polo Univ 

San Paolo, Milan, Italy;; 4Univ Coll London, UK;; 5ATHENA, HIV 

Monitoring Fndn, Academic Med Ctr, Amsterdam, The Netherlands;; 

6Copenhagen HIV Prgm, Univ of Copenhagen, Faculty of Hlth 

and Med Sci, Denmark;; 7St-Pierre Cohort, CHU St-Pierre Hosp, 

Brussels, Belgium;; and 8Inst for Social and Preventive Med, Univ of 

Lausanne, Switzerland 

4:45 62 Age and Noncalcified Coronary Plaque 

in the Multicenter AIDS Cohort Study 

Wendy Post* 1,2 , L Jacobson2 , X Li2 , F Palella3 , L Kingsley4 , 

M Witt5 , T Brown1 , M Plankey6 , M Budoff5 , and J Margolick2 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; Johns 

Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 

3 4 Northwestern Univ, Chicago, IL, US;; Univ of Pittsburgh, PA, US;; 

5 6 Harbor UCLA, US;; and Georgetown Univ, Washington, DC, US 

5:00 63 Increased Coronary Atherosclerotic Plaque 

Vulnerability Features on Computed 

Tomography Angiography among HIV + 

Subjects vs Matched HIV – Controls 

M Zanni, J Lo, B Wai, B Shah, D Hark, E Marmarelis, S Abbara, 

and Steven Grinspoon* 

Massachusetts Gen Hosp, Boston, US 

5:15 64 Elevated Numbers of CD163 + Macrophages in 

Hearts of SIV + Rhesus Macaques with Cardiac 

Disease Are Decreased Using PA300 

Joshua Walker* 1 , T Burdo1 , A Miller2 , K Misgin1 , M Sulciner1 , 

M McGrath3 , and K Williams1 1 2 Boston Coll, Chestnut Hill, MA, US;; New England Primate 

Res Ctr, Southborough, MA, US;; and 3Univ of California, San 

Francisco, US 

5:30 65 Comparison of Aspirin Use and Incident 

Myocardial Infarction Rates in HIV + and HIV – 

Patients in a Large US Healthcare System 

Sujit Suchindran*, S Regan, J Meigs, S Grinspoon, and V Triant 


5:45 66LB Monocyte Activation, but Not T Cell Activation, 

Predicts Progression of Coronary Artery 

Calcium in a Contemporary HIV Cohort 

Jason Baker* 1,2 , K Huppler Hullsiek 2 , A Singh 3 , E Wilson 3 , 

K Henry 1,2 , P Patel 4 , J Brooks 4 , H Hodis 5 , M Budoff 6 , I Sereti 3 , 

for CDC SUN Study Investigators 

1 Hennepin County Med Ctr, Minneapolis, MN, US;; 2 Univ of 

Minnesota, Minneapolis, US;; 3 NIAID, NIH, Bethesda, MD, US;; 

4 Division of HIV/AIDS Prevention, CDC, Atlanta, GA, US;; 5 Univ of 

Southern California Keck Sch of Med, Los Angeles, US;; and 6 Los 

Angeles Biomed Res Inst at Harbor-UCLA, CA, US 

e Monday, 4-6 pm; Hall B1 


New Frontiers in Hepatitis C Virus Treatment 

Conveners: 

Arthur Kim, Massachusetts Gen Hosp, 

Boston, US 

Susanna Naggie, Duke Univ Med Ctr, 

Durham, NC, US 

67 

The Test and Treat Era of Hepatitis C: 

Expanding the Individual and Public 

Health Benefits of Hepatitis C Virus 

Treatment 

John Ward 


68 

Pathogenesis of Accelerated Hepatitis C 

Virus Liver Disease Progression 

Raymond Chung 


69 

Liver Transplant in HIV + Persons: Current 

Prospects and Prospects for the New 

Therapeutic Era 

Norah Terrault 

Univ of California, San Francisco, US 

70 

Cure without Interferon: The Scientific Basis 

and Clinical Evidence 

David Thomas 

Johns Hopkins Univ, Baltimore, MD, US 


interested in the challenge of hepatitis C virus (HCV) infection. 

It is assumed that participants are familiar with basic principles 

of virology and clinical practice. At the completion of the session, 

participants will be knowledgeable about the burden of HCV 

infection in the US, the principles of testing for HCV infection, 

and how HIV accelerates the course of disease. Participants are 

also expected to appreciate upcoming treatments for HCV infection 

including the steps in the viral life cycle that they affect. 

Program � 9 

Monday 


Tuesday 



i Tuesday, 8:30-9 am; Hall B1 


The Global MSM HIV Epidemic: Time to Act 

71 

Chris Beyrer 

Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, 

MD, US 

Objectives: This session is directed to clinicians, epidemiologists, 

and scientists interested in HIV among MSM, HIV prevention, and 

stigma and discrimination. It is assumed that participants are familiar 

with both the epidemiology and risks for HIV infection among 

these men in the US and in developing countries. At the completion 

of the session, participants will be knowledgeable about why HIV 

epidemics among gay, bisexual, and other MSM continue to expand 

in 2013, and about what prevention and treatment approaches hold 

promise for prevention and control. 

j Tuesday, 9-9:30 am; Hall B1 


Evolution of the Host–Virus Interaction: A Guide to 

the Development of Novel Therapeutics? 

72 

Jonathan Stoye 

MRC-Natl Inst for Med Res, London, UK 


interested in the interaction between infecting retroviruses and 

their targets. It is assumed that participants are familiar with basic 

aspects of retrovirus replication. At the completion of the session, 

participants will be knowledgeable about the properties of restriction 

factors and ways in which this information might be used to devise 

novel therapeutic strategies. 

k Tuesday, 10 am-12 n; B406 


HIV/SIV–Host Interaction 

Moderators: 

Eric Hunter, Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US 

George Shaw, Univ of Pennsylvania, Philadelphia, US 

10:00 73 Immunologic Profile Distinguishes Aviremic 

HIV + Adults 

Christina Ramirez Kitchen* 1 , P Hunt 2 , S Lee 2 , J Toyama 1 , 

E Sinclair 2 , L Epling 2 , P Hsue 2 , F Hecht 2 , J Martin 2 , and S Deeks 2 

1 Univ of California, Los Angeles, US and 2 Univ of California, San 

Francisco, US 

10:15 74 Persistent Abnormalities of Lymphoid 

Structures in HIV Viremic Controllers 

Joyce Sanchez* 1 , P Hunt 2 , J Jessurun 1 , M Rothenberger 1 , C Reilly 1 , 

J Jasurda 1 , M Somsouk 2 , S Russ 1 , S Deeks 2 , and T Schacker 1 

1 Univ of Minnesota, Minneapolis, US and 2 Univ of California, San 

Francisco, US 

10:30 75LB Prospective ART of Asymptomatic HIV + Controllers 

Hiroyu Hatano* 1 , S Yukl 1,2 , A Ferre 3 , E Sinclair 1 , P Hunt 1 , 

P Bacchetti 1 , M Busch 1,4 , B Shacklett 3 , J Wong 1,2 , and S Deeks 1 

1 Univ of California, San Francisco, US;; 2 San Francisco VA Med Ctr, 

CA, US;; 3 Univ of California, Davis, US;; and 4 Blood Systems Res 

Inst, San Francisco, CA, US 

10:45 76 Effects of Interferon-� Treatment on Anti-HIV-1 

Intrinsic Immunity in vivo 

M Abdel-Mohsen 1 , T Liegler 1 , J Guatelli 2 , M Salama 3 , H Ghanem 3 , 

A Rauch 4 , B Ledergerber 5 , H Gunthard 5 , J Wong 1,6 , Satish Pillai* 1,6 , 

and Swiss HIV Cohort Study 

1 Univ of California, San Francisco, US;; 2 Univ of California, San Diego, 

US;; 3 Ain Shams Univ, Cairo, Egypt;; 4 Univ Hosp Berne, Switzerland;; 

5 Univ Hosp Zurich, Switzerland;; and 6 VAMC, San Francisco, CA, US 


11:00 77 Blockade of Type I Interferon during Acute SIV 

Infection Results in Accelerated Progression to 

AIDS and Death 

Netanya Sandler* 1 , R Zhu 1 , J Estes 2 , E Boritz 1 , J Lifson 2 , 

D Levin 3 , J Langer 4 , G Schreiber 3 , S Rao 1 , and D Douek 1 

1 NIH, Bethesda, MD, US;; 2 NIH, Frederick, MD, US;; 3 Weizmann 

Inst of Sci, Rehovot, Israel;; and 4 Univ of Med and Dentistry of New 

Jersey and Robert Wood Johnson Med Sch, Piscataway, US 

11:15 78 Experimental CD4 Depletion in SIV + Macaques 

Results in Macrophage and Microglia Infection, 

Rapid Turnover of Infected Cells, and Encephalitis 

L Micci 1 , R Iriele 1 , X Alvarez-Hernandez 2 , C McGary 1 , C Derdeyn 1 , 

J Estes 3 , M Davenport 4 , A Lackner 2 , G Silvestri 1 , and Mirko Paiardini* 1 

1 Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US;; 2 Tulane Natl 

Primate Res Ctr, Covington, LA, US;; 3 AIDS Cancer Virus Prgm, NCI- 

Frederick, MD, US;; and 4 Univ of New South Wales, Sydney, Australia 

11:30 79 In vivo Evaluation of a Novel Variant of SIV mac 

Lacking CD4 Tropism 

Adrienne Swanstrom* 1 , B Haggarty 1 , A Jordan 1 , G Leslie 1 , 

X Alvarez-Hernandez 2 , C LaBranche 3 , D Montefiori 3 , P Marx 2 , 

A Lackner 2 , and J Hoxie 1 

1 Univ of Pennsylvania, Philadelphia, US;; 2 Tulane Natl Primate Res 

Ctr, Covington, LA, US;; and 3 Duke Univ, Durham, NC, US 

11:45 80 Neutralization-sensitive Env with Exposed 

Co-receptor Binding Sites Dominate in vivo 

during SIV Infection of Macaques Depleted 

of CD4 + T Cells 

Nicholas Francella* 1 , Y Yi 1 , B Li 2 , S Gwyn 1 , S Elliott 1 , 

A Ortiz 2 , M Paiardini 2 , G Silvestri 2 , C Derdeyn 2 , and R Collman 1 

1 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US 

and 2 Yerkes Natl Primate Ctr, Emory Univ, Atlanta, GA, US 

k Tuesday, 10 am-12:15 pm; Ballroom 3-4 


MTCT and HIV Treatment in Children 

Moderators: 

Denise Jamieson, CDC, Atlanta, GA, US 

Denis Tindyebwa, African Network for Care of Children Affected by 

AIDS, Kampala, Uganda 

10:00 81 Birth Defects and ART in the French Perinatal 

Cohort, a Prospective Exhaustive Study among 

13,124 Live Births from 1994 to 2010 

Jeanne Sibiude* 1 , L Mandelbrot 1,2,3 , S Blanche 4 , J Le Chenadec 3,5 , 

N Boullag-Bonnet 3 , A Faye 2,6 , C Dollfus 7 , R Tubiana 8 , B Khoshnood 9 , 

J Warszawski 3,5,10 , and ANRS CO1/CO10/CO11 

1 Hosp Louis Mourier, Colombes, France;; 2 Univ Diderot Paris 

7, Paris, France;; 3 CESP, INSERM U1018, Le Kremlin-Bicetre, 

France;; 4 Hosp Necker, EA 3620, Univ Paris Descartes 5, Paris, 

France;; 5 INED, Paris, France;; 6 Hosp Robert Debre, Paris, France;; 

7 Hosp Trousseau, Paris, France;; 8 Hosp Pitie Salpetriere, INSERM 

U943, Paris, France;; 9 INSERM, UMR S953, Univ Paris-6, Paris, 

France;; and 10 Univ Paris Sud, Le Kremlin-Bicetre, France 

10:15 82 Uptake and Retention in Malawis Option B+ 

PMTCT Program: Lifelong ART for All HIV + 

Pregnant or Lactating Women 

Beth Tippett Barr* 1 , E Mhango 2 , L Tenthani 2,3 , G Zomba 2,3 , 

S Makombe 2 , M Eliya 2 , D Midiani 2 , S Gupta 1 , F Chimbwandira 2 , 

and A Jahn 2,3 

1 CDC, Lilongwe, Malawi;; 2 Ministry of Hlth, Lilongwe, Malawi;; 

and 3 Intl Training and Ed Ctr for Hlth, Lilongwe, Malawi 

10:30 83 Optimization of ART Initiation in Pregnancy 

through Linkage of Services vs Integration of 

ART into Antenatal Care 

Landon Myer* 1 , V Manuelli 2 , E Abrams 3 , J McIntyre 1,4 , and L-G Bekker 1 

1 Univ of Cape Town, South Africa;; 2 Obstetrics, Gynaecology and 

Reproductive Sci, Univ of California, San Francisco, US;; 3 Intl 

Ctr for AIDS Care and Treatment Prgm, Mailman Sch of Publ 

Hlth, Columbia Univ, New York, NY, US;; and 4 Anova Hlth Inst, 

Johannesburg, South Africa 

10:45 84LB Efficacy and Safety of 6 Months vs 6 Weeks 

Nevirapine for Prevention of Postnatal HIV-1 

Transmission 18 Month Follow-up: 

HPTN 046 Trial 

Mary Glenn Fowler* 1 , H Coovadia 2 , E Brown 3 , L Stranix-Chibanda 4 , 

D Moodley 5 , R Kisenge 6 , P Richardson 1 , S Zwerski 7 , L Mofenson 8 , and 

B Jackson 1 

1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Maternal 

Adolescent and Child Hlth, Univ of the Witwatersrand, South Africa;; 

3 Fred Hutchinson Cancer Res Ctr, Seattle, WA, US;; 4 Univ of Zimbabwe 

Coll of Med, Harare;; 5 Ctr for the AIDS Prgm of Res in South Africa, 

Nelson R Mandela Sch of Med, Univ of KwaZulu Natal, Durban;; 

6 Muhimbili Univ of Hlth and Allied Sci, Dar es Salaam, Tanzania;; 

7 NIAID, NIH, Bethesda, MD, US;; and 8 Eunice Kennedy Shriver Natl 

Inst of Child Hlth and Human Devt, NIH, Rockville, MD, US


11:00 85 Impact of Routine Laboratory Monitoring after 

ART Initiation in 1206 HIV + African Children: The 

5-Year Anti-Retroviral Research for Watoto Trial 

Adeodata Kekitiinwa* 1 , A Cook 2 , K Nathoo 3 , P Mugyenyi 4 , 

P Nahirya-Ntege 5 , M Bwakura-Dangarembizi 3 , P Munderi 5 , 

P Musoke 6 , S Walker 2 , D Gibb 2 , and ARROW Trial Team 

1 Baylor-Uganda/Paediatric Infectious Diseases Clin, Mulago;; 2 MRC 

Clinical Trials Unit, London, UK;; 3 Univ of Zimbabwe, Harare;; 4 Joint 

Clinical Res Ctr, Kampala, Uganda;; 5 MRC/UVRI Uganda Res Unit 

on AIDS, Entebbe;; and 6 Makerere Univ, Kampala, Uganda 

11:15 86 Randomized Comparison of Stopping vs 

Continuing Cotrimoxazole Prophylaxis among 

758 HIV + Children on Long-term ART: 

The Anti-Retroviral Research for Watoto Trial 

Mutsa Bwakura-Dangarembizi* 1 , L Kendall 2 , S Bakeera-Kitaka 3 , 

P Nahirya-Ntege 4 , R Keishanyu 5 , A Kekitiinwa 3 , E Natukunda 5 , 

S Walker 2 , D Gibb 2 , A Prendergast 2 , and ARROW Study Group 

1 Univ of Zimbabwe, Harare;; 2 MRC Clinical Trials Unit, London, 

UK;; 3 Baylor-Uganda, Paediatric Infectious Diseases Clin, Mulago 

Hosp, Kampala;; 4 MRC/Uganda Res Unit on AIDS, Uganda Virus 

Res Inst, Entebbe;; and 5 Joint Clinical Res Ctr, Kampala, Uganda 

11:30 87 Selection of ARV Regimen Impacts Antimalarial 

Pharmacokinetics and Treatment Outcomes in 

HIV-Malaria Co-infected Children in Uganda 

Norah Mwebaza* 1 , R Kajubi 1 , J Ssebuliba 1 , S Kiconco 1 , L Huang 2 , 

Q Gao 2 , A Kakuru 1 , J Achan 1 , F Aweeka 2 , and S Parikh 2,3 

1 Makerere Univ, Kampala, Uganda;; 2 Univ of California, San Francisco, 

US;; and 3 Yale Univ Sch of Publ Hlth and Med, New Haven, CT, US 

11:45 88LB Comparison of Virologic and Immunologic 

Outcomes between HIV + Ugandan Children 

Randomized to Ritonavir-boosted Lopinavir 

or NNRTI-based ART 

Theodore Ruel* 1 , A Kakuru 2 , G Ikilezi 2 , F Mwangwa 2 , G Dorsey 1 , 

P Rosenthal 1 , E Charlebois 1 , D Havlir 1 , M Kamya 3 , and J Achan 3 

1 Univ of California, San Francisco, US;; 2 Infectious Diseases Res 

Collaboration, Kampala;; and 3 Makerere Univ, Kampala, Uganda 

12:00 89LB A Novel Innate HIV-1 Neutralizing Protein 

Isolated from Breast Milk 

G Fouda, F Jaeger, J Amos, C Ho, K Anasti, T Ohashi, A Moseley, 

H Erickson, M Alam, and Sallie Permar* 

Duke Univ Med Ctr 

k Tuesday, 10 am-12 n; Ballroom 1-2 


North and South: Epidemiology and Engagement in 

Care 

Moderators: 

Gottfried Hirnschall, WHO, Geneva, Switzerland 

Manya Mangus, George Washington Univ, Washington, DC, US (invited) 

10:00 90 HIV Prevalence and Awareness of Infection in 

2008 and 2011 among MSM: 20 US Cities 

Cyprian Wejnert*, B Le, J Zhu, T Finlayson, A Oster, A Smith, 

G Paz-Bailey, for NHBS Study Group 


10:15 91 Age and Racial Disparities in Per-contact Risk 

of HIV Seroconversion among MSM: US 

Hyman Scott* 1,2 , E Vittinghoff 1 , and S Buchbinder 

21 Univ of California, San Francisco, US and 2 San Francisco Dept of 

Publ Hlth, CA, US 

10:30 92 Determinants of Mortality and Loss to Follow-up 

among Adult Patients in Pre-ART Care and on 

ART: Rwanda 

Chloe Teasdale* 1 , V Mugisha 1 , C Wang 1 , 

H Nuwagaba-Biribonwoha 1 , E Tayebwa 1 , E Ingabire 1 , P Ingabire 2 , 

M Lahuerta 1 , R Sahabo 1 , and E Abrams 1 

1 Intl Ctr for AIDS Care and Treatment Prgms, Columbia Univ, 

Mailman Sch of Publ Hlth, New York, NY, US and 2 Rwanda Ministry 

of Hlth, Kigali 

10:45 93 ART Initiation Substantially Improves Retention 

among Patients Enrolling in Care: Lusaka, Zambia 

M Li 1,2 , Brad Guffey* 1,3 , P Musonda 1,4 , I Sikazwe 5 , A Mwango 5 , 

B Chi 1,2 , and J Stringer 1,2 

1 Ctr for Infectious Disease Res in Zambia, Lusaka;; 2 Univ of North 

Carolina at Chapel Hill, US;; 3 Univ of Alabama at Birmingham, US;; 4 Univ 

of East Anglia, Norwich, UK;; and 5 Zambian Ministry of Hlth, Lusaka 

11:00 94 CD4 Count and Late Enrollment into HIV Care: 

Comparison between 2006 and 2011 in 4 

Sub-Saharan African Countries 

Susie Hoffman* 1,2 , Y Wu 3 , W El-Sadr 1,3 , M Lahuerta 3 , 

H Nuwagaba-Biribonwoha 3 , V Mugisha 3 , M Hawken 3 , E Chuva 4 , 

D Nash 1,2,5 , B Elul 3 , and LSTART Team and Identifying Optimal 

Models of HIV Care Collaboration 

1 HIV Ctr for Clinical and Behavioral Studies at New York State 

Psychiatric Inst and Columbia Univ, New York, US;; 2 Mailman Sch 

of Publ Hlth, Columbia Univ, New York, NY, US;; 3 Intl Ctr for AIDS 

Care and Treatment Prgms, Columbia Univ, Mailman Sch of Publ 

Hlth, New York, NY, US;; 4 Ministry of Hlth, Maputo, Mozambique;; 

and 5 CUNY Sch of Publ Hlth at Hunter Coll, New York, US 

11:15 95LB Home Assessment and Initiation of ART following 

HIV Self-Testing: A Cluster-Randomized Trial 

to Improve Linkage to ART in Blantyre, Malawi 

Peter MacPherson* 1,2 , D Lalloo1 , A Choko3 , J van Oosterhout2 , 

D Thindwa3 , E Webb4 , B Squire1 , S Makombe5 , R Hayes4 , and E Corbett3,4 1 2 Liverpool Sch of Tropical Med, UK;; Coll of Med, Univ of Malawi, 

Blantyre;; 3Malawi-Liverpool-Wellcome Trust Clin Res Prgm, 

Blantyre;; 4London Sch of Hygiene and Tropical Med, UK;; and 5HIV Dept, Ministry of Hlth, Lilongwe, Malawi 

11:30 96 Population HIV Viral Load Estimate in Swaziland: 

Assessing ART Program Effectiveness and 

Transmission Potential 

Jessica Justman* 1 , T Ellman2 , D Donnell3 , Y Duong4 , J Reed5 , 

G Bicego4 , P Ehrenkranz6 , L Wang3 , N Bock4 , and R Nkambule7 1Intl Ctr for AIDS Care and Treatment Prgms, Columbia Univ, 

Mailman Sch of Publ Hlth, New York, NY, US;; 2Columbia Univ Med 

Ctr, New York, NY, US;; 3Fred Hutchinson Cancer Res Ctr, Seattle, WA, 

US;; 4CDC, Atlanta, GA, US;; 5State Dept, Washington, DC, US;; 6CDC, Mbabane, Swaziland;; and 7Ministry of Hlth, Mbabane, Swaziland 

11:45 97 Molecular Characterization of the Source of New 

Infections in a High-risk Population in Uganda: 

Implications for Test and Treat as Prevention 

Chris Parry* 1 , J Levin1 , J Nazziwa1 , G Asiki1 , J Mpendo2 , H Njai1 , 

J Seeley1 , A Kamali1 , L Nieslen3 , and PK Kaleebu1 1 2 MRC/UVRI Research Unit on AIDS, Entebbe;; UVRI-IAVI HIV 

Vaccine Prgm, Entebbe;; and 3IAVI, Entebbe, Uganda 

k Tuesday, 10 am-12:15 pm; Hall B1 


ART: New Agents and New Insights 

Moderators: 

Roger Paredes, IrsiCaixa Inst for AIDS Res, Badalona, Catalonia, Spain 

Raymond Schinazi, Emory Univ and VAMC, Atlanta, GA, US 

10:00 98 Role of APOBEC3G in the Emergence of M184I 

in vivo 

W Shao 1 , E Wilson 2 , S Hill 2 , J Spindler 2 , R Dewar 1 , C Rehm 3 , 

M Sneller 3 , M Kearney 2 , J Coffin 4 , and Frank Maldarelli* 2 

1 SAIC-Frederick, NCI-Frederick, MD, US;; 2 NCI, Frederick Natl 

Lab for Cancer Res, MD, US;; 3 NIAID, NIH, Bethesda, MD, US;; 

and 4 Tufts Univ, Boston, MA, US 

10:15 99LB Comparative Study of Tenofovir Alafenamide 

vs Tenofovir Disoproxil Fumarate, Each with 

Elvitegravir, Cobicistat, and Emtricitabine, 

for HIV Treatment 

Andrew Zolopa* 1 , R Ortiz 2 , P Sax 3 , I Brar 4 , R Elion 5 , H Wang 6 , 

C Callebaut 6 , S Ramanathan 6 , M Fordyce 6 , and S McCallister 6 

1 Stanford Univ, Palo Alto, CA, US;; 2 Orlando Imm Ctr, FL, US;; 

3 Brigham and Women�s Hosp, Harvard Med Sch, Boston MA, US;; 

4 Henry Ford Hosp, Detroit, MI, US;; 5 George Washington Univ 

Hosp, Washington, DC, US;; and 6 Gilead Sci, Foster City, CA, US 

10:30 100 Safety and Antiviral Activity of MK-1439, a 

Novel NNRTI, in Treatment-naïve HIV + Patients 

Matt Anderson* 1 , J Gilmartin 1 , M Robberechts 1 , I De Lepeleire 1 , 

E Tetteh 1 , Y Guo 1 , D Schurman 2 , F Wagner 3 , J Wagner 1 , 

and J Butterton 1 

1 Merck Sharp & Dohme, Corp, Whitehouse Station, NJ, US;; 2 Charite 

Universitatsmedizin, Berlin, Germany;; and 3 Charite Res Org, 

Berlin, Germany 

10:45 101 Mechanism by which K103N in HIV-1 Reverse 

Transcriptase Confers Efavirenz Resistance 

Revealed by Single-molecule Fluorescence 

Spectroscopy 

Grant Schauer*, N Sluis-Cremer, and S Leuba 

Univ of Pittsburgh Sch of Med, PA, US 

Program � 11 

Tuesday 


Tuesday 



11:00 102 The E138A Mutation in HIV-1 Reverse 

Transcriptase Is More Common in Subtype C 

than B and Decreases Susceptibility to NNRTI 

Nicolas Sluis-Cremer* 1 , K Huber 1 , C Brumme 2 , C Wallis 3 , 

J Mellors 1 , and R Harrigan 2 

1 Univ of Pittsburgh Sch of Med, PA, US;; 2 BC Ctr for Excellence in 

HIV/AIDS, Vancouver, Canada;; and 3 Lancet, Johannesburg, South 

Africa 

11:15 103 Non-Catalytic Site Integrase Inhibitors Target 

the Integrase Domain during Virus Production 

and Induce a Reverse Transcription Block 

Stephen Yant*, L Tsai, C O’Sullivan, T Cihlar, and M Balakrishnan 

Gilead Sci, Foster City, CA, US 

11:30 104 Viral Particles Produced in Presence of LEDGIN 

Are Impaired for Infectivity 

B Desimmie 1 , Frauke Christ* 1 , W Thys 1 , J Demeulemeester 1 , 

D Borrenberghs 1 , R Schrijvers 1 , J Hofkens 1 , N Bannert 2 , and Z Debyser 1 

1 Katholieke Univ Leuven, Belgium and 2 Robert Koch Inst, Berlin, 

Germany 

11:45 105 Potent Antiviral Activity of 2nd Generation 

Maturation Inhibitors Against Bevirimat-resistant 

Polymorphic HIV-1 Isolates 

E Urano 1 , S Ablan 1 , D Martin 2 , T Nitz 2 , E Freed 1 , and Carl Wild* 2 

1 NCI-Frederick, MD, US and 2 DFH Pharma, Inc, Gaithersburg, MD, US 

12:00 106LB Week-24 Primary Analysis of Cenicriviroc 

vs Efavirenz, in Combination with 

Emtricitabine/Tenofovir, in Treatment-naïve 

HIV-1 + Adults with CCR5-tropic Virus 

Joseph Gathe* 1 , J Cade 2 , E DeJesus 3 , J Feinberg 4 , J Lalezari 5 , 

J Morales-Ramirez 6 , A Scarsella 7 , M Saag 8 , M Thompson 9 , 

and E Lefebvre 10 

1 Therapeutic Concepts, Houston, TX, US;; 2 Nevada AIDS Res Ed 

Society, Las Vegas, US;; 3 Orlando Immunology Ctr, FL, US;; 4 Univ 

of Cincinnati, OH, US;; 5 Quest Clin Res, San Francisco, CA, US;; 

6 Clin Res PR, Inc, San Juan, Puerto Rico;; 7 Pacific Oaks Med Group, 

Beverly Hills, CA, US;; 8 Univ of Alabama at Birmingham, US;; 9 AIDS 

Res Consortium of Atlanta, GA, US;; and 10 Tobira Therapeutics, Inc, 

San Francisco, CA, US 

b Tuesday, 1:30-2:30 pm; B402 


(see Session 95 on Monday for corresponding Poster Abstracts) 

Mining Sequence Data to Understand 

Transmission and Disease 

Discussants: 

Chanson Brumme, BC Ctr for Excellence in HIV/AIDS, Vancouver, 

Canada 

Jacques Fellay, Fed Inst of Tech, Lausanne, Switzerland 

488 The Global Transmission Network of HIV-1 

Joel Wertheim* 1 , A Leigh Brown 2 , L Hepler 1 , S Mehta 1 , D Richman 1,3 , 

D Smith 1,3 , and S Kosakovsky Pond 1 

1 Univ of California, San Diego, US;; 2 Univ of Edinburgh, UK;; and 3 VA San 

Diego Hlthcare System, CA, US 

489 Frequent HIV Introductions into Communities 

Sustain Local Epidemics in Rural Rakai, Uganda 

Mary Grabowski* 1 , J Lessler 1 , A Redd 2 , O Laeyendecker 2,3 , 

J Kagaayi 4 , T Lutalo 4 , M Wawer 1,4 , D Serwadda 4,5 , T Quinn 2,3 , R Gray 1,4 , 

and Rakai Hlth Sci Prgm 

1 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 

2 Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US;; 3 Johns 

Hopkins Univ Sch of Med, Baltimore, MD, US;; 4 Rakai Hlth Sci Prgm, 

Entebbe, Uganda;; and 5 Makerere Univ Sch of Med, Kampala, Uganda 

490 Dynamics of Non-B HIV Transmission in the UK 

Manon Ragonnet-Cronin* 1 , S Lycett 1 , E Hodcroft 1 , S Hue 2 , 

E Fearnhill 3 , D Dunn 3 , V Delpech 4 , A Leigh Brown 1 , and UK Collaborative 

Group on HIV Drug Resistance 

1 Univ of Edinburgh, UK;; 2 Univ Coll London, UK;; 3 MRC Clin Trials Unit, 

London, UK;; and 4 Hlth Protection Agency, London, UK 

491 Defining HLA Genotypes from Bulk HIV Sequences 

A Kreimer 1 , M Shaefer 2 , N Pfeifer 1 , V Tan 1 , P Goulder 3 , M John 4 , 

Z Brumme 5 , E Hunter 2 , D Heckerman 1 , Jonathan Carlson* 1 , 

and Intl and Southern Africa HIV Assn Collaboratives 

1 Microsoft Res, Los Angeles, CA, US;; 2 Emory Univ, Atlanta, GA, US;; 

3 Univ of Oxford, UK;; 4 Murdoch Univ, Australia;; and 5 Simon Fraser Univ, 

Burnaby, Canada 

492 Whole Genome Sequencing of HIV + African 

Americans with Rapid Disease Progression or Longterm 

Non-progression 

Amy Weintrob* 1,2 , K Pelak 3 , R Thomas 2 , P Ehrenberg 2 , P Shea 3 , 

J Okulicz 1 , A Ganesan 1 , B Agan 1 , N Michael 2 , and D Goldstein 3 

1 Uniformed Svcs Univ Infectious Disease Clin Res Prgm, Bethesda, MD, 

US;; 2 Military HIV Res Prgm, Bethesda, MD, US;; and 3 Duke Univ Ctr for 

Human Genome Variation, Durham, NC, US 


493 Exome Sequencing of Elite and Rapid HIV 

Progressors: Results from the Exploratory Pilot 

of the UK HIV Genomics Consortium 

Deepti Gurdasani* 1,2 , C Scott 1 , E Young 1,2 , K Porter 3 , P Kellam 1,4 , 

M Sandhu 1,2 , and UK HIV Genomics Consortium 

1 Wellcome Trust Sanger Inst, Cambridge, UK;; 2 Univ of Cambridge, UK;; 

3 MRC Clin Trials Unit, London, UK;; and 4 Univ Coll London, UK 

b Tuesday, 1:30-2:30 pm; B406 



Restriction Factors: Old and New 

Discussants: 

Nathaniel Landau, New York Univ Sch of Med, NY, US 

Stuart Neil, King’s Coll London Sch of Med, Guy’s Hosp, UK 

222 Evolutionarily Conserved Requirement of CBF-� for 

the Assembly of HIV/SIV Vif Cul5 Cullin-Ring Ligase 

Sean Evans* 1 , X Han 1,2 , X Zhou 1,2 , J Du 2 , W Zhang 2 , G Wang 2 , 

and X-F Yu 1,2 

1 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US and 

2 First Hosp of Jilin Univ, China 

223 Sooty Mangabey SIV, the Ancestor of HIV-2, 

Efficiently Counteracts Human APOBEC3G 

Michael Letko* 1 , M Ooms1 , G Silvestri2 , and V Simon1 1 2 Mt Sinai Sch of Med, New York, NY, US and Emory Univ Sch of Med, 


224 Exploring the Relationship between P-body 

Localization and Virion Incorporation of Human 

Antiviral Proteins APOBEC3G and Mov10 

Taisuke Izumi*, R Burdick, W-S Hu, and V Pathak 

HIV Drug Resistance Prgm, Natl Lab for Cancer Res, NCI-Frederick, MD, 

US 

225 HIV-1 Vpr Targets Restriction Factor CTIP2 

to Proteasomal Degradation 

Sultan Ali* 1 , C Schwartz1,2 , and O Rohr1,2 1 2 Univ of Strasbourg, France and IUT of Schiltigheim, Strasbourg, France 

226 Small Molecule Compounds Inhibit Vpu-mediated 

Down-regulation BST-2 

Zeyun Mi*, Q Zhang, J Zhou, J Ding, L Yu, and S Cen 

Inst of Med Biotech, Chinese Academy of Med Sci, Beijing 

227 Novel Regulation of SIV Vpx-mediated SAMHD1 

Degradation 

Wei Wei* 1 , H Guo 1 , X Han 1 , X Liu 1 , S Evans 2 , X Zhou 2 , W Zhang 1 , and X-F Yu 2 

1 First Hosp of Jilin Univ, Inst of Virology and AIDS Res, China and 2 Johns 

Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US 

b Tuesday, 1:30-2:30 pm; B308 



MSM in the Developing World 

Discussants: 

Chris Beyrer, John Hopkins Univ Bloomberg Sch of Publ Hlth, 

Baltimore, MD, US 

Harold Jaffe, CDC, Atlanta, GA, US 

1021 HIV Prevalence and Associated Risk Factors among 

MSM: A Respondent-driven Sampling Survey, 

Abidjan, Cote d’Ivoire 

Avi Hakim* 1 , J Aho 2 , G Semde 3 , M Diarrassouba 4 , K Ehoussou 4 , 

B Vuylsteke 2 , C Murrill 1 , M Thiam 5 , T Wingate 4 , and SHARM Study Group 

1 CDC, Atlanta, GA, US;; 2 Inst of Tropical Med, Antwerp, Belgium;; 3 Family 

Hlth Intl 360, Abidjan, Cote d’Ivoire;; 4 CDC, Abidjan, Cote d’Ivoire;; and 

5 Ministry of Hlth and Publ Hygiene, Abidjan, Cote d’Ivoire 

1022 HIV Prevalence and Correlates of Infection among 

MSM: 4 Areas in Ghana, the Ghana Men’s Health 

Study, 2010-2011 

John Aberle-Grasse* 1 , W McFarland 2,3 , A El-Adas 4 , S Quaye 1 , 

K Atuahene 4 , W Ampofo 5 , R Adanu 6 , S Chaturvedi 2 , R Fisher 2 , 

and E Harrison 5 

1 CDC, Atlanta, GA, US;; 2 Univ of California, San Francisco, US;; 3 San 

Francisco Dept of Publ Hlth, CA, US;; 4 Ghana AIDS Commission, Accra;; 

5 Univ of Ghana, Noguchi Memorial Inst for Med Res, Legon;; and 6 Univ of 

Ghana, Sch of Publ Hlth, Legon


1023 Risk Factors for Unprotected Anal Sex and HIV 

Infection among Male Sex Workers: Vietnam 

Donn Colby* 1,2,3 , N Trang 4 , T Mai 2 , T Nguyen 2 , HT Lan 4 , DD Thien 4 , 

NA Ngoc 5 , K Mayer 1,3,6 , and M Mimiaga 3,6,7,8 

1 Beth Israel Deaconess Med Ctr, Boston, MA, US;; 2 Harvard Med Sch AIDS 

Initiative in Vietnam, Ho Chi Minh City;; 3 Harvard Med Sch, Boston, MA, 

US;; 4 Life Ctr, Ho Chi Minh City, Vietnam;; 5 Ctr for Applied Res on Men and 

Hlth, Ho Chi Minh City, Vietnam;; 6 The Fenway Inst, Fenway Hlth, Boston, 

MA, US;; 7 Massachusetts Gen Hosp, Boston, US;; and 8 Harvard Sch of Publ 

Hlth, Boston, MA, US 

1024 Longitudinal Analysis of HIV-risk Behavior Patterns 

and Their Predictors in MSM: Bangkok, Thailand, 

2006-2008 

P Girault 1 , W Wimonsate 2 , Timothy Holtz* 2,3 , A Varangrat 2 , 

S Chaikummao 2 , W Thienkrua 2 , T Chemnasri 2 , W Sukwicha 2 , R Thiebaut 4 , 

and F van Griensven 2,3,5 

1 FHI 360 AsiaPacific Regional Office, Bangkok, Thailand;; 2 Thailand 

Ministry of Publ HlthCDC Collaboration, Nonthaburi;; 3 CDC, Atlanta, GA, 

US;; 4 INSERM U897 and Inst de Sante Publ, dEpidemiologie et de Devt, 

Univ Bordeaux Segalen, France;; and 5 AVRAM Corp, Miami, FL, US 

1025 Herpes Simplex 2 Virus Type 2 Incidence and 

Risk Factors among MSM: Bangkok, Thailand 

Warunee Thienkrua* 1 , W Chonwattana 1 , P Mock 1 , S Chaikummao 1 , 

W Wimonsate 1 , J Tongtoyai 1 , C Todd 1,2,3 , A Chitwarakorn 4 , M Curlin 1,5 , 


1 Thailand Ministry of Publ Hlth-CDC Collaboration, Nonthaburi;; 2 FHI360 

Asia Pacific Regional Office, Bangkok, Thailand;; 3 AVRAM Corp, Miami, FL, 

US;; 4 Thailand Ministry of Publ Hlth, Nonthaburi;; and 5 CDC, Atlanta, GA, US 

b Tuesday, 1:30-2:30 pm; B313 



Family Planning: Unintended Pregnancy and Unmet 

Need 

Discussants: 

Gina Brown, Office of AIDS Res, NIH, Bethesda, MD, US 

Sharon Hiller, Univ of Pittsburgh, Magee-Womens Res Inst, PA, US 

895 Periconception HIV Risk Behavior among Men 

and Women Reporting Serodiscordant Partners: 

KwaZulu-Natal, South Africa 

Lynn Matthews* 1 , D Bangsberg 1 , C Milford 2 , N Mosery 2 , R Greener 2 , 

A Kaida 3 , C Psaros 1 , S Safren 1 , and J Smit 2 

1 Massachusetts Gen Hosp, Boston, US;; 2 MatCH, Durban, South Africa;; 

and 3 Simon Fraser Univ, Vancouver, Canada 

896 Predictors of Unplanned Pregnancies among 

Women Living with HIV: US 

Lisa Rahangdale* 1 , S Cohn 2 , R Stewart 3 , J Levison 4 , G Lazenby 5 , 

M Badell 6 , M Nguyen 6 , M Kempf 7 , M Sturdevant 7 , P Ellis 8 , and HIV 

and OB Pregnancy Ed Study 

1 Univ of North Carolina at Chapel Hill, US;; 2 Northwestern Univ Feinberg 

Sch of Med, Chicago, IL, US;; 3 Univ of Texas Southwestern Med Ctr, Dallas, 

US;; 4 Baylor Coll of Med, Houston, TX, US;; 5 Med Univ of South Carolina, 

US;; 6 Emory Univ, Atlanta, GA, US;; 7 Univ of Alabama at Birmingham, US;; 

and 8 Louisiana State Univ, Baton Rouge, US 

897 Trends in Contraceptive Use and Choice of 

Contraceptive Method in a Rural South African 

Population-based Cohort during the ART Era, 

2005-2011 

Nuala McGrath* 1,2 , J Eaton 3 , and M-L Newell 2,4 

1 London Sch of Hygiene and Tropical Med, UK;; 2 Africa Ctr for Hlth and 

Population Studies, KwaZulu-Natal, South Africa;; 3 Imperial Coll London, 

UK;; and 4 Inst of Child Hlth, Univ Coll London, UK 

898 Unmet Need for Family Planning, Contraceptive 

Failure, and Unintended Pregnancy among Women 

Living with HIV Infection: Zimbabwe 

Sandra McCoy* 1 , R Buzdugan 1 , L Ralph 1 , A Mushavi 2 , A Mahomva 3 , 

C Watadzaushe 4 , J Dirawo 4 , C Frances 4,5 , and N Padian 1 

1 Univ of California, Berkeley, US;; 2 Ministry of Hlth and Child Welfare, 

Harare, Zimbabwe;; 3 Elizabeth Glaser Pediatric AIDS Fndn, Harare, 

Zimbabwe;; 4 Ctr for Sexual Hlth and HIV Res, Harare, Zimbabwe;; and 

5 Univ Coll London, UK 

b Tuesday, 1:30-2:30 pm; Ballroom 3-4 



The Cascade of Care 

Discussants: 

Andrea Howard, Columbia Univ Mailman Sch of Publ Hlth, New York, 

NY, US 

Ian Williams, Univ Coll London, UK 

1026 Application of Indicators to Monitor US Department 

of Health and Human Services-funded HIV Services 

in the North American AIDS Cohort Collaboration 

on Research and Design 

Keri Althoff* 1 , P Rebeiro 1 , M Horberg 2 , K Buchacz 3 , K Gebo 1 , T Sterling 4 , 

M Kitahata 5 , A Justice 6 , J Brooks 3 , R Moore 1 , for North American AIDS 

Cohort Collaboration on Res and Design 

1 Johns Hopkins Univ, Baltimore, MD, US;; 2 Kaiser Permanente Mid- 

Atlantic States, Rockville, MD, US;; 3 CDC, Atlanta, GA, US;; 4 Vanderbilt 

Univ, Nashville, TN, US;; 5 Univ of Washington, Seattle, US;; and 6 Yale Univ 

and the VA Connecticut Hlthcare System, New Haven, US 

1027 An Encouraging HIV Care Cascade: Anomaly, 

Progress, or Just More Accurate Data? 

Julia Dombrowski* 1,2 , J Kent 2 , S Buskin 1,2 , J Stekler 1,2 , E Barash 2 , 

A Bennett 2 , and M Golden 1,2 

1 Univ of Washington, Seattle, US and 2 Publ Hlth-Seattle & King County, WA, US 

1028 Health Insurance Coverage and Type Predict 

Durable Viral Suppression among HIV + Adults 

in Care: US, Medical Monitoring Project, 2009 

Kelly Quinn* and J Skarbinski 


1029 The Evolution of the Cascade of HIV Care: British 

Columbia, Canada, 1996-2010 

Julio Montaner* 1 , B Nosyk 1 , G Colley 1 , H Samji 1 , R Hogg 1 , R Gustafson 2 , 

and M Gilbert 3 

1 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada;; 2 Vancouver 

Coastal Hlth, Canada;; and 3 BC Ctr for Disease Control, Canada 

1030 The Spectrum of Engagement in HIV Care in France: 

Strengths and Gaps 

V Supervie 1 and Dominique Costagliola* 1,2 

1 INSERM U943, UMR S943, UPMC Univ Paris 06, Paris, France and 

2 APHP, Hosp Pitie Salpetriere, Paris, France 


Tuesday 


Tuesday 



b Tuesday, 1:30-2:30 pm; Ballroom 1-2 



Cardiovascular Disease: Predicting Risk and 

Monitoring Outcomes 

Discussants: 

John Brooks, CDC, Atlanta, GA, US 

Monica Shah, Natl Heart, Lung, and Blood Inst, NIH, Bethesda, MD,US 

747 Projecting 10-year, 20-year, and Lifetime Risks of 

Cardiovascular Disease in HIV + Individuals in the 

US: Competing Risks and Premature Aging 

Elena Losina* 1,2,3,4 , B Linas4,5 , E Hyle1,3 , C Rusu4 , F Noubary4 , 

B Berkowitz4 , P Sax1,2 , M Weinstein6 , R Walensky1,2,3,4 , and K Freedberg1,3,4,5 1 2 Ctr for AIDS Res, Harvard Med Sch, Boston, MA, US;; Brigham and 

Women�s Hosp, Boston, MA, US;; 3Massachusetts Gen Hosp, Boston, US;; 

4 5 Boston Med Ctr, MA, US;; Boston Univ Sch of Publ Hlth, MA, US;; and 

6Harvard Sch of Publ Hlth, Boston, MA, US 

748 Improvements in Short-term Mortality following 

Myocardial Infarction: The Data Collection on 

Adverse events of Anti-HIV Drugs Study 

Caroline Sabin* 1 , L Ryom2 , M Law3 , W El-Sadr4 , O Kirk2,5 , M Bruyand6 , 

P Reiss7 , C Pradier8 , B Ledergerber9 , J Lundgren2,5 , and D:A:D Study 

1 2 3 Univ Coll London, UK;; Copenhagen HIV Prgm, Denmark;; The Kirby 

Inst, Univ of New South Wales, Sydney, Australia;; 4Intl Ctr for AIDS Care 

and Treatment Prgms, Columbia Univ and Harlem Hosp, New York, NY, 

US;; 5Copenhagen Univ Hosp/Rigshospitalet, Denmark;; 6Univ of Bordeaux, 

ISPED, Ctr INSERM U897-Epidemiologie-Biostatistique, France;; 

7 8 Academic Med Ctr, Univ of Amsterdam, The Netherlands;; Ctr Hosp Univ, 

Nice, France;; and 9Univ Hosp Zurich, Switzerland 

749 ST2 and NT-proBNP Are Associated with Cardiac 

Dysfunction and Mortality in HIV + Individuals 

Eric Secemsky* 1 , R Scherzer2 , E Nitta2 , A Wu2 , D Lange2 , S Deeks2 , 

J Martin2 , J Snider3 , P Ganz2 , and P Hsue2 1 2 Massachusetts Gen Hosp, Boston, US;; Univ of California, San Francisco, 

US;; and 3Critical Diagnostics, San Diego, CA, US 

750 The Risk of and Survival with Preserved vs Reduced 

Ejection Fraction Heart Failure by HIV Status 

Matthew Freiberg* 1 , C-C Chang1 , KA Oursler2,3 , J Gottdiener4 , 

S Gottlieb4 , A Warner5 , D Leaf5 , M Rodriguez-Barradas6,7 , S Felter8 , 

A Butt1,9 , and VACS Project Team 

1 2 3 Univ of Pittsburgh Sch of Med, PA, US;; Baltimore VAMC, MD, US;; Univ 

of Maryland Sch of Med, Baltimore, US;; 4Univ of Maryland Med Ctr, 

Baltimore, US;; 5VA Greater Los Angeles Hlthcare System, CA, US;; 6Baylor Coll of Med, Houston, TX, US;; 7Michael E DeBakey VAMC, Houston, TX, 

US;; 8VA Pittsburgh Hlthcare System, PA, US;; and 9Sheikh Khalifa Med 

City, Abu Dhabi, United Arab Emirates 

751 Emergency Medical Service Utilization and 

Reperfusion Times among HIV + Individuals 

Presenting with ST-elevation Myocardial Infarction 

Mark Dela Cruz* 1 , K Thomas1 , D Brenner1 , A Kulkarni2 , J McCabe3 , 

P Hsue1 , P Ganz1 , and S Waldo1 1 2 Univ of California, San Francisco, US;; Massachusetts Gen Hosp, Boston, 

US;; and 3Brigham and Women�s Hosp, Boston, MA, US 


C Tuesday, 2:30-4 pm; Hall B2 



Session 56. Transcription/Reverse and Forward, Splicing/Replication 

Session 60. Restriction Factors: APOBEC and Others 

Session 62. Shutting the Door on HIV Entry 

Session 63. Transmitted/Founder Viruses 

Session 66. Markers of HIV Disease Progression 

Session 69. CD8 T Cells in HIV Infection 

Session 70. Killer T Cells 

Session 78. Viral DNA Dynamics 

Session 79. Infected Cell Dynamics on Therapy 

Session 80. What Is Latency and What Can We Do about It? 

Session 82. Novel Vaccine Strategies 

Session 88. Neuropathogenesis Mechanisms 

Session 89. Central Nervous System Inflammation and Biomarkers 

of HIV-associated Neurocognitive Disorders 

Session 90. Aging and Neurocognitive Function in HIV Infection 

Session 94. Simian Viral Reservoirs 

Session 97. HIV Subtypes: Epidemiology and Disease Progression 

Session 99. New Approaches to ARV Drug Delivery 

Session 102. ARV Pharmacokinetics: New Assays, Drugs, and 

Special Populations 

Session 110. Tropism Testing/Maraviroc Resistance 

Session 111. HIV Drug Resistance: Trends and Emergence 

Session 112. Detecting and Interpreting HIV Drug Resistance 

Session 113. Innovation in Measuring Viral Nucleic Acids 

Session 114. Transmitted Drug Resistance 

Session 115. Drug Resistance Mutational Pathways and Subtype 

Associations 

Session 116. Advances in Sequencing and Analysis 

Session 117. Detecting HIV Infection 

Session 122. Hepatitis C Virus Treatment Today and Tomorrow 

Session 123. Hepatitis C Virus Resistance and Virology 

Session 124. Innate Immunity and Hepatitis C Virus 

Session 126. Hepatic Failure and Transplantation 

Session 127. Emergence and Persistence of HPV-associated 

Malignancies in the ART Era 

Session 133. Statin Use and HIV: How Sweet Is It? 

Session 134. Dyslipidemia: Risks, Pathogenesis, and Treatment 

Session 135. Risk Prediction, Risk Factors, Biomarkers, and 

Outcomes 

Session 137. Inflammatory Biomarkers, Microparticles, and Clinical 

Outcomes in HIV 

Session 138. ART Effects: Monocyte and T Cell Activation 

Session 147. TB Screening Strategies: Diagnostics New and Old and 

Latent TB Treatment 

Session 149. Mechanisms of Immune Reconstitution 

Session 157. Hepatitis C Virus Testing in Women 

Session 163. ARV Strategies, MTCT, and HIV-free Survival 

Session 164. PMTCT Implementation: Barriers and Program 

Innovations 

Session 167. Breast Feeding and Prevention of Postnatal MTCT 

Session 168. ARV Pharmacokinetics during Pregnancy and Breast 

Feeding 

Session 169. ARV Regimens and Safety during Pregnancy 

Session 175. HIV Drug Resistance in Children and Youth 

Session 176. Co-infections among HIV-infected and -exposed Children 

Session 184. Non-human Primate Models of STI, PrEP, and Vaccines 

Session 186. Implementation and Cost-effectiveness of Male 

Circumcision 

Session 188. The Ongoing Epidemic in MSM 

Session 193. Estimating Incidence 

Session 194. New Testing Strategies 

Session 198. Adherence and Retention in RLS


e Tuesday, 4-6 pm; B406 


HIV Host–Cell Interactions 

Conveners: 

Chioma Okeoma, Univ of Iowa, Iowa 

City, US 

Paul Spearman, Emory Univ, Atlanta, 

GA, US 

107 

Interferon-inducible Siglec, CD169, Is the 

Mature Dendritic Cell Receptor Essential for 

HIV-1 Trans-infection 

W Blay Puryear 1 , H Akiyama 1 , S Geer 1 , N Ramirez 1 , X Yu 2 , 

B Reinhard 2 , and Rahm Gummuluru* 1 

1 Boston Univ Sch of Med, MA, US and 2 Boston Univ, MA, US 

108 

TRIM5� Restriction, HIV-1 Uncoating, 

and Relationship to Reverse Transcription 

Felipe Diaz-Griffero 

Albert Einstein Coll of Med, Bronx, NY, US 

109 

SAMHD1 Restricts HIV-1 Infection in Resting 

CD4 + T Cells 

Oliver Keppler 

Inst of Med Virology, Natl Reference Ctr for Retroviruses, 

Univ of Frankfurt, Germany 

110 

The Antiviral Activities of Tetherin 

RP Galao, S Pickering, A Le Tortorec, T Kueck, 

and Stuart Neil* 

Kings Coll London Sch of Med, Guys Hosp, UK 


interested in understanding the host cell factors that promote and 

restrict HIV-1 replication. It is assumed that participants are familiar 

with cell biology, the retroviral lifecycle, and the proteins encoded 

in the HIV genome. At the completion of the session, participants 

will be knowledgeable about how dendritic cells facilitate HIV 

infection through their expression of specific cell-surface proteins, 

how host restriction proteins interfere with specific steps during 

virus replication, and mechanisms by which the virus has evolved to 

escape from these restrictions. 

e Tuesday, 4-6 pm; Ballroom 3-4 


Reproductive Hormones and HIV 

Conveners: 

Ward Cates, FHI360, Research Triangle 

Park, NC, US 

Nelly Mugo, Univ of Washington, 

Nairobi, Kenya 

111 

Effects of Hormonal Contraceptives that May 

Affect Susceptibility to HIV Acquisition in 

Women 

Christine Mauck 

CONRAD, Arlington, VA, US 

112 

Assessing the Impact of Hormonal 

Contraceptives on HIV Risk and 

Prevention in Animal Models 

Gerardo Garcia-Lerma 


113 

What Have the Epidemiological Studies 

Taught Us about Hormonal Contraceptives 

and HIV-related Risks? 

Chelsea Polis *1 and R Heffron 2 

1 USAID, Office of Population and Reproductive Hlth, 

Washington, DC and 2 Univ of Washington, Seattle, US 

114 

Programmatic Implications: Balancing 

Maternal Mortality and HIV Risk 

Jennifer Smith* 1 , A Butler 1 , C Polis 2 , S Gregson 1 , D Stanton 2 , 

and T Hallett 1 

1 Imperial Coll London, UK and 2 US Agency for Intl Devt, 

Washington, DC 

5:30-6 pm 



interested in womens health, family planning, and HIV prevention. 

This session will be of interest to scientists conducting clinical 

studies of HIV prevention and epidemiologists evaluating risk 

factors for HIV acquisition and transmission. It is assumed 

that participants are familiar with reproductive biology and 

the data linking HIV risk with contraceptive hormones. At the 

completion of the session, participants will be knowledgeable 

about the epidemiologic and biologic data supporting the impact 

of reproductive and contraceptive hormones on HIV risk. In 

addition, participants will appreciate the public health impact of 

effective contraceptives and will learn how modeling studies have 

demonstrated that modest increases in HIV risk among women 

on hormonal contraceptives are offset by decreases in maternal 

mortality associated with unwanted pregnancy. 


Tuesday 


Tuesday 



e Tuesday, 4-6 pm; Ballroom 1-2 


When Worlds Collide —Adolescents and HIV, 

a symposium in memory of Edward Handelsman 

Conveners: 

Sabrina Bakeera-Kitaka, Makerere Univ, 

Kampala, Uganda 

Bill Kapogiannis, Natl Inst of Child Hlth 

and Human Devt, NIH, Bethesda, MD, US 

115 

Ethical Issues in Adolescent HIV Prevention 

Research 

Sean Philpott 

Ctr for Bioethics and Clinical Leadership, Union Grad Coll, 

Schenectady, NY, US 

116 

What’s Fueling the HIV Epidemic in Gay/ 

Bisexual Male Adolescents and other Young 

MSM? 

Gary Harper 

Univ of Michigan Sch of Publ Hlth, Ann Arbor, US 

117 

Preventing New HIV Infections among Young 

African Women—Why Is It so Difficult? 

Sinead Delany-Moretlwe 

Univ of the Witwatersrand, Johannesburg, South Africa 

118 

Behavioral Challenges in Perinatally Infected 

Youth 

Claude Ann Mellins 

New York State Psychiatric Inst and Columbia Univ, New York, US 

Objectives: This session is designed for clinicians and 

scientists interested in challenging issues pertaining 

to adolescents and young adults living with HIV. It is assumed 

that participants are familiar with basic epidemiology of HIV in 

adolescents in high- and low-resource countries, and behavioral 

and sociologic issues observed in youth with adult risk behaviors 

and perinatally acquired HIV. At the completion of the session, 

participants will be knowledgeable about ethical considerations 

surrounding youth participation in vaccine and pre- and postexposure 

prophylaxis trials, foundations and accelerators of the 

epidemic in young MSM, impediments and successes in prevention 

strategies in young women in Africa, and mental health outcomes in 

youth who acquired HIV in infancy. 


e Tuesday, 4-6 pm; Hall B1 


Opportunities and Threats to ART Success 

Conveners: 

Melanie Thompson, AIDS Res 

Consortium, Atlanta, GA, US 

Francois Venter, Wits Reproductive Hlth 

and HIV Res Inst, Johannesburg, South 

Africa 

119 

Political and Economic Threats to Sustainable 

ARV Treatment 

Jennifer Kates 

Kaiser Family Fndn, Washington, DC, US 

120 

ART and Inflammation: Implications for the 

Approach to Care in 2013 

Sharon Lewin 

Alfred Hosp, Monash Univ and Burnet Inst, Melbourne, 

Australia 

121 

ARV Drug Resistance: Global Challenges 

Raph Hamers 

Academic Med Ctr of the Univ of Amsterdam;; Amsterdam Inst 

for Global Hlth and Devt;; PharmAccess Fndn, Amsterdam, 

The Netherlands 

122 

New HIV Drugs and Formulations: Effect on 

Therapeutic Paradigms 

Roy Gulick 

Weill Cornell Med Coll, New York, NY, US 

Objectives: This session is directed to clinicians 

and scientists interested in ART including threats 

to current progress, relationship to the chronic inflammatory state, 

and the promise of new agents and formulations. It is assumed that 

participants are familiar with the essentials of HIV pathogenesis and 

ARV therapeutics. At the completion of the session, participants 

will recognize the political and economic threats to sustaining the 

progress made in the era of potent ART, understand the role that 

artGG might play in the chronic immune activation state seen in 

HIV + persons with controlled viremia, appreciate the current stateof-the-art 

of ARV drug resistance, and gain knowledge of new ARV 

drugs and formulations and the implications for changing paradigms 

of therapy.


i Wednesday, 8:30-9 am; Hall B1 


Incorporating New Drugs into Regimens 

that Will Change the TB Treatment Paradigm: 

The Magic Mountain Meets Table Mountain 

123 

Andreas Diacon 

Stellenbosch Univ, Tygerberg, Cape Town, South Africa 


interested in TB and anti-TB drugs. It is assumed that participants 

are familiar with the basics of clinical TB and current principles of 

TB treatment. At the completion of the session, participants will be 

informed about novel anti-TB drugs and regimens, the methods used 

to explore them, and how they might best be deployed to transform 

treatment of drug-susceptible and drug-resistant TB. 

j Wednesday, 9-9:30 am; Hall B1 


Treatment with Gene-modified Hematopoietic 

Stem Cells May Definitively Abolish HIV-1 Infection 

124 

Marina Cavazzana-Calvo 

U768 INSERM;; AP-HP, Hosp Univ Necker-Enfants Malades;; 

Univ Paris Descartes, Sorbonne Paris Cite, IMAGINE Inst;; CIC 

Biotherapie GHU Ouest, INSERM-APHP, Paris, France 


interested in new genetic approaches for HIV-1 infections able to 

eliminate the need for indefinite treatment of infected patients. It 

is assumed participants are familiar with the human hematopoietic 

stem cell system as well as with the biological tools able to introduce 

de novo gene functions into these cells or alternatively to disrupt 

cellular genes to confer to the hematopoietic compartment a stable 

resistance to HIV. At the completion of the session, participants will 

be knowledgeable about the first clinical results obtained in this fastmoving 

field. 

k Wednesday, 10-11:45 am; B402 


New Discoveries in Vaccines and Gene Therapy 

Moderators: 

Richard Koup, Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US 

Alexandra Trkola, Univ of Zurich, Switzerland 

10:00 125 Dendritic Cells Transduced with Vpx-packaged 

LV Vector Encoding CD40L Enhance Cytotoxic 

T Cell Responses and Disrupt HIV-1 Latency 

Thomas Norton*, E Miller, N Bhardwaj, and N Landau 

New York Univ Sch of Med, NY, US 

10:15 126 Central Memory T Cell Is the Critical 

Component for Sustained CD4 Reconstitution 

in HIV Subjects Receiving ZFN CCR5 Modified 

CD4 T Cells (SB-728-T) 

J Zeidan1 , G Lee2 , J Lalezari3 , R Mitsuyasu4 , S Wang2 , M Giedlin2 , 

G Nichol2 , W Tang2 , �� 

* 1 , and D Ando2 1Vector and Gene Therapy Inst of Florida, Port St Lucie, US;; 

2 3 Sangamo BioSci, Richmond, CA, US;; Quest Clin Res, San 

Francisco, CA, US;; and 4Univ of California, Los Angeles, US 

10:30 127 Protection of Stem Cells Results in Enhanced 

Virus-specific Immunity with Recovery of 

Unprotected CD4 + T Cells in a Primate AIDS 

Model 

Patrick Younan* 1 , P Polacino 2,3 , J Kowalski 1 , C Peterson 1 , 

N Maurice 1 , N Williams 1 , G Trobridge 1 , D Von Laer 4 , S-L Hu 2,3 , 

and H-P Kiem 1,2 

1 Fred Hutchinson Cancer Res Ctr, Seattle, WA, US;; 2 Univ of 

Washington, Seattle, US;; 3 Washington Natl Primate Res Ctr, Seattle, 

US;; and 4 Innsbruck Med Univ, Austria 

10:45 128 Levels of CD4 + CCR5 + Target T Cells in Rectal 

Mucosa Predict Risk of SIV Acquisition and 

Replication in Rhesus Macaques Vaccinated 

with SIV Gag/Tat Vectors 

Diane Carnathan* 1 , K Sheehan 2 , J Yu 1 , D Weiner 2 , H Ertl 3 , 

and G Silvestri 1 

1 Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US;; 

2 Univ of Pennsylvania, Philadelphia, US;; and 3 The Wistar Inst, 

Philadelphia, PA, US 

11:00 129 T Cells Edited to Express CCR5 or CXCR4 

Fused to the C34 Peptide from gp41 Heptad 

Repeat-2 Exhibit Robust Protection from 

Diverse HIV-1 Isolates 

George Leslie* 1 , J Wang 2 , B Haggarty 1 , A Jordan 1 , J Romano 1 , 

K Hua 2 , M Holmes 2 , and J Hoxie 1 

1 Univ of Pennsylvania, Philadelphia, US and 2 Sangamo BioSci Inc, 

Richmond, CA, US 

11:15 130 Poor Neutralizing Antibody Response Is 

Associated with Subsequent HIV-1 

Superinfection 

Gabriel Wagner* 1 , L Hepler 1 , G Caballero 2 , P Phung 3 , S Little 1 , 

S Kosakovsky Pond 1 , D Richman 1,2 , and D Smith 1,2 

1 Univ of California, San Diego, La Jolla, US;; 2 VA Hlthcare 

System, San Diego, CA, US;; and 3 Monogram Biosci Inc, South San 

Francisco, CA, US 

11:30 131LB Antibody-induced Perturbation of HIV-1 Env 

Structure Is a Quantifiable Parameter that 

Modulates the Inhibitory Potency of Antibodies 

Hillel Haim* 1,2 , I Salas 1 , and J Sodroski 1,3,4 

1 DanaFarber Cancer Inst, Harvard Med Sch, Boston, MA, US;; 

2 Carver Coll of Med, Univ of Iowa, Iowa City, US;; 3 Harvard Sch 

of Publ Hlth, Boston, MA, US;; and 4 Ragon Inst of MGH, MIT and 

Harvard, Boston, MA, US 

k Wednesday, 10 am-12 n; B406 


Virology: From the Outside In 

Moderators: 

Anna Aldovini, Children’s Hosp Boston, Harvard Univ, MA, US (invited) 

James Hoxie, Univ of Pennsylvania, Philadelphia, US 

10:00 132 Transmitted/Founder HIV-1 Virions Exhibit 

High Env Content, Efficient Dendritic Cell 

Binding, Enhanced Infectivity, and Resistance 

to Alpha Interferon 

N Parrish 1 , E Giorgi 2 , C Wilen 1 , S Iyer 1 , J Kappes 3 , F Gao 4 , 

B Haynes 4 , B Korber 2 , G Shaw 1 , and Beatrice Hahn* 1 

1 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US;; 2 Los 

Alamos Natl Lab, NM, US;; 3 Univ of Alabama at Birmingham, US;; 

and 4 Duke Univ Sch of Med, Durham, NC, US 

10:15 133 Proteolytic Processing of the HIV Envelope 

Glycoprotein Precursor Decreases 

Conformational Flexibility 

Hillel Haim* 1,2 , I Salas 1 , and J Sodroski 1,3,4 

1 DanaFarber Cancer Inst, Boston, MA, US;; 2 Carver Coll of Med, Univ 

of Iowa, Iowa City, US;; 3 Harvard Sch of Publ Hlth, Boston, MA, US;; 

and 4 Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US 

10:30 134 Siglec-1 Is a Novel Dendritic Cell Receptor 

that Mediates HIV-1 Trans-infection Through 

Recognition of Viral Membrane Gangliosides 

Nuria Izquierdo-Useros* 1 , M Lorizate 2 , M Puertas 1 , 

M Rodriguez-Plata 1 , N Zangger 3 , M Pino 1 , I Erkizia 1 , A Telenti 3 , 

H-G Krausslich 2 , and J Martinez-Picado 1,4 

1 AIDS Res Inst IrsiCaixa, Spain;; 2 Univ Heidelberg, Germany;; 3 Univ 

Hosp Ctr and Univ of Lausanne, Switzerland;; and 4 Inst Catalana de 

Recerca i Estudis Avancats, Spain 

10:45 135 Inhibition of HIV-1 Vif Function by AML Factor 

CBF�-SMMHC Fusion Proteins 

Ke Zhao* 1 , J Du 1 , P Li 1 , Y Rui 1 , M Yan 1 , W Zhang 1 , X-F Yu 1,2 , 

and G Wang 1 

1 Inst of Virology and AIDS Res, First Hosp of Jilin Univ, 

Changchun, China and 2 Johns Hopkins Univ Bloomberg Sch of Publ 

Hlth, Baltimore, MD, US 

11:00 136 Crystal Structure of HIV-1 Nef in Complex 

with the Hck SH3-SH2 Region Reveals New 

Intermolecular Interactions with Functional 

Implications 

John Jeff Alvarado*, S Tarafdar, T Smithgall, and J Yeh 

Univ of Pittsburgh, PA, US 


Wednesday 


Wednesday 



11:15 137 LIM Kinase-mediated Actin Dynamics Modulate 

Retrovirus Budding 

Xiaoyun Wen*, L Ding, E Hunter, and P Spearman 

Emory Univ, Atlanta, GA, US 

11:30 138 Incorporation of LEDGF/p75 in Viral Particles 

Is Crucial for HIV Infectivity 

B Desimmie 1 , R Schrijvers 1 , S Vets 1 , J Demeulemeester 1 , P Proost 1 , 

J De Rijck 1 , N Bannert 2 , F Christ 1 , R Gijsbers 1 , and Zeger Debyser* 1 

1 Katholieke Univ Leuven, Belgium and 2 Robert Koch Inst, Berlin, 

Germany 

11:45 139LB Treatment with Sub-optimal Doses of Raltegravir 

Leads to Aberrant HIV-1 Integrations 

Janani Varadarajan* 1 , MJ McWilliams 1 , D Hazuda 2 , and S Hughes 1 

1 HIV Drug Resistance Prgm, Frederick Natl Lab for Cancer Res, 

NIH, MD, US and 2 Merck Res Labs, West Point, PA, US 

k Wednesday, 10-11 am; Ballroom 3-4 


HIV-associated Malignancies 

Moderators: 

Kishor Bhatia, NCI, NIH, Bethesda, MD, US 

Margaret Borok-Williams, Univ of Zimbabwe, Harare 

10:00 140 Substantial Burden of Non-AIDS Cancers in 

Persons with HIV: Early Results from a 

Computerized HIV and Cancer Registry Match 

in Pune, India 

Sheela Godbole* 1 , K Nandy 2 , M Gauniyal 1 , S Koyande 3 , P Virgo 4 , 

K Bhatia 5 , R Paranjape 1 , A Risbud 1 , S Mbulaiteye 5 , and R Mitsuyasu 2 

1 Natl AIDS Res Inst-ICMR, Pune India;; 2 Univ of California, Los 

Angeles, US;; 3 Bombay Cancer Registry, Mumbai, India;; 4 Computer 

Svcs Corp, Rockville, MD, US;; and 5 NCI, NIH, Bethesda, MD, US 

10:15 141 Timing and Predictors of Cancer Incidence 

following Initiation of ART: Centers for AIDS 

Research Network of Integrated Clinical 

Systems, 1996-2011 

Elizabeth Yanik* 1 , S Napravnik 1 , S Cole 1 , C Achenbach 2 , 

S Gopal 1 , D Dittmer 1 , M Kitahata 3 , M Mugavero 4 , M Saag 4 , J Eron 1 , 

and Ctr for AIDS Res Network of Integrated Clin Systems 

1 Univ of North Carolina at Chapel Hill, US;; 2 Northwestern Univ, 

Chicago, IL, US;; 3 Univ of Washington, Seattle, US;; and 4 Univ of 

Alabama at Birmingham, US 

10:30 142 Random Biopsy Increases Diagnostic Rate and 

Total Anal High-grade Squamous Intraepithelial 

Lesions Found by High-resolution Anoscopy 

Richard Silvera*, M Gaisa, and S Goldstone 

Mt Sinai Sch of Med, New York, NY, US 

10:45 143 Evaluating Serum microRNA as Potential 

Biomarkers for Early Detection of Non-Hodgkin 

Lymphomas in HIV + Individuals 

Dharma Thapa* 1 , W-C Tran 1 , L Jacobson 2 , J Margolick 2 , J Phair 3 , 

C Rinaldo 4 , R Detels 1 , and O Martinez-Maza 1 

1 David Geffen Sch of Med, Fielding Sch of Publ Hlth, and AIDS 

Inst Univ of California, Los Angeles, US;; 2 Johns Hopkins Univ 

Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 3 Northwestern 

Univ Feinberg Sch of Med, Chicago, IL, US;; and 4 Univ of Pittsburgh 

Grad Sch of Publ Hlth, PA, US 

k Wednesday, 11 am-12:15 pm; Ballroom 3-4 


TB and Cryptococcal Meningitis 

Moderators: 

Haileyesus Getahun, WHO, Geneva, Switzerland 

Graeme Meintjes, Univ of Cape Town, South Africa 

11:00 144 ART Initiation within the First 2 Weeks of 

Cryptococcal Meningitis Is Associated with 

Higher Mortality: A Multisite Randomized Trial 

David Boulware* 1 , D Meya 2,3 , C Muzoora 4 , M Rolfes 1 , K Huppler 

Hullsiek 1 , A Musubire 2,3 , K Taseera 4 , H Nabeta 2,3 , C Schutz 5 , 

G Meintjes 5 , and Cryptococcal Optimal ART Timing Trial 

1 Univ of Minnesota, Minneapolis, US;; 2 Infectious Disease Inst, 

Kampala, Uganda;; 3 Makerere Univ, Kampala, Uganda;; 4 Mbarara 

Univ, Uganda;; and 5 Univ of Cape Town, South Africa 


11:15 145 HAART Does Not Reduce the Incidence of TB 

in HIV + Infants with Early HIV Disease Enrolled 

in a Primary TB Prevention Trial 

Bret Zeldow* 1 , S Kim 2 , G McSherry 3 , M Cotton 4 , S Madhi 5 , 

A Violari 5 , R Bobat 6 , C Mitchell 7 , and P1041 Study Team 

1 Harvard Sch of Publ Hlth, Boston, MA, US;; 2 New Jersey Med 

Sch, Newark, US;; 3 Pennsylvania State Univ Coll of Med, Hershey, 

US;; 4 Stellenbosh Univ, Cape Town, South Africa;; 5 Univ of the 

Witwatersrand, Johannesburg, South Africa;; 6 Univ of KwaZulu- 

Natal, Durban, South Africa;; and 7 Univ of Miami, FL, US 

11:30 146 Comparative Performance of Rapid Urinary 

Lipoarabinomannan Assays and Xpert 

MTB/RIF in HIV + TB Suspects: Uganda 

Maunank Shah* 1 , W Ssengooba 2 , D Armstrong 1 , L Nakiyingi 2 , 

M Holshouser 1 , J Ellner 3 , M Joloba 2 , Y Manabe 1,4 , and S Dorman 1 

1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Makerere 

Univ Coll of Hlth Sci, Kampala, Uganda;; 3 Boston Med Ctr, Boston 

Univ Sch of Med, MA, US;; and 4 Infectious Diseases Inst, Makerere 

Univ Coll of Hlth Sci, Kampala, Uganda 

11:45 147LB A Multicenter Randomized Clinical Trial 

to Evaluate High-dose Rifapentine with a 

Quinolone for Treatment of Pulmonary TB: 

The RIFAQUIN Trial 

Amina Jindani* 1 , M Hatherill 2 , S Charalambous 3 , S Mungofa 4 , 

S Zizhou 5 , J van Dijk 6 , J Shepherd 7 , P Phillips 8 , A Nunn 8 , 

D Mitchison 1 , and RIFAQUIN Trial Team 

1 St Georges, Univ of London, UK;; 2 Univ of Cape Town, South 

Africa;; 3 Aurum Inst, Johannesburg, South Africa;; 4 Harare City 

Hlth Dept, Zimbabwe;; 5 Med Directorate of Mashonaland East, 

Marondera, Zimbabwe;; 6 Macha Med Mission, Zambia;; 7 CDC/ 

BOTUSA, Gaborone, Botswana;; and 8 MRC Clin Trials Unit, 

London, UK 

12:00 148LB What Is the Right Dose of Rifampin? 

Martin Boeree* 1 , A Diacon 2 , R Dawson 3 , A Venter 2 , J du Bois 2 , 

K Narunsky 3 , M Hoelscher 4 , S Gillespie 5 , P Phillips 6 , R Aarnoutse 1 , 

and PanACEA Consortium 

1 Radboud Univ Nijmegen Med Ctr, The Netherlands;; 2 Univ of 

Stellenbosch, Cape Town, South Africa;; 3 Univ of Cape Town, South 

Africa;; 4 Med Ctr of the Univ of Munich, Germany;; 5 Univ of St 

Andrews, UK;; and 6 MRC Clin Trial Unit, London, UK 

k Wednesday, 10 am-12:15 pm; Ballroom 1-2 


Advances in ARV and Anti-Hepatitis C 

Virus Therapy 

Moderators: 

Jintanat Ananworanich, HIV-NAT, Bangkok, Thailand 

Jean-Francois Delfraissy, French Natl Agency for Res on AIDS and Viral 

Hepatitis, Paris 

10:00 149 Trend in Transmitted HIV-1 ARV Drug 

Resistance-associated Mutations: 10 HIV 

Surveillance Areas, US, 2007-2010 

David Kim* 1 , R Ziebell 1 , N Saduvala 2 , R Kline 1 , C Banez Ocfemia 1 , 

J Prejean 1 , X Zhang 1 , M Pearson 1 , I Hall 1 , and Variant, Atypical, and 

Resistant HIV Surveillance Group 

1 CDC, Atlanta, GA, US and 2 ICF Intl, Atlanta, GA, US 

10:15 150 Mortality after Starting ART in Treatment-naïve 

Adults in 3 Continents: Collaborative Analysis 

of International Epidemiologic Databases to 

Evaluate AIDS in Southern Africa and ART 

Cohort Collaboration Cohorts 

Andrew Boulle* 1 , M Schomaker 1 , M May 2 , M Egger 3 , J Sterne 2 , 

and site investigators from IeDEA-SA and ART-CC Collaborations 

1 Univ of Cape Town, South Africa;; 2 Bristol Univ, UK;; and 3 Univ of 

Bern, Switzerland 

10:30 151 Superiority of Routine Viral Load Monitoring 

in Rural Kenya: the Kericho Clinic-based ART 

Diagnostic Evaluation (CLADE) Trial 

Fredrick Sawe* 1,2 , P Yegon 1 , R Langat 1 , E Obiero 3 , J Maswai 1 , 

M Bii 1 , A Aoko 1 , K Shikuku 1 , N Close 4 , D Shaffer 1,2 , and CLADE Team 

1 Kenya Med Res Inst/Walter Reed Project, Kericho;; 2 US Military 

HIV Res Prgm, Bethesda, MD;; 3 Kenya Ministry of Med Svcs, 

Kericho;; and 4 EmpiriStat, Mt Airy, MD, US 

10:45 152 Renal Insufficiency among Women Treated with 

Tenofovir/Emtricitabine/Lopinavir/Ritonavir or 

Tenofovir/Emtricitabine/Nevirapine 

A Mwafongo 1 , K Nkanaunena 2 , Mina Hosseinipour* 1,3 , 

S Lockman 4 , M Hughes 4 , J Currier 5 , and ACTG 5208 

1 Univ of Northern Carolina Project, Lilongwe, Malawi;; 2 Coll of 

Med-John Hopkins Univ Res Project, Blantyre, Malawi;; 3 Univ of 

North Carolina at Chapel Hill, US;; 4 Harvard Sch of Publ Hlth, 

Boston, MA, US;; and 5 Univ of California, Los Angeles, US


11:00 153LB Omitting NRTI from ARV Regimens Is Not 

Inferior to Adding NRTI in Treatment-experienced 

HIV + Subjects Failing a Protease Inhibitor 

Regimen: The ACTG OPTIONS Study 

Karen Tashima* 1 , L Smeaton 2 , A Andrade 3 , J Eron 4 , C Fichtenbaum 5 , 

R Gandhi 6 , V Johnson 7 , K Klingman 8 , K Hollabaugh 2 , R Haubrich 9 , and 

A5241 Study Team 

1 The Miriam Hosp, Alpert Med Sch of Brown Univ, Providence, RI, 

US;; 2 Ctr for Biostatistics in AIDS Res, Harvard Sch of Publ Hlth, 

Boston, MA, US;; 3 Johns Hopkins Univ, Baltimore, MD, US;; 4 Univ 

of North Carolina at Chapel Hill, US;; 5 Univ of Cincinnati, OH, US;; 

6 Massachusetts Gen Hosp and Ragon Inst, Boston, US;; 7 Birmingham 

VA Med Ctr and Univ of Alabama at Birmingham Sch of Med, US;; 

8 HIV Res Branch, TRP, DAIDS, NIAID, NIH, Bethesda, MD, US;; 

and 9 Univ of California, San Diego, US 

11:15 154LB Simeprevir with Pegylated Interferon/Ribavirin 

in Patients Co-infected with Chronic Hepatitis C 

Virus and HIV-1: Week-24 Interim Analysis of 

the TMC435-C212 Study 

Douglas Dieterich* 1 , J Rockstroh 2 , C Orkin 3 , F Gutierrez 4 , 

M Klein 5 , J Reynes 6 , W Jessner 7 , O Lenz 7 , M Peeters 7 , and M 

Beumont-Mauviel 7 

1 Mt Sinai Sch of Med, New York, NY, US;; 2 Mediz Universittsklinik- 

Immunologische Ambulanz, Bonn, Germany;; 3 Royal London 

Hosp, UK;; 4 Hosp Gen de Elche and UMH, Alicante, Spain;; 5 Muhc 

Montreal Chest Inst, Canada;; 6 Hosp Gui De Chauliac, Montpellier, 

France;; and 7 Janssen Infectious Diseases BVBA, Beerse, Belgium 

11:30 155LB Suppression of Viral Load through 4 Weeks 

Post-Treatment Results of a Once-daily Regimen 

of Simeprevir + Sofosbuvir with or without 

Ribavirin in Hepatitis C Virus GT1 Null 

Responders 

Eric Lawitz* 1 , R Ghalib 2 , M Rodriguez-Torres 3 , Z Younossi 4 , 

A Corregidor 5 , I Jacobson 6 , K Callewaert 7 , W Symonds 8 , G Picchio 9 , 

and K Lindsay 9 

1 Alamo Med Res, San Antonio, TX, US;; 2 The Liver Inst, Dallas, TX, 

US;; 3 Fndn de Investigacion, San Juan, Puerto Rico;; 4 Inova Fairfax 

Hosp, Falls Church, VA, US;; 5 Borland-Groover Clin, Jacksonville, 

FL, US;; 6 Weill Cornell Med Coll, New York, NY, US;; 7 Janssen Res 

and Devt, Beerse, Belgium;; 8 Gilead Sci, Inc, Foster City, CA, US;; 

and 9 Janssen Res and Devt LLC, Titusville, FL, US 

11:45 156LB Telaprevir for Acute Hepatitis C Virus in HIV + 

Men both Shortens Treatment and Improves 

Outcome 

Daniel Fierer 

Mt Sinai Sch of Med 

12:00 157LB High Efficacy of Sofosbuvir with Weight-based 

Ribavirin for 24 Weeks in Difficult-to-Treat 

Patients 

Anu Osinusi* 1,2 , D Bon 3 , E Herrmann 3 , G Teferi 4 , R Talwani 5 , 

H Masur 6 , W Symonds 7 , J McHutchison 7 , A Fauci 1 , S Kottilil 1 , 

and NIAID SPARE Study Team 

1 LIR, NIAID, Bethesda, MD, US;; 2 CMRP, SAIC-Frederick, Inc, 

Frederick Natl Lab for Cancer Res, MD, US;; 3 IBBM, Johann 

Wolfgang Goethe Univ, Frankfurt;; 4 Unity Health Care Inc, 

Washington, DC, US;; 5 Univ of Maryland Med Ctr, Baltimore, US;; 

6 CCMD, CC, NIH, Bethesda, MD, US;; and 7 Gilead Sci, Foster City, 

CA, US 

b Wednesday, 1:30-2:30 pm; B402 



Aging and Neurocognitive Function in HIV Infection 

Discussants: 

Bruce Brew, St Vincent’s Hosp and Univ of New South Wales, Sydney, Australia 

Kevin Robertson, AIDS Dementia Ctr, Univ of North Carolina at 

Chapel Hill, US 

439 Older Age and Neurocognitive Function: 

Multi-center AIDS Cohort Study 

Karl Goodkin* 1 , E Miller 2 , C Cox 3 , S Reynolds 3 , D Ostrow 4 , O Selnes 5 , 

E Martin 6 , N Sacktor 5 , and J Becker 7 

1 AIDS Hlthcare Fndn, Los Angeles, CA, US;; 2 Univ of California, Los 

Angeles, US;; 3 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, 

MD, US;; 4 Univ of Chicago, IL, US;; 5 Johns Hopkins Univ Sch of Med, 

Baltimore, MD, US;; 6 Univ of Illinois at Chicago, US;; and 7 Univ of 

Pittsburgh, PA, US 

440 Veterans Aging Cohort Study Index Score Is 

Associated with Neurocognitive and Functional 

Impairment: A CHARTER Study 

D Franklin Jr 1 , R Heaton 1 , S Woods 1 , S Letendre 1 , A Collier 2 , D Clifford 3 , 

B Gelman 4 , J McArthur 5 , D Simpson 6 , Igor Grant* 1 , and CHARTER Group 

1 Univ of California, San Diego, US;; 2 Univ of Washington, Seattle, US;; 

3 Washington Univ, St Louis, MO, US;; 4 Univ of Texas Med Branch, 

Galveston, US;; 5 Johns Hopkins Univ, Baltimore, MD, US;; and 6 Mt Sinai 

Sch of Med, New York, NY, US 

441 Changing Cerebrospinal Fluid Concentrations 

of Neurofilament Light Chain Protein, Tau, and 

Amyloid Proteins Characterize Evolving Central 

Nervous System Injury in HIV-1 Infection 

Julia Peterson* 1 , H Zetterberg 2 , L Hagberg 2 , S Spudich 3 , M Gisslen 2 , 

and R Price 1 

1 Univ of California, San Francisco, US;; 2 Sahlgrenska Academy at Univ of 

Gothenburg, Sweden;; and 3 Yale Univ, New Haven, CT, US 

442 Prevalence of Cerebrospinal Fluid Alzheimer’s 

Disease-like Profiles in Chronic Middle-aged HIV + 

Individuals 

L Cysique 1,2 , J Lamoury 2 , T Hewitt 2,3 , K Taddei 4,5,6 , R Martins 4,5 , C Chew 5 , 

P Price 5 , and Bruce Brew* 1,2 

1 St Vincents Hosp, Sydney, Australia;; 2 Univ of New South Wales, Sydney, 

Australia;; 3 Notre Dame Univ, Sydney, Australia;; 4 Edith Cowan Univ, 

Australia;; 5 Univ of Western Australia, Perth;; and 6 Hollywood Private 

Hosp, Nedlands, Australia 

443 Axonal Disturbance in Neuroasymptomatic Patients 

off and on Suppressive ART: An Aging Effect of 

Central Nervous System Infection? 

Jan Jessen Krut* 1 , T Mellberg 1 , R Price 2 , L Hagberg 1 , D Fuchs 3 , 

L Rosengren 1 , S Nilsson 4 , H Zetterberg 1,5 , and M Gisslen 1 

1 Sahlgrenska Academy, Univ of Gothenburg, Sweden;; 2 Univ of California, 

San Francisco, US;; 3 Innsbruck Med Univ, Austria;; 4 Chalmers Univ of Tech, 

Gothenburg, Sweden;; and 5 Univ Coll London, Inst of Neurology, UK 

444 Longitudinal Association of HIV-associated 

Neurocognitive Disorders with Frailty in HIV-1 + Men 

Bryan Smith* 1 , R Skolasky 1 , F Mateen 1 , J Becker 2 , E Martin 3 , E Miller 4 , 

J Margolick 5 , O Selnes 1 , N Sacktor 1 , and Multictr AIDS Cohort Group 

1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Univ of Pittsburgh 

Sch of Med, PA, US;; 3 Univ of Illinois Sch of Med, Chicago, US;; 4 David 

Geffen Sch of Med, Univ of California, Los Angeles, US;; and 5 Johns 

Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD US 

445 HIV and Aging: New Graph Theoretical Models 

of rs-fcMRI Neuropathophysiology 

Jewell Thomas*, M Brier, and B Ances 

Washington Univ in St. Louis 




Transmitted/Founder Viruses 

Discussants: 

Feng Gao, Duke Univ, Durham, NC, US 

Thomas Hope, Northwestern Univ, Chicago, IL, US 

244 Recombination Shapes Viral Evolution during 

Early Infection in Individuals Infected with Multiple 

Transmitted/Founder HIV-1 

Hongshuo Song* 1 , F Cai1 , V Ganusov2 , J Pavlicek1 , B Keele3 , H Li4 , 

G Shaw4 , B Haynes1 , B Hahn4 , and F Gao1 1 2 Duke Univ Med Ctr, Durham, NC, US;; Univ of Tennessee, Knoxville, US;; 

3 4 SAIC-Frederick Inc, MD, US;; and Univ of Pennsylvania, Philadelphia, US 

245 MTCT Is Associated with a Gag-Protease-driven 

Viral Fitness Bottleneck 

Vanessa Naidoo* 1 , J Mann1 , J Carlson2 , C Brumme3 , C Thobakgale1 , 

P Goulder4 , D Heckerman2 , Z Brumme3,5 , M Brockman3,5 , and T Ndung’u1 1HIV Pathogenesis Prgm, Univ of KwaZulu-Natal, Durban, South Africa;; 

2 3 Microsoft Res, Los Angeles, CA, US;; BC Ctr for Excellence in HIV/ 

AIDS, Vancouver, Canada;; 4Univ of Oxford, UK;; and 5Simon Fraser Univ, 


246 Subtype C HIV-1 Variants Transmitted by 

Breastfeeding Have Less Glycosylated V2 Loops 

and Are More Susceptible to V2-Targeted Antibodies 

PG9 and PG16 

Kyle Nakamura* 1 , C Cerini1 , E Sobrera1 , L Heath2 , M Sinkala3 , 

C Kankasa4 , D Thea5 , J Mullins2 , L Kuhn6 , and G Aldrovandi1 1 2 Children�s Hosp Los Angeles, CA, US;; Univ of Washington, Seattle, US;; 

3 4 Lusaka District Hlth Mgmt Team, Zambia;; Univ of Zambia, Lusaka;; 

5 6 Boston Univ Sch of Publ Hlth, MA, US;; and Columbia Univ, New York, 

NY, US 

247 Transmitted/Founder and Chronic HIV-1 Env 

Proteins Differentially Utilize CCR5 

Zahra Parker* 1 , S Iyer1 , C Wilen1 , N Parrish1 , R Berro2 , B Lee3 , 

J Moore2 , G Shaw1 , B Hahn1 , and R Doms1,4 1 2 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US;; Weill Med 

Coll of Cornell Univ, New York, NY, US;; 3Univ of California, Los Angeles, 

US;; and 4Children�s Hosp of Philadelphia, PA, US 


Wednesday 


Wednesday 



248 Phenotypic Differences Between Transmitted/Founder 

and Chronic Env Proteins Revealed by Quantitative, 

High-Throughput Receptor Affinity Profiling 

Kelechi Chikere* 1 , N Webb 1 , T Chou 1 , P Gorry 2 , and B Lee 1 

1 Univ of California, Los Angeles, US and 2 Burnet Inst, Melbourne, Australia 

249 Transmitted/Founder Infectious Molecular Clones 

of Divergent SIV smm Strains Are Infectious and 

Replication Competent in vivo 

D Ma 1 , H Li 2 , C Xu 1 , B Keele 3 , J Estes 3 , J Lifson 3 , I Pandrea 1 , G Shaw 2 , 

B Hahn 2 , and Cristian Apetrei* 1 

1 Ctr for Vaccine Res, Univ of Pittsburgh, PA, US;; 2 Univ of Pennsylvania 

Perelman Sch of Med, Philadelphia, US;; and 3 Frederick Natl Lab, MD, US 

250 The Number and Genetic Relatedness of 

Transmitted/Founder Virus Impact Clinical 

Outcome in Vaginal R5 SHIV SF162P3N Transmission 

Lily Tsai* 1 , I Tasovski 2 , AR Leda 1 , M Chin 2 , and C Cheng-Mayer 1 

1 Aaron Diamond AIDS Res Ctr, New York, NY, US and 2 Temple Univ Sch of 

Med, Philadelphia, PA, US 




Emergence and Persistence of HPV-associated 


Discussants: 

Elizabeth Chiao , Baylor Coll of Med, Houston, TX, US 

Cynthia Firnhaber, Univ of the Witwatersrand, Johannesburg, South Africa 

730 AIDS-defining Cancers in Switzerland 1985-2011: 

Separating the Effects of Age and Period 

F Schoni-Affolter1 , L Elzi2 , R Weber3 , A Calmy4 , A Bregenzer5 , 

M Cavassini6 , H Furrer7 , G Clifford8 , M Egger1 , Olivia Keiser* 1 , 


1 2 3 Univ of Bern, Switzerland;; Univ Hosp Basel, Switzerland;; Univ Hosp 

Zurich, Switzerland;; 4Geneva Univ Hosp, Switzerland;; 5Cantonal Hosp St 

Gallen, Switzerland;; 6Univ Hosp Lausanne, Switzerland;; 7Univ Hosp Bern, 

Switzerland;; and 8Intl Agency for Res on Cancer 

731 Incidence of AIDS-defining and Non-AIDS-defining 

Cancers following Expansion of ART: Botswana 

2003-2008 

Scott Dryden-Peterson* 1,2,3 , H Medhin4 , G Seage2 , M Pusoentsi4 , S El-Halabi4 , 

T Rebbeck5 , G Suneja5 , M Mmalane3 , M Essex2,3 , and S Lockman1,2,3 1 2 Brigham and Women�s Hosp, Boston, MA, US;; Harvard Sch of Publ Hlth, 

Boston, MA, US;; 3Botswana Harvard AIDS Inst Partnership, Gaborone;; 

4 5 Botswana Ministry of Hlth, Gaborone;; and Univ of Pennsylvania, 

Philadelphia, US 

732 Frequent Detection of Human Papillomavirus before 

and after Initiation of ART among HIV + Women: 

Uganda 

Anne Rositch* 1 , P Gravitt1,2 , A Tobian1,3 , K Newell4 , T Quinn3,5 , 

D Serwadda6 , P Ssebbowa6 , V Kiggundu6 , R Gray1,6 , and S Reynolds3,5 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 

2 3 Perdana Univ Grad Sch of Med, Serdang, Malaysia;; Johns Hopkins Univ 

Sch of Med, Baltimore, MD, US;; 4Frederick Natl Lab for Cancer Res, MD, US;; 

5 6 NIAID, NIH, Bethesda, MD, US;; and Rakai Hlth Sci Prgm, Entebbe, Uganda 

733 HPV Genotype Impacts T Cell Activation and 

Cervical Cellular Infiltrates Irrespective of Lesion 

Grade in ART-suppressed Human Papillomavirus/ 

HIV-1 Co-infected Women 

Emmanouil Papasavvas* 1 , D Glencross2,3 , N Mayisela4 , T Omar2 , 

A-L Williamson5,6 , M Siminya4 , X Yin1 , Q Liu1 , C Firnhaber2,4 , 

and L Montaner1 1 2 The Wistar Inst, Philadelphia, PA, US;; Univ of the Witwatersrand, 

Johannesburg, South Africa;; 3Natl Hlth Lab Svc, Johannesburg, South 

Africa;; 4Right to Care, Johannesburg, South Africa;; 5Univ of Cape Town, 

South Africa;; and 6Natl Hlth Lab Svc, Cape Town, South Africa 

734 Human Papillomavirus, Cervical Neoplasia, and 

Invasive Cancer in Women with HIV-2 Infection in 

the ART Era: Senegal, West Africa 

S Hawes1 , Q Feng1 , S Ba2 , M Toure1,2 , M-P Sy2 , F Traore2 , R Smith1 , N Kiviat1 , 

PS Sow1,2 , Geoffrey Gottlieb* 1 , and UW-Dakar HIV-2 Study Group 

1 2 Univ of Washington, Seattle, US and Ctr Hosp Univ de Fann, Univ Cheikh 

Anta Diop de Dakar, Senegal 

735 Anal Human Papillomavirus Infection in HIV + 

Patients: Prevalence, Incidence, and Predictors 

of High-risk Human Papillomavirus Infection 

Alberto Borghetti* 1 , P Cattani2 , G Maria3 , M Sanguinetti2 , 

S D’Onghia2 , R Santangelo2 , S Marchetti2 , R Cauda1 , A De Luca1,4 , 

and S Di Giambenedetto1 1Inst of Clin Infectious Diseases, Catholic Univ of Sacred Heart, Rome, 

Italy;; 2Inst of Microbiology, Catholic Univ of Sacred Heart, Rome, Italy;; 

3Inst of Clin and Surgical Therapy, Catholic Univ of Sacred Heart, Rome, 

Italy;; and 4Siena Univ Hosp, Italy 


736 The Effect of Protease Inhibitors on the Incidence of 

HIV-associated Squamous Cell Carcinoma of the Anus 

Pamela Mbang* 1 , M Kowalkowski 2 , and E Chiao 1,2 

1 Baylor Coll of Med, Houston, TX, US and 2 Houston Hlth Svcs Res and Devt 

Ctr of Excellence, Michael E DeBakey VAMC, TX, US 

737 Prevalence and Genotypes of Human Papillomavirus at 

Penile and Perianal Sites among HIV + and HIV – MSM 

Han-Zhu Qian* 1 , Y Hu 2 , L Yin 1 , Y Ruan 2 , Y Shao 2 , and S Vermund 1 

1 Vanderbilt Univ, Nashville, TN, US and 2 Natl Ctr for STD/AIDS Control 

and Prevention of China CDC, Beijing 




Mechanisms of Immune Reconstitution 

Discussants: 

Brigitte Autran, Univ Pierre and Marie Curie, Pitie-Salpetriere Hosp, 

Paris, France (invited) 

Robert Colebunders, Inst of Tropical Med Antwerp, Belgium 

859 Early ART after Cryptococcal Meningitis Increases 

Cerebrospinal Fluid Macrophage Activation and 

Aberrant Th2 Responses in a Multisite Randomized Trial 

James Scriven* 1,2 , J Rhein 3,4 , K Huppler Hullsiek 4 , M von Hohenberg 4 , 

G Linder 4 , M Rolfes 4 , D Williams 3,4 , D Meya 3,4,5 , G Meintjes 2 , D Boulware 4 , 

and Cryptococcal Optimal ART Timing Trial 

1 Liverpool Sch of Tropical Med, UK;; 2 Univ of Cape Town, South 

Africa;; 3 Infectious Disease Inst, Kampala, Uganda;; 4 Univ of Minnesota, 

Minneapolis, US;; and 5 Makerere Univ, Kampala, Uganda 

860 Impact of TB-associated Immune Reconstitution 

Inflammatory Syndrome on T Cell Activation and 

Reconstitution in Highly Immunosuppressed HIV/TB 

Co-infected Patients Starting ART 

V Haridas 1 , P Pean 2 , L Jasenosky 1 , Y Madec 3 , D Laureillard 4 , L Borand 2 , 

O Marcy 5 , T Sok 5 , X Blanc 6 , and Anne Goldfeld* 1,5 

1 Prgm in Cellular and Molecular Med, Children�s Hosp, Boston, MA, US;; 

2 Inst Pasteur du Cambodge, Phnom Penh, Cambodia;; 3 Inst Pasteur, Paris, 

France;; 4 ANRS, Ho Chi Minh City, Vietnam;; 5 Cambodian Hlth Committee, 

Phnom Penh;; and 6 Bicetre Hosp Assistance Publ-Hosp de Paris, France 

861 Ex vivo Interferon Gamma Release Assay Responses 

to Cryptococcal Capsule Antigen Predict Outcomes 

of Death or Immune Reconstitution Inflammatory 

Syndrome after Cryptococcal Meningitis 

Darin Wiesner* 1 , A Akamps 2 , J Rhein 1,3 , D Williams 1,3 , D Meya 1,2,3 , 

P Bohjanen 1 , K Nielsen 1 , D Boulware 1 , and Cryptococcal Optimal ART 

Timing Trial 

1 Univ of Minnesota, Minneapolis, US;; 2 Makerere Univ, Kampala, Uganda;; 

and 3 Infectious Disease Inst, Kampala, Uganda 

862 Biomarkers of CD4 + T Cell Activation in HIV + 

Patients Developing Mycobacterium tuberculosisassociated 

Immune Reconstitution Inflammatory 

Syndrome 

Lisa Chakrabarti* 1 , C Boucherie 2 , F Bugault 1 , M-C Cumont 1 , 

C Roussillon 2 , G Breton 3 , O Patey 4 , L Richert 2 , G Chene 2,5 , O Lortholary 6 , 

and ANRS 129 BKVIR-CYTOK Substudy Group 

1 Inst Pasteur, Paris, France;; 2 INSERM U897, Univ Bordeaux, France;; 

3 Hosp de La Pitie-Salpetriere, Paris, France;; 4 Hosp Villeneuve St-Georges, 

France;; 5 CHU de Bordeaux, France;; and 6 Univ Paris Descartes, Hosp 

Necker Enfants Malades, APHP, Paris, France 

b Wednesday, 1:30-2:30 pm; Ballroom 3-4 



Adherence and Retention in RLS 

Discussants: 

David Bangsberg, Massachusetts Gen Ctr for Global Hlth, Boston, US 

Wafaa El-Sadr, Columbia Univ, Harlem Hosp Ctr, New York, NY, US 

1101 Validating Measures of Distance to HIV Clinic in 

Rural Uganda and Its Impact on Clinic Attendance 

Mark Siedner* 1 , A Lankowski 1 , A Tsai 1,2 , C Muzoora 3 , P Hunt 4 , 

J Martin 4 , J Haberer 1 , and D Bangsberg 1,5 

1 Massachusetts Gen Hosp Ctr for Global Hlth, Boston, US;; 2 Massachusetts 

Gen Hosp, Boston, US;; 3 Mbarara Univ of Sci and Tech, Uganda;; 4 Univ 

of California, San Francisco, US;; and 5 Ragon Inst of MGH, MIT, and 

Harvard Med Sch, Boston, US 

1102 Site and Program Determinants of Patient Retention 

in HIV Care: Nigeria 

Chinenye Ugoji* 1 , R Ake-Uzoigwe 1 , MY Ladele 1 , C Akolo 1 , G Mendy 1 , 

P Dakum 1 , M Charurat 2 , D Onotu 3 , O Nwanyanwu 3 , and W Blattner 2 

1 Inst of Human Virology Nigeria, Abuja;; 2 Inst of Human Virology, Univ of 

Maryland, Baltimore, US;; and 3 Ctr for Disease Control, Nigeria


1103 Attrition through Multiple Stages of HIV Care 

in South Africa: A Challenge for Test-and-Treat 

Matthew Fox* 1,2,3 and K Shearer 3 

1 Ctr for Global Hlth and Devt, Boston Univ, MA, US;; 2 Boston Univ Sch of 

Publ Hlth, MA, US;; and 3 Hlth Economics and Epidemiology Res Office, 


1104 Retention in Care up to ART Initiation within a 

Decentralized HIV Program in South Africa: 

The Critical Role of the First Clinic Visit 

Melanie Plazy* 1,2 , R Dray-Spira 3 , J Orne-Gliemann 1,2 , F Dabis 1,2 , 

and M-L Newell 4 

1 Univ Bordeaux, ISPED, INSERM U897, France;; 2 ISPED, INSERM 

U897, Bordeaux, France;; 3 Epidemiology of Occupational and Social 

Determinants of Hlth-Ctr for Res in Epidemiology and Population Hlth, 

INSERM U1018, Villejuif, France;; and 4 Africa Ctr for Hlth and Population 

Studies, Univ of KwaZulu-Natal, South Africa 

1105 Co-enrollment of HIV + Family Members in Care 

Is Associated with Improved Outcomes for Women 

on ART: A Cohort Study 

Landon Myer* 1 , J Duong 2 , Y Zhang 2 , E Abrams 3 , R Carter 3 , 

and MTCT-Plus Initiative 

1 Univ of Cape Town, South Africa;; 2 Mailman Sch of Publ Hlth, Columbia 

Univ, New York, US;; and 3 Intl Ctr for AIDS Care and Treatment Prgms, 

Mailman Sch of Publ Hlth, Columbia Univ, New York, NY, US 

1106 A Sampling-based Approach to Assessing 

Patient-reported Barriers to Retention among 

HIV + Patients on ART: East Africa 

Elvin Geng* 1 , T Odeny 2 , L Rita 3 , A Nakiwogga-Muwanga 4 , M Bwana 5 , 

E Bukusi 6 , G Somi 3 , P Braitstein 7 , C Yiannoutsos 7 , J Martin 1 , and East 

Africa Intl Epidemiologic Databases to Evaluate AIDS 

1 Univ of California, San Francisco, US;; 2 Family AIDS Care and Ed Svcs, 

Kisumu, Kenya;; 3 Natl AIDS Control Prgm, Dar es Salaam, Tanzania;; 

4 Infectious Disease Inst, Kampala, Uganda;; 5 Mbarara Univ of Sci 

and Tech, Uganda;; 6 Kenya Med Res Inst, Nairobi;; and 7 Indiana Univ, 

Indianapolis, US 

1107 Real-time HIV ART Adherence Monitoring 

Predicts Loss of Viral Suppression and Subsequent 

Resuppression: Rural Uganda 

Jessica Haberer* 1,2 , C Muzoora 3 , P Hunt 4 , J Martin 4 , M Siedner 1,2 , 

and D Bangsberg 1,2,3 

1 Massachusetts Gen Hosp, Boston, US;; 2 Harvard Med Sch, Boston, MA, 

US;; 3 Mbarara Univ of Sci and Tech, Uganda;; and 4 Univ of California, 

San Francisco, US 

b Wednesday, 1:30-2:30 pm; Ballroom 1-2 



Inflammatory Biomarkers, Microparticles, and 

Clinical Outcomes in HIV 

Discussants: 

Tricia Burdo, Boston Coll, MA, US 

Esteban Martinez, Hosp Clin, Barcelona, Spain (invited) 

788 Inflammatory Cytokines and Mortality in a Cohort 

of HIV + Patients with Alcohol Problems 

Daniel Fuster* 1 , D Cheng 1,2 , E Quinn 3 , K Armah 4 , R Saitz 1 , 

M Freiberg 5 , J Samet 1 , and J Tsui 1 

1 Boston Med Ctr and Boston Univ Sch of Med, MA, US;; 2 Boston Univ Sch of 

Publ Hlth, MA, US;; 3 Data Coordinating Ctr, Boston Univ Sch of Publ Hlth, 

MA, US;; 4 Univ of Pittsburgh Grad Sch of Publ Hlth, PA, US;; and 5 Univ of 

Pittsburgh, PA, US 

789 Tissue Factor Microparticles among HIV + Persons 

Are Reduced with ART and Associated with D-dimer 

Levels after Treatment 

Jason Baker* 1,2 , K Huppler Hulsiek 1 , R Bradford 3 , R Prosser 1,2 , R Tracy 4 , 

and N Key 3 

1 Univ of Minnesota, Minneapolis, US;; 2 Hennepin County Med Ctr, 

Minneapolis, MN, US;; 3 Univ of North Carolina at Chapel Hill, US;; 

and 4 Univ of Vermont, Burlington, US 

790 Soluble Markers of Inflammation and Coagulation, 

but Not T Cell Activation, Predict Non-AIDS-defining 

Events during Suppressive ART 

Allan Tenorio* 1 , E Zheng 2 , R Bosch 2 , S Deeks 3 , B Rodriguez 4 , 

S Krishnan 2 , P Hunt 3 , C Wilson 5 , M Lederman 4 , A Landay 1 , and ACTG 

1 Rush Univ Med Ctr, Chicago, IL, US;; 2 Harvard Sch of Publ Hlth, Boston, 

MA, US;; 3 San Francisco Gen Hosp and Univ of California, San Francisco, 

US;; 4 Case Western Reserve Univ Sch of Med, Cleveland, OH, US;; and 

5 Univ of Colorado Hosp, Aurora, US 

791 Inflammation and Coagulation Markers Are 

Predictive of Anemia in ARV-treated HIV Disease 

Alvaro Borges* 1 , J Weitz 2 , G Collins 3 , J Baker 3,4 , Y Levy 5 , R Davey 6 , 

A Phillips 7 , J Neaton 3 , J Lundgren 1 , S Deeks 8 , for INSIGHT SILCAAT 

Study Group 

1 Copenhagen HIV Prgm and Rigshospitalet, Denmark;; 2 Thrombosis 

and Atherosclerosis Res Inst, Hamilton, Canada;; 3 Univ of Minnesota, 

Minneapolis, US;; 4 Hennepin County Med Ctr, Minneapolis, MN, US;; 

5 Assistance Publ-Hosp de Paris, INSERM U955, Univ Paris 12, Creteil, 

France;; 6 NIAID, NIH, Bethesda, MD, US;; 7 Univ Coll London Med Sch, 

UK;; and 8 Univ of California, San Francisco, US 

792 Osteoprotegerin and Receptor Activator of Nuclear 

Factor Kappa � Ligand Are Associated with 

Subclinical Coronary Atherosclerosis: Multicenter 

AIDS Cohort Study 

Kerunne Ketlogetswe* 1 , W Post 1,2 , X Li 2 , L Jacobson 2 , F Palella 3 , 

J Margolick 2 , L Kingsley 4 , M Witt 5 , M Budoff 5 , T Brown 1,2 , and Multictr 


1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Johns Hopkins Univ 

Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 3 Northwestern Univ 

Feinberg Sch of Med, Chicago, IL, US;; 4 Univ of Pittsburgh Grad Sch of 

Publ Hlth, PA, US;; and 5 Harbor UCLA Med Ctr, Torrance, CA, US 


Wednesday 


Wednesday 



C Wednesday, 2:30-4 pm; Hall B2 



Session 54. ART, Complications, and TB 

Session 57. Accessory Proteins/Gag 

Session 61. Macrophage HIV Interactions: Cell Biology and Treatment 

Session 65. HIV Genotypes and Phenotypes 

Session 68. HIV and Monocytes, Macrophages, and Dendritic Cells 

Session 72. Microbial Translocation 

Session 76. Neutralizing Antibodies and How to Stimulate Them 

Session 81. Mechanism of HIV Latency and Reactivation 

Session 83. Gene and Adoptive Immunotherapy 

Session 91. NeuroAIDS Clinical Studies 

Session 92. Neuroimaging Studies 

Session 93. Human Genomics 

Session 103. Compartment Penetration of ARV 

Session 104. ARV Drug Interactions 

Session 107. ART: Too Early or Too Late? Or Better Late than Never! 

Session 108. ART: Host and Viral Determinants of Outcome 

Session 109. ART: Care and Adherence 

Session 125. Hepatitis C Virus Epidemiology and Clinical Outcomes 

Session 129. HIV-associated Malignancies: Lymphoma 

Session 136. Microbial Translocation Measurement and Associations 

Session 139. ART Effects: Gene Expression and Cellular Function 

Session 140. Frailty: From Mice to Men and Women 

Session 142. Renal Disease: Diagnosis, Predictors, and Drugs 

Session 145. TB: Incidence, Risk Factors, and Outcomes 

Session 146. TB Diagnostics 

Session 148. The “ART” of TB Treatment 

Session 158. HIV Risk Factors, Prevalence, and Barriers to Care 

Session 159. Family Planning: Unintended Pregnancy and Unmet Need 

Session 160. HIV in Peri- and Post-menopause 

Session 165. Pregnancy Complications among HIV + Women 

Session 166. PMTCT: Maternal and Child Health Outcomes 

Session 177. HIV and ART-related Complications and Treatment in 


Session 179. Tenofovir in Children 

Session 181. Immune Response to Perinatal HIV 

Session 182. Response to Pediatric Vaccines in Children and Youth 

Session 185. Oral PrEP and ARV Adherence 

Session 189. MSM in the Developing World 

Session 192. Disease Progression, Morbidity, and Mortality 

Session 195. Biological and Behavioral Transmission Risks 

Session 196. Reducing Risk 

Session 199. Virologic Failure, 2 nd - and 3 rd -line Therapy in RLS 


e Wednesday, 4-6 pm; B406 


Progress in Deciphering HIV Protective Immunity, 

a symposium in memory of Norman Letvin 

Conveners: 

Beatrice Hahn, Univ of Pennsylvania, 


Gary Nabel, Sanofi, Cambridge, MA, US 

158 

Viral Escape and Neutralizing Antibody 

Evolution in Early HIV-1 Infection 

Cynthia Derdeyn 


159 

The Promise and Challenge of Broad and 

Potent Neutralizing Antibody Responses to 

HIV-1 

Mark Connors 

HIV-Specific Immunity Section, NIAID, NIH, Bethesda, MD, US 

160 

The Role of CD4 T in Developing Durable 

Antibody Responses and as HIV Vaccine 

Hendrik Streeck 

US Military HIV Res Prgm, Walter Reed Army Inst of Res, Henry 

M Jackson Fndn, Silver Spring, MD 

161 

Stringent Control and Eventual Clearance of 

Highly Pathogenic SIV by Effector Memory 

T Cells 

Louis Picker 

Vaccine and Gene Therapy Inst, Oregon Natl Primate Res Ctr, 

Oregon Hlth and Sci Univ, Beaverton, US 


interested in basic immunology, the immunology of HIV infection, 

or HIV vaccine development. It is assumed that participants will 

have some knowledge of basic immunological concepts including 

the impact of HIV on the immune system. At the completion of the 

session, participants will be knowledgeable about how replicating 

vaccine vectors might provide protection against SIV, how different 

CD4 T cells populations may be active in fighting HIV infection, 

how broadly neutralizing antibodies develop in some HIV + subjects, 

and the characteristics and potential uses of newly discovered 

broadly neutralizing antibodies.


e Wednesday, 4-6 pm; Ballroom 3-4 

Session 51—Symposium 

HIV Testing and Monitoring the Epidemic: New 

Tools for Patients and Populations 

Conveners: 

Tsehaynesh Messele, African Society 

for Lab Med, Addis Ababa, Ethiopia 

Trevor Peter, Clinton Hlth Access 

Initiative, Boston, MA, US 

162 

HIV Self-testing: Opportunities and 

Challenges 

Julie Myers 

New York City Dept of Hlth and Mental Hygiene and Columbia 

Univ Med Ctr, NY, US 

163 

When Diagnosis Gets up Close and Personal: 

Point-of-Care Assays for Immunological and 

Virological Monitoring of HIV Disease 

Ilesh Jani 

Inst Nacional de Saude, Maputo, Mozambique 

164 

Accurate Cross-sectional HIV Incidence Testing 

Oliver Laeyendecker* 1,2 , R Brookmeyer 3 , M Kulich 4 , 

T Quinn 1,2 , J Konikoff 3 , M Cousins 2 , D Donnell 5,6 , and S Eshleman 2 

1 NIAID, NIH, Baltimore MD, US;; 2 Johns Hopkins Univ, 

Baltimore, MD, US;; 3 Univ of California, Los Angeles, US;; 

4 Charles Univ Prague, Czech Republic;; 5 Fred Hutchinson 

Cancer Res Ctr, Seattle, WA, US;; and 6 Univ of Washington, 

Seattle, US 

165 

Viral Load Measures: Patients, Populations, 

and Interpretations 

Irene Hall 


Objectives: The session is directed to clinicians and 

scientists interested in new laboratory methods for diagnosing HIV 

infection and monitoring the impact of treatment on individuals and 

populations. It is assumed that participants are familiar with the basic 

methods used to diagnose HIV infection and monitor the response 

to treatment. At the completion of the session, participants will be 

knowledgeable about home testing for HIV, monitoring response 

to therapy in resource-limited settings, measuring HIV incidence in 

populations, and the effect of treatment on community viral load. 

e Wednesday, 4-6 pm; Ballroom 1-2 

Session 52—Symposium 

TB on the Verge 

Conveners: 

Constance Benson, Univ of California, 

San Diego Antiviral Res Ctr, US 

Papa Salif Sow, Global Hlth Prgm, Bill & 

Melinda Gates Fndn, Seattle, WA, US 

166 

Strategies for Prevention of Active TB 

Gavin Churchyard 

Aurum Inst and Sch of Publ Hlth, Univ of the Witwatersrand, 


167 

Impact of Rapid Diagnostic Testing— 

Changing the TB Diagnostic Landscape 

Catharina Boehme 

Fndn for Innovative New Diagnostics, Geneva, Switzerland 

168 

Treatment of TB in Women and Children 

Soumya Swaminathan 

Natl Inst for Res in TB, Chennai, India 

169 

Management of Drug-resistant TB 

Alexander Pym 

KwaZulu-Natal Res Inst for TB and HIV, Nelson R Mandela Sch 

of Med, Univ of KwaZulu-Natal, Durban, South Africa 


interested in the pathogenesis, diagnosis, treatment, and prevention 

of TB. It is assumed that participants are familiar with basic aspects 

of the disease and the current tools available for management of 

the disease. At the completion of the session, participants will be 

knowledgeable about challenges and limitations in prevention of 

HIV-related TB, newer molecular diagnostic tools for detecting 

Mycobacterium tuberculosis and drug resistance, unique challenges 

in the diagnosis and treatment of TB in pregnant women and children, 

and new approaches for the treatment of multidrug resistant TB. 


Wednesday 


Poster Listings 


c Monday, 2:30-4 pm; Hall B2 

Session 53–Poster Abstracts 

HIV Persistence, Reservoirs, and Viremic Control 

170aLB Impact of Interleukin-7 and Raltegravir + Maraviroc 

Intensification on Total HIV DNA Reservoir: Results from 

ERAMUNE 01 

Christine Katlama* 1 , S Lambert 2 , L Assoumou 3 , L Papagno 4 , 

F Lecardonnel 4 , G Tambussi 5 , B Clotet 6 , M Youle 7 , D Costagliola 3 , 

B Autran 8 , and ERAMUNE-01 Study Group 

1 Hosp Pitie-Salpetriere, Paris, France;; 2 Lab of Virology, Univ Pierre 

et Marie Curie Paris 6, INSERM U943, France;; 3 Univ Pierre et Marie 

Curie Paris 6, INSERM U943, France;; 4 ORVACS with the support of 

the Bettencourt-Schueller Fndn;; 5 San Raffaele Hosp, Milan, Italy;; 6 Hosp 

Univ Germans Trias i Pujol, Fndn irsiCaixa, Badalona, Spain;; 7 Royal 

Free Hosp NHS Trust, London, UK;; and 8 Lab of Cellular and Tissular 

Immunology, Univ Pierre et Marie Curie Paris 6, INSERM U945, France 

175LB Natural Killer Cells Can Target and Eliminate Latently 

HIV-1 + Primary T Cells following Proviral Reactivation 

Mary Ann Checkley Luttge*, C Dobrowolski, M Shukla, B Luttge, 

H Mao, and J Karn 

Sch of Med, Case Western Reserve Univ, Cleveland, OH, US 

+ 176LB �� 

T Cells Is 

Associated with Lack of Progression in Viremic Individuals 

Nichole Klatt* 1,2 , S Bosinger3 , A Specht4 , M Lederman5 , D Camerini6 , 

M Paiardini3 , J Brenchley2 , F Kirchhoff4 , P Hunt7 , and G Silvestri3 1 2 Washington Natl Primate Res Ctr, Univ of Washington, Seattle, US;; Lab 

of Molecular Microbiology, NIAID, NIH, Bethesda, MD, US;; 3Yerkes Primate Res Ctr, Emory Vaccine Ctr, Emory University, Atlanta, GA, US;; 

4 5 Inst of Molecular Virology, Ulm Univ Med Ctr, Germany;; Case Western 

Reserve Univ/Univ Hosp Case Med Ctr, Cleveland, OH, US;; 6Inst for 

Immunology, Univ of California, Irvine, US;; and 7UCSF Positive Hlth 

Prgm, San Francisco, CA, US 

177LB �� 

Response in HIV-1 Superinfection 

Antoine Chaillon* 1,2 , G Wagner 1 , J Wertheim 1 , L Hepler 1 , S Kosakovsky 

Pond 1 , G Caballero 1 , M Pacold 3 , T Wrin 4 , D Richman 1,5 , and D Smith 1,5 

1 Univ of California, San Diego, La Jolla, US;; 2 INSERM UMR U966, 

Tours, France;; 3 Life Technologies, Foster City, CA, US;; 4 Monogram 

BioSci, Inc, San Francisco, CA, US;; and 5 VA San Diego Hlthcare System, 

CA, US 


c Wednesday, 2:30-4 pm; Hall B2 


ART, Complications, and TB 

178LB �� 

�� 

Results 

Scott Letendre* 1 , A Mills 2 , K Tashima 3 , D Thomas 4 , S Min 4 , S Chen 4 , 

I Song 4 , S Piscitelli 4 , and extended ING116070 Study Team 

1 UCSD Antiviral Res Ctr, San Diego, CA, US;; 2 Anthony Mills MD, Inc, 

Los Angeles, CA, US;; 3 The Miriam Hosp, Providence, RI, US;; 

and 4 GlaxoSmithKline, Research Triangle Park, NC, US 

170bLB Early Viral Dynamics after Cord Blood Stem Cell 

�� 

+ �� 

Patients 

M Nijhuis1 , M Kwon2 , J Kuball1 , P Ellerbroek1 , J Berenguer2 , A Stam1 , 

J Symons1 , D Richman3 , JL Diez-Martin2 , Annemarie Wensing* 1 , 

and European HIV Cure and Transplant Consortium 

1 2 Univ Med Ctr Utrecht, The Netherlands;; Gregorio Maranon G U Hosp, 

Madrid, Spain;; and 3Univ of California, San Diego, US 

171LB �� 

competent HIV Reservoirs in Perinatally Infected Youth 

Treated from Infancy: Towards Cure 

Katherine Luzuriaga* 1 , YH Chen2 , C Ziemniak2 , G Siberry3 , M Strain4 , 

D Richman4 , T-W Chun5 , C Cunningham6 , and D Persaud2 1 2 Univ of Massachusetts Med Sch, Worcester, US;; Johns Hopkins Univ 

Sch of Med, Baltimore, MD, US;; 3Maternal and Pediatric Infectious 

Disease Branch, NICHD, NIH, Bethesda, MD, US;; 4Univ of California 

San Diego, La Jolla and VA San Diego Hlthcare System, US;; 5NIAID, NIH, Bethesda, MD, US;; and 6Duke Univ Sch of Med, Durham, NC, US 

172LB HIV-1 DNA Decay Patterns in Blood during More than a 

�� 

Guillaume Besson* 1 , C Lalama2 , R Bosch2 , R Gandhi3 , M Bedison1 , 

E Aga2 , S Riddler1 , D McMahon1 , F Hong1 , and J Mellors1 1Univ of Pittsburgh Sch of Med, Division of Infectious Diseases, PA, US;; 

2Ctr for Biostatistics in AIDS Res, Harvard Sch of Publ Hlth, Boston, MA, 

US;; and 3Massachusetts Gen Hosp and Ragon Inst, Harvard Med Sch, 

Boston, US 

173LB Multifocal Detection of HIV-1 RNA in Lymphatic Tissues 

during Early Viral Recrudescence after Treatment Interruption 

Meghan Rothenberger* 1 , M Stevenson2 , G Beilman1 , J Chipman1 , 

A Khoruts1 , C Fletcher3 , C Reilly1 , S Wietgrefe1 , A Haase1 , and T Schacker1 1 2 3 Univ of Minesota, Minneapolis, US;; Univ of Miami, FL, US;; and Univ 

of Nebraska, Omaha, US 

174LB A Rapid Virion Recovery Assay Reveals a Larger Population 

+ �� 

T Cells than 

Previously Recognized 

Michele Sobolewski* 1 , A Cillo1 , C Lalama2 , R Bosch2 , and J Mellors1 179LB �� 

�� 

�� 

Anton Pozniak* 

1 2 Univ of Pittsburgh, PA, US and Harvard Univ, Boston, MA, US 

1 , H Mingrone2 , A Shuldyakov3 , C Brites4 , J Andrade5 , 

D Hagins6 , C Beltran Buendia7 , D Dorey8 , S Griffith9 , and S Min9 1 2 Chelsea and Westminster Hosp, London, UK;; Ciudad Autonoma de 

Buenos Aires, Argentina;; 3Saratov Regional Ctr of Prophylactic AIDS, 

Russian Federation;; 4Hosp Univ Professor Edgar Santos, Salvador, 

Brazil;; 5Hosp Civil de Guadalajare Fray Antonio Alcalde, Mexico;; 

6 7 Chatham CARE Ctr, Savannah, GA, US;; Hosp Barros Luco Trudeau, 

Santiago, Chile;; 8GlaxoSmithKline, Mississauga, Canada;; 

and 9GlaxoSmithKline, Research Triangle Park, NC, US 

180LB �� 

RTI or Raltegravir in HIV + st �� 

- 

�� 

Mark Boyd and SECOND-LINE Study Team 

The Kirby Inst, Univ of New South Wales, Sydney, Australia 

181LB Increasing Retention of Patients Starting ART: Karonga 

�� 

Rein Houben* 1 , T Mzembe2 , T van Boeckel3 , L Munthali2 , P Mzumara4 , 

A Jahn5 , F Chimbwandira5 , J Glynn1 , and A Crampin1,2 1 2 London Sch of Hygiene and Tropical Med, UK;; Karonga Prevention 

Study, Chilumba, Malawi;; 3Univ Libre de Bruxelles, Belgium;; 4Karonga District Hosp, Malawi;; and 5Ministry of Hlth, Lilongwe, Malawi 

182LB Efficacy and Safety of Maraviroc to Prevent Immune 

Reconstitution Inflammatory Syndrome in High-risk 

�� 

�� 

Juan Sierra-Madero* 1 , A Tierney2 , M Rassool3 , L Azzoni4 , I Sereti5 , 

J Andrade6 , L Mosqueda-Gomez7 , A Pineirua1 , I Sanne3 , M Lederman8 , 

and CADIRIS Study Team 

1Inst Nacional de Ciencias Med y Nutricion SZ, Mexico City, Mexico;; 

2 3 Univ of Pennsylvania, Philadelphia, US;; Clin HIV Res Unit Faculty 

of Hlth Sci, Univ of the Witwatersrand;; 4The Wistar Inst, Philadelphia, 

PA, US;; 5NIAID, NIH, Bethesda, MD, US;; 6Hosp Civil de Guadalajara, 

Mexico;; 7Capasits, Leon, Mexico;; and 8Case Western Reserve Univ, 

Cleveland, OH, US 

183LB No Difference in Risk of Preterm Birth among Pregnant 

Ugandan Women Randomized to Lopinavir/Ritonavir vs 

�� 

Deborah Cohan* 1 , P Natureeba2 , A Plenty1 , F Luwedde2 , J Mwesigwa2 , 

V Ades3 , B Nzarubara2 , T Clark1 , B Osterbauer1 , and E Charlebois1 1 2 Univ of California, San Francisco, US;; Infectious Disease Res 

Collaboration, Kampala, Uganda;; and 3New York Univ, NY, US 

st 184LB�� 

-Line ART Do Not Persist 

+ �� 

African Children: 

The 5-Year ARROW Trial 

Patricia Nahirya-Ntege* 1 , A Cook2 , V Musiime3 , A Kekitiinwa4 , K 

Nathoo5 , P Munderi1 , P Mugyenyi3 , S Bakeera-Kitaka4 , S Walker2 , and D Gibb2 1 2 MRC/UVRI Uganda Res Unit on AIDS, Entebbe;; MRC Clinical Trials 

Unit, London, UK;; 3Joint Clinical Res Ctr, Kampala, Uganda;; 4Baylor- Uganda/Paediatric Infectious Diseases Clin, Mulago, Kampala;; and 

5Univ of Zimbabwe, Harare 

185LB Non-Calcified Coronary Plaque and Macrophage Activation 

Markers Are Increased in HIV + Women 

Kathleen Fitch* 1 , S Abbara 1 , T Burdo 2 , K Williams 2 , P Eneh 1 , J Lo 1 , 

and S Grinspoon 1 

1 Massachusetts Gen Hosp, Boston, US and 2 Boston Coll, Chestnut Hill, MA, US 

186LB Effect of Statins on Immune Activation and Inflammation in 

HIV + �� 

Trial 

Grace McComsey* 1,2,3 , Y Jiang 1 , S Debanne 1 , B Clagett 1 , J Robinson 1 , 

D Labbato 1,2,3 , N Storer 1,2,3 , M Lederman 1,2 , and N Funderburg 1 

1 Case Western Reserve Univ, Cleveland, OH, US;; 2 Univ Hosp Case Med 

Ctr, Cleveland, OH, US;; and 3 �� 


187LB �� 

�� 

�� 

�� 

Craig Sponseller* 1 , R Morgan 2 , S Campbell 2 , J Aberg 3 , and M Thompson 4 

1 Kowa Pharmaceuticals America, Inc, Montgomery, AL;; 2 Kowa Res Inst, 

Inc, Morrisville, NC, US;; 3 New York Univ Sch of Med, NY, US;; and 4 AIDS 

Res Consortium of Atlanta, GA, US


188LB�� 

�� 

�� 

Kelly Dooley* 1 , A Luetkemeyer2 , J-G Park3 , R Allen4 , D Sutherland5 , 

F Aweeka2 , S Koletar6 , Y Cramer3 , J Bao7 , D Haas5 , and A5306 Study Team 

1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; Univ of 

California, San Francisco, US;; 3Statistical and Data Analysis Ctr, 

Harvard Sch of Pub Hlth, Cambridge, MA, US;; 4Social and Sci Systems, 

Inc, Silver Spring, MD, US;; 5Vanderbilt Univ Sch of Med, Nashville, 

TN, US;; 6Ohio State Univ, Columbus, US;; and 7Division of AIDS, NIH, 


189LB�� 

the Benefit of Concurrent Isoniazid Preventive Therapy with 

ART�� 

of a Randomized Controlled Trial 

Molebogeng Rangaka* 1,2,3 , R Wilkinson2,4,5,6 , K Wilkinson2,5 , J Glynn3 , 

A Boulle1 , G Maartens7 , and ART plus IPT Study Team 

1Ctr for Infectious Disease Epidemiology and Res, Sch of Hlth Sci, Cape 

Town, South Africa;; 2Clinical Infectious Disease Res Initiative, Univ of 

Cape Town, South Africa;; 3London Sch of Hygiene and Tropical Med, 

UK;; 4Inst of Infectious Diseases and Molecular Med;; 5MRC Natl Inst for 

Med Res, London, UK;; 6 201 Divergent Patterns of CCR5 versus Alternative Co-receptormediated 

Entry in Pathogenic Rhesus Macaque and Non- 

�� 

Sarah Elliott* 

Imperial Coll London, Norfolk Place, UK;; and 

7Univ of Cape Town, South Africa 

1 , N Riddick1 , N Francella1 , M Paiardini2 , C Derdeyn2 , 

G Silvestri2 , and R Collman1 1 2 Univ of Pennsylvania, Philadelphia, US and Yerkes Natl Primate Res 

Ctr, Emory Univ, Atlanta, GA, US 

202 HIV-1 Tropism and Co-receptor Binding Stoichiometry 

Melissa Zarr* 1 and R Siliciano1,2 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Howard 

Hughes Med Inst, Baltimore, MD, US 

203� �� 

Are Highly Permissive to HIV-1 ex vivo 

S Kohler, Joy Folkvord*, and E Connick 

Univ of Colorado Denver, Aurora, US 

204� �� 

Monitoring HIV-1 Envelope Maturation 

Z Stolp, S Diaz, A Stotland, B Hilton, and Roland Wolkowicz* 

San Diego State Univ, CA, US 

205� �� 

+ �� 

T Lymphocytes 

+ 190LB�� 

Patients 

in a Medium Burden TB Setting 

Jonathan Golub* 1,2 , V Saraceni3 , S Cavalcante3,4 , S Cohn1 , A Pacheco4 , 

L Moulton1,2 , R Chaisson1,2 , and B Durovni3,5 1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Johns Hopkins 

Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 3 Rio de Janeiro 

City Hlth Secretariat, Brazil;; 4 FIOCRUZ, Rio de Janeiro, Brazil;; and 

5 Federal Univ of Rio de Janeiro, Brazil 



Envelope/Entry/Tropism/Transmission 

192 Dendritic Cell-to-T Cell HIV Transmission Is a 

Drug-insensitive Mode of Infection 

Jocelyn Kim* 1,2 , A Sigal 1 , and D Baltimore 1 

Eveline Santos da Silva* 1 , M Mulinge 1 , M Lemaire 1 , A Rybicki 1 , 

C Masquelier 1 , J-Y Servais 1 , J-C Schmit 1,2 , and D Perez Bercoff 1 

1 CRP-Sante, Luxembourg and 2 Ctr Hosp de Luxembourg 

c Tuesday, 2:30-4 pm; Hall B2 


Transcription/Reverse and Forward, 

Splicing/Replication 

206 Cyclin-dependent Kinases Support HIV-1 Reverse Transcription 

Jin Leng* 1,2 , H-P Ho 3 , M Buzon 1,2 , F Pereyra 2,4 , X Yu 2 , E Chang 3 , 

and M Lichterfeld 1 

1 Massachusetts Gen Hosp, Boston, US;; 2 Ragon Inst of MGH, MIT, 

and Harvard, Boston, MA, US;; 3 City Univ of New York, NY, US;; 

and 4 �� 

1 2 California Inst of Tech, Pasadena, US and David Geffen Sch of Med, 

Univ of California, Los Angeles, US 

193 Actin Dynamics Differentially Regulate Cell-to-Cell Transfer 

+ �� 

T Cells 

Marc Permanyer*, E Pauls, B Clotet, and J Este 

IrsiCaixa AIDS Res Inst, Badalona, Spain 

194� �� 

�� 

Virological Synapse Target Cells 

Talia Swartz*, A Esposito, N Durham, and B Chen 

Mt Sinai Sch of Med, New York, NY, US 

195� �� 

�� 

Maria Blasi* 1 , P Chen2 , B Chen2 , B Balakumaran1 , D Negri1,3 , A Cara1,3 , 

and M Klotman1 1 2 Duke Univ Med Ctr, Durham, NC, US;; Mt Sinai Sch of Med, New York, 

NY, US;; and 3Inst Superiore di Sanita, Rome, Italy 

196� �� 

�� 

�� 

MS Valera1 , S Ziglio1 , Laura de Armas Rillo* 1 , J Barroso Gonzalez1 , 

L Garcia Exposito1 , I Puigdomenech2 , JD Machado1 , J Blanco2 , 

and A Valenzuela-Fernandez1 1 2 Univ of La Laguna, Spain and Univ Autonoma de Barcelona, Spain 

+ 197� �� 

�� 

Adhesion Molecule Mediated Virus Adsorption 

Joseph Kononchik Jr* and P Sun 

NIAID, NIH, Rockville, MD, US 

198� �� 

�� 

P Colin1 , Y Benureau1 , I Staropoli1 , Y Wang1 , O Hartley2 , A Brelot1 , 

F Arenzana-Seisdedos1 , and Bernard Lagane* 1 

1 2 Inst Pasteur, Paris, France and Univ of Geneva, Switzerland 

199� �� 

�� 

�� 

Kelechi Chikere* 1 , N Webb1 , T Chou1 , P Gorry2 , and B Lee1 1 2 Univ of California, Los Angeles, US and Burnet Inst, Melbourne, 

Australia 

200 HIV-1 Co-receptor Switch in Treatment-naïve Patients: 

�� 

Virginie Mortier* 1 , D Staelens1 , K Dauwe1 , L Vancoillie1 , 

W Cabooter2 , F Van Wanzeele3 , L Vandekerckhove3 , D Vogelaers3 , 

K Chalmet1 , and C Verhofstede1 207 HIV-1 Vpu and Cellular TASK Proteins Suppress 

Transcription of Unintegrated HIV-1 DNA 

Nkiruka Emeagwali* 

1 2 3 Ghent Univ, Belgium;; MSD Belgium;; and Ghent Univ Hosp, Belgium 

1 and J Hildreth2 1 2 Warren Alpert Med Sch of Brown Univ, Providence, RI, US and Univ of 

California, Davis, US 

208� �� 

�� 

Alona Kuzmina* 1 , N Verstraete2 , O Bensaude2 , and R Taube1 1 2 Ben Gurion Univ of the Negev, Beer Sheba, Israel and Inst de Biologie 

de l’Ecole Normale Superieure, Paris, France 

209 Identification of Anti-HIV Activity of RNA Processing/Splicing 

�� 

Yoon-Jeoung Koh* and J-C You 

Natl Res Lab for Molecular Virology, Catholic Univ of Korea Sch of 

Med, Seoul 

210 Staufen-1 Interacts with HIV-1 Rev and HERV-K Rec Proteins 

to Assist in Nucleocytoplasmic Viral RNA Transport 

K Hanke, O Hohn, K Fiddeke, and Norbert Bannert* 

Robert Koch Inst, Berlin, Germany 

211� �� 

in HIV Transcription 

Alba Ruiz*, E Pauls, B Clotet, and J EsteRetrovirology Lab Irsi 

Caixa, Hosp Germans Trias i Pujol, Badalona, Spain 

212� �� 

HIV-1 Replication in Jurkat T Cells 

Ananda Ayyappan Jaguva Vasudevan* 1 , M Kramer1 , A Hain1 , 

R Linka2 , R Hartig2 , B Schraven1 , D Haussinger1 , A Borkhardt1 , 

and C Munk1 1Heinrich Heine Univ, Med Faculty, Dusseldorf, Germany and 

2Otto-von-Guericke Univ of Magdeburg, Germany 



Accessory Proteins/Gag 

213� �� 

�� 

Sreya Tarafdar* 1,2 , J Poe1 , and T Smithgall1 1 2 Univ of Pittsburgh Sch of Med, PA, US and Univ of Pittsburgh Grad Sch 

of Publ Hlth, PA, US 

214 Vpr Is Required for the Expression and Replication of 

+ 

�� 

T Cells 

Benjamin Trinite*, E Ohlson, S Rana, J Alster, I Voznesensky, 

and D Levy 

New York Univ Coll of Dentistry, NY, US 


Poster Listings



215� �� 

Helix Plays an Important Role in the Viral Release and 

�� 

C De Candia, Gabriel Duette*, C Espada, H Salomon, and M Carobene 

Inst de Investigaciones Biomed en Retrovirus y SIDA, Univ de Buenos 

Aires, Consejo Nacional de Investigaciones Cientficas y Tcnicas, 

Argentina 

216� �� 

�� 

Siriphan Manocheewa* 1 , V Swain1 , E Lanxon-Cookson1 , M Kim1 , 

D Westfall1 , M Rolland2 , and J Mullins1 1 2 Univ of Washington, Seattle, US and US Military HIV Res Prgm, Henry M 

Jackson Fndn for the Advancement of Military Med, Rockville, MD, US 



Assembly—Putting It All Together 

217� �� 

�� 

Pascal Jalaguier* 1 , R Cantin1 , and M Tremblay1,2 c Tuesday, 2:30-4 pm; Hall B2 


Restriction Factors: APOBEC and Others 

228� �� 

�� 

�� 

Valentina Svicher* 

1 2 Ctr Hosp Univ de Quebec-CHUL, Canada and Univ Laval, Canada 

218� �� 

Replication 

Lillian Kuo*, K Fujii, and E Freed 

HIV Drug Resistance Prgm, NCI-Frederick, MD, US 

1 , C Alteri1 , MC Bellocchi1 , S Fourati2 , D Armenia1 , 

L Carioti1 , A-G Marcelin2 , V Calvez2 , F Ceccherini-Silberstein1 , 

C-F Perno1,3 , and DIVA Study Group 

1 2 Univ of Tor Vergata, Rome, Italy;; Hosp Pitie Salpietrere, Paris, France;; 

and 3Natl Inst for Infectious Diseases L Spallanzani, Rome, Italy 

229� �� 

�� 

�� 

Chisu Song* 1 , R Levinson2 , L Sutton2 , R Daquila1 , and J Donahue2 1Northwestern Univ, Feinberg Sch of Med, Chicago, IL, US and 

2Vanderbilt Univ Sch of Med, Nashville, TN, US 

230� �� 

Preventing Retroviral Integration But Is Dedicated to Impair 

�� 

K Belanger, M Savoie, J-F Couture, and Marc-Andre Langlois* 

Univ of Ottawa, Canada 

231 Vif-Independent in vivo Escape of HIV from Lethal 

�� 

John Krisko*, F Martinez-Torres, V Garcia, and J Foster 


219 Dual-tagged HIV-1 Provirus Enhances Dynamic Studies of 

�� 

Mingli Qi* 1 , L Ding 1 , and P Spearman 1,2 

1 2 Emory Univ, Atlanta, GA, US and �� 

220� �� 

Intracellular HIV-1 Budding 

Jiwei Ding* 1 , L Sun2 , P Du2 , S Cen1 , G Gao2 , and L Su3 1Inst of Med Biotech, Chinese Academy of Med Sci, and Peking Univ Med 

Coll, Beijing;; 2Inst of Biophysics, Chinese Academy of Med Sci, Beijing;; 

and 3 232 Computational Identification of Protein Complexes Involved 

in Cellular Regulation of HIV Infection Reduces the 

Complexity of the HIV Regulatory Network 

Kevin Olivieri* 

Univ of North Carolina at Chapel Hill Sch of Med, US 

1 , L Pache1 , S Chanda1 , J Young2 , S Jaeger3 , N Krogan3 , 

D Emig4 , and T Idekker4 1 2 Sanford-Burnham Med Res Inst, San Diego, CA, US;; Salk Inst, San 

Diego, CA, US;; 3Univ of California, San Francisco, US;; and 4Univ of 

California, San Diego, US 

233 Comparative Profiling of Deamination Rates and Target 

�� 

�� 

Kasandra Belanger*, M Savoie, and M-A Langlois 

Univ of Ottawa, Canada 

221 HIV-1 Virions Incorporate MCM DNA Helicase Which 

Modulates Viral Replication in the Newly Infected Cells 

Steven Santos* 1 , Y Obukhov 2 , S Nekhai 2 , M Bukrinsky 1 , 

and S Iordanskiy 1 

1 The George Washington Univ Sch of Med and Hlth Sci, Washington, DC, 

US and 2 Howard Univ Coll of Med, Washington, DC, US 



(see Session 28 on Tuesday for corresponding Themed Discussion) 

Restriction Factors: Old and New 

222� �� 

� for the 

�� 

Sean Evans* 1 , X Han1,2 , X Zhou1,2 , J Du2 , W Zhang2 , G Wang2 , 

and X-F Yu1,2 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US 

and 2 236� �� 

in vivo 

Marcel Ooms* 

First Hosp of Jilin Univ, China 

1 , B Brayton2 , M Letko1 , S Majdak1 , F Hecht3 , 

J Barbour2 , and V Simon1 1 2 Mt Sinai Sch of Med, New York, NY, US;; Hawaii Ctr for AIDS, Univ of 

Hawaii at Manoa, Honolulu, US;; and 3Univ of California, San Francisco, US 

227 Novel Regulation of SIV Vpx-mediated SAMHD1 Degradation 

Wei Wei* 1 , H Guo 1 , X Han 1 , X Liu 1 , S Evans 2 , X Zhou 2 , W Zhang 1 , 

and X-F Yu 2 

1 First Hosp of Jilin Univ, Inst of Virology and AIDS Res, China and 

2 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US 


234� �� 

vif Controls Viral Replication 

�� 

Ryan Troyer* 1 , J Thompson1 , J Elder2 , and S VandeWoude1 1 2 Colorado State Univ, Fort Collins, US and The Scripps Res Inst, 

La Jolla, CA, US 

235 Gelsolin Restricts HIV-1 during Early Viral Infection 

Laura de Armas Rillo*, L Garcia Exposito, S Ziglio, J Barroso 

Gonzalez, MS Valera, JD Machado, and A Valenzuela-Fernandez 

Univ of La Laguna, Spain 

223� �� 

�� 

Michael Letko* 1 , M Ooms1 , G Silvestri2 , and V Simon1 1 2 Mt Sinai Sch of Med, New York, NY, US and Emory Univ Sch of Med, 


224� �� 

and Virion Incorporation of Human Antiviral Proteins 

�� 

Taisuke Izumi*, R Burdick, W-S Hu, and V Pathak 

HIV Drug Resistance Prgm, Natl Lab for Cancer Res, NCI-Frederick, 

MD, US 

225� �� 

Degradation 

Sultan Ali* 1 , C Schwartz1,2 , and O Rohr1,2 c Wednesday, 2:30-4 pm; Hall B2 


Macrophage–HIV Interactions: Cell Biology and 

Treatment 

237� �� 

Tetraspanin and DC-SIGN Enriched Compartments that Are 

�� 

Erica Johnson*, H Chu, P Spearman, and R Chakraborty 

Emory Univ and Children�s Hlthcare of Atlanta, GA, US 

238� �� 

Acutely HIV 

1 2 Univ of Strasbourg, France and IUT of Schiltigheim, Strasbourg, France 

226� �� 

�� 

Zeyun Mi*, Q Zhang, J Zhou, J Ding, L Yu, and S Cen 

Inst of Med Biotech, Chinese Academy of Med Sci, Beijing 

+ �� 

Dwayne Baxa* 1 , M Golembieski1 , M Golembieski1 , L Shetron-Rama2 , 

and N Markowitz1 1 2 Henry Ford Hosp, Detroit, MI, US and Eastern Michigan Univ, 

Ypsilanti, US 

239� �� 

�� 

of Pre-integration Complexes 

Gokul Swaminathan*, S Navas-Martin, and J Martin-Garcia 

Drexel Univ Coll of Med, Philadelphia, PA, US 

240 17�� 

through Induction of Interferon-� 

Carley Tasker* 1 , J Ding 1 , M Schmolke 2 , A Rivera-Medina 1 , 

A Garcia-Sastre 2 , and T Chang 1 

1 Univ of Med and Dentistry of New Jersey, Newark, US and 2 Mt Sinai Sch 

of Med, New York, NY, US




Shutting the Door on HIV Entry 

241� �� 

251� �� 

�� 

�� 

Joseph Casazza*, A Vostal, D Ambrozak, B Hill, E Boritz, I Gong, 

Geoffrey Ferir*, K Palmer, and D Schols 

D Douek, and R Koup 

Rega Inst for Med Res, Univ of Leuven, Belgium 

Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US 



(see Session 45 on Wednesday for corresponding Themed Discussion) 

Transmitted/Founder Viruses 

244� �� 

Infection in Individuals Infected with Multiple Transmitted/ 

�� 

Hongshuo Song* 1 , F Cai 1 , V Ganusov 2 , J Pavlicek 1 , B Keele 3 , H Li 4 , 

G Shaw 4 , B Haynes 1 , B Hahn 4 , and F Gao 1 

1 Duke Univ Med Ctr, Durham, NC, US;; 2 Univ of Tennessee, Knoxville, 

US;; 3 SAIC-Frederick Inc, MD, US;; and 4 Univ of Pennsylvania, 


245 MTCT Is Associated with a Gag-Protease-driven Viral 

�� 

Vanessa Naidoo* 1 , J Mann 1 , J Carlson 2 , C Brumme 3 , C Thobakgale 1 , 

P Goulder 4 , D Heckerman 2 , Z Brumme 3,5 , M Brockman 3,5 , and T Ndung’u 1 

1 HIV Pathogenesis Prgm, Univ of KwaZulu-Natal, Durban, South Africa;; 

2 Microsoft Res, Los Angeles, CA, US;; 3 BC Ctr for Excellence in HIV/ 

AIDS, Vancouver, Canada;; 4 Univ of Oxford, UK;; and 5 Simon Fraser 

Univ, Burnaby, Canada 



HIV Compartments 

242� �� 

�� 

Andy Chevigne* 1 , V Fievez1 , S Delhalle1 , M Counson1 , J-M Plesseria1 , 

C Devaux1 , J-C Schmit1,2 , and S Deroo1 1 2 CRP-Sante, Luxembourg and Ctr Hosp de Luxembourg 

243� �� 

�� 

on Magnetic Proteoliposomes 

Virginie Fievez* 1 , S Deroo1 , S Delhalle1 , J Mathu1 , F Martin1 , 

C Devaux1 , J-C Schmit1,2 , and A Chevigne1 252� �� 

�� 

Matthieu Perreau* 

1 2 CRP Sante, Luxembourg and CHL, Luxembourg 

1,2 , A-L Savoye1,2 , E De Crignis1,2 , J-M Corpataux1,2 , 

R Cubas3 , E Haddad3 , L De Leval1 , C Graziosi1,2 , and G Pantaleo1,2,4 1 2 Lausanne Univ Hosp, Switzerland;; Univ of Lausanne, Switzerland;; 

3 4 Vaccine and Gene Therapy Inst of Florida, Port St Lucie, US;; and Swiss 

Vaccine Res Inst, Lausanne 

253 Low-level HIV Plasma Viremia Is Rarely Due to Viral 

�� 

Infected Cells During Systemic Inflammation 

Marta Bull* 1,2 , C Mitchell1 , S Styrchak2 , J Soria3 , A LaRosa3 , 

E Ticona3 , J McKernan-Mullin2 , B Sorensen1 , R Coombs1 , and L Frenkel1,2 1 2 Univ of Washington, Seattle, US;; Seattle Children�s Res Inst, WA, US;; 

and 3Assn Civil Impacta Salud y Educacion, Lima, Peru 



254� �� 

Genital Tract 

Elena Dukhovlinova* 1,2 , J Anderson1,3,4 , D Moore2 , M Cohen1,4 , 

R Swanstrom1,4 , and Ctr for HIV/AIDS Vaccine Immunology Consortium 

1 2 Univ of North Carolina Ctr for AIDS Res;; Univ of North Carolina 

Lineberger Comprehensive Cancer Ctr;; 3Bristol-Myers Squibb;; and 4Univ of North Carolina 

255� �� 

�� 

�� 

M Surdo 1 , C Orlandi 2 , A Casabianca 2 , F Di Santo 1 , I Malet 3 , 

MF Cortese 1 , A-G Marcelin 3 , M Magnani 2 , C-F Perno 1,4 , 

and Francesca Ceccherini-Silberstein* 1 

1 Univ of Rome Tor Vergata, Italy;; 2 Univ of Urbino Carlo Bo, Pesaro, 

Italy;; 3 Groupe Hosp Pitie-Salpetriere, UPMC Univ Paris 06, France;; 

and 4 INMI L Spallanzani, Rome, Italy 

246� �� 

�� 

�� 

Kyle Nakamura* 1 , C Cerini1 , E Sobrera1 , L Heath2 , M Sinkala3 , 

C Kankasa4 , D Thea5 , J Mullins2 , L Kuhn6 , and G Aldrovandi1 1 2 �� 

Univ of Washington, Seattle, US;; 

3 4 5 Lusaka District Hlth Mgmt Team, Zambia;; Univ of Zambia, Lusaka;; Boston 

Univ Sch of Publ Hlth, MA, US;; and 6Columbia Univ, New York, NY, US 

247� �� 

Differentially Utilize CCR5 

Zahra Parker* 1 , S Iyer1 , C Wilen1 , N Parrish1 , R Berro2 , B Lee3 , 

J Moore2 , G Shaw1 , B Hahn1 , and R Doms1,4 1 2 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US;; Weill 

Med Coll of Cornell Univ, New York, NY, US;; 3Univ of California, Los 

Angeles, US;; and 4�� 248� �� 

�� 

Throughput Receptor Affinity Profiling 

Kelechi Chikere* 1 , N Webb1 , T Chou1 , P Gorry2 , and B Lee1 1 2 Univ of California, Los Angeles, US and Burnet Inst, Melbourne, Australia 

249� �� 

Divergent SIVsmm Strains Are Infectious and Replication 

Competent in vivo 

D Ma1 , H Li2 , C Xu1 , B Keele3 , J Estes3 , J Lifson3 , I Pandrea1 , G Shaw2 , 

B Hahn2 , and Cristian Apetrei* 1 

1 2 Ctr for Vaccine Res, Univ of Pittsburgh, PA, US;; Univ of Pennsylvania 

Perelman Sch of Med, Philadelphia, US;; and 3Frederick Natl Lab, MD, US 

250� �� 

Virus Impact Clinical Outcome in Vaginal R5 SHIV�� Transmission 

Lily Tsai* 1 , I Tasovski2 , AR Leda1 , M Chin2 , and C Cheng-Mayer1 256 Evidence of Long-term Persistence of Human Effector 

�� 

1 2 Aaron Diamond AIDS Res Ctr, New York, NY, US and Temple Univ Sch 

of Med, Philadelphia, PA, US 

+ T Cells Using Replication-defective Integrated 

HIV-1 Provirus as a Genetic Marker 

Hiromi Imamichi* 1 , V Natarajan2 , T Imamichi2 , J Adelsberger2 , 

C Rehm1 , and C Lane1 1 2 NIAID, NIH, Bethesda, MD, US and SAIC-Frederick Inc, MD, US 



HIV Genotypes and Phenotypes 

257� �� 

in HIV-1 Seroconverters from Different Risk Groups 

R McGovern1 , Z Brumme1,2 , C Johnson1 , R Hogg1,2 , E Wood1,3 , T Kerr1,3 , 

M Milloy1 , R Harrigan1,3 , Art Poon* 1,3 , and VANGUARD and 

VIDUS/ACCESS Cohort Studies 

1 2 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada;; Simon Fraser 

Univ, Burnaby, Canada;; and 3Univ of British Columbia, Vancouver, 

Canada 

258a�� 

�� 

with MTCT 

Li Yin* 1 , Y Cai1 , N Veras1 , K Chang1 , B Gardner1 , W Hou1 , 

K Nakamura2 , L Kuhn3 , G Aldrovandi2 , and M Goodenow1 1 2 Univ of Florida, Gainesville, US;; �� 

Los Angeles, CA, US;; and 3Columbia Univ, New York, NY, US 

258b�� 

Viral Load 

Emma Hodcroft* 1 , E Fearnhill2 , A Phillips3 , D Dunn2 , D Pillay4 , 

J Hadfield5, A Leigh Brown1 , and UK HIV Drug Resistance Database 

1 2 Univ of Edinburgh, Scotland;; MRC Clin Trials Unit, London, UK;; 

3 4 5 Royal Free Hosp, London, UK;; Univ Coll London, UK;; and Univ of 

Oxford, UK 

259� �� 

Martha Lewis* 1 , J de la Cruz1 , P Frohnen1 , H Ng1 , E Daar2 , and O Yang1 1 2 David Geffen Sch of Med, Univ of California, Los Angeles, US and LA 

BioMed, Harbor UCLA Med Ctr, US 

260� �� 

Become Viremic Controllers 

Xiaomei Kuang* 1 , A Le 1 , P Mwimanzi 1 , T Markle 1 , R Danroth 1 , 

T Ueno 2 , T Miura 3 , B Walker 4 , Z Brumme 1,5 , M Brockman 1,5 , 

and Acute HIV and Intl HIV Controllers Study Group 

1 Simon Fraser Univ, Vancouver, Canada;; 2 Kumamoto Univ, Japan;; 3 Univ 

of Nagasaki, Japan;; 4 Ragon Inst of MGH, MIT, and Harvard, Boston, 

MA, US;; and 5 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada



261� �� 

in the Gut 

Martha Lewis*, P Frohnen, D Reed, V Iyer, J Elliott, P Anton, 

and O Yang 

David Geffen Sch of Med, Univ of California, Los Angeles, US 

262 Viral Isolates from HLA-B*57 Elite Suppressors Have 

�� 

Chronic Progressors 

Maria Salgado* 1,2 , C Pohlmeyer2 , R Buckheit III2 , R Siliciano2,3 , 

and J Blankson2 c Monday, 2:30-4 pm; Hall B2 


HIV Infection Models 

272 Plasma Virus Populations in RT-SHIV 

1AIDS Res Inst IrsiCaixa, Inst dInvestigacio en Ciencies de la Salut 

Germans Trias i Pujol, Univ Autonoma de Barcelona, Badalona, Spain;; 

2 3 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; and Howard 

Hughes Med Inst, Baltimore, MD, US 

263 HIV Evolution under the Selective Pressure of Interferon in 

vitro 

Sylvie Rato*, B Vanwalscappel, and F Mammano 

INSERM U941, Paris, France 

+ Macaques Are 

Derived from Multiple Tissues 

Mary Kearney* 1 , C Kline2 , E Anderson1 , D Kordella1 , L Smith1 , 

C Croomer1 , J Lifson3 , J Mellors2 , J Coffin4 , and Z Ambrose2 1 2 HIV Drug Resistance Prgm, NCI-Frederick, MD, US;; Univ of 

Pittsburgh, PA, US;; 3AIDS and Cancer Virus Prgm, SAIC-Frederick Inc, 

MD, US;; and 4Tufts Univ, Boston, MA, US 

273 Correlation of Changes in the Biological Properties of HIV-1 

Envelope with Disease Progression in a Clade C SHIV + 

Rhesus Macaque 

For Yue Tso* 1 , L Abrahamyan1 , R Ruprecht2,3 , and C Wood1 1 2 Univ of Nebraska, Lincoln, US;; Dana-Farber Cancer Inst, Boston, MA, 

US;; and 3Harvard Med Sch, Boston, MA, US 

274� �� 

Gut Tissues during SIV Infection 

H Li, J Gillis, T Evans, and Keith Reeves* 

New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US 



Markers of HIV Disease Progression 

264 Endothelial Activation Biomarkers Increase after HIV-1 

�� 

Disease Progression and Mortality 

Susan Graham* 1,2 , N Rajwans3 , K Tapia1 , W Jaoko2 , B Estambale2 , 

S McClelland1,2 , J Overbaugh4 , and C Liles1,3 1 2 3 Univ of Washington, Seattle, US;; Univ of Nairobi, Kenya;; Univ of 

Toronto, Canada;; and 4 275a Pathogenic SIV Infection Is Associated with Expansion of the 

Enteric Virome 

S Handley 

Fred Hutchinson Cancer Res Ctr, Seattle, WA, US 

1 , L Thackray1 , G Zhao1 , Rachel Presti* 1 , A Miller2 , 

K Mansfield2 , J Brenchley3 , R Veazey4 , D Barouch5,6 , and H Virgin1 1 2 Washington Univ Sch of Med, St Louis, MO, US;; New England Primate 

Res Ctr, Harvard Med Sch, Southborough, MA, US;; 3NIAID, NIH, 

Bethesda, MD, US;; 4Tulane Natl Primate Res Ctr, Tulane Univ Sch of 

Med, Covington, LA, US;; 5Beth Israel Deaconess Med Ctr, Boston, MA, 

US;; and 6Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US 

265� �� 

�� 

Mohamed Abdel-Mohsen* 1 , A Raposo1 , D Nixon1 , T Liegler1 , 

R Hoh1 , J Wong1,2 , S Deeks1 , and S Pillai1,2 275b�� 

Macaques Reduces T Cell Activation and Restores T Cell 

Homeostasis 

Thomas Vanderford* 

1 2 Univ of California, San Francisco, US and VAMC, San Francisco, CA, US 

1 , C Steel2 , J Zeidan2 , J Yu1 , J Ahlers2 , C Nicolette3 , 

I Tcherepanova3 , M Cameron2 , R-P Sekaly2 , and G Silvestri1 1 2 Emory Univ, Atlanta, GA, US;; Vaccine & Gene Therapy Inst, Port St 

Lucie, FL, US;; and 3Argos Therapeutics, Durham, NC, US 

+ 266� �� 

NK Cells in 

Chronic HIV-1 Infection Are Associated with Slower Disease 

Progression 

Fareed Ahmad* 1 , H Hong2 , M Jackel1 , I-N Lu1 , N Bhatnagar1 , 

J Eberhard1 , B Bollmann1 , M Ballmeier1 , R Schmidt1 , D Meyer-Olson1 , 

and HIV Labor 

1 2 Hannover Med Sch, Germany and New England Primate Res Ctr, 

Harvard Med Sch, Southborough, MA, US 

270 Epitope Escape and Virus Evolution in the HIV-1 Gag Gene 

from Controllers with Long-term Non-progression 

Ling Yue* 1 , J Okulicz 2,3 , B Agan 2 , E Hunter 1 , and V Marconi 41 

Emory Vaccine Ctr, Atlanta, GA, US;; 2 Uniformed Svcs Univ of Hlth Sci, 

Bethesda, MD, US;; 3 Brooke Army Med Ctr, San Antonio, TX, US;; and 

4 Emory Univ Sch of Med, Atlanta, GA, US 

271 Elevated Levels of Activated Regulatory T Cells May Be 

Involved in Non-progression of HIV + Viremic Long-term 

Non-progressors 

J Gaardbo 1 , A Ronit 1 , H Hartling 1 , K Thorsteinsson 2 , H Ullum 1 , A Andersen 3 , 

and Susanne Nielsen* 1 

1 Rigshospitalet, Univ Hosp of Copenhagen, Denmark;; 2 Hvidovre Hosp, 

Univ Hosp of Copenhagen, Denmark;; and 3 Univ of Southern Denmark, 

Odensen 


+ 276� �� 

Innate Lymphoid 

Cells in the SIV + �� 

Haiying Li*, T Evans, J Gillis, and K Reeves 

New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US 

+ 267� �� T Cell Counts Correlates with HIV-1 

�� 

Risk of Disease Progression 

Melissa Norstrom* 1 , N Veras2 , W Huang3 , M Prosperi2 , J Cook3 , 

W Hartogensis4 , F Hecht4 , A Karlsson1 , and M Salemi2 1 2 Karolinska Inst, Stockholm, Sweden;; Univ of Florida, Gainesville, US;; 

3 4 Monogram Biosci Inc, South San Francisco, CA, US;; and San Francisco 

Gen Hosp, Univ of California, US 

268� �� 

�� 

of HIV Disease Progression 

Ashley Olson* 1 , G Touloumi2 , R Geskus3,4 , L Meyer5 , M Prins3,4 , 

G Chene6 , A De Luca7 , D Costagliola8 , K Porter1 , and CASCADE 

Collaboration in EuroCoord 

1 2 MRC Clin Trials Unit, London, UK;; Univ of Athens, Greece;; 

3 4 Amsterdam Publ Hlth Svc, The Netherlands;; Amsterdam Med Ctr, 

The Netherlands;; 5INSERM U1018, Univ Paris Sud, Le Kremlin Bicetre, 

France;; 6INSERM U897 and CIC-EC7, Univ Bordeaux Segalen, Ctr Hosp 

Bordeaux, France;; 7Catholic Univ of the Sacred Heart, Rome, Italy;; and 

8INSERM EMI 0214, Ctr Hosp Univ Pitie Salpetriere, Paris, France 

269� �� 

�� 

Sui-Yuan Chang* 1,2 , P-H Lin2 , C-C Lai3 , M-S Tsai1 , J-L Yang4 , Y-C Su2 , 

C-J Yang5 , and C-C Hung1,2 1 2 Natl Taiwan Univ Hosp, Taipei;; Natl Taiwan Univ Coll of Med, Taipei;; 

3 4 Kaohsiung Med Univ Hosp, Taiwan;; Natl Taiwan Univ Hosp, Yun-Lin 

Branch;; and 5 277� �� 

Pathway during Chronic SIV Infection 

Sandra Bixler* and J Mattapallil 

Uniformed Svcs Univ, Bethesda, MD, US 

278 SIVAGM-Infected African Green Monkeys Respond 

�� 

Molly Perkins* 

Far Eastern Memorial Hosp, Taipei, Taiwan 

1 , N Calantone1 , S Whitted1 , L Canary1 , N Klatt1 , 

C Vinton1 , P Darrah2 , R Seder2 , V Hirsch1 , and J Brenchley1 1 2 NIAID, NIH, Bethesda, MD, US and Vaccine Res Ctr, NIAID, NIH, 


279� �� 

�� 

functionality 

Vasudha Sundaravaradan* 1 , R Saleem1,2 , M Gasper1 , A Ortiz3 , 

J Else3 , G Silvestri3 , J Aitchison1,2 , and D Sodora1 1 2 Seattle Biomed Res Inst, WA, US;; Inst of Systems Bio, Seattle, WA, US;; 

and 3Emory Univ, Atlanta, GA, US 

280� �� 

Natural Host of SIV 

Dongzhu Ma* 1 , A Jasinska 2 , K Raehtz 1 , V Wijewardana 1 , C Schmitt 2 , 

T Turner 3 , M Antonio 4 , I Pandrea 1 , N Freimer 2 , C Apetrei 1 , and Intl Consortium 

1 2 Ctr for Vaccine Res, Univ of Pittsburgh, PA, US;; Semel Inst for Neurosci 

and Human Behavior, Univ of California, Los Angeles, US;; 3Faculty of 

Natural and Agricultural Sci, Univ of the Free State, Bloemfontein, South 

Africa;; and 4MRC Unit, Gambia, West Africa 

281 In vivo�� 

of SIVagm�� in African Green Monkeys and Pigtailed Macaques 

Jan Kristoff* 1 , CW Gnanadurai2 , N Parish3 , D Ma1 , C Xu1 , L Catchpole1 , 

C Apetrei1 , B Hahn3 , F Kirchhoff2 , and I Pandrea1 1 2 Ctr for Vaccine Res, Univ of Pittsburgh, PA, US;; Inst of Molecular 

Virology, Univ of Ulm, Germany;; and 3Univ of Pennsylvania Perelman 

Sch of Med, Philadelphia, US




HIV and Monocytes, Macrophages, and Dendritic 

Cells 

Alejandro Gomez* 1 , M Ouellet 1 , and M Tremblay 1,2 

1 Laval Univ, Ctr Hosp Univ Quebec, Infectious Disease Res Ctr, Canada 

and 2 Laval Univ, Quebec, Canada 

290� �� 

Activation of Interferon-stimulated Genes 

in Antigen-presenting Cells 

N Kim, S Kukkunen, MD Martinez-Viedma, and Anna Aldovini* 

�� 



CD8 T Cells in HIV Infection 

282� �� 

�� 

Macrophages 

Charles Joly Beauparlant*, R Allary, L Robitaille, A Droit, 

J Estaquier, and J Corbeil 

Univ Laval, Quebec, Canada 

283� �� 

+ �� T Cells Are Independent of the Presence of 

the HIV-1 Envelope Glycoprotein 

Maria Rodriguez-Plata* 1 , I Puigdomenech 1 , N Izquierdo-Useros 1 , 

M Puertas 1 , J Carrillo 1 , I Erkizia 1 , B Clotet 1 , J Blanco 1 , and J Martinez-Picado 1,2 

1AIDS Res Inst IrsiCaixa, Inst dInvestigacio en Ciencies de la Salut 

Germans Trias i Pujol, Univ Autonoma de Barcelona, Badalona, Spain 

and 2Inst Catalana de Recerca i Estudis Avancats, Barcelona, Spain 

284� �� 

Cell Induced IDO Enzyme Activity: Implication for Clinical 

Outcome in HIV + Patients 

Mohammad-Ali Jenabian* 1 , M Patel1 , C Kanagaratham1 , D Radzioch1 , 

B Lebouche1 , C Tremblay2 , I Kema3 , N Gilmore1 , P Ancuta2 , and J-P Routy1,4 1 2 Res Inst of McGill Univ Hlth Ctr, Montreal, Canada;; Ctr Hosp Univ 

de Montreal Res Ctr, Canada;; 3Univ Med Ctr, Univ of Groningen, The 

Netherlands;; and 4Royal Victoria Hosp, McGill Univ Hlth Ctr, Montreal, 

Canada 

285� �� 

through a Vitamin D and Cathelicidin Dependent Autophagic 

Mechanism 

Grant Campbell* 1 and S Spector1,2 293� �� 

�� 

Primary Human CD8 T Cells 

Feras Al-Ghazawi* 

1 2 Univ of California, San Diego, La Jolla, US and �� 

San Diego, CA, US 

286� �� 

�� 

of SAMHD1 

Eduardo Pauls*, E Jimenez, A Ruiz, M Permanyer, R Pena, 

B Clotet, M Bofill, and J Este 

IrsiCaixa, Hosp Germans Trias i Pujol, Univ Autonoma de Barcelona, 

Badalona, Spain 

287� �� 

�� 

�� 

Huihui Tang* and S Spector 

�� 

288 Different Gene Expression Pattern in Mature and Immature 

�� 

E Calonge, J Garcia-Perez, A Munoz, and Jose Alcami* 

Inst de Salud Carlos III, Madrid, Spain 

289� �� 

through Type I Interferon 

1,2 , P Parmar1,2 , E Faller1,2 , S Sugden1,2 , H Cherid1,2 , 

J Kakal1 , A El Salfiti1,2 , and P MacPherson1,2,3 1 2 3 Univ of Ottawa, Canada;; Ottawa Hosp Res Inst, Canada;; and Ottawa 

Hosp, Canada 

294 Cytomegalovirus and HIV Infections Have Opposite Effects on 

CD8 + T Cell Differentiation and Proliferation 

Sulggi Lee* 1 , E Sinclair1 , Y Huang1 , D Bangsberg2 , M Lederman3 , 

F Hecht1 , J Martin1 , S Deeks1 , and P Hunt1 1 2 Univ of California, San Francisco, US;; Massachusetts Gen Hosp and 

Harvard Univ, Boston, US;; and 3Case Western Reserve Univ, Cleveland, 

OH, US 

295� �� 

+ �� T Cells in Humanized Mice 

Kei Sato* 1 , N Misawa1 , Y Satou1 , M Matsuoka1 , M Ito2 , and Y Koyanagi1 1 2 Inst for Virus Res, Kyoto Univ, Japan and Central Inst for Experimental 

Animals, Kanagawa, Japan 

296� �� 

Infection 

Mathieu Angin* 1 , M King1 , M Bhasin2 , S Sharma1 , T Murooka3 , 

T Mempel3 , B Walker1 , and M Addo1 1 2 Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US;; Beth Israel 

Deaconess Med Ctr Genomics and Proteomics Ctr, Dana-Farber/Harvard 

Cancer Ctr, Boston, MA, US;; and 3Ctr for Immunology and Inflammatory 

Diseases, Massachusetts Gen Hosp, Harvard Med Sch, Boston, US 

297 Elevated Levels of T Regulatory Cells and Immune 

�� 

Weiying Zhang*, T Nilles, K Althoff, and J Margolick 

Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US 

298 ISG15 Expression in CD8 + T Cells Aids in the Containment of 

HIV 

Ana Gonzalez* 1 , W Ochieng1 , H-H Chang2 , A Shi1 , H-X Liao3 , 

K Soderberg3 , J Schmitz1 , B Haynes3 , and N Letvin1 1Ctr for Virology and Vaccine Res, Beth Israel Deaconess Med Ctr, 

Harvard Med Sch, Boston, MA, US;; 2�� Harvard Med Sch, Boston, MA, US;; and 3Human Vaccine Inst, Duke Univ 

Sch of Med, Durham, NC, US 



Killer T Cells 

299� �� + �� 

+ �� 

Central 

�� + T Lymphocytes 

Antonio Valentin*, J Li, B Felber, and G Pavlakis 

NCI-Frederick, MD, US 



300� �� 

T Nomura 1,2 , H Ishii 1,2 , N Iwamoto 1,2 , H Yamamoto 1 , and Tetsuro Matano* 1,2 

1 Natl Inst of Infectious Diseases, Tokyo, Japan and 2 Univ of Tokyo, Japan 

301 The Efficiency of CD8 + T Cell-mediated Elimination of Nonproductively 

HIV + �� + T Cells Is a Critical Determinant of 

291 A Selectively Reduced Toll-like Receptor Responsiveness and 

�� 

in HIV-1 + Patients 

Jihong Dai*, E Jacobs, N Reilly, K Tulloch, S Hodder, 

and P Fitzgerald-Bocarsly 

Univ of Med and Dentistry of New Jersey, Newark, US 

292� �� 

�� 

�� 

N Bhatnagar1 , A Fareed1 , H Hong2 , J Eberhard1 , I-N Lu1 , M Ballmeier1 , 

R Schmidt1 , R Jacobs1 , and Dirk Meyer-Olson* 1 

HIV-1 Control 

H Yang 

1 2 Hannover Med Sch, Germany and New England Primate Res Ctr, 

Southborough, MA, US 

1 , R Smyth2 , G Hancock1 , J Mak3 , M Davenport4 , and Lucy Dorrell* 1 

1 2 3 Univ of Oxford, UK;; CNRS, Strasbourg, France;; Deakin Univ, 

Melbourne, Australia;; and 4Univ of New South Wales, Australia 

302 Pre-stimulated Cytotoxic T Lymphocytes from HIV-1 + 

+ �� 

T Cells Infected with 

HIV-1 from Viral Latent Reservoir 

Kai Deng*, L Shan, C Durand, J Blankson, and R Siliciano 


303� �� 

�� 

Untreated Progressors 

David Shasha*, F Porichis, D Karel, O Angiuli, D Kaufmann, 

and B Walker 

Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US 

304� �� 

Generation of Effector HIV-specific CD8 T Cells in Acute 

HIV Infection 

P Ngauv 1 , J Ananworanich 2,3 , F Procopio 1 , D Srinivasan 1 , C Steel 1 , 

A Schuetz 3 , M deSouza 3 , N Michael 4 , J Kim 2,4 , Lydie Trautmann* 1 , 

and RV254/SEARCH 010 Study Group 

1 Vaccine and Gene Therapy Inst, Port St Lucie, FL, US;; 2 Thai Red Cross 

AIDS Res Ctr, Bangkok;; 3 Armed Forces Res Inst of Med Sci, Bangkok, 

Thailand;; and 4 Walter Reed Army Inst of Res, Silver Spring, MD, US



305� �� 

Avidity of HIV-1-specific CD8 T Cell Responses through 

�� 

Selena Vigano* 1 , F Bellutti-Enders1 , A-L Savoye1 , V Rozot1 , 

C Cellerai1 , M Cavassini1 , S Ding2 , P-A Bart1 , G Pantaleo1,3 , and A Harari1,3 1 2 Lausanne Univ Hosp, Switzerland;; eurovacc, Amsterdam, The 

Netherlands;; and 3Swiss Vaccine Res Inst, Lausanne 

306� �� 

Markers of HIV Disease Progression and Attenuates 

Anti-HIV T Cell Responses in vitro 

Basile Siewe* 1 , J Stapleton2 , J Martinson1 , A Kesharvazian1 , 

I Pandrea3 , A French1,4 , P Demarais4 , and A Landay1 1 2 Rush Univ Med Ctr, Chicago, IL, US;; Univ of Iowa and Iowa City 

VAMC, US;; 3Ctr for Vaccine Res, Univ of Pittsburgh, PA, US;; and 4CORE Ctr, Stroger Hosp of Cook County, Chicago, IL, US 

307� �� 

Mutations within HLA-B*5701-restricted Epitopes 

Marcus Buggert* 1 , M Norstrom1 , M Salemi2 , F Hecht3 , and A Karlsson1 1 2 Karolinska Inst, Stockholm, Sweden;; Univ of Florida, Gainesville, US;; 

and 3 317� �� 

in Virologically Suppressed ART-treated Patients 

Miriam Lichtner*, R Rossi, C Mascia, R Marocco, T Tieghi, 

F Mengoni, G Russo, P Zuccala, C Mastroianni, and V Vullo 

Sapienza Polo Pontino Univ of Rome, Italy 

318 Early Treatment Leads to a Better Profile of HIV 

�� 

S Hue 

Univ of California, San Francisco, US 

1 , Laurent Hocqueloux* 2 , M Surenaud1 , C Manier1 , J Guignard2 , 

C Poillet1 , T Prazuck2 , C Lacabaratz1 , and Y Levy1 1 2 INSERM U955, Creteil, France and Ctr Hosp Regional d’Orleans, France 

319 The Long-term Persistence of Monoclonal Gammopathy 

in Patients on ART Is Associated with Epstein-Barr Virus 

Replication 

David Ouedraogo* 1,2,3 , A Makinson4 , J-P Vendrell1,2,3 , M-L Casanova4 , 

A De Jong5 , N Nagot1 , J Reynes4 , P Van de Perre1,3 , and E Tuaillon1,2,3 1 2 INSERM U1058, Univ Montpellier 1, France;; Ctr Hosp Regional 

Univ de Montpellier, Inst de Recherche en Biotherapies, France;; 3Ctr Hosp Regional Univ de Montpellier, France;; 4Ctr Hosp Regional Univ 

de Montpellier, UMI 233, France;; and 5Univ de Montpellier, Hosp la 

Colombiere, France 

308 Immune Selection in a Pigtailed Macaque Model of SIV 

Central Nervous System Disease: Costs and Consequences 

Sarah Beck*, S Queen, and J Mankowski 




Immune Restoration 

311� �� 

Successful HIV Suppression 

Emma Devitt* 1 , JM Rodriguez 1 , S Mandalia 1,2 , and A Pozniak 1 

1 Chelsea and Westminster Hosp, London, UK and 2 Imperial Coll London, UK 

+ 312� �� T Cells Is Associated with 

Impaired Immunological Recovery in HIV + Patients under 

HAART 

A Sennepin1,2,3 , F Baychelier1,3 , R Ho Tsong Fang2 , C Katlama4 , A Simon5 , 

J Crouzet2 , V Vieillard1,3 , and Patrice Debre* 1,3 

1 2 INSERM UMRS 945, Paris, France;; Innavirvax SA, Evry, France;; 

3 4 Unive Pierre et Marie Curie, Paris-6, France;; Hosp Pitie-Salpetriere, 

Svc des Maladies Infectieuses, Paris, France;; and 5Hosp Pitie-Salpetriere, 

Svc de Med Interne, Paris, France 

315 Hyaluronic Acid as a Predictor of Immune Reconstitution 

following ART 

Ala Dababneh* 1 , N Cummins 1 , G Bren 1 , Z Temesgen 1 , D Bangsberg 2 , 

and A Badley 1 

1 Mayo Clin, Rochester, MN, US and 2 Massachusetts Gen Hosp, Harvard 

Med Sch, Boston, US 

316 The Effect of HAART-induced HIV Viral Suppression on 

Markers of Immune Activation in the Multicenter AIDS 

Cohort Study 

Nikolas Wada* 1 , L Jacobson 1 , J Margolick 1 , E Breen 2 , and J Bream 1 

1 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US 

and 2 Univ of California, Los Angeles, US 




Microbial Translocation 

320� �� 

Diminished in Chronic Untreated HIV Infection 

Bjorn Corleis*, W Gostic, and D Kwon 

Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US 

309 Phenotypic CD8 + T Cell Defects in Treated HIV Infection Are 

�� 

�� 

Sulggi Lee* 1 , E Sinclair1 , Y Huang1 , M Van Natta2 , D Bangsberg3 , 

M Lederman4 , F Hecht1 , J Martin1 , S Deeks1 , and P Hunt1 1 2 Univ of California, San Francisco, US;; Johns Hopkins Univ, Baltimore, 

MD, US;; 3Massachusetts Gen Hosp and Harvard Univ, Boston, US;; and 

4Case Western Reserve Univ, Cleveland, OH, US 

310� �� 

Independent of the cART Regimen and Is Not Correlated 

�� 

Norma Rallon* 1 , B Torres2 , A Diaz2 , L Alos2 , E Martinez2 , A Leon2 , 

J Gatell2 , V Soriano1 , F Garcia2 , and JM Benito1 321 Tight Junction mRNA Expression Decreases with a Proximal 

�� 

�� 

Charlotte Chung* and A Levine 

Case Western Reserve Univ Sch of Med, Cleveland, OH, US 

322 AIDS Virus Associated Gut Epithelial Barrier Dysfunction Is 

�� 

Christopher Gaulke* 

1 2 Hosp Carlos III, Madrid, Spain and Hosp Clin, Univ of Barcelona, Spain 

1 , I Grishina1 , M George1 , J Fass1 , N Joshi1 , 

J Jovel2 , S-W Ding2 , D Lin1 , and S Dandekar1 1 2 Univ of California, Davis, US and Univ of California, Riverside, US 

323� �� 

�� 

Phenotype 

Amanda Steele*, E Lee, Z Dong, B Vestal, J Koeppe, and C Wilson 

Univ of Colorado Anchutz Med Campus, Aurora, US 

324 Immune Activation and T Cell Cycling Are Increased in 

Treated HIV Infection and Inflammatory Bowel Disease;; 

�� 

Nicholas Funderburg*, S Stubblefield-Park, H Sung, G Hardy, 

B Clagett, J Ignatz-Hoover, C Harding, J Katz, M Lederman, and A Levine 

Case Western Reserve Univ, Cleveland, OH, US 

313� �� 

Occurred Early and Was Greater in Those with More 

Advanced HIV-associated Immunodeficiency 

Denise Hsu* 1,2 , S Kerr1,2 , T Iampornsin2 , S Pett1 , A Avihingsanon2 , 

P Thongpaeng2 , S Ubolyam2 , J Ananworanich2 , A Kelleher1 , and D Cooper1 1The Kirby Inst for Infection and Immunity in Society, Univ of New South 

Wales, Sydney, Australia and 2HIVNAT Res Collaboration, Thai Red 

Cross AIDS Res Ctr, Bangkok 

314� �� 

HIV + �� 

Correlates 

Ranjini Valiathan* 1 , D Gracia2 , and D Asthana1 325 Gut Lactobacillales during HIV Infection Are Associated with 

�� 

Josue Perez-Santiago* 

1 2 Univ of Miami Miller Sch of Med, FL, US and Borinquen Hlth Care Ctr, 

Miami, FL, US 

1 , S Gianella1 , M Massanella1 , M Karris1 , 

S Var1 , D Patel1 , P Jordan1 , S Little1 , D Richman1,2 , and D Smith1,2 1 2 Univ of California, San Diego, La Jolla, US and VA San Diego Hlthcare 

System, CA, US 

326� �� 

and Mucosal Immunity after Oral Serum-derived Bovine 

�� 

David Asmuth* 1,2 , J Stombaugh3 , Z-M Ma4,5 , A Albanese1 , E Hodzic4 , 

P Troia-Cancio2 , N Flynn2 , T Yotter2 , C Miller4,5 , and R Knight3 1 2 VA Northern California Hosp, Mather, US;; Univ of California, Davis 

Med Ctr, Sacramento, US;; 3Univ of Colorado, Boulder, US;; 4Univ of 

California, Davis, US;; and 5Ctr for Comparative Med, Davis, CA, US 

327� �� 

Untreated HIV-1 Infection and Correlate with T Cell 

�� 

Stephanie Dillon* 1 , E Lee1 , G Austin1 , Z Dong1 , K Rufner1 , 

S Gianella Weibel2 , D Smith2 , and C Wilson1 1 2 Univ of Colorado Anschutz Med Campus, Aurora, US and Univ of 


328� �� 

Bacteria Is Increased in HIV-1 Infection and Is Associated 

�� 

Jennifer Manuzak*, S Dillon, E Lee, and C Wilson 

Univ of Colorado Anschutz Med Campus, Aurora, US


329 Impact of Acute HIV-1 Infection on Th17/Treg Balance and 

T Cell Activation in the Sigmoid Colon 

Alexandra Schuetz* 1,2 , Y Phuang-Ngern 1 , R Rerknimitr 3 , I Sereti 4 , 

M Robb 2 , V Ngauy 1,2 , R Dewar 5 , J Kim 2,6 , M De Souza 1,2 , 

J Ananworanich 3,6,7 , and RV254/SEARCH 010 Study Team 

1 Armed Forces Res Inst of Med Sci, Bangkok, Thailand;; 2 US Military HIV 

Res Prgm, Walter Reed Army Inst of Res, Silver Spring, MD;; 3 Faculty of 

Med, Chulalongkorn Univ, Bangkok, Thailand;; 4 NIH, Bethesda, MD, US;; 

5 SAIC-Frederick Inc, MD, US;; 6 SEARCH, Bangkok, Thailand;; and 7 The 

Thai Red Cross AIDS Res Ctr, Bangkok 

330 Paucity of Naïve Th17 Precursors as a Potential Cause for 

Memory Th17 Deficiency in HIV + Individuals 

Sandrina Da Fonseca* 1 , A Gosselin 1 , R-M Boulassel 2 , J-P Routy 2,3 , 

N Bernard 2 , C Tremblay 1 , and P Ancuta 1 

1 Ctr de Res du Ctr Hosp de lUniv de Montreal Saint Luc, Canada;; 2 Royal 

Victoria Hosp, McGill Univ Hlth Ctr, Montreal, Canada;; and 3 McGill 

Univ, Montreal, Canada 

331� �� 

�� 

Translocation and Immune Activation 

Connie Kim* 1 , C Kovacs2 , G Kandel1,3,4 , S Huibner1 , D Chege1 , 

K Shahabi1 , E Benko2 , M Loutfy1,2,5 , M Ostrowski1,3 , and R Kaul1,4 1 2 3 Univ of Toronto, Canada;; Maple Leaf Med Clin, Toronto, Canada;; St 

Michaels Hosp, Toronto, Canada;; 4Univ Hlth Network, Toronto, Canada;; 

and 5 341 Prolonged Preservation of HIV-specific Cellular Immunity in 

Recently HIV 

�� 

+ Individuals Receiving Maraviroc Intensified 

HAART 

AI Kawana-Tachikawa* 1,2 , J Llibre3 , I Bravo3 , R Escrig3 , B Mothe1,3 , 

J Miro4 , J Gatell4 , A Iwamoto2 , B Clotet1,3 , and C Brander1 1 2 IrsiCaixa AIDS Res Inst, HIVACAT, Badalona, Spain;; Inst of Med Sci, 

Univ of Tokyo, Japan;; 3Fundacio Lluita Contra La Sida, Hosp Univ 

Germans Trias i Pujol, Badalona, Spain;; and 4Hosp Clin, IDIBAPS, Univ 

of Barcelona, Spain 



Immune Activation/Function in HIV Infection 

332 Circulating Microparticles as Markers of Immune Activation 

in Treatment-naïve HIV + Patients 

B Smit, Willem Blok*, M Van Schilfgaarde, W Terpstra, 

G Van den Berk, A Leyte, and K Brinkman 

OLVG Hosp, Amsterdam, The Netherlands 

333 The Effect of HIV Infection on Markers of Inflammation among 

Men with Known HIV Seroconversion Dates in the Multicenter 


Heather McKay* 1 , J Bream 1 , J Margolick 1 , O Martinez-Maza 2 , J Phair 3 , 

C Rinaldo 4 , and L Jacobson 1 


2 Univ of California, Los Angeles, US;; 3 Northwestern Univ, Feinberg Sch of 

Med, Chicago, IL, US;; and 4 Univ of Pittsburgh Sch of Publ Hlth, PA, US 

334� �� 

Seronegative Intravenous Drug Users that Share Needles 

Compared to Non-sharing IDU Controls 

Costin Tomescu* 1 , P Smith2 , D Metzger2 , and L Montaner1 1 2 The Wistar Inst, Philadelphia, PA, US and Univ of Pennsylvania, 


335� �� 

�� 

Translocation in Primary HIV Infection 

M Chevalier1,2 , G Petitjean1 , C Didier1 , C Dunyach-Remy3,4 , P-M Girard5 , 

L Meyer6 , J-P Lavigne3,4 , F Barre-Sinoussi1 , D Scott-Algara1 , 

and Laurence Weiss* 1,7,8 

1 2 Inst Pasteur, Paris, France;; Univ Paris Diderot, Sorbonne Paris Cite, 

France;; 3INSERM U1047, Univ Montpellier 1, UFR de Medecine, Nimes, 

France;; 4Ctr Hosp Univ Caremeau, Nimes, France;; 5Hosp Saint-Antoine, 

Paris, France;; 6INSERM U 1018, Univ Paris Sud, France;; 7Univ Paris 

Descartes, Sorbonne Paris Cite, France;; and 8 c Monday, 2:30-4 pm; Hall B2 


Mucosal Factors in HIV Transmission and Infection 

344� �� 

�� 

Cindy Liu* 

Hosp Europeen Georges 

Pompidou, Paris, France 

1,2,3 , B Hungate3 , A Tobian2,4 , D Serwadda5 , R Lester1 , 

G Kigozi5 , R Galiwango5 , M Wawer4 , R Gray4 , and L Price1,6 1 2 Translational Genomics Res Inst, Flagstaff, AZ, US;; Johns Hopkins Univ 

Sch of Med, Baltimore, MD, US;; 3Northern Arizona Univ, Flagstaff, US;; 

4Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 

5 6 Rakai Hlth Sci Prgm, Entebbe, Uganda;; and George Washington Univ 

Sch of Publ Hlth, Washington, DC, US 

345� �� 

and Implications of HIV Transmission 

Minh Dinh*, R Veazey, and T Hope 

Northwestern Univ, Feinberg Sch of Med, Chicago, IL, US 

+ 337� �� 

Plasma 

Neeru Bhardwaj* and J Coffin 

Tufts Univ, Boston, MA, US 



Immune Activation, T Cell Homeostasis, and Therapy 

338 Augmented Interferon Responses and Inflammation 

Associated with Altered Tryptophan and Adrenal Steroid 

�� 

Edana Cassol* 1,2 , V Misra 1 , S Morgello 3 , and D Gabuzda 1,2 

1 Dana-Farber Cancer Inst, Boston, MA, US;; 2 Harvard Med Sch, Boston, 

MA, US;; and 3 Mt Sinai Med Ctr, New York, NY, US 

339� �� 

�� 

Infection 

Jeffrey Ahlers* 1 , R-P Sekaly 1 , M Cameron 1 , K Ghneim 1 , A Filali 1 , 

M Ghannoum 2 , P Mukherjee 2 , C Shive 3 , B Rodriguez 3 , and M Lederman 3 

1 Vaccine and Gene Therapy Inst-Florida, Port St Lucie, US;; 2 Ctr for Med 

Mycology and OHARA Case Mycology Unit, Cleveland, OH, US;; and 

3 Case Western Reserve Univ, Cleveland, OH, US 

340 Lower Activation in Periphery and Cervical Tissue 

Gene Expression Associates with Highly Exposed HIV-1 

�� 

Shaheed Abdulhaqq* 1,2 , C Tomescu 1 , V Tamayo 3 , L Azzoni 1 , 

S Garced 3 , L Showe 1 , C Irizarry 3 , C Zorrilla 3 , and L Montaner 1 

1 The Wistar Inst, Philadelphia, PA, US;; 2 Univ of Pennsylvania Perelman 

Sch of Med, Philadelphia, US;; and 3 Univ of Puerto Rico, Sch of Med, 

San Juan 

342 Clinical Impact of Altered T Cell Homeostasis in Treated HIV + 

�� 

P Ndumbi 1 , J Gillis 2 , J Raboud 2,3 , M Loufty 4 , M Klein 5 , N Machouf 6 , 

C Cooper 7 , R Hogg 8,9 , A Burchell 10 , Christos Tsoukas* 1 , 

and Canadian Observational Cohort Collaboration 

1 McGill Univ Hlth Ctr, Montreal, Canada;; 2 Univ Hlth Network, Toronto, 

Canada;; 3 Dalla Lana Sch of Publ Hlth, Univ of Toronto, Canada;; 4 Maple 

Leaf Med Clin, Toronto, Canada;; 5 Montreal Chest Inst, McGill Univ Hlth 

Ctr, Canada;; 6 Clin Med l’Actuel, Montreal, Canada;; 7 Ottawa Hosp, Univ 

of Ottawa, Canada;; 8 BC Ctr for Excellence in HIV/AIDS, Vancouver, 

Canada;; 9 Faculty of Hlth Sci, Simon Fraser Univ, Burnaby, Canada;; 

and 10 Ontario HIV Treatment Network, Toronto, Canada 

+ 343� �� 

T Cell 

Response to an Immunodominant Epstein-Barr Virus Epitope 

A Lucas1 , V Meyer-Pannwitt1 , E McKinnon1 , S Burrows2 , M Rist2 , 

S Leary1 , M Lucas1 , S Mallal1,3 , and Elizabeth Phillips* 1,3,4 

1 2 Inst for Immunology and Infectious Diseases;; Queensland Inst for Med 

Res;; 3Royal Perth Hosp;; and 4Sir Charles Gairdner Hosp 

336 Multiple Imputations and Bayesian Simulations 

�� 

�� 

Livio Azzoni* 1 , R Barbour2 , A Violari3 , M Cotton4 , D Glencross3 , 

W Stevens3 , E Papasavvas1 , A Babiker5 , D Gibb5 , and L Montaner1 1 2 The Wistar Inst, Philadelphia, PA, US;; Yale Univ, New Haven, CT, US;; 

3 4 Univ of the Witwatersrand, Johannesburg, South Africa;; Stellenbosch 

Univ, Cape Town, South Africa;; and 5 346 Effect of Schistosomiasis Infection on HIV-1 Target Cells in 

�� 

Jessica Prodger* 

MRC, London, UK 

1 , A Ssemaganda2 , N Kiwanuka2,3 , A Ssetaala2 , 

A Nanvubya2 , L Nielsen4 , P Kato2 , and R Kaul1 1 2 Univ of Toronto, Canada;; Uganda Virus Res Inst-Intl AIDS Vaccine 

Initiative, Entebbe;; 3Makerere Univ Coll of Hlth Sci, Kampala Uganda;; 

and 4Intl AIDS Vaccine Initiative, New York, NY, US 



347� �� 

Targets of Infection During Sexual Transmission 

D Stieh 1 , D Maric 1 , K Rothwangl 1 , B Beilfuss 1 , M Anderson 1 , R Veazey 2 , 

R Ruprecht 3 , F Villinger 4 , and Thomas Hope* 1 

1 Northwestern Univ, Chicago, IL, US;; 2 Tulane Univ, New Orleans, LA, 

US;; 3 Harvard Univ, Boston, MA, US;; and 4 Emory Univ, Atlanta, GA, US 

348� �� 

in Seminal Plasma and Cervical Mucus 

Susan Schader* 1 , C Gioia 1 , S Baig 1 , E Allen 1 , E Spongberg 1 , S Allen 1 , 

G Cianci 1 , D Stieh 1 , P Kiser 2 , and T Hope 1 

1 Northwestern Univ, Chicago, IL, US and 2 Univ of Utah, Salt Lake City, US



+ 349� �� 

�� 

�� 

Lyle McKinnon* 1,2 , B Nyanga1 , P Izulla1 , J Kwatampora1 , M Kimani1 , 

N Mugo3 , J Smith4 , O Anzala1,5 , J Kimani1,6 , and R Kaul1,2 1 2 3 Univ of Nairobi, Kenya;; Univ of Toronto, Canada;; Kenyatta Natl Hosp, 

Nairobi, Kenya;; 4Univ of North Carolina at Chapel Hill, US;; 5Kenyan AIDS 

Vaccine Initiative, Nairobi;; and 6Univ of Manitoba, Winnipeg, Canada 

350� �� 

�� 

Jessica Prodger* 1 , R Gray2 , G Kigozi3 , F Nalugoda3 , RM Galiwango3 , 

T Hirbod4 , M Wawer2 , D Serwadda3 , R Kaul1 , and Rakai Genital 

Immunology Res Group 

1 2 Univ of Toronto, Canada;; Johns Hopkins Univ Bloomberg Sch of 

Publ Hlth, Baltimore, MD, US;; 3Rakai Hlth Sci Prgm, Uganda;; and 

4Karolinska Inst, Stockholm, Sweden 



Neutralizing Antibodies and How to Stimulate Them 

351� �� 

Response during Primary Infection 

Christoph Carter* 1 , G Wagner1 , G Hightower1 , L Hepler1 , G Caballero2 , 

S Little1 , S Kosakovsky Pond1 , P Phung3 , D Richman1,2 , and D Smith1,2 1 2 Univ of California, San Diego, La Jolla, US;; VA Hlthcare System, San 

Diego, CA, US;; and 3Monogram Biosci Inc, South San Francisco, CA, US 

352� �� 

Present in a Cohort of Long-term Non-progressors 

Nuria Gonzalez* 1 , K McKee2 , E Yuste3 , J Mascola2 , and J Alcami1 1 2 Inst de Salud Carlos III, Madrid, Spain;; NIH, Bethesda, MD, US;; and 

3Hosp Clin, Barcelona, Spain 

353 HIV-1 Cross-Clade Neutralization Evolution in Elite 

�� 

�� 

Carolina Ferreira* 1,2 , A Merino-Mansilla1,2 , A Llano2,3 , I Perez4 , 

I Crespo5 , L Llinas5 , F Garcia2,4 , J Gatell2,4 , E Yuste1,2 , 

and V Sanchez-Merino1,2 1Inst dInvestigacions Biomed August Pi i Sunyer, Barcelona, Spain;; 

2 3 HIVACAT, Barcelona, Spain;; IrsiCaixa AIDS Res Inst, Hosp Germans 

Trias i Pujol, Badalona, Barcelona, Spain;; 4Hosp Clin, Barcelona, Spain;; 

and 5Ctr Esther Koplowitz, IDIBAPS, Barcelona, Spain 

354 Adaptation of HIV-1 Envelope Glycoproteins to Selective 

�� 

Melanie Bouvin* 1 , M Morgand1 , A Moreau1 , P Jestin2 , L Meyer2 , 

F Barin1 , and M Braibant1 1 2 INSERM U966, Univ Francois Rabelais, Tours, France and CESP 

INSERM U1018, Univ Paris Sud, Hosp de Bicetre, Le Kremlin-Bicetre, 

France 

355� �� 

�� 

Nina Lin* 1,2 , C Becerril1 , S Moyo3 , J Makhema3 , R Musonda3 , M Essex3,4 , 

S Lockman2,3,4,5 , D Kuritzkes2,5 , and M Sagar2,5 1 2 Massachusetts Gen Hosp, Boston, US;; Harvard Med Sch, Boston, MA, 

US;; 3Botswana-Harvard AIDS Inst Partnership, Gaborone;; 4Harvard Sch 

of Publ Hlth, Boston, MA, US;; and 5�� MA, US 

356� �� 

�� 

John Moore* 1 , R Sanders1,2 , R Derking2 , R Depetris1 , A Cupo1 , P Klasse1 , 

R King3 , J-P Julien4 , I Wilson4 , and A Ward4 1 2 Weill Cornell Med Coll, New York, NY, US;; Academic Med Ctr, 

Amsterdam, The Netherlands;; 3Intl AIDS Vaccine Initiative, New York, 

NY, US;; and 4 359� �� 

during Suppressive Therapy 

Viktor Dahl* 

The Scripps Res Inst, La Jolla, CA, US 

1 , M Gisslen2 , J Peterson3 , W Shao4 , S Spudich5 , 

R Price3 , and S Palmer1 1 2 Karolinska Inst, Stockholm, Sweden;; Sahlgrenska Academy at Univ of 

Gothenburg, Sweden;; 3Univ of California, San Francisco, US;; 4Advanced Biomed Computing Ctr, SAIC-Frederick Inc, Frederick Natl Lab for 

Cancer Res, MD, US;; and 5Yale Univ, New Haven, CT, US 

360 Wild-type Viremia >50 Copies/mL Arising on cART: Identical 

Viral Sequences Imply Expansion of a Clonal Source 

Elizabeth Anderson* 1 , J Spindler1 , V Boltz1 , W Shao2 , T Uldrick3 , 

C Rhem4 , M Kearney1 , J Mellors5 , J Coffin6 , and F Maldarelli1 1HIV Drug Resistance Prgm, NCI-Frederick Natl Lab, MD, US;; 

2Advanced Biomed Computing Ctr, SAIC-Frederick, Inc, NCI-Frederick 

Natl Lab, MD, US;; 3HIV & AIDS Malignancy Branch, NCI, Bethesda, 

MD, US;; 4Lab of Immunoregulation, NIAID, Bethesda, MD, US;; 5Univ of 

Pittsburgh, PA, US;; and 6 361 

Tufts Univ, Boston, MA, US 

Lack of Viral Compartmentalization in Naïve and Memory 

�� + �� 

Gabriela Khoury* 1 , A Solomon1 , L Josefsson2 , F Wightman1 , 

S Palmer2 , P Cameron1,3 , and S Lewin1,3 1 2 Monash Univ and Burnet Inst, Melbourne, Australia;; Swedish Inst for 

Infectious Disease Control and Karolinska Inst, Solna;; and 3Alfred Hosp, 

Melbourne, Australia 

362 Deep Sequencing Analysis of RT-SHIV Viremia in a Nonhuman 

Primate Model of HIV-1 Therapy: Emergence of 

�� 

Robert Kauffman* 1,2 , A Villalobos2,3 , J Higgins1 , R Schinazi2,3 , 

and T North1,2,3 1 2 Univ of California, Davis, US;; Emory Univ, Atlanta, GA, US;; 

and 3VAMC, Decatur, GA, US 



Viral DNA Dynamics 

363� �� 

RNA in Patients on Long-term Suppressive ART 

Guillaume Besson* 1 , E Anderson2 , M Kearney2 , J Coffin3 , 

T Tanzosh2 , C Rehm4 , F Maldarelli2 , and J Mellors1 1 2 3 Univ of Pittsburgh, PA, US;; NCI-Frederick, MD, US;; Tufts Univ, 

Boston, MA, US;; and 4NIAID, NIH, Bethesda, MD, US 

364 Initial Therapy with Raltegravir Increases Clearance of 

�� 

Matthew Strain* 1 , S Rought1 , S Lada1 , T Luong2 , C Woelk1 , 

A Andrade3 , D Kuritzkes4 , D Richman1 , and ACTG 5248 

1Univ of California, San Diego, La Jolla and VA San Diego Hlthcare 

System, US;; 2Univ of Michigan, Ann Arbor, US;; 3Johns Hopkins Univ, 

Baltimore, MD, US;; and 4�� 365� �� 

�� 

T Cells for Eradication Strategies 

Kersten Koelsch* 1,2 , J Murray2,3 , K McBride1,2 , Y Xu1,2 , M Bailey1,2 , 

S Emery2 , D Cooper1,2 , J Zaunders1 , A Kelleher1,2 , and PINT Study Team 

1 2 St Vincents Hosp, Ctr for Applied Med Res, Sydney, Australia;; The 

Kirby Inst for Infection and Immunity in Society, Univ of New South 

Wales, Sydney, Australia;; and 3Sch of Mathematics and Statistics, Univ of 

New South Wales, Sydney, Australia 

366� �� 

drug cART in Rhesus Macaques 

T North1,2 , Andradi Villalobos* 1 , J Deere2 , J Higgins2 , P Chatterjee1,3 , 

S-J Tao1,3 , J Kohler1,3 , P Luciw1,3 , and R Schinazi1,3 1Emory Univ Sch of Med and Emory Univ Ctr for AIDS Res, Atlanta, GA, 

US;; 2Univ of California, Davis, US;; and 3Atlanta VAMC, Decatur, GA, US 



HIV Compartmentalization and Evolution on Therapy 

357 Prevalence and Patterns of Residual Viremia in HIV + 

Patients on Long-term Suppressive ART 

Sharon Riddler* 1 , E Aga 2 , R Bosch 2 , M Bedison 1 , B Bastow 3 , J Eron 4 , 

R Gandhi 5 , J Mellors 1 , and A5276s Protocol Team 

1 Univ of Pittsburgh, PA, US;; 2 Harvard Sch of Publ Hlth, Boston, MA, US;; 

3 Social & Scientific Systems Inc, Silver Spring, MD, US;; 4 Univ of North 

Carolina at Chapel Hill, US;; and 5 Massachusetts Gen Hosp, Boston, US 

358 In-depth Phylogenetic Analyses of HIV-1 Evolution during 

Long-term Suppressive Therapy 

Lina Josefsson* 1 , N Faria 2 , S Eriksson 1 , E Sinclair 3 , W Shao 4 , 

P Hunt 3 , M Somsouk 3 , S Deeks 3 , F Hecht 3 , and S Palmer 1 

1 Karolinska Inst and Swedish Inst for Infectious Disease Control, Solna;; 

2 Rega Inst, Katholieke Univ Leuven, Belgium;; 3 Univ of California, San 

Francisco, US;; and 4 Advanced Biomed Computing Ctr, SAIC-Frederick 

Inc, NCI-Frederick, MD, US 




Infected Cell Dynamics on Therapy 

+ + 367� �� 

T Cells in HIV Naïve Patients 

�� 

Silvia Nozza* 1 , D De Battista1 , L Galli1 , A Galli1 , M Ripa1,2 , L Della 

Torre1 , S Chiappetta1,2 , G Tambussi1 , M Malnati1 , and A Lazzarin1,2 1 2 San Raffaele Sci Inst, Milan, Italy and Univ Vita Salute, San Raffaele Sci 

Inst, Milan, Italy 

368� �� 

+ �� 

T-Lymphocyte Responses 

Liang Shan* 1 , C Durand1 , R Siliciano1,2 , and J Siliciano1 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Howard 

Hughes Med Inst, Baltimore, MD, US


369� �� 

Transcriptome Profiling 

Julia di Iulio* 1,2 , M Munoz1 , J Fellay1,3 , A Telenti1 , and A Ciuffi1 1Inst of Microbiology, Lausanne Univ Hosp and Univ of Lausanne, 

Switzerland;; 2Bioinformatics and Biostats Core Facility, Sch of Life Sci, 

Ecole Polytech Fed de Lausanne, Switzerland;; and 3Global Hlth Inst, Sch 

of Life Sci, Ecole Polytech Fed de Lausanne, Switzerland 

370� �� 

T Cells Identifies Gene Expression Patterns Associated with 

the Size of the Latent HIV-1 Reservoir 

Hong Sun* 1,2 , M Buzon1,3 , Z Ouyang1 , F Pereyra1,4 , E Rosenberg3 , 

W Hide5 , X Yu1 , and M Lichterfeld3 1 2 Ragon Inst of MGH, MIT and Harvard, Boston, MA, US;; No 1 Hosp 

of China Med Univ, Shenyang;; 3 380� �� 

in vitro HIV-1 

+ �� 

Patients 

Manuela Pogliaghi* 

Massachusetts Gen Hosp, Boston, US;; 

4 5 �� 

Harvard Sch of Publ 

1,2,3 , L Papagno1 , C Katlama4 , and B Autran1 1INSERM UMRS945, Univ Pierre and Marie Curie, Hosp Pitie- 

Salpetriere, Paris, France;; 2Univ Vita-Salute, San Raffaele Sci Inst, 

Milan, Italy;; 3European AIDS Clin Soc Scholarship Program;; and 

4INSERM UMRS943, Univ Pierre and Marie Curie, Hosp Pitie- 

381 

Salpetriere, Paris, France 

Toll-like Receptor 9 Agonist Treatment Decreases the 

Proviral Reservoir in Peripheral Blood and Could Impact 

HIV-specific Immunity in Patients on cART 

Anni Winckelmann* 1 , L Munk-Petersen1 , T Aagaard Rasmussen1 , 

J Melchjorsen1 , D Montefiori2 , L Ostergaard1 , O Schmeltz Sogaard1 , 

and M Tolstrup1 1 2 Aarhus Univ Hosp, Denmark and Duke Univ Med Ctr, NC, US 

Hlth, Boston, MA, US 



(see Session 15 on Monday for corresponding Themed Discussion) 

What Is Latency and What Can We Do about It? 

373 Integrated HIV DNA and Associated Histiocyte Marker 

mRNA in Autopsy Samples of Non-lymphoid Tissue 

Including the Central Nervous System 

Benjamin Gelman* 1 , T Chen 1 , J Lisinicchia 1 , and A Rice 2 

1 Univ of Texas Med Branch, Galveston, US and 2 Baylor Coll of Med, 


375� �� 



Mechanism of HIV Latency and Reactivation 

382� �� 

Reactivation from Latency 

Vicente Planelles* 1 , L Martins1 , M Famiglietti1 , S Budhiraja2 , 

A Bosque1 , and A Rice2 1 2 Univ of Utah, Salt Lake City, US and Baylor Coll of Med, Houston, TX, US 

+ 

371� �� 

T Cells Can Be Induced to Produce Virions ex vivo with Anti- 

�� 

Anthony Cillo* 1 , M Sobolewski1 , J Coffin2 , and J Mellors1 1 2 Univ of Pittsburgh, PA, US and Tufts Univ, Boston, MA, US 

372 A Comparison of Methods Used to Measure Rectal HIV Levels 

+ �� 

T 

+ + �� 

�� Cells 

Steven Yukl* 1,2 , H Hatano2,3 , L Epling2,3 , P Hunt2,3 , P Li1,2 , D Havlir2,3 , 

M Somsouk2,3 , E Sinclair2,3 , S Deeks2,3 , J Wong1,2 , and DARE 

1 2 San Francisco VAMC, CA, US;; Univ of California, San Francisco, US;; 

and 3 383 Latency-reversing Agents Differentially Prime Resting 

�� 

San Francisco Gen Hosp, CA, US 

+ �� 

T-Lymphocytes 

Brad Jones* 1 , M Buzon1 , M Ostrowski2 , M Lichterfeld2 , D Irvine1 , 

and B Walker1 1 2 Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US and Univ of 

Toronto, Canada 

+ 

384� �� 

T Cells through TLR Stimulation 

Camille Novis*, V Planelles, and A Bosque 

Univ of Utah, Salt Lake City, US 

385 Epigenetic Control of PRC-mediated Gene Silencing on 

HIV-1 Latency 

D-H Jang, K-C Kim, C-H Yoon, SY Park, H-Y Kim, SS Kim, 

and Byeong-Sun Choi* 

Korea Natl Inst of Hlth, Osong, Chungbuk, South Korea 

386 Predicting Outcomes of Treatments to Eradicate the HIV 

Latent Reservoir 

Alison Hill* 

374 HIV Preferentially Infects Hematopoietic Progenitor Cells 

+ �� 

Hematopoietic 

�� 

Long-term Viral Suppression 

Lucy McNamara*, N Sebastian, A Onafuwa-Nuga, J Riddell, 

D Bixby, and K Collins 

Univ of Michigan, Ann Arbor, US 

1 , D Rosenbloom1 , M Nowak1 , and R Siliciano2,3 1 2 Harvard Univ, Cambridge, MA, US;; Johns Hopkins Univ Sch of Med, 

Baltimore, MD, US;; and 3Howard Hughes Med Inst, Baltimore, MD, US 

387� �� 

in vitro Memory T Cell Model of HIV-1 

Latency for High-throughput Screening and Identification of 

Agents that Activate HIV 

Helen Yu*, T Barnes, G Stepan, M Balakrishnan, K Stray, C Callebaut, 

G Wei, R Geleziunas, N Pagratis, and T Cihlar 

Gilead Sci Inc, Foster City, CA, US 

Expressed HIV-1 Proviruses 

Scott Sherrill-Mix*, K Ocwieja, N Malani, U O’Doherty, and F Bushman 


376� �� 

+ �� 

�� 

George Wei* 1 , V Chiang1 , E Fyne2 , M Balakrishnan1 , G Stepan1 , A Tsai1 , 

J Lalezari3 , J Mellors2 , R Geleziunas1 , and T Cihlar1 1 2 Gilead Sci Inc, Foster City, CA, US;; Univ of Pittsburgh Sch of Med, PA, 

US;; and 3 c Tuesday, 2:30-4 pm; Hall B2 


Novel Vaccine Strategies 

388� �� 

�� 

SIV DNA/rMVA/Particle Vaccine 

Mariana Manrique* 

Quest Clin Res, San Francisco, CA, US 

1 , A Cobo-Molinos1 , A Carville2 , P Kozlowski3 , 

and A Aldovini1 1 2 �� 

New England 

Regional Primate Res Ctr, Harvard Med Sch, Southborough, MA, US;; 

and 3Louisiana State Univ, New Orleans, US 

377� �� 

�� 

Brian Reardon* 1 , A Singhania2 , N Beliakova-Bethell1 , J Zhang2 , 

V Terry2 , C Spina1,2 , D Richman1,2 , and C Woelk1,2 1 2 Univ of California, San Diego, La Jolla, US and VA San Diego, CA, US 

378� �� 

Latent HIV-1 Infection 

Kirston Barton*, K Keedy, N Archin, and D Margolis 


379 Ex vivo�� 

HIV Long-terminal Repeat Integrated Sequences from HIV + 

Patients 

Hao Lu* 1,2 , L Gray1,2 , P Ellenberg1,2 , F Wightman1,2 , P Cameron1,2 , 

S Wesselingh1,3 , M Churchill1,2 , and S Lewin1,2,4 389 Rescue of Myeloid Dendritic Cell Dysfunction in the Setting 

�� 

Listeria monocytogenes Vectors 

Elizabeth Miller* 

1 2 Monash Univ, Melbourne, Australia;; Burnet Inst, Melbourne, Australia;; 

3 4 South Australian Hlth and Med Res Inst, Adelaide;; and Alfred Hosp, 

Melbourne, Australia 

1 , M Spadaccia1 , M Demmler1 , P Lauer2 , 

D Brockstedt2 , and N Bhardwaj1 1 2 New York Univ Sch of Med, NY, US and Aduro BioTech Inc, Berkeley, 

CA, US 

390 Potent Cellular Immune Responses Induced after 

Therapeutic Immunization of HIV + Patients with 

�� 

Lorenzo Ramirez* 1 , T Arango1 , D Shah2 , M Morrow2 , J Lee2 , 

M Naji1 , K Maffei3 , M Bagarazzi2 , P Tebas3 , and J Boyer1 1 2 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US;; Inovio 

Pharmaceuticals, Blue Bell, PA, US;; and 3Univ of Pennsylvania, 


391� �� 

�� 

in Treated Chronic HIV-1 Infection 

Anna Herasimtschuk* 1 , J Downey1 , M Nelson2 , G Moyle2 , 

A Jackson2 , R Sikut3 , M Adojaan3 , I Stanescu4 , F Gotch1 , and N Imami1 1 2 Imperial Coll London, UK;; Chelsea and Westminster Hosp, London, UK;; 

3 4 FIT Biotech Ltd, Tartu, Estonia;; and FIT Biotech Oy, Tampere, Finland 


Poster Listings



392� �� 

�� 

�� 

Christine Katlama* 1 , O Launay2 , R Ho Tsong Fang3 , H Bodilis2 , R Calin1 , 

B Autran1 , S Gharakhanian4 , V Vieillard5 , J Crouzet3 , and P Debre6 1 2 Pitie-Salpetriere Hosp, Paris, France;; Cochin Hosp and INSERM 

CIC BT505, Paris, France;; 3InnaVirVax, Evry, France;; 4InnaVirVax, Cambridge, MA, US;; 5INSERM UMR S945, Paris, France;; and 6 404� �� 

Disorders among Adults on cART and Suppressed Plasma 

Viral Load: Prospective Results from the Ontario HIV 

Treatment Network Cohort Study 

Sean Rourke* 

Univ 

Pierre and Marie Curie, Paris-6 Univ, France 

1,2,3 , J Gill4 , T Bekele1 , A Carvalhal2,3 , J McCombe5 , 

A Rachlis2 , M Atkinson1 , C Kovacs2 , T Marcotte6 , S Letendre6 , 

and OCS Cohort Study 

1 2 Ontario HIV Treatment Network, Toronto, Canada;; Univ of Toronto, 

Canada;; 3St Michael�s Hosp, Toronto, Canada;; 4Univ of Alberta, Calgary, 

Canada;; 5Univ of Alberta, Edmonton, Canada;; and 6Univ of California, 

San Diego, US 

393� �� 

Gloria Martrus* 1 , M Nevot 1 , B Clotet 1,2 , and MA Martinez 1 

1 Inst de Investigacio del Sida IrsiCaixa, Badalona, Spain and 2 Lluita 

contra la SIDA Fndn, Hosp Univ Germans Trias i Pujol, Badalona, Spain 



Gene and Adoptive Immunotherapy 

394 HIV Gene Therapy: HIV-1 pol�� 

Nucleases Targeting HIV-1 Provirus in Latent Cells 

Cheol-Hee Yoon*, SS Kim, SY Park, O-K Kwon, H-Y Kim, D-H Jang, 

and B-S Choi 

Korea Natl Inst of Hlth, Osong, Chungbuk, South Korea 

395 Promoter Targeting Small RNA Suppresses HIV-1 Infection 

in vivo 

Kazuo Suzuki* 1 , S Hattori 2 , K Marks 1 , C Ahlenstiel 1 , M Millington 3 , 

M Boyd 3 , G Symonds 3 , D Cooper 1 , S Okada 2 , and A Kelleher 1 

1 The Kirby Inst, Sydney, Australia;; 2 Ctr for AIDS Res, Kumamoto, Japan;; 

and 3 Calimmune Inc, Sydney, Australia 

396 T Cell Receptor Transfer for Boosting HIV-1-specific T Cell 

Immunity in HIV-1 + Patients 

Christiane Mummert* 1 , C Hofmann 1,2 , A Huckelhoven 1 , 

S Muller-Schmucker 1 , J Dorrie 1 , N Schaft 1 , S Bergmann 1 , E Harrer 1 , 

and T Harrer 1 

1 Univ Hosp Erlangen, Friedrich-Alexander Univ, Germany and 2 Univ of 

California, Los Angeles, US 



Progressive Multifocal Leukoencephalopathy 

and Other Central Nervous System Infections 

398 Polymorphisms in Toll-like Receptor Genes Increase 

Neurosyphilis Risk 

Christina Marra*, S Sahi, L Tantalo, E Ho, T Jones, S Dunaway, and T Hawn 


399 No Benefit of Mitarzapine Add-on to ART in HIV + Patients 

with Progressive Multifocal Leukoencephalopathy 

Ana Canestri*, K Protopapas, A-A Mazet, J-P Brosseau, Y Taoufik, 

J-F Delfraissy, and J Gasnault 

Bicetre Hosp, Le Krmlin-Bicetre, France 


405 Central Nervous System Penetration Effectiveness Score Better 

Correlates with Cognitive Performance of HIV + Patients after 

�� 

Massimiliano Fabbiani* 1 , P Grima 1,2 , B Milanini 1 , A Mondi 1 , 

M Colafigli 1 , R Gagliardini 1 , R Cauda 1 , MC Silveri 1 , A De Luca 1,3 , 

and S Di Giambenedetto 1 

1 Catholic Univ of the Sacred Heart, Rome, Italy;; 2 S Caterina Novella 

Hosp, Galatina, Italy;; and 3 Siena Univ Hosp, Italy 

406� �� 

a Higher Rate or a Different Pattern of Neurocognitive 

Impairment than Triple Drug Therapy 

Ignacio Perez-Valero* 1 , A Gonzalez-Baeza 1 , M Estebanez 1 , 

N Stella-Ascariz 1 , J Mingorance 1 , C Bayon 1 , M Lagarde 2 , F Pulido 2 , 

A Borobia 1 , J Arribas 1 , and PICASSO Study Group 

1 Hosp Univ La Paz, IdiPaz, Madrid, Spain and 2 Hosp Univ 12 de Octubre, 

i+12, Madrid, Spain 



ART, Neurocognitive Outcomes, and New Central 

Nervous System-targeted Therapies 

407 Long-term Efavirenz Use Is Associated with Worse 

�� 

Scott Letendre* 1 , F Vaida 1 , D Croteau 1 , D Clifford 2 , A Collier 3 , B Gelman 4 , 

J McArthur 5 , D Simpson 6 , R Heaton 1 , I Grant 1 , and CHARTER Group 

1 Univ of California, San Diego, US;; 2 Washington Univ, St Louis, MO, US;; 

3 Univ of Washington, Seattle, US;; 4 Univ of Texas Med Branch, Galveston, 

US;; 5 Johns Hopkins Univ, Baltimore, MD, US;; and 6 Mt Sinai Sch of Med, 

New York, NY, US 

408 Gold Nanoparticles to Improve Drug Delivery 

to the Central Nervous System 

Carolina Garrido* 1 , N Dahl 1 , C Simpson 2 , J Bresee 2 , D Feldheim 2 , 

C Melander 3 , and D Margolis 1 

1 Univ of North Carolina at Chapel Hill, US;; 2 Univ of Colorado, Boulder, 

US;; and 3 North Carolina State Univ, Raleigh, US 

409 Symptoms of Autonomic Dysfunction in HIV + Patients 

�� 

Dominic Chow* 1 , K Sullivan 1 , D Sletten 2 , M Kocher 1 , R Romine 1 , 

B Nakamoto 1,3 , T Umaki 1 , K Kallianpur 1 , C Shikuma 1 , and P Low 2 

1 Univ of Hawaii at Manoa, Honolulu, US;; 2 Mayo Clin, Rochester, MN, 

US;; and 3 Straub Med Ctr, Honolulu, HI, US 

400 Clonal Immortalized Human Glial Cell Lines Support 

Varying Levels of JC Virus Infection Due to Differences in 

Cellular Gene Expression 

Michael Ferenczy*, K Johnson, and E Major 

Natl Inst of Neurological Disorders and Stroke, NIH, Bethesda, MD, US 



Central Nervous System Penetration, ART 

Intensification, and Cerebrospinal Fluid Escape 

401� �� 

�� 

Scott Letendre* 1 , D McClernon2 , R Deutsch1 , D Cookson1 , M Cherner1 , 

M Crescini1 , I Grant1 , and R Ellis1 410� �� 

+ 

�� 

�� 

Atazanavir 

Kevin Robertson* 

1 2 Univ of California, San Diego, US and bioMONTR, Research Triangle 

Park, NC, US 

1 , P Maruff2 , D Wohl1 , L Bhatti3 , C Small4 , 

H Edelstein5 , H Zhao6 , D Margolis6 , L Ross6 , M Shaefer7 , 

for ASSURE EPZ113734 Study Team 

1 2 Univ of North Carolina at Chapel Hill, US;; Cogstate Ltd, Melbourne, 

Australia;; 3AIDS HlthCare Fndn, Beverly Hills, CA, US;; 4New York 

Med Coll, Vahalla, US;; 5Alameda County Med Ctr, Oakland, CA, US;; 

6 7 GlaxoSmithKline, Research Triangle Park, NC, US;; and ViiV HlthCare, 

Research Triangle Park, NC, US 

411 Impact of Minocycline on Markers of Oxidative Stress 

+ �� 

Individuals with Cognitive 

Impairment 

Ned Sacktor* 1 , S Miyahara 2 , S Evans 2 , G Schifitto 3 , B Cohen 4 , 

N Haughey 1 , D Graham 1 , A Nath 5 , D Clifford 6 , and AACTG A5235 Team 

1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Harvard Sch of 

402� �� 

�� 

the Central Nervous System HIV ART Effects Research and 

�� 

Ignacio Perez-Valero* 1,2 , S Letendre2 , R Deutsch2 , R Heaton2 , 

D Clifford3 , J McArthur4 , S Morgello5 , B Gelman6 , A Collier7 , I Grant2 , 

and CHARTER and HNRP Study Groups 

1 2 Hosp Univ La Paz, Madrid, Spain;; Univ of California, San Diego, US;; 

3 4 Washington Univ Sch of Med, St Louis, MO, US;; Johns Hopkins Univ 

Sch of Med, Baltimore, MD, US;; 5 Publ Hlth, Boston, MA, US;; 

Mt Sinai Hosp, New York, NY, US;; 

6 7 Univ of Texas, Galveston, US;; and Univ of Washington, US 

403 Maraviroc Intensification in Virally Suppressed HIV 

�� 

Performance and Declines in Immune Activation 

Lishomwa Ndhlovu*, T Umaki, G Chew, M Agsalda, K Amina, 

N Hanks, B Nakamoto, J Barbour, B Shiramizu, and C Shikuma 

Univ of Hawaii, Manoa, US 

3Univ of Rochester, NY, US;; 4Northwestern Univ, Chicago, IL, US;; 5NIH, Bethesda, MD, US;; and 6Washington Univ 

Sch of Med, St Louis, MO, US 

412� �� 

HIV-1 + �� 

Brain Barrier Model 

A McFarren1 , Dina Tsukrov* 2 , E Eugenin3 , A Morgenstern4 , 

F Bruchertseifer4 , S Zolla-Pazner5,6 , M Gorny5 , A Casadevall2 , J Berman2 , 

and E Dadachova2 1 2 Children�s Hosp at Montefiore, Bronx, NY, US;; Albert Einstein Coll of 

Med, Bronx, NY, US;; 3Univ of Med and Dentistry of New Jersey, Newark, 

US;; 4European Commission, Joint Res Ctr, Inst for Transuranium 

Elemens, Karlsruhe, Germany;; 5New York Univ, NY, US;; and 6VAMC, NY, US


413 Risk of Clinically Significant Depression in HIV + Patients: 

Effect of ARV Drugs 

Felix Gutierrez* 1 , L Garcia 2 , S Padilla 1 , D Alvarez 3 , S Moreno 4 , 

G Navarro 5 , JL Gomez-Sirvent 6 , F Vidal 7 , V Asensi 8 , M Masia 1 , 

and CoRIS 

1 Hosp Gen Univ de Elche, Alicante, Spain;; 2 Hosp Univ Sant Joan 

d�Alacant, Alicante, Spain;; 3 Ctr Natl de Epidemiologia, Inst de Salud 

Carlos III, Madrid, Spain;; 4 Hosp Ramon y Cajal, Madrid, Spain;; 5 Hosp 

Parc Tauli, Sabadell, Barcelona, Spain;; 6 Hosp Univ de Canarias, Santa 

Cruz de Tenerife, Spain;; 7 Hosp Univ Joan XXIII, Tarragona, Spain;; and 

8 Hosp Univ Central de Asturias, Oviedo, Spain 



Central Nervous System Viral Evolution and 


417 Correlating Neuropathogenesis with Brain Infection Dynamics 

in the SIV ��-infected CD8-depleted Rhesus Macaque Model 

Using Bayesian Phylogeography 

Samantha Strickland* 1 , N Veras 1 , M Prosperi 1 , T Burdo 2 , D Nolan 1 , 

M Suchard 3 , K Williams 2 , and M Salemi 1 

1 Univ of Florida, Gainesville, US;; 2 Boston Coll, Chestnut Hill, MA, US;; 

and 3 Univ of California, Los Angeles, US 

418 Distinct Regional Compartmentalization in the Central 

Nervous System of an R5 SHIV + Rhesus Macaque with 

Severe Encephalitis 

K Zhuang 1 , Ana Rachel Leda* 1 , C Harbison 2 , H Knight 2 , 

S Westmoreland 2 , and C Cheng-Mayer 1 

1 Aaron Diamond AIDS Res Ctr, New York, NY, US and 2 New England 

Primate Res Ctr, Harvard Med Sch, Southborough, MA, US 



Neuropathogenesis Mechanisms 

419 Proteomic Analysis of Molecular Interactions of the 

Macrophage-derived Protease Cathepsin B During HIV-1 

Infection in vitro 

Yisel Cantres-Rosario* 1 , M Plaud-Valentin 1 , R Quiles 2,3 , 

J Perez-Laspiur 1 , Y Rodriguez 1 , S Shaffer 4 , and L Melendez 1 

1 Univ of Puerto Rico Med Sci Campus, San Juan;; 2 Univ of Puerto Rico 

Rio Pedras, San Juan;; 3 Interamerican Univ of Puerto Rico, Bayamon;; 

and 4 Univ of Massachussets, Boston, US 

420 Heme Oxygenase-1 RNA Is Increased in HIV + Brains with 

Neurocognitive Disorders and in HIV + Encephalitic Brains 

Surendra Ambegaokar* 1 , A Gill 1 , C Kovacsics 1 , S Cross 1 , 

B Gelman 2 , and D Kolson 1 

1 Univ of Pennsylvania, Philadelphia, US and 2 Univ of Texas Med Branch, 

Galveston, US 

424� �� 

SAMHD1 during Lentiviral Infection of Astrocytes and 

Macrophages 

Erin Buchanan*, D Espinoza, A Moyer, J Clements, and K Witwer 


425� �� 

Resultant Neurotoxic Activity via Voltage-gated Potassium 

�� 

P Xu, Jianuo Liu*, and H Xiong 


426 Morphologic and Molecular Pathology in the Spinal Cord of 

SIV + Macaques 

Lisa Mangus*, J Dorsey, and J Mankowski 


414� �� 

Neurocognitive Impairment in an Indian Cohort 

Myres Tilghman* 1 , S Deshpande2 , J Bhattacharya2 , M Ghate2 , 

T Marcotte1 , D Smith1,3 , and S Mehendale4 1 2 Univ of California, San Diego, La Jolla, US;; Natl AIDS Res Inst, Pune, 

India;; 3VA San Diego Hlthcare System, La Jolla, CA, US;; and 4Natl Inst 

of Epidemiology, Chennai, India 

415� �� 

�� 

Sequencing 

Tiffany Yuh* 1 , J Chiarella1 , B Reese2 , E St John2 , B Simen2 , 

M Mohiuddin2 , J Peterson3 , R Price3 , M Kozal1 , and S Spudich1 1 2 Yale Univ Sch of Med, New Haven, CT, US;; 454 Life Sci, Branford, CT, 

US;; and 3Univ of California, San Francisco, US 

416 Clade-specific Differences in HIV-1 Pathogenesis 

�� 

Santhi Gorantla* 1 , E Makarov1 , S Adem1 , L Wu1 , C Wood2 , 

L Poluektova1 , and H Gendelman1 427 The �7-Nicotinic Acetylcholine Receptor Is Up-regulated in a 

Transgenic Mouse Model for HIV 

Coral Capo-Velez* 

1 2 Univ of Nebraska Med Ctr, Omaha, US and Univ of Nebraska-Lincoln, US 

1 , B Morales1 , R Melendez2 , and J Lasalde-Dominicci1 1 2 Univ of Puerto Rico, San Juan and Univ of Puerto Rico, Med Sci, San Juan 

428 The Effects of Pediatric SIV Infection on the Integrity of the 

Hippocampus 

K Bradshaw1 , K Curtis1 , M Rollins1 , S Graham1 , D Jackson1 , M M’Baye1 , 

H Carryl1 , T Heinbockel1 , K Abel2 , and Mark Burke* 1 

1 2 Howard Univ, Washington, DC, US and Univ of North Carolina at 

Chapel Hill, US 

429 Cocaine Potentiates Cathepsin B Secretion in the Plasma of 

HIV + Hispanic Women 

Frances Zenon*, M Plaud, V Wojna, and L Melendez 

Univ of Puerto Rico Sch of Med and NeuroAIDS Prgm, Med Sci Campus 



Central Nervous System Inflammation and 

Biomarkers of HIV-associated Neurocognitive 

Disorders 



430� �� 

Initiation of ART in Individuals with Chronic HIV Infection 

in Thailand 

Bonnie Slike* 1 , V Valcour 2 , S Krebs 1 , P Sithinamsuwan 3 , 

P Saengtawan 4 , A Schuetz 5 , J Kim 1 , N Michael 1 , J Ananworanich 4,6 , 

M Marovich 1 , and SEARCH 011 Study Team 

1 US Military HIV Res Prgm, Silver Spring, MD;; 2 Univ of California, San 

Francisco, US;; 3 Phramongkutklao Hosp, Bangkok, Thailand;; 4 SEARCH 

and Thai Red Cross AIDS Res Ctr, Bangkok;; 5 Armed Forces Res Inst 

of Med Sci, Bangkok, Thailand;; and 6 Chulalongkorn Univ, Bangkok, 

Thailand 

431� �� 

�� 

HIV-associated Neuro-inflammation 

Meera Singh* 1 , D Davidson 1 , S Ramirez 2 , J Silva 1 , and S Maggirwar 1 

1 Univ of Rochester Med Ctr, NY, US and 2 Temple Univ Sch of Med, 

Philadelphia, PA, US 

432� �� 

the Spectrum of HIV Disease Progression 

Sheila Keating* 1,2 , J Peterson 2 , M Gisslen 3 , J Heitman 1 , S Wu 1 , 

S Spudich 4 , P Norris 1,2 , and R Price 2 

1 Blood Systems Res Inst, San Francisco, CA, US;; 2 Univ of California, 

San Francisco, US;; 3 Univ of Gothenburg, Sweden;; and 4 Yale Univ, New 

Haven, CT, US 

433� �� 

in HIV-1 + Brain: Implications for HIV-related Aging and 

Alzheimer’s Disease 

Dong Tran*, N Kumar, C Teodorof, A Adame, B Gouaux, D Moore, 

W Dumaop, S Michael, E Masliah, K Singh, and HIV Neurobehavioral 

Res Prgm 

Univ of California, San Diego, La Jolla, US 

421 Suppression of Brain Heme Oxygenase-1 in HIV Infection: 

�� 

Alexander Gill* 1 , S Cross1 , C Kovacsics1 , B Gelman2 , and D Kolson1 1 2 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US and Univ 

of Texas Med Branch, Galveston, US 

422� �� 

�� 

�� 

and Astrocytes 

Stephanie Cross* 1 , A Gill1 , C Kovacsics1 , S Ambegaokar1 , P Vance1 , 

L Kolson1 , B Gelman2 , and D Kolson1 434 Modeling the Development of Chronic Neuroinflammation 

following Blunting of Primary Viremia through Partial 

Vaccine Protection 

Debbie Ferguson* 

1 2 Univ of Pennsylvania, Philadelphia, US and Univ of Texas Med Branch, 

Galveston, US 

423 SIV Infection and Interferon-� Modulate microRNA Profiles 

of Macaque Astrocytes 

Diego Espinoza*, E Buchanan, A Moyer, J Clements, and K Witwer 


1 , S Clarke1 , C Ham1 , A Das2 , B Berkhout2 , A Meiser3 , 

S Patterson3 , N Berry1 , and N Almond1 1 2 Natl Inst for Bio Standards and Control, Potters Bar, UK;; Academic 

Med Ctr, Univ of Amsterdam;; and 3Imperial Coll London, UK 

435� �� + HIV DNA Predicts HIV-associated Neurocognitive 

Impairment and Regional Brain Atrophy in Treatment-naïve 

�� 

Victor Valcour* 1 , J Ananworanich2,3,4 , M Agsalda5 , K Kallianpur5 , 

T Chalermchai3 , P Sithinamsuwan6 , S Tipsuk3 , A Schuetz7 , C-Y Liang5 , 

B Shiramizu5 , and SEARCH 007 and 011 Study Groups 

1 2 Univ of California, San Francisco, US;; Chulalongkorn Univ, Bangkok, 

Thailand;; 3South East Asia Res Collaboration with the Univ of Hawaii, 

Bangkok, Thailand;; 4HIVNAT Res Collaboration, Bangkok, Thailand;; 5Univ of Hawaii at Manoa, Honolulu, US;; 6Phramongkutklao Hosp, Bangkok, 

Thailand;; and 7US Armed Forces Res Inst of Med Sci, Bangkok, Thailand



436� �� + Cell Count despite Effective ART is Associated 

with Elevated Monocyte Activation 

and Poor Neurocognitive Performance 

Alessandra Bandera* 1 , M Saresella 2 , G Lapadula 1 , A Muscatello 1 , 

I Marventano 2 , S Limonta 1 , V Pastore 1 , E Cappelletti 1 , M Clerici 3 , 

and A Gori 1 

1 S Gerardo Hosp, Monza, Italy;; 2 Don C Gnocchi Fndn, Milan, Italy;; 

and 3 Univ of Milan, Italy 

437� �� 

� Levels Inversely Correlate 

with Processing and Motor Speed in HIV + �� 

Cognitive Complaints with and without HIV-associated 

Neurocognitive Disorder 

Albert Anderson* 1,2 , J Lennox1,2 , D Loring1 , and W Tyor1 1 2 Emory Univ Sch of Med, Atlanta, GA, US and Grady Hlth System 

Infectious Diseases Prgm, Atlanta, GA, US 

445 HIV and Aging: New Graph Theoretical Models of rs-fcMRI 

Neuropathophysiology 

Jewell Thomas*, M Brier, and B Ances 

Washington Univ in St. Louis 




NeuroAIDS Clinical Studies 

446 Neurological Characterization of HIV Controllers 

Evelyn Lee* 1 , J Peterson 1 , R Walter 1 , J Javerbaum 1 , S Deeks 1 , 

R Price 1 , K Robertson 2 , D Meyerhoff 1 , B Shacklett 3 , and S Spudich 4 

1 Univ of California, San Francisco, US;; 2 Univ of North Carolina at 

Chapel Hill, US;; 3 Univ of California, Davis, US;; and 4 Yale Univ Sch of 

Med, New Haven, CT, US 

438� �� 

in HIV + Very Late-presenters 

Andrea Calcagno* 1 , C Atzori2 , D Imperiale2 , F Lipani1 , S Audagnotto1 , 

G Orofino3 , V Ghisetti3 , G Marietti2 , G Di Perri1 , and S Bonora1 1 2 Univ of Torino, Italy;; Ospedale Maria Vittoria, ASLTO2, Torino, Italy;; 

and 3Ospedale Amedeo di Savoia, ASLTO2, Torino, Italy 




Aging and Neurocognitive Function in HIV Infection 

439� �� 

Cohort Study 

Karl Goodkin* 1 , E Miller2 , C Cox3 , S Reynolds3 , D Ostrow4 , O Selnes5 , 

E Martin6 , N Sacktor5 , and J Becker7 1 2 AIDS Hlthcare Fndn, Los Angeles, CA, US;; Univ of California, 

Los Angeles, US;; 3Johns Hopkins Univ Bloomberg Sch of Publ Hlth, 

Baltimore, MD, US;; 4Univ of Chicago, IL, US;; 5Johns Hopkins Univ Sch 

of Med, Baltimore, MD, US;; 6Univ of Illinois at Chicago, US;; and 7Univ of Pittsburgh, PA, US 

440 Veterans Aging Cohort Study Index Score Is Associated with 

�� 

Study 

D Franklin Jr1 , R Heaton1 , S Woods1 , S Letendre1 , A Collier2 , D Clifford3 , 

B Gelman4 , J McArthur5 , D Simpson6 , Igor Grant* 1 , and CHARTER Group 

1 2 Univ of California, San Diego, US;; Univ of Washington, Seattle, US;; 

3 4 Washington Univ, St Louis, MO, US;; Univ of Texas Med Branch, 

Galveston, US;; 5Johns Hopkins Univ, Baltimore, MD, US;; and 6Mt Sinai 

Sch of Med, New York, NY, US 

441� �� 

�� 

Proteins Characterize Evolving Central Nervous System 

�� 

Julia Peterson* 1 , H Zetterberg2 , L Hagberg2 , S Spudich3 , M Gisslen2 , 

and R Price1 1 2 Univ of California, San Francisco, US;; Sahlgrenska Academy at Univ of 

Gothenburg, Sweden;; and 3Yale Univ, New Haven, CT, US 

442� �� 

Profiles in Chronic Middle-aged HIV + Individuals 

L Cysique1,2 , J Lamoury2 , T Hewitt2,3 , K Taddei4,5,6 , R Martins4,5 , C Chew5 , 

P Price5 , and Bruce Brew* 1,2 

1 2 St Vincents Hosp, Sydney, Australia;; Univ of New South Wales, Sydney, 

Australia;; 3Notre Dame Univ, Sydney, Australia;; 4Edith Cowan Univ, 

Australia;; 5Univ of Western Australia, Perth;; and 6Hollywood Private 

Hosp, Nedlands, Australia 

443� �� 

on Suppressive ART: An Aging Effect of Central Nervous 

System Infection? 

Jan Jessen Krut* 1 , T Mellberg1 , R Price2 , L Hagberg1 , D Fuchs3 , 

L Rosengren1 , S Nilsson4 , H Zetterberg1,5 , and M Gisslen1 1 2 Sahlgrenska Academy, Univ of Gothenburg, Sweden;; Univ of California, 

San Francisco, US;; 3Innsbruck Med Univ, Austria;; 4Chalmers Univ of Tech, 

Gothenburg, Sweden;; and 5Univ Coll London, Inst of Neurology, UK 

444 Longitudinal Association of HIV-associated Neurocognitive 

+ �� 

Men 

Bryan Smith* 1 , R Skolasky1 , F Mateen1 , J Becker2 , E Martin3 , E Miller4 , 

J Margolick5 , O Selnes1 , N Sacktor1 , and Multictr AIDS Cohort Group 

1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; Univ of Pittsburgh 

Sch of Med, PA, US;; 3Univ of Illinois Sch of Med, Chicago, US;; 4David Geffen Sch of Med, Univ of California, Los Angeles, US;; and 5 447 Neurovirological Correlation with HIV-associated 

Neurocognitive Disorders and Encephalitis in a HAART-era 

Cohort 

Benjamin Gelman* 

Johns 

Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD US 

1 , J Lisinicchia1 , S Morgello2 , E Masliah3 , 

D Commins4 , I Grant3 , E Singer5 , S Sherman6 , G Gensler6 , V Soukup1 , 

and Natl NeuroAIDS Tissue Network 

1 2 Univ of Texas Med Branch, Galveston, US;; Mt Sinai Med Ctr, New 

York, NY, US;; 3Univ of California, San Diego, La Jolla, US;; 4Univ of 

Southern California, Los Angeles, US;; 5Univ of California, Los Angeles, 

US;; and 6The EMMES Corp, Rockville, MD, US 

448� �� 

�� 

Andrea De Luca* 1,2 , N Ciccarelli1 , P Grima1,3 , M Colafigli1 , M Fabbiani1 , 

E Baldonero1 , A Borghetti1 , E Tamburrini1 , R Cauda1 , 

and S Di Giambenedetto1 1 2 Catholic Univ of the Sacred Heart, Rome, Italy;; Univ of Siena, Italy;; 

and 3S Caterina Novella Hosp, Galatina, Italy 

449� �� 

cART Era: Neuradapt Study 

Matteo Vassallo* 1,2 , B Dunais2 , J Durant2 , V Biscay2 , M Laffont3 , 

C Lebrun-Frenay3 , J Cottalorda2 , M Ticchioni2 , C Pradier2 , 

P Dellamonica2 , and Neuradapt Study Group 

1 2 Pierre Nouveau Hosp, Cannes, France;; LArchet Hosp, Univ of Nice, 

France;; and 3Pasteur Hosp, Univ of Nice, France 

450 HIV-associated Neurocognitive Disorders in a Community 

�� 

Standardized Neuropsychological Assessment 

Mark Bloch* 1 , A Carberry1 , J Kamminga2 , M Bailey3 , T Vincent1 , 

D Quan1 , B Brew4,5 , and L Cysique4,5 1 2 Holdsworth House Med Practice, Sydney, Australia;; Macquarie Univ, 

Sydney, Australia;; 3Monash Univ, Melbourne, Australia;; 4Univ of New 

South Wales, Sydney, Australia;; and 5St Vincents Hosp, Sydney, Australia 

451 Trails A Test Improves Performance Characteristics of the 

International HIV Dementia Scale to Identify Symptomatic 

HIV-associated Neurocognitive Disorder 

T Chalermchai1 , J Ananworanich1,2,3 , P Sithinamsuwan4 , S Pinyakorn1 , 

D Clifford5 , R Paul6 , V DeGruttola7 , S Ratto-Kim8 , C Shikuma9 , 

Victor Valcour* 10 , and SEARCH 007 and 011 Study Groups 

1South East Asia Res Collaboration with the Univ of Hawaii, Bangkok, 

Thailand;; 2Chulalongkorn Univ, Bangkok, Thailand;; 3HIV-NAT Res 

Collaboration, Bangkok;; 4Phramongkutklao Hosp, Bangkok, Thailand;; 

5 6 Washington Univ in St Louis, MO, US;; Univ of Missouri, St Louis, US;; 

7 8 Harvard Sch of Publ Hlth, Boston, MA, US;; Walter Reed Army Inst of 

Res, Silver Spring, MD, US;; 9Univ of Hawaii at Manoa, Honolulu, US;; 

and 10Univ of California, San Francisco, US 

452 High Grade Liver Steatosis and Cognitive Impairment in 

HIV + Patients 

Pierfrancesco Grima* 1,2 , M Fabbiani1 , A Mondi1 , A D’Avino1 , S 

Limiti1 , 

M Colafigli1 , B Milanini1 , E Baldonero1 , R Cauda1 , 

and S Di Giambenedetto1 1 2 Catholic Univ of the Sacred Heart, Rome, Italy and S Caterina Novella 

Hosp, Galatina, Italy 

453 Minimal Cognitive Impairment in UK HIV + Men Who Have 

Sex with Men;; Comparison with the General Population and 

across Classification Systems 

J McDonnell1 , Fiona Lampe* 1 , L Haddow1 , A Phillips1 , L Sherr1 , 

R Gilson1 , J Harrison2 , A Antinori3 , M Johnson4 , A Rodger1 , 

and CIPHER Study Group 

1 2 3 Univ Coll London, UK;; Imperial Coll London, UK;; Natl Inst for 

Infectious Diseases, Rome, Italy;; and 4Royal Free Hosp, London, UK 

454 

455 

Progression Rates of Neuro-AIDS and Its Neuropsychological 

Patterns in the cART Era 

Gabriele Arendt*, E Orhan, and T Nolting 

Univ of Dusseldorf, Germany 

Performance of Screening Tools for the Detection of 

Neurocognitive Impairment in HIV Patients 

Andrea Antinori*, P Balestra, P Lorenzini, R Libertone, G Cataldo, 

L Giancola, C Pinnetti, and V Tozzi 

INMI L Spallanzani, Rome, Italy


456 A Longitudinal Study of the Effects of Aging and HIV-1 

Infection on Cognitive Performance 

Becky Haynes* 1 , T Karren 1 , S Casey 2 , J Dunn 1 , F Zelaya 1 , 

M Pitkanen 1 , R Kulasegaram 3 , G Barker 1 , and M Kopelman 1 

1 Kings Coll London, Inst of Psychiatry, UK;; 2 Acquired Brain Injury 

Ireland, Dublin;; and 3 Guys and St Thomas NHS Fndn Trust, London, UK 

457 Genome-wide Association Study of Peripheral Neuropathy 

�� 

Paul Leger* 1 , D Johnson 1 , G Robbins 2 , R Shafer 3 , D Clifford 4 , J Li 1 , 

P McLaren 5,6 , and D Haas 1 

1 Vanderbilt Univ Sch of Med, Nashville, TN, US;; 2 Massachusetts Gen 

Hosp, Harvard Univ, Boston, US;; 3 Stanford Univ, CA, US;; 4 Washington 

Univ Sch of Med, St Louis, MO, US;; 5 Broad Inst of MIT and Harvard, 

Cambridge, MA, US;; and 6 Ecole Polytechnique Federale de Lausanne, 

Univ of Lausanne, Switzerland 

461a Moderate Neurocognitive Decline Can Be Detected over a 

�� 

Grace Lu* 1 , L Cysique1,2,3,4 , K Siefried4 , B Draper5 , and B Brew1,3,4 1Univ of New South Wales, St Vincents Hosp Clin Sch, Sydney Australia;; 

2 3 Neurosci Res Australia, Sydney;; St Vincents Ctr for Applied Med Res, 

Sydney, Australia;; 4St Vincents Hosp, Sydney, Australia;; and 5Sch of 

Psychiatry, Univ of New South Wales, Sydney Australia 

463 Matrix Metalloproteinases and Relation to Brain Status in 

Early HV Infection 

Ann Ragin* 1 , H Du 2 , Y Gao 1 , S Li 1 , R Mahadevia 1 , C Sammet 1 , Y Wu 2 , 

and L Epstein 1 

1 Northwestern Univ, Chicago, IL, US and 2 NorthShore Univ Hlth System, 

Evanston, IL, US 

464 Effects of HIV Clade B and C on Brain Volumetric 

Measurements 

Mario Ortega* 1 , J Joska 2 , J Heaps 3 , F Vaida 4 , A Agrawal 1 , R Paul 3 , 

and B Ances 1 

1 Washington Univ, St Louis, MO, US;; 2 Univ of Cape Town, South Africa;; 

3 Univ of Missouri, St Louis, US;; and 4 Univ of California, San Diego, US 

466 Effects of Primary and Chronic HIV Infection on White Matter 

Integrity Using Diffusion Tensor Imaging 

Patrick Wright* 1 , R Fernandez 2 , D Meyerhoff 3 , R Price 3 , 

K Robertson 4 , E Lee 3 , J Rutlin 1 , J Shimony 1 , S Spudich 5 , and B Ances 1 

1 Washington Univ in St Louis, MO, US;; 2 Univ of Puerto Rico, Rio 

Piedras;; 3 Univ of California, San Francisco, US;; 4 Univ of North Carolina 

at Chapel Hill, US;; and 5 Yale Univ, New Haven, CT, US 

467 Effects of HIV and Hepatitis C Co-infection on White Matter 

Structural Integrity and White Matter Volumes 

Jodi Heaps* 1 , P Wright 2 , B Ances 2 , D Clifford 2 , and R Paul 1 

1 Univ of Missouri-St Louis, US and 2 Washington Univ Sch of Med, 

St Louis, MO, US 

458� �� 

with Asymptomatic Neurocognitive Impairment and Minor 

�� 

A Livelli1,2 , �� * 1 , L Pia3 , S Carosella1 , M Farenga1 , 

V Ghisetti1 , A Calcagno1,3 , and P Caramello1 1 2 Amedeo of Savoia Hosp, Turin, Italy;; CRT, G Goria Fndn, Turin, Italy;; 

and 3Univ of Turin, Italy 

459� �� 

�� 

Jordan Lake* 1 , Q Vo2 , L Jacobson3 , N Sacktor3 , W Post3 , J Becker4 , 

F Palella5 , A Ragin5 , and T Brown3 1 2 Univ of California, Los Angeles, US;; Henry M Jackson Fndn for the 

Advancement of Military Med, Bethesda, MD, US;; 3Johns Hopkins Univ, 

Baltimore, MD, US;; 4Univ of Pittsburgh, PA, US;; and 5 460 

Northwestern 

Univ, Chicago, IL, US 

Proteinuria Is Associated with Neurocognitive Impairment in 

HIV + �� 

Robert Kalayjian* 1 , K Wu2 , S Evans2 , M Pallaki3 , D Clifford4 , 

and M Smurzynski2 1 2 MetroHlth Med Ctr, Cleveland, OH, US;; Harvard Sch of Publ Hlth, 

Boston, MA, US;; 3 468 Neuroimaging Correlates of Prior Immunosuppression and 

Cognitive Status in HIV 

Christine Fennema-Notestine* 

Louis Stokes VAMC, Cleveland, OH, US;; and 

4Washington Univ, St Louis, MO, US 

1 , M Taylor1 , R Notestine1 , T Wolfson2 , 

A Gamst1,2 , S Archibald1 , R Theilmann1 , R Heaton1 , C Marra3 , I Grant1 , 

and CHARTER Group 

1 2 Univ of California, San Diego, La Jolla, US;; San Diego Supercomputer 

Ctr, La Jolla, CA, US;; and 3Univ of Washington, Seattle, US 

469 Diffusion Tensor Imaging Uncovers Specific Brain 

Microstructural Deficits during Chronic HIV-1 Infection of 

Humanized Mice 

Prasanta Dash*, J Knibbe, T Gutti, E Makarov, D Baber, S Gorantla, 

L Poluektova, H Gendelman, and M Boska 




Human Genomics 

470 Genome-Wide Association Study of Phenotypic HIV-1 

Co-receptor Usage in Treatment-naïve Patients from the 

ACTG A5095 Trial 

Timothy Henrich* 1,2 , P McLaren1,2,3,4 , S Rao5 , N Lin2,6 , F Giguel6 , 

H Ribaudo2,7 , R Gulick8 , P de Bakker1,2,3 , and D Kuritzkes1,2 1 2 �� 

Harvard Med Sch, 

Boston, MA, US;; 3Broad Inst of Harvard and MIT, Cambridge, MA, 

US;; 4Ecole Polytechnique Federale de Lausanne and Univ of Lausanne, 

Switzerland;; 5Harvard Univ, Cambridge, MA, US;; 6Massachusetts Gen 

Hosp, Boston, US;; 7Harvard Sch of Publ Hlth, Boston, MA, US;; and 

8Weill Med Coll of Cornell Univ, New York, NY, US 

461b�� 

H Predicts HIV-1-related Neurocognitive Impairment and 

�� 

Kumud Singh*, F Vaida, C Fennema-Notestine, R Ellis, S Letendre, 

D Franklin Jr, D Rosario, R Heaton, I Grant, and CHARTER Group 

Univ of California San Diego, La Jolla, US 



Neuroimaging Studies 

462� �� 

Weeks in HIV + Individuals Commencing ART 

Alan Winston* 1 , R Puls2 , S Kerr2 , C Duncombe3 , P Li4 , J Gill5 , 

R Ramautarsing5 , S Taylor-Robinson1 , S Emery2 , D Cooper2 , 

for ALTAIR Study Group 

1 2 3 Imperial Coll London, UK;; The Kirby Inst, Sydney, Australia;; HIVNAT, 

Bangkok;; 4Queen Elizabeth Hosp, Hong Kong, China;; and 5 471 Novel HLA Associations with HIV Control in a Previously 

Uncharacterized Immunogenetic Context 

Humberto Valenzuela-Ponce*, S Avila-Rios, M Soto-Nava, 

D Garrido-Rodriguez, T Garcia-Tellez, V Quiroz-Morales, 

C Garcia-Morales, R Hernandez-Juan, A Murakami-Ogasawara, 

G Reyes-Teran, and Mexican HIV Molecular Epidemiology Project Group 

Natl Inst of Respiratory Diseases, Mexico City, Mexico 

472� �� 

�� 

HLA-B*57 

C Granier 

Calgary Hlth, 

Canada 

1 , Emilie Battivelli* 1 , A Venet2 , C Lecouroux2 , O Lambotte3 , 

C Delaugerre1 , J-M Molina4 , F Clavel1 , and A Hance1 1 2 INSERM U941, Hosp St Louis, Paris, France;; INSERM U1012, Faculte 

de Med Paris-Sud, France;; 3Hosp de Bicetre, le Kremlin-Bicetre, France;; 

and 4Hosp St Louis, Paris, France 

473 Human MHC Gene Variants and Immune Control of HIV-1 

�� 

the Immunochip 

Heather Prentice* 1 , N Pajewski2 , E Brown1 , S Allen3 , E Hunter3 , 

R Kaslow1 , and J Tang1 1 2 Univ of Alabama at Birmingham, US;; Wake Forest Univ, Winston- 

Salem, NC, US;; and 3Emory Univ, Atlanta, GA, US 

474 Gene Expression Profiling Identifies Genes with a Mechanistic 

+ �� 

Individuals on ART 

Nadejda Beliakova-Bethell* 1 , S Little1 , P Du2 , S Rought2 , 

D Richman1,2 , and C Woelk1,2 1 2 Univ of California, San Diego, La Jolla, US and VA San Diego, CA, US 

475 HLA Associations with Immunological Recovery and Drug 

Toxicities in HIV-1 + Adults 

Jane O’Halloran* 1 , J Crowley 2 , M Fagan 2 , C Hickey 2 , S Stokes 2 , 

A Kinsella 2 , H Tuite 1 , R Hagan 2 , and C Bergin 1 

1 St Jamess Hosp, Dublin, Ireland and 2 Irish Blood Transfusion Svc, 

Dublin, Ireland 

465� �� 

�� 

Magnetic Resonance Spectroscopy in Primary HIV Infection 

Marie Grill* 1 , J Peterson1 , E Lee1 , R Walter1 , D Fuchs2 , L Hagberg3 , 

D Meyerhoff1 , R Price1 , and S Spudich4 476� �� 

Genes Differentially Expressed in HIV 

1 2 Univ of California, San Francisco, US;; Innsbruck Med Univ, Austria;; 

3 4 Univ of Gothenburg, Sweden;; and Yale Univ, New Haven, CT, US 

+ Individuals following 

ART 

Marta Massanella* 1 , A Singhania2 , N Beliakova-Bethell3 , J Perez-Santiago3 , 

R Pier3 , C White2,3 , J Blanco1 , D Richman2,3 , S Little3 , and C Woelk2,3 1Fndn irsiCaixa-HIVACAT, Inst de Recerca en Ciencies de la Salut 

Germans Trias i Pujol, Hosp Germans Trias, Univ Autonoma de 

Barcelona, Spain;; 2VA San Diego Hlthcare System, CA, US;; and 3Univ of 

California, San Diego, La Jolla, US 


Poster Listings



477� �� 

HIV-1 Infection in Africans 

Travis Porter* 1 , W Song1 , M Price2 , E Cormier2 , P Amornkul2 , 

S Lakhi2 , A Kamali2 , R Kaslow1 , J Gilmour2 , J Tang1 c Monday, 2:30-4 pm; Hall B2 


, and IAVI African 


HIV Res Network 

Mining Sequence Data to Understand 

1 2 Univ of Alabama at Birmingham, US and Intl AIDS Vaccine Initiative, 


Transmission and Disease 

478 The Additive Effect of Specific Activating KIR Interactions 

with Putative HLA Ligands Protects from HIV Infection and 

Disease Progression 

Daniela Garrido-Rodriguez*, S Avila-Rios, H Valenzuela-Ponce, 

T Garcia-Tellez, V Quiroz-Morales, C Garcia-Morales, M Soto-Nava, 

J Vazquez-Perez, R Hernandez-Juan, and G Reyes-Teran 

Natl Inst of Respiratory Diseases, Mexico City, Mexico 

483� �� 

Strains Isolated in Mustached Monkeys (C. cephus�� 

�� 

Florian Liegeois* 1,2 , V Boue 1,2 , C Butel 1 , P Ngari 2 , F Mouacha 1 , 

B Mve Ondo 2 , L Eric 2 , M Peeters 1 , and F Rouet 2 

1 UMI 233, Inst de Recherche pour le Devt and Univ of Montpellier, 

France and 2 Ctr Intl de Recherches Med de Franceville, Gabon 

484 Gorillas in Southwest Cameroon Are the Reservoir of HIV-1 

Group P Ancestors 

Mirela D’arc* 1,2 , A Ayouba 1 , A Esteban 1 , L Etienne 1 , S Locatelli 1 , 

A Aghokeng 1,3 , E Delaporte 1 , EM Ngole 3 , and M Peeters 1 

1 UMI 233, IRD and Univ of Montpellier 1, France;; 2 Univ Federal do Rio 

de Janeiro, Brazil;; and 3 Projet PRESICA and IMPM/CREMER, Yaounde, 

Cameroon 

487 Co-infection of Wild African Primates with SIV and Simian 

�� 

Tony Goldberg* 1,2,3 , M Lauck 2 , W Switzer 4 , D Hyeroba 3 , A Tumukunde 3 , 

J Kuhn 5 , C Chapman 6 , N Ting 7 , T Friedrich 1,2 , and D O’Connor 1,2 

1 Univ of Wisconsin-Madison, US;; 2 Wisconsin Natl Primate Res Ctr, 

Madison, US;; 3 Kibale EcoHlth Project, Makerere Univ Bio Field Station, 

Kanyawara, Uganda;; 4 CDC, Atlanta, GA, US;; 5 IRF-Frederick, NIH, Fort 

Detrick, MD, US;; 6 Sch of Environment, McGill Univ, Montreal, Canada;; 

and 7 Univ of Oregon, Eugene, US 


mus 

488� �� 

Joel Wertheim* 1 , A Leigh Brown 2 , L Hepler 1 , S Mehta 1 , 

D Richman 1,3 , D Smith 1,3 , and S Kosakovsky Pond 1 

1 Univ of California, San Diego, US;; 2 Univ of Edinburgh, UK;; 

and 3 VA San Diego Hlthcare System, CA, US 

479� �� 

+ �� Thais 

Masahiko Mori* 1,2,3,4 , N Wichukchinda5 , R Miyahara1 , A Rojanawiwat1 , 

P Pathipvanich6 , T Maekawa1 , P Goulder2 , M Yasunami1 , K Ariyoshi1,4 , 

and P Sawanpanyalert5 1 2 3 Nagasaki Univ, Japan;; Univ of Oxford, UK;; Japan Fndn for AIDS 

Prevention, Tokyo;; 4Nagasaki Univ Global COE Prgm, Japan;; 5Ministry of Publ Hlth, Nonthaburi, Thailand;; and 6 480 

Lampang Hosp, Thailand 

A Targeted Transcriptomic Approach Reveals HIV-1 

�� 

�� 

Ivan Tasovski*, J Purushe, and M Chin 

Temple Univ Sch of Med, Philadelphia, PA, US 

481 Exome Sequencing to Assess the Role for Rare Coding 

Mutations in the Host Genome in HIV-1 Control 

Paul McLaren* 1,2 , P Shea3 , I Bartha1,2 , D Goldstein3 , and J Fellay1,2 1 2 Ecole Polytechnique Federale de Lausanne, Switzerland;; Univ Hosp 

Lausanne, Switzerland;; and 3Duke Univ Sch of Med, Durham, NC, US 




Simian Viral Reservoirs 

482 Discovery of Novel and Highly Divergent SIV in Three Wild 

�� 

William Switzer* 1 , M Lauck2 , A Shankar1 , D Hyeroba3,4 , A Tumukunde4 , 

C Chapman4,5,6 , N Ting7 , T Friedrich2,8 , D O’Connor2,8 , and T Goldberg2,4,6,8 1 2 3 CDC, Atlanta, GA, US;; Univ of Wisconsin-Madison, US;; Jane Goodall 

Inst, Entebbe, Uganda;; 4Kibale EcoHlth Project, Makerere Univ Bio 

Field Station, Kanyawara, Uganda;; 5McGill Univ, Montreal, Canada;; 

6 7 Makerere Univ, Kampala, Uganda;; Univ of Oregon, Eugene, US;; 

and 8 489� �� 

�� 

Mary Grabowski* 

Wisconsin Natl Primate Res Ctr, Madison, US 

1 , J Lessler1 , A Redd2 , O Laeyendecker2,3 , 

J Kagaayi4 , T Lutalo4 , M Wawer1,4 , D Serwadda4,5 , T Quinn2,3 , R Gray1,4 , 

and Rakai Hlth Sci Prgm 


2 3 Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US;; Johns 

Hopkins Univ Sch of Med, Baltimore, MD, US;; 4Rakai Hlth Sci Prgm, 

Entebbe, Uganda;; and 5Makerere Univ Sch of Med, Kampala, Uganda 

490 Dynamics of Non-B HIV Transmission in the UK 

Manon Ragonnet-Cronin* 1 , S Lycett1 , E Hodcroft1 , S Hue2 , 

E Fearnhill3 , D Dunn3 , V Delpech4 , A Leigh Brown1 , and UK Collaborative 

Group on HIV Drug Resistance 

1 2 3 Univ of Edinburgh, UK;; Univ Coll London, UK;; MRC Clin Trials Unit, 

London, UK;; and 4Hlth Protection Agency, London, UK 

491 Defining HLA Genotypes from Bulk HIV Sequences 

A Kreimer1 , M Shaefer2 , N Pfeifer1 , V Tan1 , P Goulder3 , M John4 , Z Brumme5 , 

E Hunter2 , D Heckerman1 , Jonathan Carlson* 1 , and Intl and Southern 

Africa HIV Assn Collaboratives 

1 2 Microsoft Res, Los Angeles, CA, US;; Emory Univ, Atlanta, GA, US;; 

3 4 5 Univ of Oxford, UK;; Murdoch Univ, Australia;; and Simon Fraser Univ, 


492 Whole Genome Sequencing of HIV + African Americans with 

Rapid Disease progression or Long-term Non-progression 

Amy Weintrob* 1,2 , K Pelak3 , R Thomas2 , P Ehrenberg2 , P Shea3 , 

J Okulicz1 , A Ganesan1 , B Agan1 , N Michael2 , and D Goldstein3 1Uniformed Svcs Univ Infectious Disease Clin Res Prgm, Bethesda, MD, 

US;; 2Military HIV Res Prgm, Bethesda, MD, US;; and 3Duke Univ Ctr for 

Human Genome Variation, Durham, NC, US 

493 Exome Sequencing of Elite and Rapid HIV Progressors: 

Results from the Exploratory Pilot of the UK HIV Genomics 

Consortium 

Deepti Gurdasani* 1,2 , C Scott1 , E Young1,2 , K Porter3 , P Kellam1,4 , 

M Sandhu1,2 , and UK HIV Genomics Consortium 

1 2 Wellcome Trust Sanger Inst, Cambridge, UK;; Univ of Cambridge, UK;; 

3 4 MRC Clin Trials Unit, London, UK;; and Univ Coll London, UK 



Transmission Clusters 

494� �� 

�� 

Alessia Lai* 1 , M Franzetti 1 , M Prosperi 2 , G Sterrantino 3 , F Saladini 4 , 

B Bruzzone 5 , M Zazzi 4 , M Ciccozzi 6 , C Balotta 1 , and A Deluca 7 

1 L Sacco Hosp, Univ of Milan, Italy;; 2 Univ of Florida, Coll of Med, 

Emerging Pathogens Inst, US;; 3 Infectious Diseases of Careggi, Florence, 

Italy;; 4 Univ of Siena, Italy;; 5 Lab of Hygiene, San Martino Hosp, Italy;; 

6 Italian Inst of Hlth, Rome;; and 7 Siena Univ Hosp, Italy 

485� �� 

cpzPtt Infection in Wild-living 

�� 

Vanina Boue* 1,2 , F Liegeois1,2 , AP Okouga2 , S Locatelli1 , C Butel1 , 

P Ngari2 , E Delaporte1 , M Peeters1 , and F Rouet2 1UMI 233, Inst de Recherche pour le Devt and Univ of Montpellier, 

France and 2Ctr Intl de Recherches Med de Franceville, Gabon 

486� �� 

�� 

and Uakari Monkeys from Brazil 

Claudia Muniz* 1 , A Santos1 , H Jia2 , L Troncoso1 , L Faria1 , 

A Augusto3 , L Fedullo3 , A Pissinatti4 , M Soares1,5 , and W Switzer2 1 2 3 Univ Federal do Rio de Janeiro, Brazil;; CDC, Atlanta, GA, US;; Fndn 

Rio-Zoo, Rio de Janeiro, Brazil;; 4Ctr de Primatologia do Rio de Janeiro, 

Brazil;; and 5 495 HIV Transmission Patterns among Immigrant Latinos 

�� 

Data 

Ann Dennis* 

Prgm de Oncovirologia, Inst Nacional de Cancer, Rio de 

Janeiro, Brazil 

1 , S Hue2 , S Napravnik1 , D Pasquale1 , L Hightow-Weidman1 , 

J Sebastian3 , D Pillay2 , and J Eron1 1 2 Univ of North Carolina at Chapel Hill, US;; Univ Coll London, UK;; 

and 3Lab Corp of America, Research Triangle Park, NC, US 

496 Improving the Sensitivity of Molecular Epidemiology Using 

Ultra-deep Sequencing 

Lance Hepler* 1 , G Wagner1 , S Little1 , D Richman1,2 , J Wertheim1 , 

S Mehta1 , D Smith1,2 , and S Kosakovsky Pond1 1 2 Univ of California, San Diego, La Jolla, US and VA San Diego Hlthcare 


497 Chronic Infections Drive HIV Transmission Networks among 

High-risk Populations 

Philip Chan* 1 , A Huang1 , M Salemi2 , M Prosperi2 , M Reitsma1 , 

and R Kantor1 1 2 Brown Univ, Providence, RI, US and Univ of Florida, Gainesville, US




HIV Subtypes: Epidemiology and Disease 

Progression 

498� �� 

Progression in Chinese HIV-1 Sexually Infected Patients 

Y Li1 , Y Han1 , J Xie1 , L Gu2 , L Li3 , W Li4 , H Wang1 , T Ishida2 , 

A Iwamoto2 , Taisheng Li* 1 , on behalf of CACT0810 Group 

1 2 Peking Union Med Coll Hosp, Beijing, China;; Univ of Tokyo, Japan;; 

3 4 Beijing Inst of Microbio and Epi, China;; and Beijing Youan Hosp, 

Capital Med Univ, China 

503� �� 

Vita Laga* 1 , E Kazennova 1 , A Vasilyev 1 , I Lapovok 1 , A Kuz’mina 2 , 

Y Mikryukova 2 , A Aleksashkina 2 , and M Bobkova 1 

1 DI Ivanovsky Inst of Virology, Moscow, Russian Federation and 

2 Regional AIDS Ctr, Vladivostok, Russian Federation 



Within-patient Diversity Compartmentalization, 

Dual Infection, and Recombination 

506 Migratory Pathways of HIV-1 during the Natural History of 

Intra-patient Infection Identify Targets for HIV Eradication 

Nazle Veras* 1 , A Lowe 1 , M Salemi 1 , J Sleasman 2 , and M Goodenow 1 

1 Univ of Florida, Gainesville, US and 2 Univ of South Florida, Tampa, US 

507 Genetic Analysis of HIV Genomic DNA Sequences from 

+ �� 

�� 

Eli Boritz* 1 , B Hill1 , M Rolland2 , and D Douek1 1 2 Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US and US Military HIV 

Res Prgm, Silver Spring, MD 

508� �� 

in Mixed Populations 

Francesca Di Giallonardo* 1,2 , M Rey 3 , A Topfer 4 , S Prabhakaran 3 , 

Y Duport 1 , M Kuenzli-Gontarczyk 5 , H Gunthard 1 , N Beerenwinkel 4,6 , 

V Roth 3 , and K Metzner 1 

1 Univ Hosp Zurich, Univ of Zurich, Switzerland;; 2 Life Sci Zurich Grad Sch, 

Univ of Zurich, Switzerland;; 3 Univ of Basel, Switzerland;; 4 ETH Zurich, 

Basel, Switzerland;; 5 Functional Genomics Ctr Zurich, Univ of Zurich, ETH 

Zurich, Switzerland;; and 6 SIB Swiss Inst of Bioinformatics, Basel 

509� �� 

�� 

Susanna Lamers* 1 , D Nolan 2 , S Strickland 2 , and M Salemi 2 

1 Bioinfoexperts, LLC, Thibodaux, LA, US and 2 Univ of Florida, 

Gainesville, US 

510 High Rates of Intraclade HIV-1 Dual Infection among MSM 

in San Diego 

Gabriel Wagner* 1 , M Pacold 2 , S Kosakovsky Pond 1 , G Caballero 3 , 

D Richman 1,3 , S Little 1 , and D Smith 1,3 

1 Univ of California, San Diego, US;; 2 Life Technologies, Foster City, CA, 

US;; and 3 VA Hlthcare System, San Diego, CA, US 

499� �� 

Infections among MSM in Thailand 

Wanna Leelawiwat* 1 , F Mueanpai1 , O Kongpechsatit1 , S Pattanasin1 , 

W Chonwattana1 , A Sriporn1 , S Chaikummao1 , F van Griensven2 , 

and M Curlin3 1Thailand Ministry of Publ Hlth-CDC Collaboration, Nonthaburi;; 

2 3 AVRAM Corp, Miami, FL, US;; and CDC, Atlanta, GA, US 

500� �� 

�� 

Caitlin Lam* 1 , T Holtz2,3 , W Leelawiwat2 , P Mock2 , W Chonwattana2 , 

W Wimonsate2 , A Varangrat2 , W Thienkrua2 , A Chitwarakorn4 , 

and M Curlin2,3 1 2 Emory Univ Sch of Publ Hlth, Atlanta, GA, US;; Thailand Ministry of 

Publ Hlth-CDC Collaboration, Nonthaburi;; 3CDC, Atlanta, GA, US;; 

and 4Thailand Ministry of Publ Hlth, Nonthaburi 

501� �� 

�� 

Marie Leoz* 1 , C Charpentier2 , C Delaugerre3 , M Wirden4 , V Lemee1 , 

and JC Plantier1 1 2 CHU Charles Nicolle, Rouen, France;; CHU Bichat Claude Bernard, 

Paris, France;; 3CHU St Louis, Paris, France;; and 4CHU Pitie Salpetriere, 

Paris, France 

502� �� 

Intravenous Drugs Users in Athens Metropolitan Area: A 

Longitudinal Study 

Dimitrios Paraskevis* 1 , G Nikolopoulos2 , M Malliori3 , J Kremastinou2 , 

and A Hatzakis1 1Natl Retrovirus Reference Ctr, Univ of Athens Med Sch, Greece;; 

2Hellenic Ctr for Disease Control and Prevention, Athens, Greece;; 

and 3 c Tuesday, 2:30-4 pm; Hall B2 



New Approaches to ARV Drug Delivery 

512a� �� 

�� 

Pavan Puligujja*, H Gendelman, L Kendrick, N Smith, S Balkundi, 

U Roy, R Veerubhotla, J McMillan, and X Liu 


512b Development of Small Magnetite ARV Nanoparticles for 

Targeted Drug Delivery to Viral Reservoirs 

Dongwei Guo*, T Li, J McMillan, M Boska, X Liu, and H Gendelman 


513 Enhanced Pharmacological Properties of Efavirenz 

�� 

P Martin 

Org Against Drugs, Athens, Greece 

1 , Neill Liptrott* 1 , T McDonald1 , M Giardiello1 , P Roberts1 , 

P Curley1 , D Smith2 , M Siccardi1 , S Rannard1 , and A Owen1 1 2 Univ of Liverpool, UK and Univ of Northumbria, Newcastle Upon Tyne, UK 



ARV Pharmacogenetics: Metabolism, Drug 

Interactions, and Response 

514 Prediction of Etravirine Pharmacogenetics Using a 

Physiologically Based Pharmacokinetic Approach 

Marco Siccardi*, A Olagunju, P Curley, J Hobson, S Khoo, D Back, 

and A Owen 

Univ of Liverpool, UK 

504 High-throughput DNA Sequencing Is a Powerful Tool 

�� 

Application to the Study in DRC 

Eiji Ido* 1 , S Karhemere2 , M Ebengho3 , S Nakamura4 , T Nakaya5 , 

J Brandful6 , J Barnor6 , W Ampofo6 , S Yamaoka1 , and J-J Muyembe2 1 2 Tokyo Med and Dental Univ, Japan;; Natl Inst of Biomed Res, Kinshasa, 

Democratic Republic of the Congo;; 3AMO-Congo, Mbandaka;; 4Inst of 

Microbial Diseases, Osaka Univ, Japan;; 5Kyoto Prefectural Univ, Japan;; 

and 6 505 

Noguchi Memorial Inst for Med Res, Univ of Ghana, Accra 

New Insights into HIV-1 Group O Diversity 

Marie Leoz* 1 , F Damond2 , J Kfutwah3 , JC Plantier1 , 

and French RES-O Network 

1 2 CHU Charles Nicolle, Rouen, France;; CHU Bichat Claude Bernard, 

Paris, France;; and 3 515� �� 

�� 

Thomas Kakuda* 

Ctr Pasteur du Cameroun, Yaounde 

1 , S Nijs2 , G van Hoecke2 , F Tomaka1 , and R Hoetelmans2 1 2 Janssen Res & Devt, LLC, Titusville, NJ, US and Janssen Infectious 

Diseases BVBA, Beerse, Belgium 

516� �� 

without and with Isoniazid in Healthy Volunteers with 

�� 

Lawrence Lee* 1,2 , GH Soon1,2 , N Chew2 , L Else3 , A Amara3 , and S Khoo3 1 2 3 Natl Univ of Singapore;; Natl Univ Hlth System, Singapore;; and Univ of 

Liverpool, UK 

517� �� 

�� 

Genotyped Human Liver Microsomes 

M Court1 , F Almutairi1 , D Greenblatt1 , S Duan1 , K Klein2 , U Zanger2 , 

and Awewura Kwara* 3,4 

1 2 Tufts Univ Sch of Med, Boston, MA, US;; Dr Margarete Fischer- 

Bosch Inst of Clin Pharmacology, Stuttgart, Germany;; 3Miriam Hosp, 

Providence, RI, US;; and 4Warren Alpert Med Sch of Brown Univ, 

Providence, RI, US 



518� �� 

Response to Efavirenz-containing Regimens in Port-au- 

�� 

David Haas* 1 , P Severe 2 , M-A Juste 2 , J Pape 2,3 , and D Fitzgerald 2,3 

1 Vanderbilt Univ Sch of Med, Nashville, TN, US;; 2 GHESKIO Ctrs, 

Port-au-Prince, Haiti;; and 3 Weill Cornell Med Coll, New York, NY, US 

519 Proposed Host Pharmacogenetic Polymorphisms Predict 

�� 

Discontinuation in Patients Receiving HAART 

Chanson Brumme* 1 , C Chui 1 , JE Min 1 , W Dong 1 , G Colley 1 , B Yip 1 , 

and R Harrigan 1,2 

1 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada and 2 Faculty of 

Med, Univ of British Columbia, Canada



520 Genome-wide Association Study of Atazanavir 

�� 

Daniel Johnson* 1 , C Venuto2 , E Daar3 , G Morse4 , P Sax5 , M Fischl6 , 

A Collier7 , P McLaren8,9 , M Ritchie10 , D Haas1 , and ACTG 

1 2 Vanderbilt Univ Sch of Med, Nashville, TN, US;; Univ of Rochester, NY, 

US;; 3Los Angeles Biomed Res Inst at Harbor-UCLA Med Ctr, Torrance, 

CA, US;; 4Univ at Buffalo, SUNY, US;; 5�� Boston, MA, US;; 6Univ of Miami Miller Sch of Med, FL, US;; 7Univ of 

Washington, Seattle, US;; 8Broad Inst of MIT and Harvard, Cambridge, 

MA, US;; 9Ecole Polytech Federale de Lausanne, Univ of Lausanne, 

Switzerland;; and 10 529 Tenofovir Alafenamide Pharmacokinetics in Renal Impairment: 

�� 

Srini Ramanathan* 

Pennsylvania State Univ, Univ Park, US 

1 , J Custodio1 , M Fordyce1 , W Garner1 , M Vimal1 , 

G Klein2 , K Farbakhsh3 , P Pergola4 , A Cheng1 , and B Kearney1 1 2 3 Gilead Sci, Inc, CA, US;; APEX GmbH, Munich, Germany;; DaVita Clin Res, 

Minneapolis, Minnesota, US;; and 4Renal Assoc, PA, San Antonio, Texas, US 



Compartment Penetration of ARV 



ARV Drug Exposure, Safety, and Efficacy 

521 Efavirenz Pharmacokinetics Are Independently Associated 

�� 

Adriana Andrade* 1 , G Baheti2 , L Smeaton3 , M Yang3 , N Kumarasamy4 , 

T Flanigan5 , J Hakim6 , K Klingman7 , T Campbell8 , C Fletcher2 , and ACTG 

5175 Team 

1 2 Johns Hopkins Univ, Baltimore, MD, US;; Univ of Nebraska Med Ctr, 

Omaha, US;; 3Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, 

Boston, MA, US;; 4YR Gaitonde Ctr for AIDS Res and Ed, Chennai, India;; 

5 6 7 Miriam Hosp, Providence, RI, US;; Univ of Zimbabwe, Harare;; NIAID, 

NIH, Bethesda, MD, US;; and 8Univ of Colorado Denver, Aurora, US 

522� �� 

Ritonavir Use—Increase Tenofovir Exposure in a Large 

Unselected Cohort of HIV + Women 

S Baxi1 , R Greenblatt1 , P Bacchetti1 , K Anastos2 , C Ponath1 , M Cohen3 , 

H Minkoff4 , S Gange5 , Monica Gandhi* 1 , and Women�s Interagency 

HIV Study 

1 2 Univ of California, San Francisco, US;; Albert Einstein Coll of Med, 

Bronx, NY, US;; 3Stroger Cook County Hosp, Chicago, IL, US;; 4SUNY Downstate Med Ctr, Brooklyn, US;; and 5 530� �� 

and Blood Plasma: Applying the Law of Mass Action to 

Predict Protein-free Drug Concentration 

Lindsay Avery*, N Sacktor, J McArthur, and C Hendrix 


531 Single and Multiple Dose Dolutegravir Pharmacokinetics in 

the Genital Tract and Colorectum of HIV 

Johns Hopkins Univ Bloomberg 

Sch of Publ Hlth, Baltimore, MD, US 

� Men and Women 

Benjamin Greener* 1 , J Adams1 , K Patterson2 , H Prince2 , C Sykes1 , 

M Wai1 , J Dumond1 , N Shaheen2 , M Cohen2 , and A Kashuba1,2 1Univ of North Carolina at Chapel Hill Eshelman Sch of Pharmacy, US 

and 2Univ of North Carolina at Chapel Hill Sch of Med, US 

532� �� 

�� 

in HIV Prevention 

Melanie Nicol* 1 , Y Fedoriw1 , M Mathews1 , J Micheli2 , D Kroetz2 , 

and A Kashuba1 1 2 Univ of North Carolina at Chapel Hill, US and Univ of California, 




ARV Drug Interactions 

523� �� 

and Drug Exposure in HIV + 533 In vitro Induction of Influx and Efflux Transporters and 

Patients 

�� 

Cristina Gervasoni*, P Meraviglia, S Landonio, S Baldelli, S Fucile, 

�� 

L Castagnoli, E Clementi, M Galli, A Riva, and D Cattaneo 

Beth Williamson* 

Luigi Sacco Hosp, Milan, Italy 

524� �� 

Exposure-safety Relationship following Administration of 

�� 

Srini Ramanathan*, Y-P Liu, H Wang, A Plummer, M Fordyce, 

L Zhong, F Jin, A Cheng, J Szwarcberg, and B Kearney 

Gilead Sci, Inc, Foster City, CA, US 

1 , K Dooley2 , D Back1 , and A Owen1 1 2 Univ of Liverpool, UK and Johns Hopkins Univ, Baltimore, MD, US 

534� �� 

�� 

�� 

L Zhu, C Hwang, V Shah, M Hruska, P Hu, B Vakkalagadda, M Furlong, 

X Xu, G Hanna, and Richard Bertz* 

Bristol-Myers Squibb, Princeton, NJ, US 



ARV Pharmacokinetics: New Assays, Drugs, and 

Special Populations 


535 Dolutegravir Has No Effect on Pharmacokinetics of Methadone 

or Oral Contraceptives with Norgestimate and Ethinyl Estradiol 

I Song 1 , S Mark 1 , J Borland 1 , S Chen 1 , T Wajima 2 , A Peppercorn 1 , 

and Stephen Piscitelli* 1 

1 GlaxoSmithKline, Research Triangle Park, NC, US and Mississauga, 

Canada and 2 Shionogi and Co, Ltd, Osaka, Japan 

525 Tenofovir Diphosphate in Dried Blood Spots in HIV� vs HIV + 

Individuals 

Jose Castillo-Mancilla* 1 , J Rower1 , J-H Zheng1 , A Meditz1 , E Gardner2 , 

K McAllister1 , B Klein1 , J Kiser1 , L Bushman1 , and P Anderson1 1 2 Univ of Colorado-AMC, Aurora, US and Denver Hlth Med Ctr, CO, US 

526� �� 

Chromatography and Self-reported Adherence in Patients on 

ART 

Eva Muro* 1,2 , L George1 , W Dolmans3 , D Burger3,4 , and E Kisanga1,2 1 2 Kilimanjaro Christian Med Univ Coll, Moshi, Tanzania;; Kilimanjaro 

Clinical Res Inst, Moshi, Tanzania;; 3Inst for Infection, Inflammation and 

Immunity, Nijmegen, The Netherlands;; and 4Radboud Univ Med Ctr, 

Nijmegen, The Netherlands 

527� �� 

�� 

�� 

Matt Anderson* 1 , J Gilmartin1 , M Robberechts1 , I De Lepeleire1 , 

L van Bortel2 , M Dockendorf Fallon1 , Y Guo1 , J Wagner1 , and J Butterton1 1 2 Merck Sharp & Dohme, Corp, Whitehouse Station, NJ, US and Drug 

Res Unit, Ghent, Belgium 

528 Pharmacokinetic Study of Raltegravir in HIV + Patients with 

�� 

C Barau1 , J Braun2 , C Vincent2 , S Haim-Boukobza3,4 , J-M Molina5,6 , 

P Miailhes7,8 , J-P Aboulker2 , J-C Duclos-Vallee3,9 , A-M Taburet1 , 

Elina Teicher* 1,3 , and ANRS 148 Study Group 

1 2 Bicetre Hosp, Le Kremlin-Bicetre, France;; INSERM SC10-US019, 

Villejuif, France;; 3Paul-Brousse Hosp, Villejuif, France;; 4INSERM U785, 

Villejuif, France;; 5St Louis Hosp, Paris, France;; 6 536� �� 

sparing Regimen Raltegravir plus Nevirapine in HIV-1 

Paris VII Univ, France;; 

7 8 Croix-Rousse Hosp, Lyon, France;; INSERM U1052, Lyon, France;; and 

9CHB UMR-S 785, Villejuif, France 

+ Patients 

Chiara Montrucchio* 1 , A Calcagno1 , M Lanzafame2 , G Cenderello3 , 

M Simiele1 , MC Tettoni1 , P Bigliano1 , A D’Avolio1 , G Di Perri1 , 

and S Bonora1 1 2 3 Univ of Torino, Italy;; GB Rossi Univ Hosp, Verona, Italy;; and San 

Martino Hosp Genoa, Univ of Genoa, Italy 

537� �� 

�� 

and HIV-1 NNRTI Rilpivirine 

Elizabeth Rhee*, H-P Feng, F Xuan, W Lin, C Smith, Y Zhu, 

and J Butterton 

Merck & Co, Inc, Whitehouse Station, NJ, US 

538� �� 

�� 

Co-administration in Hepatitis C Virus Infected Patients 

Adriana Andrade* 1 , C Hendrix1 , E Fuchs1 , C Radebaugh1 , 

M Sulkowski1 , L Bushman2 , M Ray2 , and J Kiser2 1 2 Johns Hopkins Univ, Baltimore, MD, US and Univ of Colorado Denver, 

Aurora, US 

539 Pharmacokinetics of Two Doses of Raltegravir in 

�� 

�� 

H Sauvageon1 , B Grinsztejn2 , V Arnold3 , V Veloso2 , C Vorsatz2 , JH Pilotto4 , 

C Grondin3 , G Chene3 , Anne-Marie Taburet* 5 , and J-M Molina1,6 1 2 Hosp St Louis, Paris, France;; IPEC, Fiocruz, Rio de Janeiro, Brazil;; 

3 4 INSERM U897, Univ Bordeaux, France;; Hosp Geral de Nova Iguacu, 

Brazil;; 5Hosp Bicetre, Kremlin-Bicetre, France;; and 6Univ Paris Diderot, 

Paris, France




New ARV Agents 

551 Early Hospitalization and Mortality in Patients Starting ART 

�� 

�� 

Eunice Obiero* 1 , P Yegon2 , A Aoko2 , R Langat2 , J Maswai2 , J Tarus2 , 

M Bii2 , M Omondi3 , F Sawe2,4 , and D Shaffer2,4 1 2 Kenya Ministry of Med Svcs, Kericho;; Kenya Med Res Inst/Walter Reed 

Project, Kericho;; 3Kenya Med Res Inst/Walter Reed Project, Kisumu;; and 

4US Military HIV Res Prgm, Bethesda, MD 

552 Association Between Early Virologic Response and 

Immunologic Outcomes in Raltegravir-treated Patients 

Christos Tsoukas* 1 , A Rodgers2 , H Teppler2 , R Leavitt2 , B-Y Nguyen2 , 

and P Sklar2 1 2 McGill Univ, Montreal, Canada and Merck Sharp & Dohme, Corp, 

Whitehouse Station, NJ, US 

553� �� 

�� 

�� 

Andrew Zolopa* 1 , J Rockstroh2 , C Orkin3 , H-J Stellbrink4 , S Walmsley5 , 

D Cooper6 , L Zhong7 , M Fordyce7 , M Rhee7 , and J Szwarcberg7 1 2 Stanford Univ, Palo Alto, CA, US;; Univ of Bonn, HIV-Outpatient Clin, 

Bonn, Germany;; 3Barts and the London NHS Trust, UK;; 4ICH Study Ctr, 

Hamburg, Germany;; 5Univ Hlth Network, Toronto Gen Hosp, Canada;; 6St Vincent�s Hosp, Sydney, Australia;; and 7Gilead Sci, Foster City, CA, US 

554� �� 

+ �� 

Individuals 

Cynthia Brinson* 1 , S Walmsley2 , K Arasteh3 , M Gorgolas4 , 

L Schneider5 , F Raffi6 , C Brennan7 , K Pappa7 , S Almond8 , C Granier9 , 

and Extended SPRING-2 and SINGLE Study Teams 

1 2 Central Texas Clin Res, Austin, US;; Univ Hlth Network, Toronto, 

Canada;; 3EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, 

Germany;; 4Fndn Jimenez Diaz, Madrid, Spain;; 5Internistische Praxis, 

Fuerth, Germany;; 6Univ of Nantes, France;; 7GlaxoSmithKline, Research 

Triangle Park, NC, US;; 8GlaxoSmithKline, Mississauga, Canada;; and 

9GlaxoSmithKline, Stockley Park, UK 

555� �� 

�� 

�� 

Steven van Lelyveld* 1 , J Drylewicz1 , C Richter2 , R Soetekouw3 , 

J Prins4 , K Brinkman5 , JW Mulder6 , M Nijhuis1 , K Tesselaar1 , 

A Hoepelman1 , and MIRS Study Group 

1 2 Univ Med Ctr Utrecht, The Netherlands;; Rijnstate Hosp, Arnhem, The 

Netherlands;; 3Kennemer Gasthuis, Haarlem, The Netherlands;; 4Academic Med Ctr, Amsterdam, The Netherlands;; 5Onze Lieve Vrouwe Gasthuis, 

Amsterdam, The Netherlands;; and 6Slotervaart Hosp, Amsterdam, The 

Netherlands 

556� �� 

�� 

�� 

Stefano Bonora* 1 , O Vigano2 , A Calcagno1 , J Cusato1 , M Lanzafame3 , 

A Trentalange1 , A D’Avolio1 , M Galli2 , S Rusconi2 , and G Di Perri1 1 2 3 Univ of Torino, Italy;; Univ of Milan, Italy;; and GB Rossi Hosp, Verona, 

Italy 

557 Baseline Characteristics and Acceptance of Regimens 

�� 

�� 

Karen Tashima* 1 , K Mollan2 , L Na2 , R Gandhi3 , K Klingman4 , 

C Fichtenbaum5 , A Andrade6 , V Johnson7 , J Eron8 , and R Haubrich9 1 2 Miriam Hosp, Alpert Med Sch of Brown Univ, Providence, RI, US;; Ctr 

for Biostatistics in AIDS Res, Harvard Sch of Publ Hlth, Boston, MA, US;; 

3 4 Massachusetts Gen Hosp, Boston, US;; DAIDS, NIAID, NIH, Bethesda, 

MD, US;; 5Univ of Cincinnati, OH, US;; 6Johns Hopkins Univ, Baltimore, 

MD, US;; 7Birmingham VAMC and Univ of Alabama at Birmingham Sch 

of Med, US;; 8Univ of North Carolina at Chapel Hill, US;; and 9 540� �� 

�� 

�� 

Rujuta Bam*, S Yant, and T Cihlar 

Gilead Sci, Foster City, CA, US 

541� �� 

�� 

of Wild-type and Mutant HIV-1 Reverse Transcriptase 

Robert Domaoal* 

Univ of 


1 , M Detorio1 , C Montero1 , L Bondada1 , S Amiralaei1 , 

T Nie1 , E Anandarajah1 , S Coats2 , and R Schinazi1 1 2 Emory Univ and VAMC, Decatur, GA, US and RFS Pharma, LLC, 

Tucker, GA, US 

542� �� 

�� 

David Langley*, R Kimura, P Sivaprakasam, N Zhou, I Dicker, 

T Wang, J Kadow, N Meanwell, and M Krystal 

Bristol-Myers Squibb Res and Devt, Wallingford, CT, US 

543� �� 

�� 

Svenja Weiss* 1 , R Duerr1 , M Hust2 , J Este3 , C Kuecherer4 , R Schmidt5 , 

and U Dietrich1 1Georg-Speyer-Haus, Inst for Biomed Res, Frankfurt am Main, Germany;; 

2 3 Tech Univ Braunschweig, Germany;; Irsi Caixa, Univ Barcelona, Spain;; 

4 5 Robert-Koch Inst, Berlin, Germany;; and Hannover Med Sch, Germany 

544� �� 

of a High-Throughput Chemical Screen 

Alon Herschorn* 1 , G Christopher1 , V Misra1 , D Flood2 , and J Sodroski1,3,4 1 2 Dana-Farber Cancer Inst and Harvard Med Sch, Boston, MA, US;; Inst 

of Chemistry and Cell Bio, Harvard Med Sch, Boston, MA, US;; 3Harvard Sch of Publ Hlth, Boston, MA, US;; and 4Ragon Inst of MGH, MIT, and 

Harvard, Boston, MA, US 

545� �� 

Throughput Screening for Direct Antagonists of Nef 

�� 

Lori Emert-Sedlak* 1 , P Narute1 , S Shu1 , H Shi1 , N Yanamala1 , 

JJ Alvarado1 , J Lazo1,2 , J Yeh1 , P Johnston1,3 , and T Smithgall1 1 2 Univ of Pittsburgh Sch of Med, PA, US;; Univ of Virginia, 

Charlottesville, US;; and 3Univ of Pittsburgh Sch of Pharmacy, PA, US 

546� �� 

�� 

Jerrod Poe*, L Vollmer, A Vogt, and T Smithgall 

Univ of Pittsburgh Sch of Med, PA, US 

547� �� 

�� 

Virions after Integration 

E Le Rouzic1 , D Bonnard1 , S Chasset1 , J-M Bruneau1 , F Chevreuil1 , 

F Le Strat1 , S Emiliani2 , B Ledoussal1 , F Moreau1 , and Richard Benarous* 1 

1 2 BIODIM Mutabilis, Romainville, France and INSERM, Paris, France 

548� �� 

of the HIV Integrase Catalytic Activity with a High Barrier to 

Resistance 

Frauke Christ* 1 , B Desimmie1 , J Demeulemeester1 , V Suchaud2 , 

O Taltynov1 , C Lion2 , F Bailly2 , S Strelkov1 , P Cotelle2 , and Z Debyser1 1 2 Katholieke Univ Leuven, Belgium and Univ of Lille, France 



Randomized Trials of ART: A Potpourri 

549 A Randomized Trial of Time-limited ART in Acute and Early 

HIV Infection 

Joseph Margolick* 1 , L Apuzzo 1 , J Singer 2 , H Wong 2 , T Lee 2 , M Loutfy 3 , 

A Rachlis 4 , P El-Helou 5 , H Tossonian 6 , and B Conway 7 

1 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, 

US;; 2 Canadian Trials Network, Vancouver;; 3 Maple Leaf Clin, Toronto, 

Canada;; 4 Sunnybrook Clin, Toronto, Canada;; 5 McMaster Univ Sch 

of Med, Hamilton, Canada;; 6 Downtown Infectious Diseases Clin, 

Vancouver, Canada;; and 7 Univ of British Columbia, Vancouver, Canada 

550 Acceptance of ART in the Delay Arm after Notification of 

�� 

J Batani 1 , T Brum 2 , G Calvet 3 , P Dusara 4 , S Dhayarkar 5 , Theresa Gamble* 6 , 

X Li 7 , RA Lira 8 , M Maliwichi 9 , M McCauley 10 , and HPTN 052 Study Team 

1 Univ of Zimbabwe, Harare;; 2 Hosp Geral de Nova Iguacu, Rio de 

Janeiro, Brazil;; 3 Inst de Pesquisa Clin Evandro Chagas, Fiocruz, Rio de 

Janeiro, Brazil;; 4 Botswana Harvard AIDS Inst, Gaborone;; 5 Natl AIDS 

Res Inst, Pune, India;; 6 FHI 360, Durham, NC, US;; 7 Fred Hutchinson 

Cancer Res Ctr, Seattle, WA, US;; 8 Hosp Nossa Senhora da Conceicao, 

Porto Alegre, Brazil;; 9 UNC Project, Lilongwe, Malawi;; and 10 FHI 360, 

Washington, DC, US 



558� �� 

�� 

Yu Zheng* 1 , M Hughes 1 , S Lockman 1 , M Hosseinipour 2 , T Campbell 3 , 

R Salata 4 , R Gulick 5 , E Daar 6 , C Benson 7 , and J Currier 8 

1 Harvard Sch of Publ Hlth, Boston, MA, US;; 2 Univ of North Carolina at 

Chapel Hill, US;; 3 Univ of Colorado Denver, Aurora, US;; 4 Case Western 

Reserve Univ, Cleveland, OH, US;; 5 Weill Med Coll, Cornell Univ, New 

York, NY, US;; 6 Los Angeles Biomed Res Inst at Harbor-UCLA Me Ctr, 

Torrance, CA, US;; 7 Univ of California, San Diego, US;; and 8 Univ of 

California, Los Angeles, US 

559� �� 

+ �� 

Patients in 

a Resource-Limited Setting 

Nathan Clumeck* 1 , M Claude2 , K Kabamba1 , S Matanda2 , D Vaira3 , 

C Necsoi1 , D Kadiebwe2 , C Milolo2 , J Ilunga2 , and L Kapend2 1 2 St-Pierre Univ Hosp Brussels, Belgium;; Lubumbashi Network and 

PNMLS, Democratic Republic of the Congo;; and 3CHU Liege, Belgium





ART: Too Early or Too Late? Or Better Late than Never! 

560 Kinetics of Resting Memory B Cells in Naïve HIV + Patients 

Treated during Primary and Chronic HIV Infection 

Marco Ripa*, S Pensieroso, S Nozza, L Galli, G Scarlatti, 

and G Tambussi 

San Raffaele Sci Inst, Milan, Italy 

561 Predictors of Virologic Suppression in Persons Who Start 

ART during Primary HIV Infection 

Maile Karris* 1 , Y-T Kao 1 , F Vaida 1 , C Spina 1,2 , D Richman 1,2 , S Little 1,2 , 

and D Smith 1,2 

1 Univ of California, San Diego, La Jolla, US and 2 VA San Diego Hlthcare 


562 Early Intermittent ART in HIV + �� 

mm � �� 

Lionel Piroth* 1 , L Moinot 2 , P Yeni 3 , J Reynes 4 , P-M Girard 5 , 

X Anglaret 2 , A Taieb 2 , B Autran 6 , C Rouzioux 7 , C Fagard 2 , and ANRS 141 

TIPI Trial Study Group 

1 Hosp Bocage, Univ de Bourgogne, Dijon, France;; 2 INSERM U897, Univ 

Bordeaux, France;; 3 Hosp Bichat-Claude Bernard, Paris, France;; 4 Hosp 

Gui De Chauliac, Montpellier, France;; 5 Hosp St-Antoine, Paris, France;; 

6 Hosp Pitie-Salpetriere, Paris, France;; and 7 Hosp Necker, Paris, France 




ART: Host and Viral Determinants of Outcome 

569 European Mitochondrial Haplogroups Are Associated with 

�� + T Cell Recovery in HIV + Patients on cART 

M Guzman-Fulgencio 1 , Juan Berenguer* 2 , A Fernandez-Rodriguez 1 , 

D Micheloud 2 , M GarciaAlvarez 1 , MA Jimenez-Sousa 1 , JM Bellon 2 , 

J Cosin 2 , T Aldamiz-Echevarria 2 , and S Resino 1 

1 Natl Ctr of Microbio, Inst de Salud Carlos III, Majadahonda, Madrid, 

Spain and 2 Hosp Gen Univ Gregorio Maranon, Madrid, Spain 

570 Impact of HIV + �� 

Response and ARV Pharmacokinetics 

MP Le 1 , K Champenois 2 , C Charpentier 1 , R Landman 1 , V Joly 1 , P Yeni 1 , 

D Descamps 1 , Y Yazdanpanah 1 , and Gilles Peytavin* 1 

1 APHP, EA4409 Univ Paris 7 Diderot, Bichat-Claude Bernard Hosp, 

France and 2 Equipe Atip/Avenir INSERM U738, Univ Paris 7 Diderot, 

France 

563� �� 

in Very Early Compared to Chronic HIV Infection 

Frederick Hecht* 1 , W Hartogensis1 , S Saha1 , S Little2 , M Markowitz3 , 

J Margolick4 , B Walker5 , V Jain1 , C Pilcher1 , P Bacchetti1 , and Acute 

Infection Early Disease Res Prgm 

1 2 Univ of California, San Francisco, US;; Univ of California, San 

Diego, US;; 3Aaron Diamond AIDS Res Ctr, New York, NY, US;; 4Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; and 

5Massachusetts Gen Hosp, Boston, US 

564� �� 

�� 

Sophie Jose* 1 , S Fidler2 , C Sabin1 , and UK Collaborative HIV Cohort 

Study 

1 2 Univ Coll London, UK and St Marys Hosp, London, UK 

565� �� 

and Immune Activation in HIV + �� 

Mohammad-Ali Jenabian* 1 , M Patel1 , C Kanagaratham1 , D Radzioch1 , 

P Ancuta2 , I Kema3 , R Thomas4 , J Singer5 , J Angel6 , and J-P Routy7 1 2 Res Inst of McGill Univ Hlth Ctr, Montreal, Canada;; CHUM Res Ctr, 

Montreal, Canada;; 3Univ Med Ctr, Univ of Groningen, The Netherlands;; 

4 5 Lactuel Med Clin, Montreal, Canada;; CIHR Canadian HIV Trials 

Network, Vancouver;; 6Ottawa Hosp Res Inst, Canada;; and 7 571 Weight Change at 1 Month of ART Is Associated with 

�� 

HIV 

Royal 

Victoria Hosp, McGill Univ Hlth Ctr, Montreal, Canada 

+ Adult Cohort 

Christopher Sudfeld* 1 , S Isanaka1 , F Mugusi2 , S Aboud2 , M Wang1 , 

G Chalamilla3 , and W Fawzi1 1 2 Harvard Sch of Publ Hlth, Boston, MA, US;; Muhimbili Univ of Hlth 

and Allied Sci, Dar es Salaam, Tanzania;; and 3Mgmt and Devt for Hlth, 

Dar es Salaam, Tanzania 

572� �� 

Response to Initial cART: A European Multicohort Study 

Linda Wittkop on behalf of EuroCoord-CHAIN Subtype Project Team 

INSERM U897-Epidemiologie-Biostatistique, Univ Bordeaux and Univ 

Hosp, France 

573 Can the Veterans Aging Cohort Study Index Improve Clinical 

Judgment? 

Amy Justice* 1,2 , J Tate1,2 , S Brown3,4 , C Gibert5,6 , M Rodriguez- 

Barradas7,8 , D Rimland9,10 , K Akgun1,2 , and K Bryant11 1 2 Yale Univ, New Haven, CT, US;; VA Connecticut Hlthcare System, 

West Haven, US;; 3James J Peters VAMC, New York NY, US;; 4Mt Sinai 

Sch of Med, New York, NY, US;; 5George Washington Univ Sch of Med, 

Washington, DC, US;; 6Washington DC VAMC, US;; 7Baylor Coll of Med, 

Houston TX, US;; 8Michael E DeBakey VAMC, Houston, TX, US;; 9Emory Univ Sch of Med, Atlanta, GA, US;; 10Atlanta VAMC, GA, US;; and 11Natl Inst on Alcohol Abuse and Alcoholism, Bethesda, MD, US 

574� �� 

�� 

Adriana Ammassari*, I Abbate, P Lorenzini, G Rozera, S Ottou, 

C Pinnetti, A Amendola, M Zaccarelli, A Antinori, and MR Capobianchi 

Natl Inst for Infectious Disease L Spallanzani, Rome, Italy 

566 Maraviroc + Raltegravir Dual Therapy in Aviremic HIV + 

Patients with Lipodystrophy: Results from the ROCnRAL 

Agence Nationale de la Recherche 157 Study 

Christine Katlama* 1 , L Assoumou1 , M-A Valantin1 , C Duvivier2 , 

C Soulie1 , L Chablais1 , G Pialoux3 , P Mercie4 , G Peytavin5 , A-G Marcelin1 , 

and ANRS 157 Study Group 

1 2 INSERM U943, Paris VI Pitie Salpetriere Univ Hosp, France;; Inst 

Pasteur Paris, Necker Hosp, France;; 3Tenon, Paris VI Univ, France;; 

4 5 INSERM U897 Hosp St-Andre, Bordeaux, France;; and Bichat Univ 

Hosp, Paris, France 

567� �� 

�� 

of MIDAS 

Babafemi Taiwo* 1 , D Lu2 , S Swindells3 , B Berzins1 , P Ryscavage4 , 

J Lalezari5 , J Castro6 , O Adeyemi7 , D Kuritzkes2 , J Eron8 , and MIDAS 

Study Team 

1 2 Northwestern Univ, Chicago, IL, US;; Harvard Univ, Cambridge, MA, 

US;; 3Univ of Nebraska, Omaha, US;; 4Univ of Maryland, Baltimore, US;; 

5 6 7 Quest Clin Res, San Francisco, CA, US;; Univ of Miami, FL, US;; CORE 

Ctr, Chicago, IL, US;; and 8Univ of North Carolina at Chapel Hill, US 

568� �� 

Expectancy of ART-treated HIV + Individuals Compared with 

the General Population 

Margaret May* 1 , A Mocroft2 , J Guest3 , H Crane4 , P Reiss5 , 

A dArminio Monforte6 , P Labarga7 , J-C Wasmuth8 , S Ingle1 , R Hogg9,10 , 

and ART Cohort Collaboration 

1 2 3 Univ of Bristol, UK;; Univ Coll London Med Sch, UK;; Atlanta VAMC, 

Decatur, GA, US;; 4Univ of Washington Sch of Med, Seattle, US;; 5Univ of Amsterdam, The Netherlands;; 6Univ of Milan, Italy;; 7Hosp Carlos III, 

Madrid, Spain;; 8 575 A Low HIV DNA Level in Peripheral Blood Mononuclear 

�� 

�� 

L Assoumou 

Rheinische Friedrich-Wilhelms-Univ Bonn, Germany;; 

9 10 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada;; and Simon 

Fraser Univ, Burnaby, Canada 

1,2 , L Weiss3,4 , C Piketty3 , M Burgard5 , A Melard5 , J-M Ragnaud6 , 

P-M Girard7 , D Costagliola1,2 , Christine Rouzioux* 4,5 , and ANRS 116 

SALTO Study Group 

1 2 INSERM U943, Paris, France;; UPMC Univ Paris 06, UMR S 943, 

France;; 3AP-HP Hosp Europeen Georges Pompidou, Paris, France;; 

4 5 Univ Rene Descartes Paris 05, France;; AP-HP Hosp Necker Paris, 

France;; 6Hosp Pellegrin, Bordeaux, France;; and 7AP-HP Hosp 

St-Antoine, Paris, France 

576 Viremia Copy-years as a Measure of Viral Load Burden 

and Associated Mortality Risk among ART Patients: 

�� 

Alana Brennan* 1,2 , M Maskew2 , I Sanne2,3 , and M Fox1,2,4 1 2 Ctr for Global Hlth and Devt, Boston Univ, MA, US;; Sch of Clin Med, 

Faculty of Hlth Sci, Univ of the Witwatersrand, Johannesburg, South 

Africa;; 3Right to Care, Johannesburg, South Africa;; and 4Boston Univ Sch 

of Publ Hlth, MA, US 

577 Mortality of Treated HIV-1 + Individuals according to Viral 

�� 

Margaret May* 1 , M Gill2 , R Harrigan3 , M Klein4 , P Reiss5 , A Mocroft6 , 

A dArminio Monforte7 , R Zangerle8 , M Cavassini9 , J Sterne1 , and ART 

Cohort Collaboration 

1 2 3 Univ of Bristol, UK;; Univ of Calgary, Canada;; BC Ctr for Excellence 

in HIV/AIDS and Univ of British Columbia, Vancouver, Canada;; 4McGill Univ, Montreal, Canada;; 5Univ of Amsterdam, The Netherlands;; 6Univ Coll London Med Sch, UK;; 7Univ of Milan, Italy;; 8Innsbruck Med Univ, 

Austria;; and 9Ctr Hosp Univ Vaudois, Lausanne, Switzerland




ART: Care and Adherence 

578 Outcomes for HIV + Patients Receiving Care at Multiple HIV 

Clinics 

Baligh Yehia* 1 , A Schranz 1 , F Momplaisir 2 , S Keller 1 , R Gross 1 , 

J Metlay 1 , and K Brady 3 

1 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US;; 2 Temple 

Univ Sch of Med, Philadelphia, PA, US;; and 3 Philadelphia Dept of Publ 

Hlth AIDS Activities Coordinating Office, PA, US 

586 Does HIV-1 Proviral DNA Envelope Sequence Predict Trofile 

Co-receptor Usage upon Treatment Interruption? 

Elizabeth White* 1 , M Balamane 1 , K Henry 2 , H Valdez 3 , D Margolis 4 , 

D Skiest 5 , P Tebas 6 , D Katzenstein 1 , and ACTG NWCS 303 Team 

1 Stanford Univ, CA, US;; 2 Hennepin County Med Ctr, Minneapolis, MN, 

US;; 3 Pfizer Inc, New York, NY, US;; 4 Univ of North Carolina at Chapel 

Hill, US;; 5 Tufts Univ Sch of Med, Springfield, MA, US;; and 6 Univ of 

Pennsylvania, Philadelphia, US 

588 A Common Mechanism of Clinical HIV-1 Resistance to 

Maraviroc despite Divergent Resistance Levels and Lack of 

�� 

Renee Duncan* 1 , M Roche 1 , H Salimi 1,2 , J Sterjovski 1 , M Moore 1 , 

B Lee 3 , M Westby 4 , R Payne 5 , M Churchill 1,2 , and P Gorry 1,2,6 

1 Burnet Inst, Melbourne, Australia;; 2 Monash Univ, Clayton, Australia;; 

3 David Geffen Sch of Med, Univ of California, Los Angeles, US;; 4 Pfizer 

Global Res and Devt, Sandwich, UK;; 5 Univ of Sydney, Australia;; and 

6 Univ of Melbourne, Australia 

579� �� 

�� 

F Engsig1 , J Gerstoft1 , Marie Helleberg* 1 , G Kronborg2 , L Mathiesen2 , 

1 2 Copenhagen Univ Hosp, Rigshospitalet, Denmark and Copenhagen Univ 

Hosp, Hvidovre, Denmark 

580� �� 

Longitudinal Study of Homeless and Marginally Housed HIV + 

�� 

Sheri Weiser* 1 , K Yuan2 , D Guzman1,3 , E Frongillo4 , E Riley1 , 

D Bangsberg5,6,7 , and M Kushel2 1 2 Univ of California, San Francisco, US;; Sch of Med, Univ of California, 

San Francisco, US;; 3San Francisco Gen Hosp, CA, US;; 4Arnold Sch of 

Publ Hlth, Univ of South Carolina, Columbia, US;; 5Massachusetts Gen 

Hosp Ctr for Global Hlth, Boston, US;; 6Ragon Inst of MGH, MIT, and 

Harvard, Boston, MA, US;; and 7Harvard Med Sch, Boston, MA, US 

581 Care Engagement and Viral Suppression in Comprehensive 

HIV Care Coordination Clients: Baseline Characteristics and 

Pre- and Post-enrollment Outcomes 

M Irvine1 , S Chamberlin1 , R Robbins2 , J Myers1 , X Yang2 , G Harriman1 , 

S Braunstein1 , F Laraque1 , B Mitts1 , and Denis Nash* 2 

589 Impact of Maraviroc-resistant and Low CCR5-adapted 

Mutations Induced in vitro Passage on Sensitivity to Anti-Env 

�� 

Kazuhisa Yoshimura* 

1 2 New York City Dept of Hlth and Mental Hygiene, NY, US and CUNY 

Sch of Publ Hlth at Hunter Coll, New York, NY, US 

1,2 , S Harada1 , S Boonchawalit2 , and S Matsushita2 1 2 AIDS Res Ctr, Natl Inst of Infectious Diseases, Tokyo, Japan and Ctr for 

AIDS Res, Kumamoto Univ, Japan 



HIV Drug Resistance: Trends and Emergence 

590 Trends in Darunavir Resistance-associated Mutations and 

�� 

Erkki Lathouwers* 1 , C Kambili2 , M Haddad3 , A Paquet3 , S De Meyer1 , 

and B Baugh4 1 2 Janssen Infectious Diseases BVBA, Beerse, Belgium;; Janssen Res and 

Devt, LLC, Titusville, NJ, US;; 3Monogram Biosci, South San Francisco, 

CA, US;; and 4 591 

Janssen Therapeutics, Titusville, NJ, US 

Characterization of Resistance to Integrase Strand Transfer 

�� 

�� 

Christopher Hurt* 1 , J Sebastian2 , C Hicks3 , and J Eron1 1 2 Univ of North Carolina at Chapel Hill, US;; Lab Corp of America, 

Research Triangle Park, NC, US;; and 3Duke Univ, Durham, NC, US 

582� �� 

Nikoloz Chkhartishvili* 1 , L Sharvadze1,2 , O Chokoshvili1 , 

P Gabunia1 , and T Tsertsvadze1,2 1Infectious Diseases, AIDS and Clin Immunology Res Ctr, Tbilisi, Georgia 

and 2Tbilisi State Univ, Georgia 

583� �� 

Adherence with Viral Suppression in 5 HIV Cohort Studies 

Suzanne Ingle* 1 , T Glass2 , H Crane3 , R Hogg4 , J Gill5 , A Ammassari6 , 

M Mugavero7 , J Tate8 , N Turner1 , J Sterne1 , and ART Cohort 

Collaboration 

1 2 3 Univ of Bristol, UK;; Univ of Basel, Switzerland;; Univ of Washington, 

Seattle, US;; 4Simon Fraser Univ, Burnaby, Canada;; 5Univ of Calgary, 

Canada;; 6INMI, L Spallanzani, Rome, Italy;; 7Univ of Alabama at 

Birmingham, US;; and 8Yale Univ Sch of Med and Publ Hlth and VA 

Connecticut Hlthcare System, New Haven, US 

584� �� 

Persons Living with HIV vs HIV� Persons 

Stephen Berry* 1 , K Gebo1 , R Moore1 , and J Fleishman2 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Agency for 

Hlthcare Res and Quality, Rockville, MD, US 



Tropism Testing/Maraviroc Resistance 

585� �� 

Tropism Testing 

Christian Pou* 1,2,3 , R Bellido1,2,3 , M Casadella1,2,3 , T Puig1,2,3 , B Clotet1,2,3,4 , 

R Harrigan5 , and R Paredes1,2,3,4 1 2 IrsiCaixa Inst for AIDS Res, Badalona, Catalonia, Spain;; Hosp Germans 

Trias i Pujol, Badalona, Catalonia, Spain;; 3Univ Autonoma de Barcelona, 

Cerdanyola del Valles, Catalonia, Spain;; 4Fnd Lluita Contra la SIDA, 

Badalona, Catalonia, Spain;; and 5 592 15 Years after the Introduction of ART in Senegal: Virological 

Response and Risk of Resistance in the Agence Nationale de 

�� 

Assane Diouf* 

BC Ctr for Excellence in HIV/AIDS, 

Vancouver, Canada 

1 , P De Beaudrap2 , M Thiam3 , C Toure-Kane3 , 

N Ngom-Gueye4 , N Vidal2 , S Mboup3 , I Ndoye5 , PS Sow4 , E Delaporte2 , 

and ANRS 1215 Study Group 

1Ctr Regional de Recherche et Formation sur le VIH/SIDA, Univ Cheikh 

Anta Diop, Dakar, Senegal;; 2Inst de Recherche pour le Devt, Univ de 

Montpellier 1, France;; 3Hosp Le Dantec, Dakar, Senegal;; 4CHU de Fann, 

Dakar, Senegal;; and 5Multisectorial AIDS Prgm, Dakar, Senegal 

593� �� 

�� 

�� 

J Gweshe1 , A Jonas1 , A Shiningavamwe2 , T Desta3 , G Hunt4 , H Sheehan5 , 

K Lau5 , A Trotter5,6 , M Jordan5,6 , and Steven Hong* 5,6 

1Republic of Namibia Ministry of Hlth and Social Svcs, Windhoek;; 

2 3 Namibia Inst of Pathology, Windhoek;; WHO, Klein Windhoek, Namibia;; 

4 5 Natl Inst of Communicable Diseases, Johannesburg, South Africa;; Tufts 

Univ Sch of Med, Boston, MA, US;; and 6Tufts Med Ctr, Boston, MA, US 

594� �� 

Resistance Reports among ART-experienced Patients: UK 

David Dolling* 1 , M Nelson2 , A Schwenk3 , D Churchill4 , D Pillay5 , 

D Dunn1 , and UK HIV Drug Resistance Database and UK Collaborative 

HIV Cohort Study 

1 2 MRC Clin Trials Unit, London, UK;; Chelsea and Westminster Hosp, 

London, UK;; 3North Middlesex Univ Hosp NHS Trust, London, UK;; 

4 5 Brighton and Sussex Univ Hosp NHS Trust, Brighton, UK;; and Univ 

Coll London, UK 

595 Baseline HIV Drug Resistance Is Independently Associated 

�� 

�� 

ACTG A5175 

Rami Kantor* 1 , L Smeaton2 , S Vardhanabhuti2 , S Tripathi3 , 

M Morgado4 , S Saravanan5 , C Wallis6 , S Hudelson7 , T Campbell8 , 

S Eshleman7 , on behalf of A5175 Study Investigators 

1 2 3 Brown Univ, Providence, RI, US;; Harvard Univ, Boston, MA, US;; Natl 

AIDS Res Inst, Pune, India;; 4Oswaldo Cruz Inst, Rio de Janeiro, Brazil;; 

5 6 YRG CARE, Chennai, India;; Lancet Labs, Johannesburg, South Africa;; 

7 8 Johns Hopkins Univ, Baltimore, MD, US;; and Univ of Colorado Denver, 

Aurora, US 

587� �� 

Primary Resistance of R5-tropic HIV-1 to Maraviroc 

Pierre Delobel* 1,2 , M Cazabat1,2 , A Saliou1 , M Requena1,2 , S Raymond1,2 , 

B Marchou2 , P Massip2 , and J Izopet1,2 596� �� 

�� 

�� 

Kirsten White*, M Abram, R Kulkarni, M Rhee, M Fordyce, 

J Szwarcberg, and M Miller 

Gilead Sci, Inc, Foster City, CA, US 

1 2 INSERM UMR1043, Toulouse, France and Toulouse Univ Hosp, France 


Poster Listings





Detecting and Interpreting HIV Drug Resistance 

597� �� 

HIV-1 Drug-resistance Mutations Associated with Pre- 

Exposure Prophylaxis 

Guoqing Zhang* 1 , H Guo1 , J DeVos1 , I Lorenzana de Rivera2 , I Zulu3 , 

N Wadonda-Kabondo4 , C Ndongmo3 , J Nkengasong1 , F Gao5 , and C Yang1 1 2 CDC, Atlanta, GA, US;; Natl Autonomous Univ of Honduras, 

Tegucigalpa;; 3CDC-Zambia, Lusaka;; 4CDC-Malawi, Lilongwe;; and 5Duke Univ Med Ctr, Durham, NC, US 

598� �� 

Interpretation in Europe 

Charlotte Charpentier* 1 , R Camacho2 , J Ruelle3 , R Kaiser4 , J Eberle5 , 

A Pironti6 , M Stuermer7 , F Brun-Vezinet1 , D Descamps1 , and M Obermeier6 1 2 Hosp Bichat-Claude Bernard, Paris, France;; Univ Nova de Lisboa, 

Portugal;; 3Univ Catholique de Louvain, Brussels, Belgium;; 4Univ of 

Cologne, Germany;; 5Ludwig Maximilian Univ Munich, Germany;; 6Med Labor Dr Berg, Berlin, Germany;; and 7Johann Wolfgang Goethe-Univ 

Hosp, Frankfurt, Germany 

599 The Individualized Genetic Barrier Predicts Treatment 

Response in a Large Cohort of HIV-1 + Patients 

N Beerenwinkel 1 , H Knotzsch 1 , P Knupfer 1 , V von Wyl2 , S Yerly3 , J Boni4 , 

T Klimkait 5 , V Aubert 6 , Huldrych Gunthard* 2 , and Swiss HIV Cohort Study 

1 2 3 ETH Zurich, Basel, Switzerland;; Univ Hosp Zurich, Switzerland;; Univ 

Hosp Geneva, Switzerland;; 4Univ of Zurich, Switzerland;; 5Univ of Basel, 

Switzerland;; and 6Ctr Hosp Univ Vaudois, Lausanne, Switzerland 

600� �� 

st �� 

Anne Derache* 1 , C Wallis2 , J Bartlett3 , E Aga4 , M Norton5 , 

K Klingman6 , W Stevens7 , D Katzenstein1 , and ACTG5230 Team 

1 2 Stanford Univ, CA, US;; Lancet Labs, Johannesburg, South Africa;; 

3 4 Duke Univ Med Ctr, Durham, NC, US;; Statistical Data Analysis Ctr 

at Harvard Univ, Cambridge, MA, US;; 5Abbott Labs, Abbott Park, 

IL, US;; 6DAIDS, NIAID, NIH, Bethesda, MD, US;; and 7Univ of the 

Witswatersrand, Johannesburg, South Africa 

601 Low-level HIV Viremia and Drug Resistance 

Alejandro Gonzalez-Serna* 1 , JE Min1 , C Woods1 , J Li2 , R Harrigan1 , 

and L Swenson1 1 2 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada and Brigham 

�� 



Innovation in Measuring Viral Nucleic Acids 

602� �� 

cleared Plasma HIV-1 RNA Assay Platforms for Determination 

�� 

Christina Lalama* 1 , C Jennings2 , V Johnson3,4 , R Coombs5 , J McKinnon6 , 

J Bremer2 , B Cobb7 , G Cloherty8 , H Ribaudo1 , and J Mellors9 1 2 Harvard Sch of Publ Hlth, Boston, MA, US;; Rush Univ Med Ctr, 

Chicago, IL, US;; 3Birmingham VAMC, AL, US;; 4Univ of Alabama at 

Birmingham Sch of Med, US;; 5Univ of Washington, Seattle, US;; 6Henry Ford Hosp, Detroit, MI, US;; 7Roche Diagnostics, Pleasanton, CA, US;; 

8 9 Abbott Molecular, Des Plaines, IL, US;; and Univ of Pittsburgh, PA, US 

603� �� 

�� 

John McKinnon* 1 , C Lalama2 , S Riddler3 , R Haubrich4 , M Hughes2 , 

D Vagrattian3 , and J Mellors3 1 2 Henry Ford Hosp, Detroit, MI, US;; Harvard Sch of Publ Hlth, Boston, 

MA, US;; 3Univ of Pittsburgh, PA, US;; and 4 606 Dried Blood Spots for HIV-1 Viral Load and Drug Resistance 

Monitoring in HAART-treated Patients from Africa and 

Asia: The Agence de Nationale de Recherche sur le Sida 

�� 

Ahidjo Ayouba* 

Univ of California, San 

Diego, US 

1 , M Monleau1 , S Eymard-Duvernay1 , A Dagnra2 , 

D Kania3 , N Ngo-Giang-Huong4 , C Toure-Kane5 , L Truong6 , M-L Chaix7 , 

A Aghokeng8 , and ANRS 12235 Study Group 

1 2 IRD and Univ de Montpellier 1, France;; BIOLIM, FMMP/UL, Lome, 

Togo;; 3Ctr Muraz, Bobo-Dioulasso, Burkina Faso;; 4Chiang Mai Univ, 

Thailand;; 5Hosp Le Dantec, Dakar, Senegal;; 6Inst Pasteur, Ho Chi Minh 

City, Vietnam;; 7Hosp Necker, Paris, France;; and 8CREMER/IMPM/IRD, Yaounde, Cameroon 

607 Evaluation of Point-of-Care Nucleic Acid Testing for HIV 

Viral Load and Early Infant Diagnosis in Primary Health 

�� 

Ilesh Jani* 1 , B Meggi1 , A Vubil1 , N Sitoe1 , N Bhatt1 , O Tobaiwa2 , 

J Quevedo2 , O Loquiha3 , J Lehe2 , and T Peter2 1 2 Inst Nacional de Saude, Maputo, Mozambique;; Clinton Hlth Access 

Initiative, Maputo, Mozambique;; and 3Univ Eduardo Mondlane, Maputo, 

Mozambique 

608� �� 

�� 

Carol Metcalf* 1 , E Fajardo1 , P Pannus2 , L Trevino3 , I Panunzi2 , 

T Ellman1 , R Coulborn2 , A Kamiza4 , R Mbewa5 , and P Chaillet6 1 2 Medecins Sans Frontieres, Cape Town, South Africa;; Medecins Sans 

Frontieres, Thyolo, Malawi;; 3Medecins Sans Frontieres, Blantyre, 

Malawi;; 4Malawi Ministry of Hlth, Thyolo;; 5Malawi Ministry of Hlth, 

Lilongwe;; and 6Medecins Sans Frontieres, Brussels, Belgium 

609� �� 

�� 

�� 

Eric Ramos*, M Chang, J Ortega, G Daza, E Goecker, S Harb, 

J Dragavon, and R Coombs 


610 Real-time Polymerase Chain Reaction Evaluation of Seminal 

HIV Viral Load 

Roberto Rodriguez-Diaz* 1 , E Mendez-Hernandez1 , M Flores-Hernandez1 , 

E Mendoza-Guadarrama1 , L Rojo-Gutierrez2 , C Hernandez-Martinez1 , 

and L Soto-Ramirez1 1Inst Nacional de Ciencias Med y Nutricion Salvador Zubiran, Mexico 

City, Mexico and 2Hosp Med Sur, Mexico City, Mexico 

611� �� 

�� 

Korea 

H Kim1 , NS Ku1 , SB Kim1 , SJ Jeong1 , SH Han1 , JM Kim1 , D Smith2 , 

and Jun Yong Choi* 1 

1 2 AIDS Res Inst, Yonsei Univ Coll of Med, Seoul, Korea and Univ of 

California, San Diego, La Jolla, US 

612 Efficiency of HIV-1 Pooled Viral Load Testing to Reduce the 

Cost of Monitoring ART in a Resource-limited Setting: Rural 

Malawi 

Pieter Pannus* 1 , E Fajardo1 , C Metcalf1 , L Trivino2 , D Garone2 , 

R Coulborn2 , H Bygrave1 , T Ellman1 , M Murowa3 , and R Mwenda4 1Medecins Sans Frontieres, South African Med Unit, Cape Town, South 

Africa;; 2Medecins Sans Frontieres, Thyolo, Malawi;; 3Ministry of Hlth, 

District Mgmt Office, Thyolo, Malawi;; and 4Ministry of Hlth, DDTSS, 

Lilongwe, Malawi 

613� �� 

Testing in Resource-limited Settings 

Emily Hyle* 1 , I Jani2 , J Lehe3 , R Wood4 , A Su1 , J Quevedo3 , E Losina1,5,6 , 

I Bassett1,5 , T Peter3 , and R Walensky1,5,6 1 2 Med Practice Evaluation Ctr, Massachusetts Gen Hosp, Boston, US;; Inst 

Nacional da Saude, Maputo, Mozambique;; 3Clinton Hlth Access Initiative, 

Maputo, Mozambique;; 4Desmond Tutu HIV Fndn, Univ of Cape Town, 

South Africa;; 5Ctr for AIDS Res, Harvard Med Sch, Boston, MA, US;; 

and 6�� 604 Refining Approaches to Viral Load Monitoring Using Dried 

Blood Spots 

Carole Wallis* 1 , E Aga 2 , H Ribaudo 2 , C Chevallier 3 , K Klingman 4 , 

W Stevens 5 , N Kumarasamy 6 , J Bartlett 7 , D Katzenstein 8 , and A5230 Team 

1 Lancet Labs, Johannesburg, South Africa;; 2 Statistical Data Analysis 

Ctr, Harvard Sch of Publ Hlth, Boston, MA, US;; 3 Clinton Hlth Access 

Initiative, Papua New Guinea;; 4 NIAID, NIH, Bethesda, MD, US;; 5 Univ of 

the Witwatersrand, Johannesburg, South Africa;; 6 YRG Care, Voluntary 

Hlth Svcs, Chennai, India;; 7 Duke Univ Med Ctr, Durham, NC, US;; and 

8 Stanford Univ, CA, US 

605 Assessment of Treatment Efficacy with Virological and 

Pharmacological Evaluations on Capillary Dried Blood Spots 

in HIV + Patients Enrolled in a West African Cohort 

M Daou 1,2 , M Le 3 , B Madougou 1,2 , C Delaugerre 4 , T Maillard 4 , G Peytavin 3 , 

E Adehossi 1 , M Saidou 1 , E Rouveix 2,5 , and Pierre de Truchis* 2,5 

1 Hosp Natl, Niamey, Niger;; 2 Gip-ESTHER Niger, France;; 3 Hosp Bichat 

Claude Bernard APHP, Paris, France;; 4 Hosp St Louis, APHP, Paris, 

France;; and 5 GH A Pare-R Poincare, Garches, France 




Transmitted Drug Resistance 

614 Origin of Minority Drug-resistant HIV-1 Variants in Primary 

HIV-1 Infection 

Karin Metzner*, A Scherrer, B Preiswerk, B Joos, V von Wyl, C Leemann, 

D Braun, C Grube, H Kuster, H Gunthard, and Swiss HIV Cohort Study 

Univ Hosp Zurich, Univ of Zurich, Switzerland 

615 Trends in Genotypic Resistance Testing Use and Results 

among ARV-naïve Patients in the HIV Outpatient Study 

Kate Buchacz* 1 , B Young 2,3 , F Palella 4 , C Armon 5 , J Brooks 1 , 

and HIV Outpatient Study Investigators 

1 CDC, Atlanta, GA, US;; 2 Apex Family Med and Res, Denver, CO, 

US;; 3 Intl Assn of Physicians in AIDS Care, Washington, DC, US;; 

4 Northwestern Univ Sch of Med, Chicago, IL, US;; and 5 Cerner Corp, 

Vienna, VA, US


616� �� 

Immigrant HIV Clinic 

Rachel Chasan* 1 , K Sigel1 , J Karimjee2 , and C Salama1,2 1 2 Mt Sinai Sch of Med, New York, NY, US and Elmhurst Hosp Ctr, 


617 HIV Molecular Epidemiology and Transmitted Drug 

Resistance Surveillance: Mesoamerican Region 

Claudia Garcia-Morales* 1 , S Avila-Rios1 , D Tapia-Trejo1 , 

C Mejia-Villatoro2 , J Pascale3 , G Porras-Cortes4 , R Mendizabal2 , Y Zaldivar3 , 

B Hernandez4 , G Reyes-Teran1 , and HIV Molecular Epidemiology and TDR 

Surveillance in the Mesoamerican Region Study Group 

1Inst Nacional de Enfermedades Respiratorias, Mexico City, Mexico;; 

2 3 Hosp Roosevelt, Guatemala;; Inst Conmemorativo Gorgas, Panama;; 

and 4Hosp Metropolitano, Managua, Nicaragua 

618� �� 

a Transmitted Reverse Transcriptase Multi-resistant HIV-1 

�� 

Isabel Viciana* 1 , N Chueca2 , A del Arco3 , F Tellez4 , F Jarilla5 , 

JD Colmenero6 , F Gardia2 , and J Santos1 1 2 Hosp Virgen de la Victoria, Malaga, Spain;; Hosp San Cecilio, Granada, 

Spain;; 3Hosp Costa del Sol, Marbella, Spain;; 4Hosp de la Linea, Cadiz, 

Spain;; 5Hosp de Antequera, Malaga, Spain;; and 6Hosp Carlos Haya, 

Malaga, Spain 

619� �� 

�� 

Adults 

S Monge1 , M Alvarez2 , V Guillot2 , P Viciana3 , C Rodriguez4 , S Perez-Elias5 , 

JL Gomez-Sirvent6 , D Dalmau7 , M Rivero8 , Federico Garcia* 2 , 

and CORIS Resistance Study Group 

1 2 Ctr Nacional de Epidemiologia, CoRIS, Madrid, Spain;; HU San Cecilio, 

Granada, Spain;; 3HU Virgen del Rocio, Sevilla, Spain;; 4Ctr Sandoval, 

Madrid, Spain;; 5HU Ramon y Cajal, Madrid, Spain;; 6HU Canarias, 

Spain;; 7Mutua Terrassa, Spain;; and 8 626 Impact of Experimental Conditions on the Utility of Primer 

ID Tagging for Next-generation HIV Sequencing 

Richard Liang* 

HU Navarra, Spain 

1 , T Mo1 , W Dong1 , G Lee1 , L Swenson1 , 

R McCloskey1 , C Woods1 , C Brumme1 , R Harrigan1,2 , and A Poon1,2 1 2 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada and Univ of 

627 

British Columbia, Vancouver, Canada 

Accurately Identifying Low-frequency Variation in Viral 

�� 

Sampling 

John Archer* 1 , A Rambaut2,3 , and D Robertson1 1 2 Univ of Manchester, UK;; Inst of Evolutionary Bio, Univ of Edinburgh, 

UK;; and 3Fogarty Intl Ctr, NIH, US 

628� �� 

HIV-1 Co-receptor Tropism 

John Archer* 1 , J Weber2 , K Henry3 , R Gibson3 , L Lee4 , E Paxinos4 , 

E Arts3 , D Robertson1 , L Mimms5 , and M Quinones-Mateu3,6 1 2 Univ of Manchester, UK;; Inst of Organic Chemistry and Biochemistry, 

Prague, Czech Republic;; 3Case Western Reserve Univ, Cleveland, OH, 

US;; 4Pacific Biosci, Menlo Park, CA, US;; 5Quidel Corp, San Diego, 

CA, US;; and 6Univ Hosp Translational Lab, Univ Hosp Case Med Ctr, 


629 An Evaluation of Phylogenetic Methods for Reconstructing 

Transmitted HIV Variants Using Longitudinal Clonal HIV 

Sequence Data 

Rosemary McCloskey* 1 , R Liang1 , R Harrigan1 , Z Brumme2 , 

and A Poon1 1 2 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada and Simon 

Fraser Univ, Burnaby, Canada 



Detecting HIV Infection 



Drug Resistance Mutational Pathways and Subtype 

Associations 

620� �� 

�� 

Shigeyoshi Harada* 1 , S Boonchawalit1,2 , T Narumi3 , H Tamamura3 , 

S Matsushita2 , and K Yoshimura1,2 1 2 Natl Inst of Infectious Diseases, Tokyo, Japan;; Kumamoto Univ, Japan;; 

and 3Tokyo Med and Dental Univ, Japan 

621� �� 

�� 

S Fourati1,2 , C Charpentier3,4 , D Armenia5 , L Morand-Joubert1,6,7 , 

M Wirden1,2 , A Artese8 , F Ceccherini-Silberstein5 , D Descamps3,4 , 

V Calvez1,2,6 , and Anne-Genevieve Marcelin* 1,2,6 

1 2 INSERM UMR S-943, Paris, France;; Hosp Pitie-Salpetriere, Paris, 

France;; 3Hosp Bichat Claude Bernard, Paris, France;; 4Univ Paris 

Diderot, Paris, France;; 5Univ of Tor Vergata, Rome, Italy;; 6Univ Pierre 

and Marie Curie, Paris, France;; 7 622 

Hosp St-Antoine, Paris, France;; and 

8Univ Catanzaro Magna Graecia, Italy 

In vitro Accumulation of Drug Resistance Mutations in 

�� 

Tenofovir and Didanosine 

Rodrigo Cunha* 1 , C Abreu1 , V Mabombo1 , A Sousa1 , M Nijhuis2 , 

D de Jong2 , R Brindeiro1 , and A Tanuri1 1 2 Federal Univ of Rio de Janeiro, Brazil and Univ Med Ctr Utrecht, 

The Netherlands 

623 Varying Effects of the Integrase G118R-linked Mutations 

�� 

�� 

Peter Quashie* 1,2 , T Mesplede1 , Y Han1 , H-T Xu1 , B Spira1 , R Sloan1 , 

T Veres1 , M Wainberg1,2 , and B Brenner1 1McGill Univ AIDS Ctr, Lady Davis Inst-Jewish Gen Hosp, Montreal, 

Canada and 2McGill Univ, Montreal, Canada 

624� �� 

Selected in vitro with Dolutegravir on Integrase Activity and 

�� 

Thibault Mesplede*, P Quashie, N Osman, Y Han, D Singhroy, 

A Sabbah, M Charabati, B Spira, and M Wainberg 

McGill Univ AIDS Ctr, Montreal, Canada 



Advances in Sequencing and Analysis 

625 Rapid Sequencing of HIV-1 Genomes as Single Molecules 

from Simple and Complex Samples 

Michael Brown* 1 , Y Guo1 , M Schaefer2 , W Kilembe3 , S Allen2 , 

E Hunter2 , and E Paxinos1 1 2 Pacific Biosci, Menlo Park, CA, US;; Emory Univ, Atlanta, GA, US;; 

and 3 th 630� �� 

Generation HIV 

�� 

Mark Manak* 

Zambia Emory HIV Res Project, Lusaka 

1 , LA Eller2 , J Malia3 , M De Souza4 , K Shikuku5 , C Lueer1 , 

A Taylor6 , N Michael3 , M Robb2 , and S Peel3 1 2 Mbeye Med Res Prgm, Tanzania;; US Military HIV Res Prgm, Henry 

M Jackson Fndn for the Advancement of Military Med, Rockville, MD;; 

3US Military HIV Res Prgm, Walter Reed Inst of Res, Silver Spring, MD;; 

4 5 AFRIMS, Bangkok, Thailand;; Walter Reed Project, Keicho, Kenya;; and 

6Makerere Univ Walter Reed Project, Kampala, Uganda 

631� �� 

Detect Acute Infections in a High-prevalence Cross-sectional 

Population: Swaziland 

Yen Duong* 1 , Y Mavengere2 , J Manjengwa2 , D Sibandze3 , J Chang1 , 

LM Emel4 , J Justman2 , R Jason1 , G Bicego5 , B Parekh1 , and SHIMS Study 

Team 

1 2 CDC, Atlanta, GA, US;; Intl Ctr for AIDS Care and Treatment, Columbia 

Univ, New York, NY, US;; 3Ministry of Hlth, Mbabane, Swaziland;; 

4Statistical Ctr for HIV/AIDS Res and Prevention, Seattle, WA, US;; 

and 5CDC, Mbabane, Swaziland 

632� �� 

Proportion of Acute HIV Infections and Improves HIV 

�� 

Philip Peters* 1 , E Westheimer2 , N Moss3 , C Gay4,5 , B Tsoi2 , M Pandori3 , 

L Hightow-Weidman4,5 , L Hall6 , P Patel1 , and STOP Study Group 

1 2 CDC, Atlanta, GA, US;; New York City Dept of Hlth and Mental 

Hygiene, NY, US;; 3San Francisco Dept of Publ Hlth, CA, US;; 4Univ of 

North Carolina at Chapel Hill, US;; 5North Carolina Dept of Publ Hlth 

Collaboration, Raleigh, US;; and 6ICF Intl, Atlanta, GA, US 

633� �� 

Performance: Taiwan 

Chun-Kai Chang* 1 , P-H Lin1 , S-Y Ho2 , S-Y Chang1,2 , C Kao3 , 

and J-Y Yang3 1 2 Natl Taiwan Univ Coll of Med, Taipei;; Natl Taiwan Univ Hosp, Taipei;; 

and 3Ctr for Disease Control, Taiwan 

634� �� 

Generation Enzyme Immunoassay 

Jintanat Ananworanich* 1,2,3,4 , J Fletcher1,2 , S Pinyakorn1,2,3 , 

FV Griensven2 , T Pankam2 , R Trichaviroj5 , P Phanuphak1,2,3 , N Chomont6 , 

J Kim1,5,7 , M de Souza5 , and RV254/SEARCH 010 Study Group 

1 2 SEARCH, Bangkok, Thailand;; The Thai Red Cross AIDS Res Ctr, 

Bangkok;; 3HIVNAT, Bangkok, Thailand;; 4Faculty of Med, Chulalongkorn 

Univ, Bangkok, Thailand;; 5Armed Forces Res Inst of Med Sci, Bangkok, 

Thailand;; 6Vaccine and Gene Therapy Inst, Port St Lucie, FL, US;; and 

7US Military HIV Res Prgm, Rockville, MD 

635 Streamlining HIV Testing during Pre-exposure Prophylaxis 

Use: Lessons from the Pre-exposure Prophylaxis Initiative 

Trial 

Juan Guanira* 1 , T Liegler2 , R Hance3 , D Glidden2 , and R Grant2,3 1 2 Investigaciones Med en Salud, Lima, Peru;; Univ of California, 

San Francisco, US;; and 3Gladstone Inst, San Francisco, CA, US 


Poster Listings



636 Challenges and Missed Opportunities in the Diagnosis of 

Acute HIV 

Suzanne McCluskey* 1 , S Heath2 , and K Bar3 1 2 Massachusetts Gen Hosp, Boston, US;; Univ of Alabama at Birmingham, 

US;; and 3Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US 



Hepatic Injury and Fibrosis 

638 Incidence and Progression to Cirrhosis of Hepatitis C Virus 

Superinfection in Persons Living with HIV 

Massimo Puoti* 1 , P Lorenzini 2 , E Girardi 2 , A Cozzi-Lepri 3 , A Gori 4 , 

C Mastroianni 5 , G Rizzardini 6 , G Mazzarello 7 , A Antinori 2 , 

A d’Arminio Monforte 8 , and Icona Fndn Study Group 

1 Niguarda Ca’ Granda Hosp, Milan, Italy;; 2 Natl Inst of Infectious Disease 

Lazzaro Spallanzani, Rome, Italy;; 3 Hampstead Coll Univ Coll London, 

UK;; 4 San Gerardo de’ Tintori Hosp, Monza, Italy;; 5 La Sapienza Rome 

Univ Polo Pontino, Latina, Italy;; 6 Luigi Sacco Hosp, Milan, Italy;; 7 San 

Martino Hosp, Genova, Italy;; and 8 Univ of Milan, Italy 

643 Apoptosis and Oxidative Stress Are Associated with Liver 

Disease Progression in HIV/Hepatitis C Virus Co-Infection 

Marianna Baum* 1 , K Sherman 2 , S Martinez 1 , D-H Shin 1 , D Jayaweera 3 , 

P Greer 1 , S Williams 1 , M Parsons 1 , J Martinez 1 , and A Campa 1 

1 Florida Intl Univ, Miami, US;; 2 Univ of Cincinnati, OH, US;; and 3 Univ of 

Miami, FL, US 

644� �� 

�� 

Virus Co-infected Individuals 

Laurence Brunet* 1 , E Moodie1 , J Young2 , M Tyndall3 , M Hull4 , 

C Cooper3,5 , S Walmsley6 , J Gill7 , M Potter2 , M Klein1,2 , and Canadian 

Co-infection Cohort Study 

1 2 McGill Univ, Montreal, Canada;; McGill Univ Hlth Ctr, Montreal, 

Canada;; 3Univ of Ottawa, Canada;; 4BC Ctr for Excellence in HIV/AIDS, 

Vancouver, Canada;; 5Ottawa Hosp, Canada;; 6Univ of Toronto, Canada;; 

and 7Southern Alberta HIV Clinic, Calgary, Canada 

645� �� 

Progression in ARV-treated HIV/Hepatitis C Virus Co-infected 

Patients 

Curtis Cooper* 1 , K Rollet2 , C Vasquez1 , M Potter2 , J Gill3 , N Pick4 , 

S Walmsley5 , M Tyndall1 , M Klein2 , and Canadian Co-infection Cohort 

Study Investigators 

1 2 Univ of Ottawa, Ottawa Hosp Res Inst, Canada;; McGill Univ, Montreal, 

Canada;; 3Univ of Calgary, Canada;; 4Univ of British Columbia, Canada;; 

and 5 653� �� 

�� 

Hepatitis C Virus Co-infected Patients 

N Frulio, J Asselineau, M Hessamfar, F Maire, P Perez, J Delaune, 

M-A Vandenhende, V De Ledinghen, H Trillaud, and Philippe Morlat* 

Univ Hosp, Bordeaux, France 

654� �� 

in Patients with HIV and Hepatitis B Virus Co-infection: 

Nigeria 

Oche Agbaji* 

Univ of Toronto, Canada 

1 , P Ugoagwu1 , R Murphy2 , C Thio3 , C Ani1 , C Okafo1 , 

M Auwal1 , E Wallender4 , and C Hawkins2 1 2 Jos Univ Teaching Hosp, Nigeria;; Northwestern Univ, Chicago, IL, US;; 

3 4 Johns Hopkins Univ, Baltimore MD, US;; and Vanderbilt Univ Med Ctr, 

Nashville, TN, US 

655 Liver Stiffness Predicts Liver-related Complications and 

Mortality in HIV/Hepatitis C Virus Co-infected patients 

Jose Vicente Fernandez-Montero*, P Barreiro, E Vispo, P Labarga, 

C Sanchez-Parra, M Arredondo, and V Soriano 

Hosp Carlos III, Madrid, Spain 


646� �� 

Virus and HIV/Hepatitis C Virus-infected Patients: Thailand 

Reshmie Ramautarsing* 1,2 , P Tangkijvanich 3 , S Jirajariyavej 4 , 

S Chittmittrapap 3 , T Apornpong 1 , P Chaihong 1 , S Ubolyam 1 , 

W Khowidhunkit 3 , K Ruxrungtham 1,3 , and A Avihingsanon 1,3 

1 HIVNAT Res Collaboration, Bangkok, Thailand;; 2 Amsterdam Inst for 

Global Hlth and Devt, The Netherlands;; 3 King Chulalongkorn Memorial 

Hosp, Bangkok, Thailand;; and 4 Thaksin Hosp, Bangkok, Thailand 

637 Does Persistent Hepatitis C Viremia Lead to Advanced Liver 

�� 

in HIV Co-infection? 

Christoph Boesecke* 1 , T Reiberger2 , S Mauss3 , H-J Stellbrink4 , 

M Mandorfer2 , M Nelson5 , S Bhagani6 , M-A Valantin7 , P Ingiliz8 , 

J Rockstroh1 , and NEAT Study Group 

1 2 3 Bonn Univ Hosp, Germany;; Med Univ of Vienna, Austria;; Ctr for HIV 

and Hepatogastroenterology, Dusseldorf, Germany;; 4ICH Study Ctr, 

Hamburg, Germany;; 5Chelsea and Westminster Hosp, London, UK;; 

6 7 Royal Free Hosp, London, UK;; AP-HP, Hosp La Pitie Salpetriere, 

Paris, France;; and 8 647� �� 

�� 

HIV Study 

Seema Desai* 

MIB, Berlin, Germany 

1 , J Dodge2 , A Landay1 , M Glesby3 , P Latham4 , 

M Villacres5 , A French6 , N Amali2 , R Greenblatt2 , and M Peters2 1 2 Rush Univ Med Ctr, Chicago, IL, US;; Univ of California, San 

Francisco, US;; 3Weill Cornel Med Coll, New York, NY, US;; 4George Washington Univ, Washington, DC, US;; 5Univ of Southern California, 

Los Angeles, US;; and 6Stroger Hosp Cook County, Chicago, IL, US 

648� �� 

on Serum Inflammatory Mediators in HIV Infection: The 

�� 

Sheila Keating* 1,2 , J Dodge1 , P Norris1,2 , A French3 , M Glesby4 , B Edlin5 , 

P Latham6 , N Ameli1 , R Greenblatt1 , M Peters1 , and Women�s Interagency 

HIV Study 

1 2 Univ of California, San Francisco, US;; Blood Systems Res Inst, San 

Francisco, CA, US;; 3Stroger Hosp of Cook County, Chicago, IL, US;; 

4 5 Weill Cornell Med Coll, New York, NY, US;; SUNY Downstate, Brooklyn, 

US;; and 6Georgetown Univ, Washington, DC, US 

+ 

639� �� 

Individuals 

E Anadol1 , K Tack1 , C Schwarzer-Zander1 , N Elfimova2 , C Boesecke1 , 

J-C Wasmuth1 , T Sauerbruch1 , J Rockstroh1 , M Odenthal2 , 

and Jonel Trebicka* 1 

1 2 Univ of Bonn, Germany and Univ of Cologne, Germany 

640� �� 

HIV-1/Hepatitis C Virus Co-infection Reveals Plasma 

�� 

Carlos Enrique Melendez-Pena* 1 , C Santamaria1 , 

B Conway2 , C Cooper3 , B Segatto1 , B Ward1 , M Ndao1 , M Klein1 , 

and Canadian Co-infection Cohort Study Group 

1 2 McGill Univ Hlth Ctr, Montreal, Canada;; Univ of British Columbia, 

Vancouver, Canada;; and 3Univ of Ottawa at the Ottawa Hosp, Canada 

641 Increased Risk of ARV Drug Discontinuation among Patients 

�� 

Daniel Grint* 1 , L Peters2 , J Rockstroh3 , J Lundgren2 , S De Wit4 , 

V Mitsura5 , B Kynsz6 , C Pedersen7 , O Kirk2 , A Mocroft1 , and EuroSIDA 

1 2 3 Univ Coll London, UK;; Copenhagen HIV Prgm, Denmark;; Univ of Bonn, 

Germany;; 4St-Pierre Hosp, Brussels, Belgium;; 5Gomel State Med Univ, 

Belarus;; 6Med Univ, Wroclaw, Poland;; and 7Odense Univ Hosp, Denmark 

642� �� 

�� 

Co-infection 

Aimee Hodowanec* 1,2 , R Lee3 , K Brady2 , W Gao4 , S Kincaid1 , J Plants2 , 

M Bahk1 , A Landay2 , N Mackman3 , and G Huhn1,2 1 2 Ruth M Rothstein CORE Ctr, Chicago, IL, US;; Rush Univ Med Ctr, 

Chicago, IL, US;; 3Univ of North Carolina at Chapel Hill, US;; and 4 649 ARV-induced Very Low Density Lipoprotein Apolipoprotein 

Increases Are Associated with Change in Hepatitis C Viral 

Load in HIV/Hepatitis C Virus Co-infected Individuals 

Susanna Naggie* 

Univ 

of Illinois at Chicago, US 

1 , K Patel1 , J Guyton1 , L-Y Yang1 , S Chow1 , M Kang2 , 

V Johnson3 , A Muir1 , M Sulkowski4 , and C Hicks1 1 2 3 Duke Univ, Durham, NC, US;; Harvard Univ, Boston, MA, US;; Univ 

of Alabama at Birmingham and Birmingham VAMC, US;; and 4Johns Hopkins Univ, Baltimore, MD, US 

650 Association of LDLR Haplotypes with Hepatitis C Virus 

Viral Load and Sustained Virological Response in HIV 

�� 

Antonio Caruz* 1 , K Neukam2 , A Rivero-Juarez3 , L-M Real2 , F-J Marquez1 , 

A Camacho3 , P Barreiro4 , V Soriano4 , A Rivero3 , and J Pineda2 1 2 3 Univ de Jaen, Spain;; Hosp Univ de Valme, Sevilla, Spain;; Hosp Univ 

Reina Sofia, Cordoba, Spain;; and 4Hosp Carlos III, Madrid, Spain 

651 HIV + �� 

Infection are Associated with Shorter Leukocyte Telomere 

Length in a Cohort of HIV + and HIV� Adults 

DeAnna Zanet* 1 , A Thorne2 , B Sattha1 , E Maan3 , I Gadawski1 , 

M Murray1,3,4 , J Singer1,2 , D Money1,3,4 , N Pick1,3,4 , H Cote1,4 , 

and CIHR Emerging Team in HIV Therapy and Aging 

1 2 Univ of British Columbia, Vancouver, Canada;; CIHR Canadian HIV 

Trials Network, Vancouver;; 3Oak Tree Clin, Vancouver, Canada;; 

and 4Women�s Hlth Res Inst, Vancouver, Canada 



Laboratory Assessment and Imaging of Hepatic 

Injury 

652� �� 

�� 

Hepatic Steatosis 

Eva Recio* 1 , K Neukam1 , C Cifuentes1 , M Mancebo1 , J Macias1 , 

C Almeida1 , N Merchante1 , J Mira1 , A Rivero-Juarez2 , and J Pineda1 1 2 Hosp Univ de Valme, Seville, Spain and Maimonides Inst for Biomed 

Res, Hosp Univ Reina Sofia, Cordoba, Spain


656 Comparison of Transient Elastography and Hepatic Gradient 

Venous Pressure for Predicting Liver Complications or 

Death in Patients with Hepatitis C Virus Cirrhosis 

Leire Perez-Latorre* 1,2 , M Sanchez-Conde 1,2 , JM Bellon 2 , P Miralles 1,2 , 

D Rincon 1,2 , JC Lopez 1,2 , J Cosin 1,2 , R Banares 1,2,3 , and J Berenguer 1,2 

1 Hosp Gregorio Maranon, Madrid, Spain;; 2 Inst de Investigacion Sanitaria 

Gregorio Maranon, Madrid, Spain;; and 3 CIBEREHD, Spain 

657 Worse Clinical and Immunological Outcomes Associated 

with Hepatitis C Virus Infection in HIV Elite Controllers 

Mohammad Sajadi*, R Redfield, and R Talwani 

Inst of Human Virology, Baltimore, MD, US 

658 Prognostic Utility of Transient Elastography in HIV + Patients 

with Liver Cirrhosis 

Maria Luisa Montes Ramirez* 1 , MA Von Wichmann 2 , J Miro 3 , 

C Quereda 4 , C Tural 5 , E Ortega 6 , J Berenguer 7 , J Sanz 8 , A Hernando 9 , 

J Arribas 1 , and GESIDA-CIRROSIS Study Group 

1 Hosp Univ La Paz, IdiPaz, Madrid, Spain;; 2 Hosp de Donostia, San 

Sebastian, Spain;; 3 Hosp Clin-IDIBAPS, Univ of Barcelona, Spain;; 4 Hosp 

Ramon y Cajal, Madrid, Spain;; 5 Hosp Germans Trials y Pujol, Badalona, 

Spain;; 6 Hosp Univ Gen de Valencia, Spain;; 7 Hosp Univ Gregorio 

Maranon, Madrid, Spain;; 8 Hosp Univ Principe de Asturias, Madrid, 

Spain;; and 9 Hosp 12 de Octubre, Univ Europea de Madrid, Spain 



Hepatitis E Virus 

663 Seroepidemiology and Genotyping of Hepatitis E Virus 

among MSM in the Era of cART: Taiwan 

Chien-Ching Hung*, S-Y Chang, Z-Y Yang, W-C Liu, C-H Wu, 

and P-J Chen 

Natl Taiwan Univ Hosp and Natl Taiwan Univ Coll Med, Taipei 

666� �� 

Is an Accurate Predictor of Long-term Hepatitis B Envelope 

Antigen Loss in HIV/Hepatitis B Virus Co-infected Patients 

Treated with Tenofovir 

Anders Boyd* 1 , S Maylin 2 , C Lascoux-Combe 2 , P Miailhes 3 , 

J Gozlan 4 , C Delaugerre 2 , P-M Girard 1,4,5 , and K Lacombe 1,4,5 

1 INSERM UMR-S707, France;; 2 Hosp St-Louis, AP-HP, Paris, France;; 

3 Hosp Croix-Rousse, Hospices Civils de Lyon, France;; 4 Hosp St-Antoine, 

AP-HP, Paris, France;; and 5 UPMC, Paris VI, France 

667 History of Lamivudine Predicts Lower Likelihood of 

Hepatitis B Viral Suppression on Tenofovir in HIV/Hepatitis 

B Virus Co-infected Patients: The Centers for AIDS Research 

Network of Integrated Clinical Systems Cohort 

Nina Kim* 1 , C Rodriguez 1 , S Van Rompaey 1 , H Crane 1 , M Saag 2 , 

J Eron 3 , J Martin 4 , M Kitahata 1 , and Ctr for AIDS Res Network of Clinical 

Integrated Systems 

1 Univ of Washington, Seattle, US;; 2 Univ of Alabama at Birmingham, US;; 

3 Univ of North Carolina at Chapel Hill, US;; and 4 Univ of California, San 

Francisco, US 

659 Association of HIV Mono-infection and HIV/Hepatitis C 

�� 

Markers Aspartate Aminotransferase to Platelet Ratio Index 

�� 

Phyllis Tien* 1,2 , R Scherzer1,2 , R Bailony1 , M Plankey3 , M Peters1 , 

G Huhn4 , and Women�s Interagency HIV Study 

1 2 Univ of California, San Francisco, US;; San Francisco VAMC, CA, US;; 

3 4 Georgetown Univ Med Ctr, Washington, DC, US;; and Stroger Hosp and 

Rush Univ, Chicago, IL, US 

660� �� 

among HIV/Hepatitis C Virus Co-infected Patients 

A Fernandez-Rodriguez1 , Juan Berenguer* 2 , MA Jimenez-Sousa1 , 

M Guzman-Fulgencio1 , D Micheloud2 , JC Lopez2 , E Alvarez2 , JM Bellon2 , 

P Miralles2 , and S Resino1 1 2 Natl Ctr for Microbio, Majadahonda, Madrid, Spain and Hosp Gen Univ 

Gregorio Maranon, Madrid, Spain 

661� �� 

Hepatitis C Virus Genotype 1 in the Setting of Low Viremic 

Samples 

P Braun1 , F Wiesmann1 , A Berger2 , R Kaiser3 , G Naeth1 , R Ehret4 , 

and Heribert Knechten* 1 

1 2 3 PZB Aachen, Germany;; Inst of Virology, Frankfurt, Germany;; Inst of 

Virology, Cologne, Germany;; and 4Med Lab Berg, Berlin, Germany 

662 Sensitive Detection of Minor Variants and Viral Haplotypes 

�� 

A Sethuraman1 , Y Guo1 , M Brown1 , J Toma2 , A Newton2 , W Huang2 , 

M Sugiyama3 , C Petropoulos2 , M Mizokami3 , and Ellen Paxinos* 1 

1 2 Pacific Biosci, Menlo Park, CA, US;; Monogram Biosci, South San 

Francisco, CA, US;; and 3 668 Intensification with Pegylated Interferon during Treatment 

with Tenofovir in HIV/Hepatitis B Virus Co-infected Patients 

Anders Boyd* 

Res Ctr for Hepatitis and Immunology, Natl Ctr 

for Global Med, Ichikawa, Japan 

1 , P Miailhes2 , S Maylin3 , J Gozlan4 , 

C Lascoux-Combe3 , C Delaugerre3 , P-M Girard1,4,5 , and K Lacombe1,4,5 1 2 INSERM UMR-S707, France;; Hosp Croix-Rousse, Hospices Civils de 

Lyon, France;; 3Hosp St-Louis, AP-HP, Paris, France;; 4Hosp St-Antoine, 

AP-HP, Paris, France;; and 5 669 

UPMC, Paris VI, France 

Additional Pegylated Interferon in HBeAg + HIV Co-infected 

Patients on cART Including Tenofovir: The ANRS HB01 

EMVIPEG Study 

Patrick Miailhes* 1 , M Maynard-Muet1 , F Carrat2 , C Lascoux-Combe3 , 

D Rey4 , P Sogni5 , S Pol5 , P Cacoub6 , F Zoulim1 , and L Piroth7 1Hospices Civils de Lyon, INSERM U1052, Croix-Rousse Hosp, Lyon, 

France;; 2UMRS-707, Univ Paris 6 et INSERM, Sante Publique, APHP, 

Paris, France;; 3St-Louis Hosp, APHP, Paris, France;; 4Hosp Univ, HIV 

Infection Ctr, Strasbourg, France;; 5Univ Paris Descartes, INSERM 

U1016, APHP, Cochin Hosp, Paris, France;; 6La Pitie-Salpetriere Hosp, 

CNRS UMR 7087, Pierre et Marie Curie Univ, Paris, France;; and 7CHU Dijon and Univ of Burgundy, France 

670 Brief ARV Interruptions Do Not Increase the Risk of Liver 

�� 

Dual-active Treatment 

Huw Price* 1 , D Dunn2 , D Pillay1 , T Zachary3 , T Vudriko4 , C Kityo3 , 

P Munderi4 , J Hakim5 , C Gilks6 , R Gilson1 , and DART Virology Group 

1 2 3 Univ Coll London, UK;; MRC, London, UK;; Joint Clin Res Ctr, 

Kampala, Uganda;; 4MRC/UVRI, Entebbe, Uganda;; 5Univ of Zimbabwe 

Clin Res Ctr, Harare;; and 6Imperial Coll London, UK 

671 Key Patterns of Mutations in Hepatitis B Virus S Open 

�� 

Levels of Serum Hepatitis B Virus DNA in vivo 

C Mirabelli1 , V Cento1 , C Alteri1 , R Salpini1 , M Surdo1 , M Pollicita1 , 

C Gori2 , A Bertoli1 , C-F Perno1 , and Valentina Svicher* 1 

1 2 Univ of Tor Vergata Rome, Italy and Natl Inst for Infectious Diseases L 

Spallanzani, Rome, Italy 



672 Treatment of Hepatitis Delta with Tenofovir±Lamivudine/ 

�� 

�� 

�� 

Rocio Sierra-Enguita* 1 , Z Plaza 1 , V Soriano 1 , MD Gonzalez 1 , JM Benito 1 , 

A Aguilera 2 , A Mena 3 , J Pedreira 2 , L Martin-Carbonero 1 , and E Poveda 1 

1 Hosp Carlos III, Madrid, Spain;; 2 Hosp Conxo-CHUS, Santiago de 

Compostela, Spain;; and 3 Hosp Univ A Coruna, Spain 

664 Chronic Hepatitis E Causes Rapid Progression to Liver 

�� 

�� 

Karin Neukam* 1,2 , P Barreiro3 , J Echevarria4 , J Macias1 , P Labarga3 , 

A Avellon4 , M Parra-Sanchez1 , N Merchante1 , V Soriano3 , and J Pineda1 1 2 Hosp Univ de Valme, Seville, Spain;; Royal Free Hosp, London, 

UK;; 3Hosp Carlos III, Madrid, Spain;; and 4 673 Seroepidemiology of Hepatitis D Virus Infection among HIV 

Inst de Salud Carlos III, 

Majadahonda, Spain 

+ 

Patients with Hepatitis B Virus Co-infection: Taiwan 

Sui-Yuan Chang* 1,2 , S-M Wu2 , Y-C Su2 , S-F Chang2 , W-C Liu1 , 

C-H Wu1 , and C-C Hung1,2 1 2 Natl Taiwan Univ Hosp, Taipei and Natl Taiwan Univ Coll Med, Taipei 



Hepatitis C Virus Treatment Today and Tomorrow 



Hepatitis B Virus 

665 Virologic/Serologic Outcomes in HIV/Hepatitis B Virus 

�� 

and Dual- Hepatitis B Virus Therapy: ACTG Longitudinal 

Linked Randomized Trials 

M Kang1 , K Hollabough1 , V Pham2 , S Koletar3 , K Wu1 , M Smurzynski1 , 

and Judith Aberg* 2 

1 2 Harvard Sch of Publ Hlth, Boston, MA, US;; New York Univ Sch of Med, 

NY, US;; and 3 675� �� 

Therapy for Chronic Hepatitis C Virus Genotype 1 in Hepatitis 

C Virus/HIV Co-infected Patients: Early Response and Viral 

Resistance 

Kenneth Sherman* 

Ohio State Univ Med Ctr, Columbus, US 

1 , D Bartels2 , M Bsharat2 , R Rubin2 , T Kieffer2 , 

and M Sulkowski3 1 2 Univ of Cincinnati Coll of Med, OH, US;; Vertex Pharmaceuticals Inc, 

Cambridge, MA, US;; and 3Johns Hopkins Univ Sch of Med, Baltimore, 

MD, US



676� �� 

�� 

Boceprevir Regardless HIV Status 

Jose Miguel Benito* 1 , K Bichoupan2 , V Soriano1 , I Maida3 , A Branch2 , 

C Sanchez1 , N Rallon1 , A Aguilera4 , P Barreiro1 , and D Dieterich2 1 2 3 Hosp Carlos III, Madrid, Spain;; Mt Sinai Hosp, New York, NY, US;; Univ 

of Sassari, Italy;; and 4Hosp de Conxo, Santiago de Compostela, Spain 

677 Risk of Anemia in HIV/Hepatitis C Virus Co-infected Patients 

�� 

Jay Kostman*, J Gilmore, A Binkley, K Lynn, R Bahirwani, B Appolo, 

L Sinese, R Reddy, and V Lo Re 

Perelman Sch of Med of the Univ of Pennsylvania, Philadelphia, US 

678� �� 

�� 

Early Data from the OUTLOOK Study 

Steven Flamm* 1 , E Martin2 , A Muir3 , N Shores4 , L Jeffers5 , S Harrison6 , 

R Reddy7 , and M Friedman2 1 2 Northwestern Univ, Chicago, IL, US;; Vertex Pharmaceuticals Inc, 

Cambridge, MA, US;; 3Duke Clinical Res Inst, Durham, NC, US;; 4Tulane Univ Hlth Sci Ctr, New Orleans, LA, US;; 5South Florida VA Fndn for Res 

and Ed, Miami, US;; 6San Antonio Military Med Ctr-Brooke Army Med Ctr, 

Fort Sam Houston, TX, US;; and 7Univ of Pennsylvania, Philadelphia, US 

679� �� 

Treatment Are Similar in HIV/Hepatitis C Virus Co-infected 

and Hepatitis C Virus Mono-infected Patients 

Valerie Martel-Laferriere* 1 , S Brinkley2 , K Bichoupan1 , S Posner1 , 

A Stivala1 , P Perumalswami1 , T Schiano1 , M Sulkowski2 , D Dieterich1 , 

and A Branch1 1 2 Mt Sinai Sch of Med, New York, NY, US and John Hopkins Univ, 


680� �� 

Treatment-nïave Patients: Sustained Virologic Response in 

�� 

R Bruno1 , Paola Nasta* 2 , A Capetti3 , V Ravasio4 , M Galli3 , E Raise5 , 

A Caputo5 , C Iannacone6 , and M Puoti7 1 2 Fndn IRCCS Policlin San Matteo, Pavia, Italy;; Brescia Hosp, Italy;; 

3 4 Univ Hosp Luigi Sacco, Milan, Italy;; Riuniti Hosp, Bergamo, Italy;; 

5 6 7 DellAngelo Hosp, Mestre, Italy;; Roche Spa, Monza, Italy;; and SPARC 

681 

Consulting, Milan, Italy 

Treatment of Chronic Hepatitis C May Improve Clinical 

Outcomes Despite Lack of Sustained Virological Response in 

HIV/ Hepatitis C Virus Co-infected Patients 

Pablo Labarga*, JV Fernandez, E Vispo, JM Benito, N Rallon, 

C Sanchez, I Perez, C Garcia-Delgado, P Barreiro, and V Soriano 

Hosp Carlos III, Madrid, Spain 

682 Does Choice of HIV Therapy Impact Overall Sustained 

Virological Response Rates in HIV/Hepatitis C Virus 

Co-infected Individuals? 

Stefan Mauss* 1 , A Baumgarten2 , T Lutz3 , B Bieniek4 , S Koeppe5 , 

M Freiwald5 , U Alshuth6 , R Goesseringer6 , and J Rockstroh7 1 2 Ctr for HIV and Hepatogastroenterology, Duesseldorf, Germany;; MIB, 

Berlin, Germany;; 3Infektiologikum, Frankfurt, Germany;; 4Practice City Ost, Berlin, Germany;; 5Private Practice, Berlin, Germany;; 6Roche Pharma AG, Germany;; and 7Universittsklinikum Poliklinik, Bonn, 

Germany 

683� �� 

�� 

Patients Co-infected with HIV and Hepatitis C Virus 

T Aldamiz1 , Juan Berenguer* 1 , F Zamora2 , M Von Wichmann3 , 

M Crespo4 , M Tellez5 , J Sanz6 , H Esteban7 , JM Bellon1 , J Gonzalez2 , 

and GESIDA 3603 and 5006 Study Groups 

1 2 Hosp Gen Univ Gregorio Maranon, Madrid, Spain;; Hosp Univ La Paz, 

Madrid, Spain;; 3Hosp de Donostia, San Sebastian, Spain;; 4Hosp Vall 

dHebron, Barcelona, Spain;; 5Hosp Clin de San Carlos, Madrid, Spain;; 

6 7 Hosp Principe de Asturias, Alcala de Henares, Spain;; and Fndn SEIMC/ 

GESIDA, Madrid, Spain 

684 Single Nucleotide Polymorphisms at Multiple Genes Predict 

�� 

�� 

Karin Neukam* 1,2 , A Caruz3 , P Barreiro4 , A Rivero-Juarez5 , D Merino6 , 

M Marquez7 , E Perez-Navarro1 , V Soriano4 , A Rivero5 , and J Pineda1 1 2 Hosp Univ de Valme, Seville, Spain;; Royal Free Hosp, London, UK;; 

3 4 5 Univ of Jaen, Spain;; Hosp Carlos III, Madrid, Spain;; Hosp Univ Reina 

Sofia, Cordoba, Spain;; 6Hosp Juan Ramon Jimenez, Huelva, Spain;; and 

7Hosp Univ Virgen de la Victoria, Malaga, Spain 

685� �� IL28B Genotypes Are Associated with Spontaneous 

�� 

Hepatitis C Virus Co-infected Individuals 

Nasheed Moqueet* 1 , J Young1 , C Lisle2 , R Carter2 , M Klein1 686� �� 

Associated with Response to Therapy against Hepatitis C 

�� 

Karin Neukam* 

, 

and Canadian Co-infection Cohort 

1 2 McGill Univ, Montreal, Canada and Bay Area Genetic Lab, Hamilton, 

Canada 

1,2 , A Rivero-Juarez3 , A Caruz4 , P Labarga5 , M Marquez6 , 

L Real1 , R Herrero4 , A Rivero3 , V Soriano5 , and J Pineda1 1 2 3 Hosp Univ de Valme, Seville, Spain;; Royal Free Hosp, London, UK;; Hosp 

Univ Reina Sofia, Cordoba, Spain;; 4Univ of Jaen, Spain;; 5Hosp Carlos III, 

Madrid, Spain;; and 6Hosp Univ Virgen de la Victoria, Malaga, Spain 

687 Baseline Plasma Lipopolysaccharide Predicts Sustained 

Virological Response in HIV/Hepatitis C Virus Co-infected 

�� 

Jessica Nystrom*, J Stenkvist, P Nowak, J Svard, O Weiland, 

and A Sonnerborg 

Karolinska Inst, Stockholm, Sweden 

688 Interferon-stimulated Gene Expression Is a Better Predictor of 

�� 

Virus Co-infected Patients 

Norma Rallon* 1 , L Lpez-Fernndez2 , C Restrepo1 , M Garcia2 , 

V Soriano1 , and JM Benito1 1 2 Hosp Carlos III, Madrid, Spain and Hosp Gregorio Maranon, Madrid, 

Spain 

689� �� 

like Memory B Cells Predict Relapse in HIV/Hepatitis C 

�� 

Ashton Shaffer* 1 , A Kohli2 , E Meissner1 , B Santich1 , E Funk1 , 

P Burbelo1 , M Polis1 , S Moir1 , S Kottilil1 , and H Masur1 1 2 NIH, Bethesda, MD, US and SAIC-Frederick, Inc, Frederick Natl Lab 

for Cancer Res, MD, US 

690 Acute and Chronic Immune Biomarker Changes after 

�� 

C Virus Co-infected Patients 

Mamta Jain* 1 , B Adams-Huet1 , R Bedimo1,2 , L Kushner3 , D Terekhova1 , 

and M Holodniy3,4 1 2 Univ of Texas Southwestern, Dallas, US;; North Texas VAMC, Dallas, US;; 

3 4 VA Palo Alto Hlth Care System, CA, US;; and Stanford Univ, CA, US 

691� �� 

HIV + and HIV/Hepatitis C Virus Co-infected Patients: The 

PISCIS Cohort 

A Esteve1 , Jose Miro* 2 , C Campbell1 , A Gallois1 , D Podzamczer1 , 

C Tural3 , J Murillas4 , F Segura5 , C Cifuentes6 , J Casabona1 , and PISCIS 

Study Group 

1 2 CEEISCAT, Badalona, Spain;; Hosp Clin-Idibaps, Univ de Barcelona, 

Spain;; 3Fndn Lluita contra la Sida, Fndn irsicaixa, Hosp Univ Germans 

Trias i Pujol, Univ Autonoma de Barcelona, Badalona, Spain;; 4Hosp Son 

Espases de Mallorca, Palma de Mallorca, Spain;; 5Corp Sanitaria Univ 

Parc Tauli, Univ Autonoma de Barcelona, Sabadell, Spain;; and 6Hosp Son Llatzer, Palma de Mallorca, Spain 

692� �� 

�� 

�� 

Mark Sulkowski* 1 , M Kang2 , R Matining2 , D Wyles3 , V Johnson4 , 

G Morse5 , V Amorosa6 , D Bhattacharya7 , F Wong-Staal8 , M Glesby9 , 

and A5277 Protocol Team 

1 2 Johns Hopkins Univ, Baltimore, MD, US;; Harvard Sch of Publ Hlth, 

Boston, MA, US;; 3Univ of California, San Diego, US;; 4Birmingham VAMC and Univ of Alabama at Birmingham Sch of Med, US;; 5Univ at Buffalo, the State Univ of New York, US;; 6Univ of Pennsylvania, 

Philadelphia, US;; 7Univ of California, Los Angeles, US;; 8iTherX, San 

Diego, CA, US;; and 9Weill Med Coll of Cornell Univ, New York, NY US 



Hepatitis C Virus Resistance and Virology 

693 High-resolution Primer ID Sequencing of Hepatitis C Virus 

�� 

existing Resistance-associated Variants in Co- vs Mono- 

�� 

Cassandra Jabara*, F Hu, C Jones, P Menezes, M Fried, J Eron, 

R Swanstrom, and S Lemon 


694� �� 

�� 

�� 

Sandrine Ortiou* 1 , J-Y Servais1 , D Perez-Bercoff1 , J Fritz1,2 , D Vaira3 , 

J Delwaide4 , V Arendt1,5 , T Staub5 , J-C Schmit1,5 , and C Devaux1 1 2 3 CRP-Sante, Luxembourg;; Univ of Luxembourg;; Univ of Liege, Belgium;; 

4 5 Univ Hosp of Liege, Belgium;; and CHL, Luxembourg 

695� �� 

Hepatitis C Infection in HIV Co-infected Patients 

M Nevot1 , C Boesecke2 , M Parera1 , C Andres1 , B Revollo3 , C Tural3 , 

B Clotet1,3 , J Rockstroh2 , Miguel Angel Martinez* 1 , 

and NEAT Study Group 

1 2 Fndn irsiCaixa, Badalona, Spain;; Bonn Univ Hosp, Germany;; 

and 3Fndn Lluita contra la Sida, Badalona, Spain 

48 � 20th Conference on Retroviruses and Opportunistic Infections




Innate Immunity and Hepatitis C Virus 

696 Intra- and Extra-Hepatic Correlates of Plasma Viral 

Clearance in Patients with Chronic Hepatitis C Virus 

�� 

Eric Meissner* 1 , A Osinusi 1,2 , H Wang 3 , L Heytens 3 , A Nelson 1 , 

M Polis 1 , H Masur 3 , W Symonds 4 , A Fauci 1 , and S Kottilil 1 

1 NIAID, NIH, Bethesda, MD, US;; 2 SAIC-Frederick, MD, US;; 3 Clinical 

Ctr, NIH, Bethesda, MD, US;; and 4 Gilead Sci, Foster City, CA, US 

697� �� 

�� 

�� 

Yu-Jin Lee* 1 , A Osinusi1,2 , M Kang3 , T Umbleja3 , V Amorosa4 , 

S Kottilil1 , M Peters5 , and ACTG5269 Study Group 

1 2 3 NIH, Bethesda, MD, US;; SAIC-Frederick Inc, MD, US;; Harvard Sch of 

Publ Hlth, Boston, MA, US;; 4VAMC, Philadelphia, PA, US;; and 5Univ of 

California, San Francisco, US 

698� �� 

C Virus Viral Clearance and Sustained Virological Response 

in HIV/Hepatitis C Virus Co-infected Patients 

Antonio Rivero-Juarez* 1 , R Gonzalez1 , A Camacho1 , 

B Manzanares-Martin1 , A Caruz2 , A Martinez-Peinado1 , 

L Martinez-Duenas1 , J Pineda3 , J Pena1 , and A Rivero1 1Inst Maimonides de Investigacion Biomed de Cordoba, Hosp Reina Sofia de 

Cordoba, Spain;; 2Univ de Jaen, Spain;; and 3 708 Hepatitis C Virus Re-infections in HIV 

Hosp de Valme, Seville, Spain 

+ MSM: Evidence for 

Partial Protective Immunity 

X Thomas1 , B Grady2 , J van der Meer1 , F Lambers2 , M Prins1,2 , 

M van der Valk2 , S Rebers1 , R Molenkamp1 , Janke Schinkel* 1 , 

on behalf of MOSAIC Study Group 

1 2 Academic Med Ctr, Amsterdam, The Netherlands and Publ Hlth Svc, 

Amsterdam, The Netherlands 

709 Trends in Prevalence of Hepatitis C Virus among the HIV + 

Population: Spain 

Sergio Serrano-Villar* 1 , P Sobrino-Vegas2 , M Riera3 , JA Iribarren4 , 

I Santos5 , R Rubio6 , L Munoz7 , B Clotet8 , J del Amo2 , S Moreno1 , 

and CoRIS 

1 2 Hosp Univ Ramon y Cajal, Madrid, Spain;; Ctr Nacional de 

Epidemiologia, Inst de Salud Carlos III, Madrid, Spain;; 3Hosp Univ Son 

Espases, Palma, Spain;; 4Hosp Univ de Donostia, San Sebastian, Spain;; 

5 6 Hosp Univ de la Princesa, Madrid, Spain;; Hosp Univ Doce de Octubre, 

Madrid, Spain;; 7Hosp Univ San Cecilio, Granada, Spain;; and 8Hosp Univ 

Germans Trias i Pujol, Badalona, Spain 

704 Most Incident Hepatitis C Virus Infections among HIV + 

Persons in a Contemporary Cohort Are Not Acquired 

Parenterally 

Lynn Taylor* 1 , T Bush 2 , P Patel 2 , K Henry 3 , L Conley 2 , J Hammer 4 , 

N Onen 5 , C Carpenter 1 , and J Brooks 2 

1 Brown Univ, Providence, RI, US;; 2 CDC, Atlanta, GA, US;; 3 Hennepin 

County Med Ctr, Minneapolis, MN, US;; 4 Denver Infectious Diseases 

Consultants, CO, US;; and 5 Washington Univ, St Louis, MO, US 

706 Acute Hepatitis C Virus Infection in Young Adults 

Carrie Jennings* and K Sherman 

Univ of Cincinnati Coll of Med, UC Hlth, OH, US 

707 Location on HIV Phylogeny Is Indicative of the Risk of 

Hepatitis C Virus Co-infection 

Roger Kouyos* 1,2 , A Rauch 3 , V Aubert 4 , S Yerly 5 , J Boni 1 , 

T Klimkait 6 , B Ledergerber 1,2 , H Gunthard 1,2 , and Swiss HIV Cohort Study 

1 Univ of Zurich, Switzerland;; 2 Univ Hosp Zurich, Switzerland;; 3 Univ of 

Bern, Switzerland;; 4 Ctr Hosp Univ Vaudois, Lausanne, Switzerland;; 5 Univ 

Hosp Geneva, Switzerland;; and 6 Univ of Basel, Switzerland 

699� �� 

�� 

Clearance of Acute Hepatitis C in HIV + Patients 

Pavlos Kokordelis* 1 , B Kramer1 , C Boesecke1 , C Korner1 , E Voigt2 , 

P Ingiliz3 , A Glassner1 , U Spengler1 , J Rockstroh1 , and J Nattermann1 1 2 Dept of Internal Med I, Bonn, Germany;; Praxis Theisen, Wiesel and Voigt, 

Cologne, Germany;; and 3Med Ctr for Infectious Diseases, Berlin, Germany 

700� �� 

�� 

Progression in HIV/Hepatitis C Virus Co-infected Patients 

Andreas Glassner*, P Kokordelis, M Eisenhardt, B Kramer, F Wolter, 

C Korner, C Boesecke, J Rockstroh, U Spengler, and J Nattermann 

Univ of Bonn, Germany 

701 HIV-associated Down-regulation of the Activating Natural 

�� 

and Natural Course of Hepatitis C Virus Infection 

Benjamin Kramer* 1 , P Kokordelis 1 , S Diegeler 1 , A Glassner 1 , M Eisenhardt 1 , 

P Ingiliz 2 , C Boesecke 1 , U Spengler 1 , J Rockstroh 1 , and J Nattermann 1 

1 2 Univ of Bonn, Germany and Med Ctr for Infectious Diseases, Berlin, 

Germany 

702� �� 

Activity of Natural Killer Cells and May Be Involved in 

Spontaneous Clearance of Acute Hepatitis C in HIV + Patients 

Marianne Eisenhardt* 1 , A Glaessner1 , P Kokordelis1 , B Kraemer1 , 

F Wolter1 , E Voigt2 , C Boesecke1 , U Spengler1 , J Rockstroh1 , 

and J Nattermann1 1 2 Univ of Bonn, Germany and Ctr Theisen, Wiesel, and Voigt, Cologne, 

Germany 

703� �� 

Protein-10 in Patients Given an All-Oral Anti-Hepatitis C 

Virus Regimen 

Jennifer Lin* 1 , F Habersetzer2 , M Rodriguez-Torres3 , M Paulson4 , 

Y Zhu4 , M Subramanian4 , J McHutchison4 , M Sulkowski5 , D Wyles1 , 

and R Schooley1 1 2 Univ of California, San Diego, La Jolla, US;; Univ Hosp Strasbourg, 

France;; 3Fndn de Investigacion de Diego, San Juan, Puerto Rico;; 4Gilead Sci, Inc, Foster City, CA, US;; and 5 710 Prevalence of Hepatitis C Virus Infection in US Hispanics/ 

Latinos: Results from the NHANES 

�� 

Mark Kuniholm* 

Johns Hopkins Univ Sch of Med, 




Hepatitis C Virus Epidemiology and Clinical Outcomes 

1 , M Jung1 , J Everhart2 , S Cotler3 , G Heiss4 , 

G McQuillan5 , B Thyagarajan6 , M Youngblood4 , R Kaplan1 , and G Ho1 1 2 Albert Einstein Coll of Med, Bronx, NY, US;; Natl Inst of Diabetes 

and Digestive and Kidney Diseases, NIH, Bethesda, MD, US;; 3Univ of Illinois, Chicago, US;; 4Univ of North Carolina at Chapel Hill, US;; 

5 6 CDC, Hyattsville, MD, US;; and Univ of Minnesota Med Ctr, Fairview, 

Minneapolis, US 

711 Diversity of Hepatitis C Virus Infection among HIV + �� 

Drugs Users in India: Implications for HIV and Hepatitis C 

Virus Treatment 

Sunil Solomon* 1,2,3 , S Shanmugam2 , A Srikrishnan2 , S Iqbal2 , 

C Vasudevan2 , M Kumar2 , D Persaud1 , S Solomon2 , S Ray1 , and S Mehta3 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; YRG CARE, 

Chennai, India;; and 3Johns Hopkins Univ Bloomberg Sch of Publ Hlth, 


712 Identifying Priorities for Improving Hepatitis C Virus Care 

in the Era of Directly Acting Antiviral Therapy 

Benjamin Linas* 1,2 , D Barter1 , J Leff3 , S Assoumou1 , A Kim4 , 

and B Schackman3 1 2 3 Boston Med Ctr, MA, US;; Boston Univ Sch of Publ Hlth, MA, US;; Weill 

Cornell Med Coll, New York, NY, US;; and 4Massachusetts Gen Hosp, 

Boston, US 

713 Using an HIV Primary Care Model for the Treatment of 

Hepatitis C 

Lucas Hill*, C Ballard, B Colwell, D Wyles, F Torriani, W Mathews, 

and E Cachay 


714� �� 

of Hepatitis C Virus Transmission: A Mathematical Model 

Viviane Lima* 1 , B Nosyk1 , M Krajden2 , M Hull1 , T Kerr1 , E Wood1 , 

E Yoshida3 , Z Wu4 , and J Montaner1 1 2 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada;; BC Ctr 

for Disease Control, Vancouver, Canada;; 3Univ of British Columbia, 

Vancouver, Canada;; and 4Natl Ctr for AIDS/STD Control and Prevention, 

Chinese Ctr for Disease Control and Prevention, Beijing 

715 The Effect of Hepatitis C Virologic Clearance on Cardiovascular 

Disease Biomarkers in HIV/Hepatitis C Virus Co-infection 

Kara Chew* 1 , L Hua2 , D Bhattacharya1 , A Butt3,4 , R Chung5 , 

J Andersen2 , and J Currier1 1 2 David Geffen Sch of Med, Univ of California, Los Angeles, US;; Harvard 

Sch of Publ Hlth, Boston, MA, US;; 3Univ of Pittsburgh Sch of Med, PA, 

US;; 4Sheikh Khalifa Med City, Abu Dhabi, United Arab Emirates;; and 

5Harvard Med Sch, Massachusetts Gen Hosp, Boston, US 

716� �� 

Hepatitis C Virus and HIV/Hepatitis C Virus 

Kara Chew* 

705 Acute Hepatitis C Virus Infection in Studies of Elvitegravir/ 

�� 

�� 

Erin Quirk*, H Graham, H Liu, and J Szwarcberg 

Gilead Sci Inc, Foster City, CA, US 

1 , D Bhattacharya1 , K McGinnis2 , J Currier1 , and A Butt3,4 1 2 David Geffen Sch of Med, Univ of California, Los Angeles, US;; VA 

Pittsburgh Hlthcare System, PA, US;; 3Univ of Pittsburgh Sch of Med, PA, 

US;; and 4Sheikh Khalifa Med City, Abu Dhabi, United Arab Emirates 

717 Methamphetamine Promotes Cardiac Dysfunction in 

Genetically Engineered Hepatitis C Virus Mice 

Rebecca Torres*, E Fields, C Koczor, R Russ, T Ludaway, 

K Jackson, Q Qin, and W Lewis 



Poster Listings



718 Hepatitis C Co-infection and the Risk of Chronic Kidney Disease 

in HIV + Individuals: Does Hepatitis C Viremia Matter? 

Gregory Lucas*, Y Jing, M Sulkowski, A Abraham, M Atta, D Fine, 

R Moore, M Estrella, and North American AIDS Cohort Collaboration 

on Res and Design of IeDEA 


719 Trends and Patterns of Healthcare Utilization among 

�� 

Co-infected Veterans: Understanding the Burden of Disease 

Shereen Katrak* 1,2 , L Park2 , C Woods1,2 , A Muir1 , C Hicks1 , and S Naggie1,2 728 Determinants of Hepatic Decompensation in ARV-treated 

HIV/Hepatitis C Virus Co-infected Patients 

Vincent Lo Re* 

1 2 Duke Univ, Durham, NC, US and Durham VAMC, NC, US 

1,2 , M Kallan1 , J Tate3,4 , R Localio1 , J Lim3,4 , M Goetz5 , 

A Butt6 , S Brown7 , J Kostman1 , A Justice3,4 , and Veterans Aging Cohort Study 

1 2 3 Univ of Pennsylvania, Philadelphia, US;; Philadelphia VAMC, PA, US;; VA 

Connecticut Hlthcare System, West Haven, US;; 4Yale Univ, New Haven, CT, 

US;; 5VA Greater Los Angeles Hlthcare System, CA, US;; 6Univ of Pittsburgh 

Sch of Med, PA, US;; and 7James J Peters VAMC, New York, NY, US 

729 When to Start ART in the Post-transplant Period in HIV + 

Patients 

Mrianna Menozzi*, S Cocchi, M Codeluppi, E Garlassi, S Zona, 

R Montalti, N De Ruvo, F Di Benedetto, GE Gerunda, and G Guaraldi 

Modena and Reggio Emilia Univ, Modena, Italy 

720 Impact of Hepatitis Serostatus on Hospitalization Rates and 

Reasons for Admission in a Multi-center Cohort of Persons 

Living with HIV in the USA 

Trevor Crowell*, K Gebo, A Balagopal, S Berry, and HIV Res Network 


721 Hepatitis C Virus Infection and Severe Sepsis Are Associated 

with a Higher Risk of Death among HIV + Patients Admitted 

at Intensive Care Units 

Jose Medrano* 1,2 , A Alvaro-Meca 3 , A Boyer 4 , D Gruson 4 , H Rue 5 , 

E Fernandez 6 , and S Resino 7 

1 Hosp Univ de Araba, Vitoria-Gasteiz, Spain;; 2 Facultad de Med-UDM 

Araba, Univ del Pais Vasco;; 3 Univ Rey Juan Carlos, Alcorcon, Spain;; 

4 Ctr Hosp Univ Pellegrin, Bordeaux, France;; 5 Norwegian Univ of Sci and 

Tech, Trondheim;; 6 Hosp Infanta Sofia, San Sebastian de los Reyes, Spain;; 

and 7 Inst de Salud Carlos III, Majadahonda, Spain 

722 Chronic Hepatitis C Infection Is Independently Associated 

with Mortality in a Cohort of HIV + Patients with Alcohol 

�� 

Daniel Fuster* 1 , D Cheng 1,2 , E Quinn 3 , D Nunes 1 , R Saitz 1 , J Samet 1 , 

and J Tsui 1 

1 Boston Med Ctr and Boston Univ Sch of Med, MA, US;; 2 Boston Univ Sch 

of Publ Hlth, MA, US;; and 3 Data Coordinating Ctr, Boston Univ Sch of 

Publ Hlth, MA, US 

723 Predictors of Mortality among US Veterans with HIV and 

Hepatitis C Virus Co-infection 

Sebhat Erqou* 1 , A Mohanty 1 , and A Butt 2 

1 Univ of Pittsburgh Med Ctr, PA, US and 2 Univ of Pittsburgh Sch of Med, 

PA, US 

724 Incidence of Hepatocellular Carcinoma in HIV + Patients and 

Risk in HIV/Hepatitis C Virus Co-infected Patients after 

Sustained Virological Response: Spain 

Nicolas Merchante* 1 , E Merino 2 , C Tural 3 , J Lopez-Aldeguer 4 , F Jover 5 , 

A Rivero-Juarez 6 , M Delgado-Fernandez 7 , MJ Galindo 8 , A Romero- 

Palacios 9 , and J Pineda 1 

1 Hosp Univ de Valme, Sevilla, Spain;; 2 Hosp General Univ de Alicante, 

Spain;; 3 Hosp Germans Trias i Pujol, Badalona, Spain;; 4 Hosp Univ 

y Politecnico La Fe, Valencia, Spain;; 5 Hosp Clin Univ de San Juan, 

Alicante, Spain;; 6 Hosp Univ Reina Sofia, Cordoba, Spain;; 7 Hosp Regional 

Carlos Haya, Malaga, Spain;; 8 Hosp Clin de Valencia, Spain;; and 9 Hosp 

Univ de Puerto Real, Cadiz, Spain 





Emergence and Persistence of HPV-associated 


730� �� 

the Effects of Age and Period 

F Schoni-Affolter 1 , L Elzi 2 , R Weber 3 , A Calmy 4 , A Bregenzer 5 , 

M Cavassini 6 , H Furrer 7 , G Clifford 8 , M Egger 1 , Olivia Keiser* 1 , 


1 Univ of Bern, Switzerland;; 2 Univ Hosp Basel, Switzerland;; 3 Univ Hosp 

Zurich, Switzerland;; 4 Geneva Univ Hosp, Switzerland;; 5 Cantonal Hosp 

St Gallen, Switzerland;; 6 Univ Hosp Lausanne, Switzerland;; 7 Univ Hosp 

Bern, Switzerland;; and 8 Intl Agency for Res on Cancer 

731 Incidence of AIDS-defining and Non-AIDS-defining Cancers 

�� 

Scott Dryden-Peterson* 1,2,3 , H Medhin 4 , G Seage 2 , M Pusoentsi 4 , 

S El-Halabi 4 , T Rebbeck 5 , G Suneja 5 , M Mmalane 3 , M Essex 2,3 , 

and S Lockman 1,2,3 

1 Brigham and Women�s Hosp, Boston, MA, US;; 2 Harvard Sch of Publ 

Hlth, Boston, MA, US;; 3 Botswana Harvard AIDS Inst Partnership, 

Gaborone;; 4 Botswana Ministry of Hlth, Gaborone;; and 5 Univ of 

Pennsylvania, Philadelphia, US 

732� �� 

after Initiation of ART among HIV + Women: Uganda 

Anne Rositch* 1 , P Gravitt 1,2 , A Tobian 1,3 , K Newell 4 , T Quinn 3,5 , 

D Serwadda 6 , P Ssebbowa 6 , V Kiggundu 6 , R Gray 1,6 , and S Reynolds 3,5 


2 Perdana Univ Grad Sch of Med, Serdang, Malaysia;; 3 Johns Hopkins 

Univ Sch of Med, Baltimore, MD, US;; 4 Frederick Natl Lab for Cancer 

Res, MD, US;; 5 NIAID, NIH, Bethesda, MD, US;; and 6 Rakai Hlth Sci 

Prgm, Entebbe, Uganda 

725� �� 

Hypertension in HIV + Patients 

O Marin1 , P Miralles2 , M Montes2 , C Quereda3 , M Tellez4 , J Sanz5 , 

C Barros6 , A Carrero1 , and Juan Berenguer* 1 

1 2 Hosp Gen Univ Gregorio Maranon, Madrid, Spain;; Hosp Univ La Paz, 

Madrid, Spain;; 3Hosp Ramon y Cajal, Madrid, Spain;; 4Hosp Clin de San 

Carlos, Madrid, Spain;; 5Hosp Principe de Asturias, Alcala de Henares, 

Spain;; and 6Hosp Univ de Mostoles, Spain 



Hepatic Failure and Transplantation 

726 Liver Retransplantation in HIV + Patients: A Multicenter and 

Multinational Cohort Study 

J Miro1 , Fernando Aguero* 1 , P Stock2 , P Grossi3 , J Rockstroh4 , 

K Agarwal5 , C Garzoni6 , LA Barcan7 , F Maltez8 , A Rimola1 , 

and FIPSE/NIH HIVTR/NEAT023 Investigators 

1 2 Hosp Clin-IDIBAPS, Univ of Barcelona, Spain;; Univ of California, San 

Francisco, US;; 3Univ of Insubria, Circolo Hosp and Macchi Fndn, Varese, 

Italy;; 4Univ of Bonn, Germany;; 5Kings Coll Hosp Fndn Trust/Kings Hlth 

Partners, London, UK;; 6Clin Luganese, Switzerland;; 7Hosp Italiano, 

Buenos Aires, Argentina;; and 8 727 

Hosp Curry Cabral, Lisbon, Portugal 

Risk of Decompensation of Cirrhosis among HIV/Hepatitis 

�� 

Implications for the Timing of Therapy against Hepatitis C 

Virus 

Juan Macias* 1 , A Camacho2 , M von Wichmann3 , L Lopez-Cortes4 , 

E Ortega5 , C Tural6 , MJ Rios7 , D Merino8 , F Tellez9 , and J Pineda1 1 2 Hosp Univ de Valme, Seville, Spain;; Hosp Univ Reina Sofia, Cordoba, 

Spain;; 3Hosp Donostia, San Sebastian, Spain;; 4Hosp Univ Virgen del 

Rocio, Seville, Spain;; 5Hosp Gen Univ de Valencia, Spain;; 6Hosp Univ 

Germans Trias i Pujol, Barcelona, Spain;; 7Hosp Univ Virgen Macarena, 

Seville, Spain;; 8Complejo Hosp de Huelva, Spain;; and 9 733 HPV Genotype Impacts T Cell Activation and Cervical 

Cellular Infiltrates Irrespective of Lesion Grade in ARTsuppressed 

Human Papillomavirus/HIV-1 Co-infected 

Women 

Emmanouil Papasavvas* 

Hosp de La Linea 

de la Concepcion, Cadiz, Spain 

1 , D Glencross2,3 , N Mayisela4 , T Omar2 , 

A-L Williamson5,6 , M Siminya4 , X Yin1 , Q Liu1 , C Firnhaber2,4 , 

and L Montaner1 1 2 The Wistar Inst, Philadelphia, PA, US;; Univ of the Witwatersrand, 

Johannesburg, South Africa;; 3Natl Hlth Lab Svc, Johannesburg, South 

Africa;; 4Right to Care, Johannesburg, South Africa;; 5Univ of Cape Town, 

South Africa;; and 6Natl Hlth Lab Svc, Cape Town, South Africa 

734� �� 

�� 

Senegal 

S Hawes1 , Q Feng1 , S Ba2 , M Toure1,2 , M-P Sy2 , F Traore2 , R Smith1 , 

N Kiviat1 , PS Sow1,2 , Geoffrey Gottlieb* 1 , and UW-Dakar HIV-2 Study 

Group 

1 2 Univ of Washington, Seattle, US and Ctr Hosp Univ de Fann, Univ 

Cheikh Anta Diop de Dakar, Senegal 

735 Anal Human Papillomavirus Infection in HIV + Patients: 

�� 

Papillomavirus Infection 

Alberto Borghetti* 1 , P Cattani2 , G Maria3 , M Sanguinetti2 , 

S D’Onghia2 , R Santangelo2 , S Marchetti2 , R Cauda1 , A De Luca1,4 , 

and S Di Giambenedetto1 1Inst of Clin Infectious Diseases, Catholic Univ of Sacred Heart, Rome, 

Italy;; 2Inst of Microbiology, Catholic Univ of Sacred Heart, Rome, Italy;; 

3Inst of Clin and Surgical Therapy, Catholic Univ of Sacred Heart, Rome, 

Italy;; and 4Siena Univ Hosp, Italy 

736� �� 

associated Squamous Cell Carcinoma of the Anus 

Pamela Mbang* 1 , M Kowalkowski2 , and E Chiao1,2 1 2 Baylor Coll of Med, Houston, TX, US and Houston Hlth Svcs Res and 

Devt Ctr of Excellence, Michael E DeBakey VAMC, TX, US 

737 Prevalence and Genotypes of Human Papillomavirus at 

Penile and Perianal Sites among HIV + and HIV��MSM Han-Zhu Qian* 1 , Y Hu2 , L Yin1 , Y Ruan2 , Y Shao2 , and S Vermund1 1 2 Vanderbilt Univ, Nashville, TN, US and Natl Ctr for STD/AIDS Control 

and Prevention of China CDC, Beijing




HIV-associated Malignancies: Miscellaneous 

738 Incidence of Kaposi Sarcoma in South Africa in the ART 

Era: Prospective Multi-cohort Study 

J Bohlius 1 , F Valeri 1 , M Maskew 2 , H Prozesky 3 , C Chimbetete 4 , 

P Lumano-Mulenga 5 , D Garone 6 , Matthias Egger* 1 , 

and Intl Epidemiologic Databases to Evaluate AIDS Southern Africa 

1 Univ of Bern, Switzerland;; 2 Univ of the Witwatersrand, Johannesburg, 

South Africa;; 3 Univ of Stellenbosch, Cape Town, South Africa;; 4 Newlands 

Clin, Harare, Zimbabwe;; 5 Ctr for Infectious Diseases and Res in Zambia, 

Lusaka;; and 6 Medecins Sans Frontieres, South Africa 

739� �� 

�� 

�� 

Salvinia Mletzko* 1 , A Rai 1 , S Westrop 1 , N Imami 1 , Y Shahrabi 1 , 

J Williams 2 , M Jones 2 , F Gotch 1 , and M Bower 1 

1 Imperial Coll, Chelsea and Westminster Hosp, London, UK and 2 MRC 

Clinical Sci Ctr, Imperial Coll, Hammersmith Hosp, London, UK 

740 Prognosis in HIV + Patients with Non-small Cell Lung Cancer 

Keith Sigel* 1 , K Crothers 2 , K Krauskopf 1 , R Dubrow 3 , J Jao 1 , C Sigel 4 , 

and J Wisnivesky 1 

1 Mt Sinai Sch of Med, New York, NY, US;; 2 Univ of Washington Sch of 

Med, Seattle, US;; 3 Yale Univ Sch of Med and Publ Hlth, New Haven, CT, 

US;; and 4 Memorial Sloan-Kettering Hosp, New York, NY, US 

741 Lung Cancer Screening Indicators in HIV + Patients 

K Chen 1 , S Olender 2 , and Noga Shalev* 2 

1 Ben Gurion Univ, Israel and 2 Columbia Univ Med Ctr, New York, NY, US 

742c Serum-free Testosterone Predicts Human Papillomavirus 

�� 

Dorothy Wiley* 1 , T Brown 2 , X Li 3 , S Young 4 , R Cranston 5 , G D’Souza 3 , 

L Jacobson 3 , O Martinez-Maza 6 , E Seaberg 3 , R Detels 7 , and MultiCtr AIDS 

Cohort Study 

1 Univ of California, Los Angeles, Sch of Nursing, US;; 2 Johns Hopkins 

Univ, Sch of Med, Baltimore, MD, US;; 3 Johns Hopkins Univ Bloomberg 

Sch of Publ Hlth, Baltimore, MD, US;; 4 Tricore Reference Labs, Univ of 

New Mexico, Albuquerque, US;; 5 Univ of Pittsburgh, PA, US;; 6 Univ of 

California, Los Angeles AIDS Inst and David Geffen Sch of Med, US;; 

and 7 Univ of California, Los Angeles Jonathan and Karen Fielding Sch 

of Publ Hlth, US 



HIV-associated Malignancies: Lymphoma 

743 A Novel Prognostic Model for HIV + Diffuse Large B Cell 

Lymphoma 

Chun Chao* 1 , M Silverberg 2 , O Martinez-Maza 3,4 , D Abrams 5 , R Haque 1 , 

H Zha 6 , L-H Chen 1 , L Xu 1 , M Chi 1 , and J Said 3 

1 Kaiser Permanente Southern California, Pasadena, US;; 2 Kaiser 

Permanente Northern California, Oakland, US;; 3 David Geffen Sch of 

Med, Univ of California, Los Angeles, US;; 4 Sch of Publ Hlth, Univ 

of California, Los Angeles, US;; 5 San Francisco Gen Hosp and Univ 

of California, San Francisco, US;; and 6 Los Angeles Med Ctr, Kaiser 

Permanente Southern California, US 

745 Hodgkin Lymphoma Is Almost as Prevalent as Non-Hodgkin 

Lymphoma in HIV + Patients with Sustained Viral Suppression 

and Limited Immune Deficiency 

Christian Hoffmann* 1 , D Gillor 2 , G Behrens 3 , A Stoehr 4 , J van Lunzen 5 , 

M Hentrich 6 , M Hensel 7 , J Thoden 8 , C Wyen 2 , and G Fatkenheuer 2 

1 ICH, Hamburg, Germany;; 2 Univ Hosp of Cologne, Germany;; 3 Med Sch 

of Hannover, Germany;; 4 ifi Hamburg, Germany;; 5 Univ Hosp Eppendorf, 

Hamburg, Germany;; 6 Hosp Harlaching, Munich, Germany;; 7 Mannheim 

Oncology Ctr MOP, Germany;; and 8 Univ Hosp Freiburg, Germany 

746� �� 

Large B Cell Lymphoma and Kaposi Sarcoma 

Sara Browne*, J Diaz-Perez, H-Y Wang, H Li, E Reid, and S VandenBerg 





Cardiovascular Disease: Predicting Risk and 

Monitoring Outcomes 



747� �� 

Cardiovascular Disease in HIV + Individuals in the US: 

Competing Risks and Premature Aging 

Elena Losina* 1,2,3,4 , B Linas 4,5 , E Hyle 1,3 , C Rusu 4 , F Noubary 4 , 

B Berkowitz 4 , P Sax 1,2 , M Weinstein 6 , R Walensky 1,2,3,4 , and K Freedberg 1,3,4,5 

1 Ctr for AIDS Res, Harvard Med Sch, Boston, MA, US;; 2 Brigham and 

Women�s Hosp, Boston, MA, US;; 3 Massachusetts Gen Hosp, Boston, US;; 

4 Boston Med Ctr, MA, US;; 5 Boston Univ Sch of Publ Hlth, MA, US;; and 

6 Harvard Sch of Publ Hlth, Boston, MA, US 

742a Prior HIV Testing in Newly Diagnosed Black Cancer Patients: 

�� 

Mazvita Sengayi* 1 , C Babb2 , and M Urban2 1NHLS Natl Cancer Registry and Res and Intl Epidemiological Databases 

to Evaluate AIDS, Johannesburg, South Africa and 2NHLS/MRC Cancer 

Epidemiology Res Group, Johannesburg, South Africa 

742b�� 

cART: The D:A:D Study 

Mathias Bruyand* 1 , L Ryom 2 , L Shepherd 3 , P Reiss 4 , S de Wit 5 , 

A d’Arminio Monforte 6 , M Rickenbach 7 , A Phillips 3 , J Lundgren 8 , 

C Sabin 3 , and D:A:D Study Group 

1INSERM, ISPED, Ctr INSERM U897-Epidemiologie-Biostatistique, 

CHU de Bordeaux, COREVIH Aquitaine, France;; 2Copenhagen HIV 

Prgm, Univ of Copenhagen, Faculty of Hlth Sci, Denmark;; 3Res Dept 

of Infection and Population Hlth, UCL, London, UK;; 4Academic Med 

Ctr, Univ of Amsterdam, The Netherlands;; 5CHU Saint-Pierre, Dept 

of Infectious Diseases, Brussels, Belgium;; 6Dipartimento di Med, 

Chirurgia e Odontoiatria, Clin di Malattie Infettive e Tropicali, Azienda 

Ospedaliera-Polo Univ San Paolo, Milan, Italy;; 7Inst for Social and 

Preventive Med, Univ of Lausanne, Switzerland;; and 8 748 Improvements in Short-term Mortality following Myocardial 

Infarction: The Data Collection on Adverse events of Anti- 

HIV Drugs Study 

Caroline Sabin* 

Copenhagen HIV 

Prgm, Univ of Copenhagen, Faculty of Hlth Sci and Epidemiklinikken 

M5132, Copenhagen Univ Hosp/Rigshospitalet, Denmark 

1 , L Ryom2 , M Law3 , W El-Sadr4 , O Kirk2,5 , M Bruyand6 , 

P Reiss7 , C Pradier8 , B Ledergerber9 , J Lundgren2,5 , and D:A:D Study 

1 2 3 Univ Coll London, UK;; Copenhagen HIV Prgm, Denmark;; The Kirby 

Inst, Univ of New South Wales, Sydney, Australia;; 4Intl Ctr for AIDS 

Care and Treatment Prgms, Columbia Univ and Harlem Hosp, New 

York, NY, US;; 5Copenhagen Univ Hosp/Rigshospitalet, Denmark;; 6Univ of Bordeaux, ISPED, Ctr INSERM U897-Epidemiologie-Biostatistique, 

France;; 7Academic Med Ctr, Univ of Amsterdam, The Netherlands;; 8Ctr Hosp Univ, Nice, France;; and 9Univ Hosp Zurich, Switzerland 

749� �� 

Dysfunction and Mortality in HIV + Individuals 

Eric Secemsky* 1 , R Scherzer2 , E Nitta2 , A Wu2 , D Lange2 , S Deeks2 , 

J Martin2 , J Snider3 , P Ganz2 , and P Hsue2 1 2 Massachusetts Gen Hosp, Boston, US;; Univ of California, San 

Francisco, US;; and 3Critical Diagnostics, San Diego, CA, US 

750� �� 

�� 

Matthew Freiberg* 1 , C-C Chang1 , KA Oursler2,3 , J Gottdiener4 , S Gottlieb4 , 

A Warner5 , D Leaf5 , M Rodriguez-Barradas6,7 , S Felter8 , A Butt1,9 , 

and VACS Project Team 

1 2 Univ of Pittsburgh Sch of Med, PA, US;; Baltimore VAMC, MD, US;; 

3 4 Univ of Maryland Sch of Med, Baltimore, US;; Univ of Maryland Med 

Ctr, Baltimore, US;; 5VA Greater Los Angeles Hlthcare System, CA, US;; 

6 7 Baylor Coll of Med, Houston, TX, US;; Michael E DeBakey VAMC, 

Houston, TX, US;; 8VA Pittsburgh Hlthcare System, PA, US;; and 9Sheikh Khalifa Med City, Abu Dhabi, United Arab Emirates 

751 Emergency Medical Service Utilization and Reperfusion 

Times among HIV + Individuals Presenting with ST-elevation 

Myocardial Infarction 

Mark Dela Cruz* 1 , K Thomas 1 , D Brenner 1 , A Kulkarni 2 , J McCabe 3 , 

P Hsue 1 , P Ganz 1 , and S Waldo 1 

1 Univ of California, San Francisco, US;; 2 Massachusetts Gen Hosp, 

Boston, US;; and 3 Brigham and Women�s Hosp, Boston, MA, US 



Endothelial Dysfunction in HIV Infection 

744� �� 

HIV + 752 Early Changes in Adhesion Molecules Expression and 

�� 

Atazanavir or Lopinavir 

Alessandra Bandera* 

Patients with Hodgkin Lymphoma Receiving Adriamyc 

�� 

Karim Ibrahim* and S Milliken 

St Vincents Hosp, Sydney, Australia 

1 , D Trabattoni2 , N Squillace1 , A Muscatello1 , 

F Calascibetta2 , A Maloberti3 , C Giannattasio3 , V Marcandalli1 , M Clerici2 , 

and A Gori1 1 2 3 S Gerardo Hosp, Monza, Italy;; Univ of Milan, Italy;; and Milan-Bicocca 

Univ, Milan, Italy 

753� �� 

Endothelial Dysfunction in HIV + Individuals 

R Parikh1 , R Scherzer1 , C Grunfeld1 , E Nitta1 , A Leone2 , J Martin1 , S Deeks1 , 

P Ganz1 , and Priscilla Hsue* 1 

1 2 Univ of California, San Francisco, US and Oxonon BioAnalysis, 

Emeryville, CA, US



754 Endothelial Dysfunction in HIV Infection Results from 

�� 

Inflammation Biomarkers 

Mariola Lopez* 1 , M Masia2 , J San Roman3 , S Padilla2 , E Vispo1 , 

V Estrada4 , P Parra1 , JM Benito1 , F Gutierrez2 , and V Soriano1 1 2 3 Hosp Carlos III, Madrid, Spain;; Gen Univ Hosp, Elche, Spain;; Rey 

Juan Carlos Univ, Madrid, Spain;; and 4Clin San Carlos Hosp, Madrid, 

Spain 

755 Pentoxifylline neither Reduces Systemic Inflammation 

+ �� 

Persons Not 

Receiving ART 

Samir Gupta* 1 , D Mi1 , M Dube2 , C Saha1 , R Johnson1 , J Stein3 , 

M Clauss1 , K Mather1 , Z Desta1 , and Z Liu1 1 2 Indiana Univ Sch of Med, Indianapolis, US;; Univ of Southern California 

Keck Sch of Med, Los Angeles, US;; and 3Univ of Wisconsin Sch of Med 

and Publ Hlth, Madison, US 

756 HIV Elite Controllers Have Lower Asymmetric 

�� 

Compared to Individuals with Treated and Suppressed HIV 

R Parikh1 , R Scherzer1 , C Grunfeld1 , E Nitta1 , A Leone2 , J Martin1 , S Deeks1 , 

P Ganz1 , and Priscilla Hsue* 1 




Statin Use and HIV: How Sweet Is It? 

764 Statin Therapy and Mortality in HIV 

1 2 Univ of California, San Francisco, US and Oxonon BioAnalysis, 

Emeryville, CA, US 

+ Individuals: A Danish 

�� 

Line Rasmussen* 1 , G Kronborg2 , C Larsen3 , C Pedersen1 , J Gerstoft4 , 

and N Obel4 1 2 Odense Univ Hosp, Denmark;; Copenhagen Univ Hosp, Hvidovre, 

Denmark;; 3Aarhus Univ Hosp, Skejby, Denmark;; and 4Copenhagen Univ 

Hosp, Rigshospitalet, Denmark 

765 Impact of Statin Exposure on Mortality and Non-AIDS 

Complications in HIV Patients on HAART 

Henning Drechsler* 1,2 , S Zhang2 , N Maalouf2 , J Cutrell2 , P Tebas3 , 

and R Bedimo1,2 1 2 VA North Texas Hlth Care System, Dallas, US;; Univ of Texas Southwestern 

Med Ctr, Dallas, US;; and 3Univ of Pennsylvania, Philadelphia, US 

766� �� 

Occurrence among HIV-1 + Patients Receiving ART 

Vincenzo Spagnuolo* 1 , L Galli1 , A Poli1 , S Salpietro1 , N Gianotti1 , 

P Piatti1 , C Vinci1 , E Carini1 , A Lazzarin1,2 , and A Castagna1 1 2 San Raffaele Sci Inst, Milan, Italy and Univ Vita-Salute San Raffaele, 

Milan, Italy 



Vascular Imaging and Subclinical Atherosclerosis 

757 HIV and Coronary Artery Calcium Score: Comparison of 

Hawaii Aging with HIV Cardiovascular Study and the Multi- 

Ethnic Study of Atherosclerosis 

Dominic Chow* 1 , J Barbour 1 , L Ndhlovu 1 , P Norris 2,3 , R Young 4 , 

R Kronmal 4 , M Budoff 5 , N Valcour 1 , C-Y Liang 1 , C Shikuma 1 , 

and Multi-ethnic Study of Atherosclerosis AC 388 

1 Univ of Hawaii at Manoa, Honolulu, US;; 2 Blood Systems Res Inst, San 

Francisco, CA, US;; 3 Univ of California, San Francisco, US;; 4 Univ of 

Washington, Seattle, US;; and 5 Los Angeles Biomed Res Inst, CA, US 

758 Elite Controllers and Coronary Plaque in the Multicenter 


Wendy Post* 1,2 , L Jacobson 2 , C Coley 2 , S Grinspoon 3 , F Palella 4 , 

L Kingsley 5 , M Witt 6 , T Brown 1 , M Budoff 6 , and J Margolick 2 

1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Johns Hopkins 

Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 3 Massachusetts 

Gen Hosp, Boston, US;; 4 Northwestern Univ, Chicago, IL, US;; 5 Univ of 

Pittsburgh, PA, US;; and 6 Harbor UCLA, US 

759� �� 

Associated with Lower Carotid Artery Intima-media 

Thickness in HIV + Adults 

Jason Barbour* 1 , E Jalbert1 , D Chow1 , H Hodis2 , L Nagamine1 , T Seto1,3 , 

N Parikh1,3 , C-Y Liang1 , L Ndhlovu1 , and C Shikuma1 1 2 Univ of Hawaii Manoa, US;; Univ of Southern California, Los Angeles, 

US;; and 3Queen�s Med Ctr, Honolulu, HI, US 

760� �� 

Atherosclerosis: Multicenter AIDS Cohort Study 

Kerunne Ketlogetswe* 1 , W Post1,2 , X Li2 , L Jacobson2 , F Palella3 , 

J Margolick2 , L Kingsley4 , M Witt5 , M Budoff5 , T Brown1,2 , 

and Multictr AIDS Cohort Study 

1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; Johns Hopkins 

Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 3Northwestern Univ Feinberg Sch of Med, Chicago, IL, US;; 4Univ of Pittsburgh, PA, US;; 

and 5Harbor UCLA Med Ctr, Torrance, CA, US 

761� �� 

Thickness Progression in HIV + Adults Naïve to ART 

Corrilynn Hileman* 1,2 , C Longenecker2,3 , T Carman2,3 , D Labbato3 , 

N Storer3 , V Tangpricha4 , and G McComsey2,3 1 2 MetroHlth Med Ctr, Cleveland, OH, US;; Case Western Reserve Sch of 

Med, Cleveland, OH, US;; 3Univ Hosp Case Med Ctr, Cleveland, OH, US;; 

and 4Emory Univ Sch of Med, Atlanta, GA, US 

762� �� 

Vascular Disease in HIV + Patients on ART 

Chris Longenecker* 1,2 , W Dunn2 , Y Jiang2 , S Debanne 2 , and G McComsey 1,2 

1 2 Univ Hosp Case Med Ctr, Cleveland, OH, US and Case Western 

Reserve Univ, Cleveland, OH, US 

763� �� 

Pressure in HIV Infection: Results of a Nationwide Crosssectional 

Study 

Giuseppe Vittorio De Socio* 1 , P Maggi2 , G Madeddu3 , G Parruti4 , 

G Penco5 , G Orofino6 , B Menzaghi7 , M Franzetti8 , P Bonfanti9 , G Schillaci10 , 

and CISAI Study Group 

1 2 Santa Maria della Misericordia Hosp, Perugia, Italy;; Univ of Bari, 

Italy;; 3Univ of Sassari, Italy;; 4Pescara Hosp, Italy;; 5Galliera Hosp, 

Genoa, Italy;; 6Amedeo di Savoia Hosp, Turin, Italy;; 7Busto Arsizio Hosp, 

Italy;; 8Univ of Milan, Italy;; 9Manzoni Hosp, Lecco, Italy;; and 10 769 Dyslipidemia in HIV 

Univ of 

Perugia, Italy 

+ �� 

�� 

�� 

AM Grandi1 , E Nicolini2 , L Rizzi2 , S Caputo2 , F Annoni1 , AM Cremona1 , 

C Marchesi2 , AM Maresca1 , and Paolo Grossi* 1 

1 2 Univ of Insubria, Varese, Italy and Ospedale di Circolo, Varese, Italy 

770 Modulation of Liver X Receptor and Genes Involved in 

�� 

Federica Gnudi* 1,2 , M De Luca1,2 , M Biasin1,2 , G Rizzardini1 , M Clerici2 , 

D Trabattoni1,2 , and S Piconi1 1 2 Hosp L Sacco Milan, Italy and Univ of Milan, Italy 

771 10% of HIV + Men Who Are Not Taking Statins Should Be 

Anne Monroe* 1 , M Zikusoka1 , W Fu2 , L Jacobson2 , M Witt3 , F Palella4 , 

L Kingsley5 , W Post1 , and T Brown1 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; Johns Hopkins 

Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 3Los Angeles 

Biomed Res Inst at Harbor UCLA Med Ctr, Torrance, CA, US;; 

4 5 Northwestern Univ, Feinberg Sch of Med, Chicago, IL, US;; and Univ of 

Pittsburgh Grad Sch of Pub Hlth, PA, US 

772� �� 

in Patients Starting Atazanavir/Ritonavir- or Darunavir/ 

Ritonavir-containing Therapy 

Esteban Martinez* 1 , D Podzamczer2 , P Domingo3 , E Negredo4 , 

F Gutierrez5 , J Portilla6 , E Ribera7 , J Murillas8 , J Arribas9 , J Gatell1 , 

and ATADAR Study Group 

1 2 Hosp Clin-IDIBAPS and Univ of Barcelona, Spain;; Hosp Univ de 

Bellvitge and Univ of Barcelona, LHosp de Llobregat, Spain;; 3Hosp de 

Sant Pau and Univ Autonoma de Barcelona, Spain;; 4Hosp Germans Trias 

i Pujol and Luita contra la SIDA Fndn, Badalona, Barcelona, Spain;; 

5Hosp Univ de Elche and Univ Miguel Hernandez, Alicante, Spain;; 

6 7 Hosp Gen Univ de Alicante, Spain;; Hosp Univ Vall dHebron and Univ 

Autonoma de Barcelona, Spain;; 8Hosp Univ Son Espases, Palma de 

Mallorca, Spain;; and 9Hosp Univ La Paz, Madrid, Spain 


767� �� 

Patients in the HIV Outpatient Study 

Kenneth Lichtenstein* 1 , R Debes 2 , K Wood 2 , S Bozzette 2,3 , K Buchacz 4 , 

J Brooks 4 , and HIV Outpatient Study Investigators 

1 Natl Jewish Hlth, Denver, CO, US;; 2 Cerner Corp, Kansas City, MO, US;; 

3 Univ of California, San Diego, US;; and 4 CDC, Atlanta, GA, US 



Dyslipidemia: Risks, Pathogenesis, and Treatment 

768� �� 

in Lipid Parameters among HIV + Patients Receiving ART 

Enju Liu* 1 , D Spiegelman 1 , G Chalamilla 2 , M Njelekela 3 , C Hawkins 4 , 

E Aris 2 , L Hirschhorn 5 , N Li 1 , C Armstrong 6 , and W Fawzi 1 

1 Harvard Sch of Publ Hlth, Boston, MA, US;; 2 Mgmt and Devt for Hlth, 

Dar es Salaam, Tanzania;; 3 Muhimbili Univ of Hlth and Allied Sci, Dar es 

Salaam, Tanzania;; 4 Northwestern Univ, Feinberg Sch of Med, Chicago, 

IL, US;; 5 Harvard Med Sch, Boston, MA, US;; and 6 Beth Israel Deaconess 

Med Ctr, Boston, MA, US




Risk Prediction, Risk Factors, Biomarkers, and 

Outcomes 

773 The Veterans Aging Cohort Study Index Predicts Mortality 

+ �� 

Population Starting HAART 

I Bebu1 , J Tate2 , O Mesner1 , G Macalino1 , D Rimland1 , A Ganesan1 , 

A Weintrob1 , A Justice2 , and Brian Agan* 1 

1Infectious Disease Clin Res Prgm, Uniformed Svcs Univ of the Hlth Sci, 

Bethesda, MD, US and 2Yale Univ and the VA Hlthcare System, West 

Haven, CT, US 

777� �� 

of HIV + Adults Receiving Medical Care in the US: Medical 

�� 

Angela Thompson-Paul*, S Wei, C Mattson, and J Skarbinski 


778 High Prevalence and Severity of Pulmonary Emphysema Is 

�� 

Giovanni Guaraldi* 1 , G Besutti 1 , R Scaglioni 1 , A Santoro 1 , S Zona 1 , 

E Garlassi 1 , G Ligabue 1 , D Sin 2,3 , J Leipsic 2,3 , and P Man 2,3 

1 Modena and Reggio Emilia Univ, Modena, Italy;; 2 British Columbia 

Univ, James Hogg Res Ctr, Vancouver, Canada;; and 3 St Pauls Hosp, 


782 Effect of HIV Seroconversion and ART Initiation on Multiple 

�� 

Kaku Armah* 1 , J Lim 2 , V Lo Re 3 , J Baker 4 , R Tracy 5 , A Butt 2,6 , 

B Agan 7,8 , D Rimland 9,10 , A Justice 11,12 , M Freiberg 2 , and VACS Project Team 

1 Univ of Pittsburgh Grad Sch of Publ Hlth, PA, US;; 2 Univ of Pittsburgh 

Sch of Med, PA, US;; 3 Univ of Pennsylvania Sch of Med, Philadelphia, 

US;; 4 Univ of Minnesota Med Sch, Minneapolis, US;; 5 Univ of Vermont, 

Burlington, US;; 6 Sheikh Khalifa Med City, Abu Dhabi, United Arab 

Emirates;; 7 Infectious Disease Clin Res Prgm, Bethesda, MD, US;; 

8 Uniformed Svs Univ of the Hlth Sci, Bethesda, MD, US;; 9 Emory Univ 

Sch of Med, Atlanta, GA, US;; 10 VAMC, Atlanta, GA, US;; 11 VA Connecticut 

Hlth Care System and Med Ctr, West Haven, CT, US;; and 12 Yale Univ Sch 

of Med, New Haven, CT, US 



Microbial Translocation Measurement and 

Associations 

783� �� 

May Underestimate Lipopolysaccharide Levels in Those with 

�� 

Helen Byakwaga* 1,2 , P Hsue 2 , E Sambrano 2 , E Sinclair 2 , Y Huang 2 , 

R Tracy 3 , T Burdo 4 , J Martin 2 , C Grunfeld 2 , and P Hunt 2 

1 Mbarara Univ of Sci and Tech, Uganda;; 2 Univ of California, San Francisco, 

US;; 3 Univ of Vermont, Burlington, US;; and 4 Boston Coll, MA, US 

774� �� 

HIV + Patients and HIV �� Stefan Esser* 1 , T Neumann1 , B Bokhof2 , L Eisele2 , B Schwarz1 , 

V Holzendorf3 , R Erbel1 , K-H Joeckel2 , D Schadendorf1 , N Reinsch1 , 

and HIV-HEART Study Group and Heinz Nixdorf Recall Study Group 

1 2 Univ Hosp Essen, Germany;; Inst for Med Informatics, Biometry and 

Epidemiology, Univ Hosp Essen, Germany;; and 3Univ of Leipzig, Clin 

Trial Ctr, Germany 

775 Cigarette Smoking among HIV + Adults in Care: Medical 

�� 

Rennatus Mdodo*, E Frazier, C Mattson, M Sutton, J Brooks, 

and J Skarbinski 


776� �� 

Large HIV + Cohort: Mildmay Uganda Cohort 

Farrah Mateen* 1 , S Kanters2 , A Funk3 , E Kyegonza3 , and E Mills4 1 2 Johns Hopkins Univ, Baltimore, MD, US;; Univ of British Columbia, 

Vancouver, Canada;; 3Mildmay Uganda, Kampala;; and 4 784� �� 

Translocation and Inflammation in Chronic HIV Infection 

Gretchen Volpe* 

Univ of Ottawa, 

Canada 

1,2 , C Duffalo1 , D Dinh1 , S Bhalchandra1 , M Mwamburi2 , 

A Kane1,2 , H Ward1,2 , and C Wanke1,2 1 2 Tufts Med Ctr, Boston, MA, US and Tufts Univ, Boston, MA, US 

785� �� 

Cellular Immune Activation Biomarkers and HAART 

Outcomes in Resource-limited Settings 

A Balagopal1 , D Asmuth2 , L Smeaton3 , N Gupte1 , V Franco1 , J Hakim4 , 

R Pollard2 , T Campbell5 , D Thomas1 , Amita Gupta* 1 , for ACTG5175 

and NWCS319 Study Group 

1 2 Johns Hopkins Univ, Baltimore, MD, US;; Univ of California, Davis, 

Sacramento, US;; 3Harvard Sch of Publ Hlth, Boston, MA, US;; 4Univ of 

Zimbabwe, Harare;; and 5Univ of Colorado Denver, US 

786 Asymmetric and Symmetric Dimethylarginine Are 

�� 

+ �� 

Individuals 

I Manner1 , M Baekken1 , I Os1,2 , O Oektedalen1 , D Kvale1,2 , I Seljeflot1,2 , 

and Marius Troseid* 1 

1 2 Oslo Univ Hosp, Norway and Univ of Oslo, Norway 



787� �� 

Non-infectious Diarrhea in HIV + Individuals: Results from 

�� 

Rodger MacArthur* 1 , T Hawkins 2 , S Brown 3 , A LaMarca 4 , P Golden 5 , 

R Rolleri 5 , E Bortey 5 , C Paterson 5 , and W Forbes 5 

1 Wayne State Univ, Detroit, MI, US;; 2 Southwest CARE, Santa Fe, NM, 

US;; 3 AIDS Res Alliance, Los Angeles, CA, US;; 4 Therafirst Med Ctr, Ft 

Lauderdale, FL, US;; and 5 Salix Pharmaceuticals, Inc, Raleigh, NC, US 

779� �� 

Disease Risk in HIV: A Balance of Pro-Inflammatory and 

�� 

Allison Ross Eckard* 1 , C Longenecker2,3 , Y Jiang2 , S Debanne2 , 

D Labbato2,3 , N Storer2,3 , and G McComsey2,3 1�� 2 3 Case Western Reserve Univ, Cleveland, OH, US;; and Univ Hosp Case 

Med Ctr, Cleveland, OH, US 

780� �� 

of All-cause Mortality among Adults Receiving cART in 

Botswana: Results from a Clinical Trial 

Bethan McDonald* 1,2 , S Moyo2 , L Gabaitiri3 , S Gaseitsiwe1,2 , 

H Bussmann2 , J Koethe4 , J Makhema2 , R Marlink1,2 , W Wester2,4 , 

and M Essex1,2 1 2 Harvard Sch of Publ Hlth, Boston, MA, US;; Botswana-Harvard 

AIDS Inst Partnership, Gaborone;; 3Univ of Botswana, Gaborone;; 

and 4Vanderbilt Univ Sch of Med, Nashville, TN, US 

781� �� 

Pashtoon Kasi* 1 , A Mohanty1 , S Erqou1 , K McGinnis2 , K Crothers3 , 

K Corey4,5 , R Chung4,5 , M Freiberg2 , and A Butt2,6 1 2 Univ of Pittsburgh Med Ctr, PA, US;; Univ of Pittsburgh Sch of Med, PA, 

US;; 3Univ of Washington, Seattle, US;; 4Massachusetts Gen Hosp, Boston, 

US;; 5Harvard Med Sch, Boston, MA, US;; and 6 c Tuesday, 2:30-4 pm; Hall B2 



Inflammatory Biomarkers, Microparticles, 

and Clinical Outcomes in HIV 

788 Inflammatory Cytokines and Mortality in a Cohort of HIV 

Sheikh Khalifa Med City, 

Abu Dhabi, United Arab Emirates 

+ 

�� 

Daniel Fuster* 1 , D Cheng1,2 , E Quinn3 , K Armah4 , R Saitz1 , 

M Freiberg5 , J Samet1 , and J Tsui1 1 2 Boston Med Ctr and Boston Univ Sch of Med, MA, US;; Boston Univ Sch 

of Publ Hlth, MA, US;; 3Data Coordinating Ctr, Boston Univ Sch of Publ 

Hlth, MA, US;; 4Univ of Pittsburgh Grad Sch of Publ Hlth, PA, US;; and 

5Univ of Pittsburgh, PA, US 

+ 789� �� 

Persons Are Reduced 

with ART and Associated with D-dimer Levels after Treatment 

Jason Baker* 1,2 , K Huppler Hulsiek1 , R Bradford3 , R Prosser1,2 , R Tracy4 , 

and N Key3 1 2 Univ of Minnesota, Minneapolis, US;; Hennepin County Med Ctr, 

Minneapolis, MN, US;; 3Univ of North Carolina at Chapel Hill, US;; 

and 4Univ of Vermont, Burlington, US 

790� �� 

�� 

Suppressive ART 

Allan Tenorio* 1 , E Zheng2 , R Bosch2 , S Deeks3 , B Rodriguez4 , S 

Krishnan2 , P Hunt3 , C Wilson5 , M Lederman4 , A Landay1 , and ACTG 

1 2 Rush Univ Med Ctr, Chicago, IL, US;; Harvard Sch of Publ Hlth, 

Boston, MA, US;; 3San Francisco Gen Hosp and Univ of California, San 

Francisco, US;; 4Case Western Reserve Univ Sch of Med, Cleveland, OH, 

US;; and 5Univ of Colorado Hosp, Aurora, US 

791 Inflammation and Coagulation Markers Are Predictive of 

Anemia in ARV-treated HIV Disease 

Alvaro Borges* 1 , J Weitz 2 , G Collins 3 , J Baker 3,4 , Y Levy 5 , R Davey 6 , 

A Phillips 7 , J Neaton 3 , J Lundgren 1 , S Deeks 8 , for INSIGHT SILCAAT 

Study Group 

1 Copenhagen HIV Prgm and Rigshospitalet, Denmark;; 2 Thrombosis 

and Atherosclerosis Res Inst, Hamilton, Canada;; 3 Univ of Minnesota, 

Minneapolis, US;; 4 Hennepin County Med Ctr, Minneapolis, MN, US;; 

5 Assistance Publ-Hosp de Paris, INSERM U955, Univ Paris 12, Creteil, 

France;; 6 NIAID, NIH, Bethesda, MD, US;; 7 Univ Coll London Med Sch, 

UK;; and 8 Univ of California, San Francisco, US



792� �� 

Kappa �� 

Atherosclerosis: Multicenter AIDS Cohort Study 

Kerunne Ketlogetswe* 1 , W Post1,2 , X Li2 , L Jacobson2 , F Palella3 , 

J Margolick2 , L Kingsley4 , M Witt5 , M Budoff5 , T Brown1,2 , and Multictr 


1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; Johns Hopkins 

Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 3Northwestern Univ 

Feinberg Sch of Med, Chicago, IL, US;; 4Univ of Pittsburgh Grad Sch of 

Publ Hlth, PA, US;; and 5 801� �� 

Women with or at Risk for HIV Infection 

Todd Brown* 

Harbor UCLA Med Ctr, Torrance, CA, US 

1 , G Springer1 , H Cohen2 , C Cox1 , H Hoffman3 , M Yin4 , 

and M Plankey5 1 2 Johns Hopkins Univ, Baltimore, MD, US;; Baylor Coll of Med, Houston, 

TX, US;; 3NIH, Bethesda, MD, US;; 4Columbia Univ, New York, NY, US;; 

and 5Georgetown Univ, Washington, DC, US 

802� �� 

�� 

in Middle-aged Adults with HIV 

Kristine Erlandson*, A Allshouse, R Rapaport, C Jankowski, 

S MaWhinney, W Kohrt, C Wilson, and T Campbell 

Univ of Colorado-Anschutz Med Campus, Aurora, US 



ART Effects: Monocyte and T Cell Activation 

793 The Prognostic Capacity of CD8 T Cell Activation during 

�� 

Judith Lok* 1 , P Hunt 2 , A Collier 3 , C Benson 4 , M Witt 5 , A Luque 6 , 

S Deeks 2 , and R Bosch 1 

1 Harvard Sch of Publ Hlth, Boston, MA, US;; 2 Univ of California, San 

Francisco, US;; 3 Univ of Washington Sch of Med, Seattle, US;; 4 Univ of 

California, San Diego, US;; 5 David Geffen Sch of Med, Univ of California, 

Los Angeles, US;; and 6 Univ of Rochester Med Ctr, NY, US 



ART Effects: Gene Expression and Cellular Function 

796� �� 

in Hepatocytes and Adipocytes 

Metodi Stankov* 1 , D Panayotova-Dimitrova 2 , M Leverkus 2 , F Vondran 1 , 

R Bauerfeind 1 , A Binz 1 , R Schmidt 1 , and G Behrens 1 

1 Hannover Med Sch, Germany and 2 Mannheim Clin of Univ of 

Heidelberg, Germany 

797� �� 

Pattern with 1st-line Treatment Containing either Efavirenz 

or Lopinavir/ritonavir 

Lander Egana-Gorrono* 1 , E Martinez2 , M Lonca2 , T Escriba1 , P Domingo3 , 

J Fontdevila2 , F Vidal4 , E Negredo5 , J Gatell1,2 , and M Arnedo1 1 2 3 AIDS Res Unit, Barcelona, Spain;; Hosp Clin, Barcelona, Spain;; Hosp 

de la Santa Creu i Sant Pau, Barcelona, Spain;; 4Hosp Univ de Tarragona 

Joan XXIII, Spain;; and 5 806� �� 

�� 

�� 

Magdalena Sobieszczyk* 

Fndn lluita contra la SIDA, Hosp Germans Trias 

i Pujol, Badalona, Spain 

1,2 , L Werner1 , N Garrett1 , K Mlisana1,3 , 

A Feinstein2 , N Naicker1 , C Gray4 , C Williamson4 , S Abdool Karim1,2 , 

and CAPRISA002 Acute HIV Infection Study Team 

1Ctr for the AIDS Prgm of Res in South Africa, Univ of KwaZulu-Natal, 

Durban;; 2Columbia Univ, New York, NY, US;; 3Natl Hlth Lab Svcs, 

Durban, South Africa;; and 4Inst of Infectious Diseases and Molecular 

Med, Univ of Cape Town, South Africa 



Frailty: From Mice to Men and Women 

798 Zidovudine Worsens Exercise Performance in Aged 

Transgenic AIDS Mice in vivo: Insights into Age-related 

Changes in Patients Treated with NRTI 

Rebecca Torres*, T Ludaway, E Fields, R Russ, and W Lewis 


799� �� 

�� 

Marrow Mesenchymal Stem Cells 

Carine Beaupere* 1 , S Hernandez-Vallejo1 , J Capeau1,2 , and C Lagathu1 1 2 INSERM UMRS938, UPMC, Paris, France and APHP, Hosp Tenon, 

Paris, France 

+ 

800� �� 

and HIV� Men in the Multi-center AIDS Cohort Study 

Joseph Margolick* 1 , O Martinez-Maza2 , L Jacobson1 , J Lopez1 , X Li1 , 

J Phair3 , C Rinaldo4 , and J Bream1 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, 

US;; 2David Geffen Sch of Med and Fielding Sch of Publ Hlth, Univ of 

California, Los Angeles, US;; 3Northwestern Univ Feinberg Sch of Med, 

Chicago, IL, US;; and 4 c Wednesday, 2:30-4 pm; Hall B2 


Renal Disease: Diagnosis, Predictors, and Drugs 

808� �� 

Using Cockcroft-Gault and the Chronic Kidney Disease 

�� 

Amanda Mocroft* 

Univ of Pittsburgh Grad Sch of Publ Hlth, PA, US 

1 , L Ryom2 , P Reiss3 , B Ledergerber1 , A d’Arminio 

Monforte4 , J Gatell5 , S de Wit6 , M Beniowski7 , J Lundgren2,8 , O Kirk2,8 , 

and EuroSIDA in EuroCOORD 

1 2 Univ Hosp Zurich, Swtizerland;; Univ of Copenhagen, Denmark;; 

3 4 Academic Med Ctr, Univ of Amsterdam, The Netherlands;; Istituto 

Di Clinica Malattie Infettive e Tropicale, Milan, Italy;; 5Hosp Clin i 

Provincial, Barcelona, Spain;; 6St-Pierre Hosp, Brussels, Belgium;; 

7Osrodek Diagnostyki i Terapii AIDS, Chorzow, Poland;; and 

8Rigshospitalet, Copenhagen, Denmark 


803� �� 

�� 

Virologically Suppressed HIV + Individuals 

J Blanco 1 , M Massanella 1,2 , E Garcia 1 , E Gomez 1 , D Giles 3 , M Bernado 3 , 

J Puig 4 , E Negredo 4 , B Clotet 1,4 , and Cecilia Cabrera* 1 

1 Irsicaixa Fndn, Badalona, Barcelona, Spain;; 2 Univ of California, San 

Diego, US;; 3 Biokit, LLica dAmunt, Barcelona, Spain;; and 4 Fndn LLuita 

contra la Sida, Badalona, Barcelona, Spain 

794� �� 

�� 

�� 

Jordan Lake* 1 , G McComsey2 , T Hulgan3 , C Wanke4 , A Mangili4 , 

S Walmsley5 , S Boger6 , S Stramotas1 , and J Currier1 1 2 Univ of California, Los Angeles, US;; Case Western Reserve Univ, 

Cleveland, OH, US;; 3Vanderbilt Univ, Nashville, TN, US;; 4Tufts Univ, 

Boston, MA, US;; 5Univ of Toronto, Canada;; and 6 c Monday, 2:30-4 pm; Hall B2 


Diabetes, Metabolic Syndrome, and Vitamin D 

Deficiency 

804� �� 

cART Initiation 

Med Univ of South 

Melissa Herrin* 

Carolina, Charleston, US 

795 Activated Proinflammatory Monocytes Are Consistently 

�� 

B Torres, M Plana, A Guardo, A Leon, L Leal, M Laguno, 

A Gonzalez-Cordon, J Mallolas, J Gatell, and Felipe Garcia* 

Hosp Clin, Barcelona, Spain 

1 , J Tate1,2 , M Freiberg3 , J Chang3 , K Crothers4 , 

C Gibert5 , D Leaf6 , D Rimland7,8 , M Rodriguez-Barradas9,10 , and A Justice1,2 1 2 Yale Univ, New Haven, CT, US;; VA Connecticut Hlthcare System, West 

Haven, US;; 3Univ of Pittsburgh Sch of Med, PA, US;; 4Univ of Washington 

Sch of Med, Seattle, US;; 5Washington DC VAMC, US;; 6Greater Los 

Angeles VA Hlthcare System, CA, US;; 7Emory Univ Sch of Med, Atlanta, 

GA, US;; 8Atlanta VAMC, GA, US;; 9Baylor Coll of Med, Houston, TX, US;; 

and 10Michael E DeBakey VAMC, Houston, TX, US 

805� �� 

�� 

Study 

Melissa Frasco* 1 , W Mack1 , K Anastos2 , M Cohen3 , S Gange4 , 

D Gustafson5 , C Lui6 , P Tien7 , and CL Pearce1 1 2 Univ of Southern California, Los Angeles, US;; Montefiore Med Ctr 

and Albert Einstein Coll of Med, Bronx, NY, US;; 3Stroger Hosp and 

Rush Univ, Chicago, IL, US;; 4Johns Hopkins Univ Bloomberg Sch of 

Publ Hlth, Baltimore, MD, US;; 5SUNY Downstate Med Ctr, Brooklyn, 

US;; 6Georgetown Univ Sch of Med, Washington, DC, US;; and 7Univ of 


+ 

807� �� 

Women with Hypovitaminosis D on Efavirenz: Data from the 

�� 

Oluwatoyin Adeyemi* 1 , B Livak1 , P Tien2 , A Sharma3 , M Glesby4 , 

E Golub5 , M Villacres6 , M Young7 , and M Cohen1 1 2 CORE Ctr, Cook County Hlth and Hosp System, Chicago, IL, US;; Univ of 

California, San Francisco, US;; 3SUNY Downstate Med Ctr, Brooklyn, US;; 

4 5 Weill Cornell Univ, New York, NY, US;; Johns Hopkins Univ Bloomberg 

Sch of Publ Hlth, Baltimore, MD, US;; 6Univ of Southern California, Los 

Angeles, US;; and 7Georgetown Univ, Washington, DC, US


809 Prevalence of Chronic Kidney Disease among HIV + Adults in 

818� �� 

�� Cortical Microarchitecture in Men Infected with HIV Early 

Shikha Garg*, C Furlow-Parmley, E Frazier, and J Skarbinski 

in Life 


Michael Yin* 1 , E Broun1 , J Shah1 , M Foca1 , N Neu1 , J Nelson1 , D Bell1 , 

A Zhang1 , M Ueno2 , and S Arpadi1 1 2 Columbia Univ Med Ctr, New York, NY, US and Georgetown Univ Sch 

of Med, Washington, DC, US 

810 Predictors of Advanced Chronic Kidney Disease and Endstage 

Renal Disease in HIV + Persons: D:A:D 

Lene Ryom* 1 , A Mocroft 2 , O Kirk 1,3 , W El-Sadr 4 , M Ross 5 , P Reiss 6 , 

S De Wit 7 , P Morlat 8 , C Fux 9 , J Lundgren 1,3 , and D:A:D Study Group 

1 Copenhagen HIV Prgm, Univ of Copenhagen, Faculty of Hlth and 

Med Sci, Denmark;; 2 Univ Coll London, UK;; 3 Epidemiklinikken M5132, 

Copenhagen Univ Hosp/Rigshospitalet, Denmark;; 4 Intl Ctr for AIDS Care 

and Treatment Prgms, Columbia Univ and Harlem Hosp, New York, NY, 

US;; 5 Mt Sinai Sch of Med, New York, NY, US;; 6 Academic Med Ctr, Univ 

of Amsterdam, The Netherlands;; 7 CHU St-Pierre, Brussels, Belgium;; 

8 Univ Bordeaux Segalen, INSERM U 897, CHU de Bordeaux, France;; 

and 9 Clin for Infectious Diseases and Hosp Hygiene, Kantonsspital 

Aarau, Switzerland 

�� 

Sophie Jose* 1 , L Hamzah 2 , L Campbell 2 , D Nitsch 3 , R Jones 4 , 

C Sabin 1 , F Post 2 , and UK CHIC 

1 Univ Coll London, UK;; 2 Kings Coll London, UK;; 3 London Sch of 

Hygiene and Tropical Med, UK;; and 4 Chelsea and Westminster Hosp, 

London, UK 

819� �� 

Change in Bone Mineral Density in Middle-aged HIV + and 

HIV � Women 

Anjali Sharma* 1 , P Flom 2 , E Schoenbaum 3 , and C Rosen 4 

1 SUNY Downstate Med Ctr, Brooklyn, US;; 2 Peter Flom Consulting, New 

York, NY, US;; 3 Albert Einstein Coll of Med, Bronx, NY, US;; and 4 Maine 

Med Ctr Res Inst, Scarborough, US 

811 Long-term Changes in Renal Parameters in ART-naïve 

�� 

�� 

�� 

�� 

Samir Gupta* 1 , D Kitch2 , C Tierney2 , P Sax3 , E Daar4 , L Szczech5 , P Tebas6 , 

B Ha7 , K Melbourne8 , G McComsey9 , and ACTG A5224s Study Team 

1 2 Indiana Univ Sch of Med, Indianapolis, US;; Harvard Sch of Publ Hlth, 

Boston, MA, US;; 3�� Boston, MA, US;; 4Los Angeles Biomed Res Inst at Harbor-UCLA Med 

Ctr, Torrance, CA, US;; 5PPD, LLC, Research Triangle Park, NC, US;; 

6 7 Univ of Pennsylvania, Philadelphia, US;; GlaxoSmithKline, Research 

Triangle Park, NC, US;; 8Gilead Sci, Foster City, CA, US;; and 9Case Western Reserve Univ, Cleveland, OH, US 

812 Urinary �� 

�� 

�� 

A Diagnostic Accuracy Study 

Takeshi Nishijima* 1,2 , T Shimbo1 , H Komatsu3 , M Takano1 , J Tanuma1 , 

K Tsukada1 , K Teruya1 , H Gatanaga1,2 , Y Kikuchi1 , and S Oka1,2 1 2 Natl Ctr for Global Hlth and Med, Tokyo, Japan;; Ctr for AIDS Res, 

Kumamoto, Japan;; and 3 + 820� �� 

Medicare Beneficiaries 

Amy Warriner*, W Smith, J Curtis, K Saag, and E Delzell 

Univ of Alabama at Birmingham, US 

821 B Cell Dysregulation Promotes HIV-induced Bone Loss 

Kehmia Titanji* 

Saku Central Hosp, Nagano, Japan 

813� �� 

1 , A Vunnava1 , A Sheth1 , J Lennox1 , N Weitzmann1,2 , 

and I Ofotokun1 1 2 Emory Univ, Atlanta, GA, US and Atlanta VAMC, Decatur, GA, US 



ART and Bone Disease 

822 Bone Mineral Density and Prevalence of Asymptomatic 

+ �� 

Patients on cART 

Daria Gotti*, M Gianizza, T Porcelli, L Albini, E Foca, F Castelli, 

A Giustina, and E Quiros-Roldan 

Univ of Brescia, Italy 

823� �� 

Mineral Density after ART Initiation 

Philip Grant* 1 , D Kitch2 , G McComsey3 , M Dube4 , R Haubrich5 , 

J Huang5 , S Riddler6 , P Tebas7 , A Zolopa1 , and T Brown8 1 2 Stanford Univ, CA, US;; Harvard Sch of Publ Hlth, Boston, MA, US;; 

3 4 Case Western, Cleveland, OH, US;; Univ of Southern California, Los 

Angeles, US;; 5Univ of California, San Diego, US;; 6Univ of Pittsburgh, PA, 

US;; 7Univ of Pennsylvania, Philadelphia, US;; and 8Johns Hopkins Univ, 


814� �� 

Progression of Renal Impairment amongst HIV + Patients: 

India 

Sanjay Pujari* 1 , C Smith2 , A Makane1 , M Youle3 , M Johnson3 , 

and S Bhagani3 1 2 Inst of Infectious Diseases, Pune, India;; Univ Coll London, UK;; 

and 3Royal Free London Fndn Trust, UK 

815 5-Year Evolution of Creatinine Clearance in HIV-1 + Adults 

Initiating Tenofovir- vs Zidovudine-containing HAART: 

Thailand 

Gonzague Jourdain* 1,2,3 , L Harrison1 , P Kantipong4 , T Cressey1,2,3 , 

M Techapornroong5 , G Halue6 , S Banchongkit7 , M Lallemant1,2,3 , 

N Ngo-Giang-Huong1,2,3 , C Bowonwattanuwong8 , and Prgm for HIV 

Prevention and Treatment 

1 2 Inst de Recherche pour le Devt, Marseille, France;; Harvard Sch of 

Publ Hlth, Boston, MA, US;; 3Associated Med Sci, Chiang Mai Univ, 

Thailand;; 4Chiangrai Prachanukroh Hosp, Thailand;; 5Prapokklao Hosp, 

Chantaburi, Thailand;; 6Phayao Provincial Hosp, Thailand;; 7Rayong Hosp, Thailand;; and 8Chonburi Regional Hosp, Thailand 

816� �� 

�� 

Lloyd Mulenga* 1 , A Mwango2 , P Musonda1 , M-A Davies3 , 

A Mweemba4 , A Calmy5 , J Stringer1 , O Keiser6 , B Chi1 , G Wandeler6,7 , 

and IeDEA-Southern Africa 

1 2 Ctr for Infectious Disease Res in Zambia;; Zambian Ministry of Hlth;; 

3 4 Univ of Cape Town, South Africa;; Univ Teaching Hosp, Lusaka, 

Zambia;; 5Univ Hosp Geneva, Switzerland;; 6Univ of Bern, Switzerland;; 

and 7Univ Hosp Bern, Switzerland 



Bone Loss: Risk Factors and Pathogenesis 

817 HIV Is an Independent Predictor of Lower Bone Mineral 

Density in HIV + � �� 

�� 

Aoife Cotter* 1,2 , C Sabin3 , S Simelane1 , A Macken1 , B Rogers1 , 

E Kavanagh2 , J Brady2 , P Mallon1,2 , and HIV UPBEAT Study Group 

1HIV Molecular Res Group, Sch of Med and Med Sci, Univ Coll Dublin, 

Ireland;; 2Mater Misericordiae Univ Hosp, Dublin, Ireland;; and 3 824 Multicenter Randomized Study to Assess Changes in HIV 

�� 

�� 

Eugenia Negredo* 

Univ 

Coll London, UK 

1 , P Domingo2 , N Perez-Alvarez1,3 , M Gutierrez2 , 

J Puig1 , J Munoz2 , G Mateo2 , A Bonjoch1 , E Redondo2 , and B Clotet4 1Lluita contra la Sida Fndn, Germans Trias i Pujol Univ Hosp, Badalona, 

Spain;; 2Santa Creu i Sant Pau Hosp, Barcelona, Spain;; 3Univ Politecnica 

de Catalunya, Barcelona, Spain;; and 4Irscaixa Fndn, Germans Trias i 

Pujol Univ Hosp, Badalona, Spain 

825 Change in Lean Body Mass and Association with Bone 

�� 

�� 

�� 

Kristine Erlandson* 1 , D Kitch2 , C Tierney2 , P Sax3 , E Daar4 , P Tebas5 , 

K Melbourne6 , B Ha7 , N Jahed8 , and G McComsey9 1 2 Univ of Colorado-Anschutz Med Campus, Aurora, US;; Harvard Sch of 

Publ Hlth, Boston, MA, US;; 3Brigham and Women�s Hosp, Harvard Med 

Sch, Boston, MA, US;; 4Los Angeles Biomed Res Inst at Harbor-UCLA 

Med Ctr, Torrance, CA, US;; 5Univ of Pennsylvania, Philadelphia, US;; 

6 7 Gilead Sci, Foster City, CA, US;; GlaxoSmithKline, Research Triangle, 

NC, US;; 8Social & Scientific Systems, Inc, Silver Spring, MD, US;; and 

9Case Western Reserve Univ, Cleveland, OH, US 

826 Changes in Bone Biomarkers in Randomized Studies of ARV 

� �� Volunteers 

Aoife Cotter* 1,2 , C Sabin3 , J Brady2 , B Rogers1 , D Cooper4,5 , A Carr4 , 

P Mallon1,2 , and SAMA001 and SAMA002 Study Groups 

1HIV Molecular Res Group, Sch of Med and Med Sci, Univ Coll Dublin, 

Ireland;; 2Mater Misericordiae Univ Hosp, Dublin, Ireland;; 3Univ Coll 

London Med Sch, UK;; 4St Vincent’s Hosp, Sydney, Australia;; and 5Kirby Inst, Univ of New South Wales, Sydney, Australia 

827� �� 

with Intermittent ART vs Continuous ART: Strategies for 

�� 

Daniel Nixon* 1 , B Grund2 , H Wand3 , A Carr3,4 , D Duprez2 , J Hoy5 , 

N Mueller6 , M Roediger2 , J-P Viard7 , F Rhame2 , and INSIGHT SMART 

Study Team 

1 2 Virginia Commonwealth Univ, Richmond, US;; Univ of Minnesota, 

Minneapolis, US;; 3Univ of New South Wales, Sydney, Australia;; 4St 5 �� 

Alfred Hosp and Monash Univ, 

Melbourne, Australia;; 6Hosp Zurich, Switzerland;; and 7Hosp Hotel Dieu, 

Paris, France 


Poster Listings





TB: Incidence, Risk Factors, and Outcomes 

Lydia Nakiyingi* 1 , W Ssengooba 2 , O Mbabazi 1 , J Sempa 1 , 

D Armstrong 3 , M Holshouser 3 , M Joloba 2 , J Ellner 4 , S Dorman 3 , 

and Y Manabe 1,3 

1 Infectious Diseases Inst, Makerere Univ Coll of Hlth Sci, Kampala, 

Uganda;; 2 Makerere Univ Coll of Hlth Sci, Kampala, Uganda;; 3 Johns 

Hopkins Univ Sch of Med, Baltimore, MD, US;; and 4 Boston Med Ctr, 

Boston Univ Sch of Med, MA, US 

830 Body Mass Index and Advanced WHO Clinical Stage Are 

Predictors of TB Incidence among Patients on HAART in 

Botswana: Results from a Clinical Trial 

Simani Gaseitsiwe* 1 , V Maiswe 1 , S Moyo 1 , H Bussmann 1 , W Wester 2 , 

R Musonda 1 , M Mmalane 1 , J Makhema 1 , R Marlink 3 , and M Essex 3 

1 Botswana Harvard AIDS Inst Partnership, Gaborone;; 2 Vanderbilt Univ 

Sch of Med, Vanderbilt Inst for Global Hlth, Nashville, TN, US;; and 

3 Harvard Sch of Publ Hlth AIDS Inst, Boston, MA, US 

831 The Burden of TB among Patients Dying with HIV/AIDS while 

on ART: Western Kenya 

Fatuma Some* 1,2,3 , A Gardner 1,2,4,5 , A Mwangi 1,2 , D Chumba 1,2 , 

M Karoney 3 , P Koskei 3 , I Maulid 3 , K Kenina 3 , and A Siika 1,2,3 

1 Academic Model Providing Access to Hlthcare, Eldoret, Kenya;; 

2 Moi Univ Sch of Med, Eldoret, Kenya;; 3 Moi Univ Clin Res Ctr, Eldoret, 

Kenya;; 4 Alpert Med Sch of Brown Univ, Providence, RI, US;; and 5 Indiana 

Univ Sch of Med, US 

833 Malnutrition Predicts Treatment Outcome and Death in 

South African Multidrug-resistant TB/HIV Co-infected 

Children 

Robert Hicks* 1,2 , N Padayatchi 2 , S Shah 1 , A Wolf 1 , L Werner 2 , 

B Sunkari 3 , and M O’Donnell 1,2 

1 Albert Einstein Coll of Med, Bronx, NY, US;; 2 CAPRISA, Durban, 

South Africa;; and 3 King George V Hosp, Sydenham, South Africa 

834 High Risk of Early Mortality among Persons Suspected of 

TB: South Africa 

Kerrigan McCarthy* 1,2 , K Fielding 3 , A Grant 3 , V Chihota 1 , B Ndlazi 1 , 

S Mngcozelo 1 , L Vezi 1 , D Mametja 4 , W Stevens 5 , G Churchyard 1,2,3 , 

and XTEND Investigators and Collaborators 

1 The Aurum Inst, Johannesburg, South Africa;; 2 Univ of the Witwatersrand, 

Johannesburg, South Africa;; 3 London Sch of Hygiene and Tropical Med, 

UK;; 4 Natl Dept of Hlth, Tshwane, South Africa;; and 5 Natl Hlth Lab Svcs, 


837 Undiagnosed Infectious TB in Adult Home Deaths: South 

Africa 

Neil Martinson* 1,2 , T Omar 3 , M Rakgokong 1 , E Moroe 1 , L Lebina 1 , 

and E Variava 4 

1 Perinatal HIV Res Unit, Univ of the Witwatersrand, Johannesburg, 

South Africa;; 2 Johns Hopkins Univ Ctr for TB Res, Baltimore, MD, 

US;; 3 Natl Hlth Lab Svc and Univ of the Witwatersrand, Johannesburg, 

South Africa;; and 4 Klerksdorp-Tshepong Hosp Complex and Univ of the 

Witwatersrand, Matlosana, South Africa 




TB Diagnostics 

828� �� 

Epidemics 

M Zignol, D Falzon, and Haileyesus Getahun* 

WHO, Geneva, Switzerland 

829� �� 

Mortality among HIV + 838� �� 

Cohort of TB Suspects: South Africa 

Colleen Hanrahan* 

Smear-negative TB Suspects: Uganda 

1 , K Selibas2 , B Cunningham2 , C Deery2 , L Scott2 , 

W Stevens2,3 , I Sanne2 , and A Van Rie1 1Univ of North Carolina Gillings Sch of Global Publ Hlth, Chapel Hill, 

US;; 2Univ of the Witwatersrand, Johannesburg, South Africa;; and 3Natl Hlth Lab Svcs, Johannesburg, South Africa 

839 Use of Rapid Molecular Testing of Sputum to Predict Cases 

of Drug-resistant TB among HIV Co-infected Patients: South 

Africa 

A Campbell 1 , James Brust* 1,2 , T Mthiyane 3 , K Mlisana 4,5 , 

T van der Merwe 6 , I Master 7 , S Lachman 8 , S Shah 1,2 , and N Gandhi 9 

1 Albert Einstein Coll of Med, Bronx, NY, US;; 2 Montefiore Med Ctr, Bronx, 

NY, US;; 3 MRC, Durban, South Africa;; 4 Natl Hlth Lab Svc, Johannesburg, 

South Africa;; 5 Univ of KwaZulu-Natal, Durban, South Africa;; 6 Church 

of Scotland Hosp, Tugela Ferry, South Africa;; 7 King George V Hosp, 

Durban, South Africa;; 8 Murchison Provincial Hosp, Port Shepstone, 

South Africa;; and 9 Emory Univ, Atlanta, GA, US 

840� �� 

Rifampin Resistance in HIV + TB Suspects in High HIV/TB 

Prevalence Resource-limited Settings 

Anne Luetkemeyer* 1 , M Kendall 2 , X Wu 2 , MC Lourenco 3 , 

S Swindells 4 , C Ganoza 5 , D Havlir 1 , B Grinsztejn 3 , I Sanne 6 , C Firnhaber 6 , 

and AACTG A5255 Study Group 

1 San Francisco Gen Hosp and Univ of California, San Francisco, US;; 

2 Harvard Sch of Publ Hlth, Boston, MA, US;; 3 Fndn Oswaldo Cruz, 

Rio de Janeiro, Brazil;; 4 Univ of Nebraska Med Ctr, Omaha, US;; 

5 Assn Civil Impacta Salud y Educacion, Lima, Peru;; and 6 Univ of the 

Witswatersrand, Johannesburg, South Africa 

832 Early Mortality following Initiation of ART in Rural South 

�� 

Portia Mutevedzi* 1,2 , R Lessells1,3 , and M-L Newell1,4 1Africa Ctr for Hlth and Population Studies, Univ of KwaZulu-Natal, 

Somkhele, South Africa;; 2Univ Coll London, UK;; 3London Sch of Hygiene 

and Tropical Med, UK;; and 4 841 Diagnosing TB in Those Hardest to Diagnose: 

�� 

Extrapulmonary TB 

Annelies Van Rie* 

Univ Coll London Inst of Child Hlth, UK 

1 , E Jong2 , M Mkhwanazi3 , and I Sanne2,3 1 2 Univ of North Carolina at Chapel Hill, US;; Univ of the Witwatersrand, 

Johannesburg, South Africa;; and 3Right to Care, Johannesburg, 

South Africa 



TB Screening Strategies: Diagnostics New and Old 

and Latent TB Treatment 

842� �� 

Test for Pulmonary or Extrapulmonary TB among HIV + Adults: 

South Africa 

Paul Drain* 1,2 , E Losina 1,2 , S Coleman 3 , J Giddy 4 , D Ross 5 , G Parker 4 , 

J Katz 2 , R Walensky 1,2 , K Freedberg 1 , and I Bassett 1 

1 Massachusetts Gen Hosp, Boston, US;; 2 �� 

Boston, MA, US;; 3 Boston Univ, MA, US;; 4 McCord Hosp, Durban, South 

Africa;; and 5 St Marys Hosp, Durban, South Africa 

835� �� 

Treatment in a High HIV Prevalence Setting 

Dominique Pepper* 1 , M Schomaker2 , R Wilkinson2 , V DeAzevedo3 , 

and G Maartens2 1 2 Univ of Mississippi Med Ctr, Jackson, US;; Univ of Cape Town, 

South Africa;; and 3City Hlth, Cape Town, South Africa 

+ 

836� �� 

�� 

Ben Andrews* 1,2 , L Muchemwa2 , S Lakhi2,3 , A Kruuner4,5 , P Seidenberg6 , 

J Mwaba3 , D Heimburger1 , and G Bernard 

11 2 Vanderbilt Univ, Nashville, TN, US;; Univ of Zambia Sch of Med, 

Lusaka;; 3Univ Teaching Hosp, Lusaka, Zambia;; 4Ctr for Infectious 

Disease Res in Zambia, Lusaka;; 5Univ of Alabama at Birmingham, US;; 

and 6 843 Diagnostic Accuracy of Novel Sputum and Urine Assays 

for HIV-associated TB: Correlation with C-reactive Protein 

Concentration and Mortality Risk 

Andrew Kerkhoff* 

Univ of New Mexico, Albuquerque, US 

1,2 , R Wood2 , M Vogt2 , and S Lawn2,3 1 2 George Washington Univ, Washington, DC, US;; Desmond Tutu HIV 

Ctr, Cape Town, South Africa;; and 3London Sch of Hygiene and Tropical 

Med, UK 

844 Sequencing of Drug Resistant Mycobacterium tuberculosis 

Samples from a Cohort of Patients in a TB Hospital: 

�� 

Lynsey Isherwood* 1 , N Kushner2 , F Conradie1,3 , D Fallow2 , R Louw4 , 

C Veldsman5 , A Axcell6 , P Diniso1,7 , Y Nkosi3 , and A Duse1,7 1 2 Univ of the Witwatersrand, Johannesburg, South Africa;; Univ of Med 

and Dentistry of New Jersey, US;; 3Right to Care, Johannesburg, South 

Africa;; 4Sizwe Tropical Diseases Hosp, Johannesburg, South Africa;; 

5 6 Hain Lifescience SA Pty Ltd, Johannesburg, South Africa;; Natl Inst of 

Communicable Diseases, Johannesburg, South Africa;; and 7Natl Hlth Lab 

Svc, Johannesburg, South Africa 

845� �� 

Counseling and Testing Clients 

Andrew Voetsch* 1 , S Lanje 1 , M Boima 2 , P Loeto 1 , G Machao 3,4 , 

L Manthe 2 , K Molosiwa 2 , S Motsisi 2 , and R Ncube 4 

1 CDC, Gaborone, Botswana;; 2 Tebelopele Voluntary Counseling and 

Testing Ctr, Gaborone, Botswana;; 3 Intl Training and Ed Ctr for Hlth, 

Gaborone, Botswana;; and 4 Ministry of Hlth, Gaborone, Botswana 

846� �� 

+ 

�� 

Adults: South Africa 

Gabriel Cohen* 1 , P Drain2,3 , F Noubary2 , C Cloete4 , K Nixon4 , G Parker4 , 

and I Bassett2 1 2 New York Univ Sch of Med, NY, US;; Massachusetts Gen Hosp, Boston, 

US;; 3 4 �� 

McCord Hosp, 

Durban, South Africa


847 Improving TB Screening and Isoniazid Preventative Therapy 

�� 

Sandra Zaeh* 1 , R Kempker1 , E Stenehjem1 , H Blumberg1 , 

I Ofotokun1 , and A Tenna2 1 2 Emory Univ Sch of Med, Atlanta, GA, US and Addis Ababa Univ Sch of 

Med, Ethiopia 

848 Genetic Diversity of Mycobacterium tuberculosis among HIV + 

�� 

Marie Ballif* 1 , L Fenner1 , A Abimiku2 , J Obasanya3 , J Carter4 , 

B Pederson4 , L-G Bekker5 , K Middelkoop5 , M Egger1 , S Gagneux6 , 

and Intl Epidemiologic Databases to Evaluate AIDS 

1 2 Inst of Social and Preventive Med, Univ of Bern, Switzerland;; Inst of 

Human Virology, Nigeria;; 3Natl TB and Leprosy Training Ctr, Zaria, 

Nigeria;; 4USAID AMPATH, Eldoret, Kenya;; 5Desmond Tutu HIV Ctr, 

Inst of Infectious Disease and Molecular Med, Univ of Cape Town, 

South Africa;; and 6Swiss Tropical and Publ Hlth Inst and Univ of Basel 

849 Diagnostic Value of Percutaneous Liver Biopsy in HIV + 

�� 

Surasak Wiboonchutikul* 1 , W Manosuthi1 , B Kowadisaiburana1 , 

and S Sungkanuparph2 1Bamrasnaradura Infectious Diseases Inst, Minister of Publ Hlth, 

Nonthaburi, Thailand and 2 857� �� 

Thrice-weekly Compared to Daily Anti-TB Treatment among 

HIV 

Faculty of Med, Ramathibodi Hosp, Mahidol 

Univ, Bangkok, Thailand 

+ TB Patients 

Narendran Gopalan* 1 , RK Santhanakrishnan1 , V Perumal1 , 

M Aravind Menon1 , N Gomathi1 , S Lakshmanan1 , C Chokalingam2 , 

S Rathinam3 , C Suresh1 , and S Swaminathan1 1 2 Natl Inst for Res in Tuberculosis, Chennai, India;; Govt Hosp of Thoracic 

Med, Tambaram, Chennai;; and 3Govt Stanley Hosp, Chennai, India 

858 Intensive Phase Bacillary Elimination Rate Predicts Clinical 

Outcome in HIV + and HIV� Malawian Adults with Smearpositive 

Pulmonary TB 

Derek Sloan* 1,2,3 , H Mwandumba1,2 , C Guwende1 , G Chipungu2 , 

A Butterworth1,2 , J Dutton3 , R Heyderman1,2 , E Corbett1,2 , S Khoo3 , 

and G Davies1,2,3 1 2 Malawi-Liverpool-Wellcome Trust Clin Res Prgm;; Coll of Med, 

Univ of Malawi;; and 3Univ of Liverpool, UK 


Session 149—Poster Abstracts 


Mechanisms of Immune Reconstitution 

850� �� 

Regimen of Rifapentine + Isoniazid for Treatment of Latent 

�� 

Margarita Villarino* 1 , R Moro1 , A Borisov1 , F Adkinson2 , E Phillips3 , 

G Shepherd4 , C Ho1 , S Weis5 , T Sterling6 , and TB Trials Consortium 

1 2 CDC, Atlanta, GA, US;; Johns Hopkins Univ, Baltimore, MD, US;; 

3 4 Murdoch Univ, Australia;; New York Presbyterian/Weil Cornell Hosp, 

NY, US;; 5 859 Early ART after Cryptococcal Meningitis Increases 

�� 

Univ of North Texas Hlth Sci Ctr, Forth Worth, US;; and 

6Vanderbilt Univ, Nashville, TN, US 

Responses in a Multisite Randomized Trial 

James Scriven* 1,2 , J Rhein3,4 , K Huppler Hullsiek4 , M von Hohenberg4 , 

G Linder4 , M Rolfes4 , D Williams3,4 , D Meya3,4,5 , G Meintjes2 , D Boulware4 , 


1 2 Liverpool Sch of Tropical Med, UK;; Univ of Cape Town, South 

Africa;; 3Infectious Disease Inst, Kampala, Uganda;; 4Univ of Minnesota, 

Minneapolis, US;; and 5Makerere Univ, Kampala, Uganda 

851� �� 

�� 

South Africa 

Faiz Ahmad Khan* 1 , S Verkuijl2 , F Chikwava2 , R Ntumy2 , and A Howard1 1Intl Ctr for AIDS Care and Treatment Prgms, Columbia Univ, New York, 

NY, US and 2Intl Ctr for AIDS Care and Treatment Prgms, Columbia 

Univ, Pretoria, South Africa 

852� �� 

�� 

Africa 

Christopher Deery* 1 , C Hanrahan2 , K Selibas1 , J Bassett3 , I Sanne4 , 

and A Van Rie2 1 2 Clinical HIV Res Unit, Johannesburg, South Africa;; Univ of North 

Carolina Gillings Sch of Global Publ Hlth, Chapel Hill, US;; 3Witkoppen Hlth and Welfare Ctr, Johannesburg, South Africa;; and 4 860 Impact of TB-associated Immune Reconstitution 

Inflammatory Syndrome on T Cell Activation and 

Reconstitution in Highly Immunosuppressed HIV/TB 

Co-infected Patients Starting ART 

V Haridas 

Right to Care, 


1 , P Pean2 , L Jasenosky1 , Y Madec3 , D Laureillard4 , L Borand2 , 

O Marcy5 , T Sok5 , X Blanc6 , and Anne Goldfeld* 1,5 

1�� US;; 2Inst Pasteur du Cambodge, Phnom Penh, Cambodia;; 3Inst Pasteur, 

Paris, France;; 4ANRS, Ho Chi Minh City, Vietnam;; 5Cambodian Hlth 

Committee, Phnom Penh;; and 6Bicetre Hosp Assistance Publ-Hosp de 

Paris, France 

861 ex vivo Interferon Gamma Release Assay Responses to 

Cryptococcal Capsule Antigen Predict Outcomes of Death 

or Immune Reconstitution Inflammatory Syndrome after 

Cryptococcal Meningitis 

Darin Wiesner* 1 , A Akamps2 , J Rhein1,3 , D Williams1,3 , D Meya1,2,3 , 

P Bohjanen1 , K Nielsen1 , D Boulware1 , and Cryptococcal Optimal ART 

Timing Trial 

1 2 Univ of Minnesota, Minneapolis, US;; Makerere Univ, Kampala, 

Uganda;; and 3Infectious Disease Inst, Kampala, Uganda 



The “ART” of TB Treatment 

853 Efficacy and Safety of Raltegravir vs Efavirenz for the 

�� 

�� 

Beatriz Grinsztejn* 1 , N De Castro2 , V Arnold3 , V Veloso1 , JH Pilotto4 , 

C Brites5 , C Vorsatz1 , C Grondin3 , G Chene3,6 , and J-M Molina2 1 2 IPEC, Fiocruz, Rio de Janeiro, Brazil;; Hosp St-Louis, Univ Paris 

Diderot, Paris France;; 3INSERM U897, Univ Bordeaux, France;; 4Hosp Geral de Nova Iguacu, Brazil;; 5Hosp Univ Pr Edgar Santos, Salvador, 

Brazil;; and 6 + + 862� �� T Cell Activation in HIV Patients 

Developing Mycobacterium tuberculosis-associated Immune 

Reconstitution Inflammatory Syndrome 

Lisa Chakrabarti* 

CHU de Bordeaux, France 

1 , C Boucherie2 , F Bugault1 , M-C Cumont1 , 

C Roussillon2 , G Breton3 , O Patey4 , L Richert2 , G Chene2,5 , O Lortholary6 , 

and ANRS 129 BKVIR-CYTOK Substudy Group 

1 2 Inst Pasteur, Paris, France;; INSERM U897, Univ Bordeaux, France;; 

3 4 Hosp de La Pitie-Salpetriere, Paris, France;; Hosp Villeneuve 

St-Georges, France;; 5CHU de Bordeaux, France;; and 6Univ Paris 

Descartes, Hosp Necker Enfants Malades, APHP, Paris, France 

854 Completion Rate and Viro-Immunological Response to 

�� 

Study 

Alberto Matteelli* 1 , AC Carvalho1 , A Apostoli1 , C Tinelli2 , L Scudeller2 , 

I El Hamad3 , S Bonora4 , E Girardi5 , A Gori6 , and C Mussini7 1 2 3 Univ of Brescia, Italy;; IRCCS San Matteo Pavia, Italy;; Spedali Civili of 

Brescia, Italy;; 4Univ of Torino, Italy;; 5IRCCS Spallanzani, Rome, Italy;; 

6 7 Univ of Milan, Italy;; and Univ of Modena, Italy 

855� �� 

�� 

Pharmacokinetic Study 

Alberto Matteelli* 1 , AC Carvalho1 , S Kouanda2 , N Saleri1 , 

G Ouedraogo2 , A Roggi1 , P Villani3 , M Regazzi3 , L Monno4 , 

and S Diagbouga2 1 2 Inst of Infectious and Tropical Diseases, Univ of Brescia, Italy;; Natl TB 

Prgm, Ministry of Hlth, Burkina Faso;; 3IRCCS, San Matteo, Pavia, Italy;; 

and 4 c Monday, 2:30-4 pm; Hall B2 


Cryptococcal Infections 

863� �� 

Assay as a Diagnostic and Prognostic Tool for Cryptococcal 

Meningitis 

Taseera Kabanda* 

Clin of Infectious Diseases, Univ of Bari, Italy 

1 , C Muzoora1 , M Siedner2 , and D Boulware3 1 2 Mbarara Univ, Uganda;; Massachusetts Gen Hosp, Boston, US;; 

and 3Univ of Minnesota, Minneapolis, US 

864 No Association of Cryptococcal Antigenemia with Death or 

�� 

Christopher Smitson* 1 , A Tenna2 , M Tsegaye3 , A Shiferaw4 , 

A Aseffa4 , H Blumberg1 , and R Kempker1 1 2 3 Emory Univ, Atlanta, GA, US;; Addis Ababa Univ, Ethiopia;; All Africa 

Leprosy, TB and Rehabilitation Training Ctr, Addis Ababa, Ethiopia;; and 

4Armaeur-Hansen Res Inst, Addis Ababa, Ethiopia 

856� �� 

�� 

Alejandro Sanchez* 1 , X Zhang 2 , D Havlir 3 , A Luetkemeyer 3 , 

J Kumwenda 4 , I Sanne 5 , P Ive 5 , and F Sattler 1 

1 Univ of Southern California, Los Angeles, US;; 2 Harvard Sch of Publ 

Hlth, Boston, MA, US;; 3 Univ of California, San Francisco, US;; 4 Univ 

of Malawi Coll of Med, Blantye;; and 5 Univ of the Witwatersrand, 




865 Pichia�� 

Activity against Candida and Cryptococcus�� 

�� 

J Chandra, P Mukherjee, Mahmoud Ghannoum*, 

and OHARA/ACTG Mycology Unit 

Case Western Reserve Univ, Cleveland, OH, US



866� �� 

Cryptococcus 

neoformans Isolates from HIV + �� 

Beatrice Achan* 1 , D Boulware2 , D Meya1,2,3 , K Nielsen2 , 


1 2 Makerere Univ, Kampala, Uganda;; Univ of Minnesota, Minneapolis, 

US;; and 3 875 Development of a Taqman Real-time Polymerase Chain 

Reaction Assay for Rapid Detection of Penicillium marneffei 

Infection 

Ha Hien* 

Infectious Disease Inst, Kampala, Uganda 

1 , T Thanh1 , N Thu1 , N Cuc2 , N Lan2 , N Hoa1 , C Shikuma3 , 

J Farrar1 , J Day1 , and T Le1,3 1 2 Oxford Univ Clin Res Unit, Vietnam;; Hosp for Tropical Diseases, Ho 

Chi Minh City, Vietnam;; and 3Hawaii Ctr for AIDS, Univ of Hawaii at 

Manoa, Honolulu 



Herpes Zoster 

867 Incidence of Herpes Zoster among HIV + Patients on ART in 

�� 

K Shearer1 , M Maskew1 , T Ajayi2 , P Majuba3 , I Sanne1,3 , 

and Matthew Fox* 1,2,4 

1Sch of Clin Med, Faculty of Hlth Sci, Univ of the Witwatersrand, 

Johannesburg, South Africa;; 2Ctr for Global Hlth and Devt, Boston Univ, 

MA, US;; 3Right to Care, Johannesburg, South Africa;; and 4 876� �� 

+ �� 

�� 

�� 

Paula Brentlinger* 

Sch of Publ 

Hlth, Boston Univ, MA, US 

1 , W Silva1 , E Valverde1 , M Buene1 , L Morais1 , 

M da Rocha2 , J Azarate Jahar3 , and T Moon1 1 2 Friends in Global Hlth, Quelimane, Mozambique;; District Directorate 

of Hlth, Namacurra, Mozambique;; and 3District Directorate of Hlth, 

Inhassunge, Mozambique 

877 HIV-associated Salivary Gland Disease: Identification of a 

�� 

L Jeffers, R Burger-Calderon, and Jennifer Webster-Cyriaque* 


868 Acyclovir Prophylaxis Reduces the Incidence of Herpes 

Zoster among HIV + Individuals: 

Results of a Randomized Clinical Trial 

Ruanne Barnabas* 1 , J Baeten 1 , J Lingappa 1 , K Thomas 1 , J Hughes 1 , 

S Delany-Moretlwe 2 , G Gray 2 , A Ronald 3 , A Wald 1 , C Celum 1 , and 

Partners in Prevention HSV/HIV Transmission Study Team 

1 Univ of Washington, Seattle, US;; 2 Univ of the Witwatersrand, 

Johannesburg, South Africa;; and 3 Univ of Manitoba, Winnipeg, Canada 



Cytomegalovirus–Host Pathogen Interactions 

872� �� 

Benzathine Penicillin in the Treatment of Early Syphilis in 

HIV + Patients 

Chia-Jui Yang and Taiwan HIV Infection and Syphilis Study Group 

Far Eastern Memorial Hosp, New Taipei City, Taiwan 




Vaccines: TB, Pneumococcus, and Influenza 

+ 878� �� 

�� 

+ �� 

�� 

mm� Gavin Churchyard* 1,2 , B Landry3 , M Snowden3 , R Pandian3 , 

M Douoguih4 , and T Evans3 1 2 Aurum Inst, Johannesburg, South Africa;; Univ of the Witwatersrand, 

Johannesburg, South Africa;; 3Aeras, Rockville, MD, US;; and 4Crucell, Leiden, The Netherlands 

869 Predictive Value of Antigenemia Assay in the Diagnosis of 

Cytomegalovirus Gastrointestinal Diseases 

Yohhei Hamada* 1 , N Nagata2 , K Teruya1 , H Gatanaga1 , Y Kikuchi1 , 

and S Oka1 1AIDS Clin Ctr, Natl Ctr for Global Hlth and Med, Tokyo, Japan and 

2Natl Ctr for Global Hlth and Med, Tokyo, Japan 

870� �� 

1- and CMV-specific CD8 + T Cells Reveals Distinct Immune 

Reconstitution Potential 

Nathali Grageda* 1 , S Westrop1 , M Nelson2 , C Burton1 , G Rosignoli1 , 

S Mandalia1,2 , A Jackson2 , G Moyle2 , and N Imami1 879� �� 

�� 

Seroprotection after H1N1 Vaccination 

Lorenzo Ramirez* 

1 2 Imperial Coll London, UK and Chelsea and Westminster Hosp, London, UK 



Syphilis: Not Gone, Not Forgotten 

1 , P Tebas2 , A Daniel1 , I Frank2 , and J Boyer1 1 2 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US and Univ 

of Pennsylvania, Philadelphia, US 

880� �� 

+ �� 

�� 

Pneumococcal Polysaccharide Vaccination 

Marshall Glesby* 1 , C Brinson2 , R Greenberg3 , J Lalezari4 , D Scott5 , 

B Schmoele-Thoma6 , A Gurtman5 , R Natuk5 , M Patton7 , and W Watson8 1 2 Weill Cornell Med Coll, New York, NY, US;; Central Texas Clin Res, 

LLC, Austin, US;; 3Univ of Kentucky Med Ctr, Lexington, US;; 4Quest Clin 

Res, San Francisco, CA, US;; 5Pfizer, Inc, Pearl River, NY, US;; 6Pfizer Pharma GmbH, Berlin, Germany;; 7Pfizer, Inc, Maidenhead, UK;; and 

8Pfizer, Inc, Collegeville, PA, US 

871 The Increase in Syphilis Cases in the HIV Natural History 

�� 

Anuradha Ganesan* 1,2 , O Mesner1 , C Olsen1,3 , C Bradley1,3 , J Maguire1,4 , 

M Bavaro1,5 , A Weintrob1,2 , J Okulicz1,3 , G Macalino1 , B Agan1 , and IDCRP 

HIV/STI Working Group 

1Infectious Disease Clin Res Prgm, Uniformed Svcs Univ, Bethesda, 

MD, US;; 2Walter Reed Natl Military Med Ctr, Bethesda, MD, US;; 3San Antonio Military Med Ctr, TX, US;; 4Naval Med Ctr Portsmouth, VA, US;; 



HIV Shedding and Impact of Infection on Immune 

Cells in Women 

Naval Med Ctr San Diego, CA, US 

881 Cervico-vaginal HIV-1 Shedding in Women Taking ART: 

�� 

A Low1 , I Konate2 , Nicolas Nagot* 3 , H Weiss1 , D Kania2 , P Vickerman1 , 

M Segondy3 , N Meda2 , P van de Perre3 , P Mayaud1 , and Yerelon Study Group 

1 2 London Sch of Hygiene and Tropical Med, UK;; Ctr Muraz, Bobo- 

Dioulasso, Burkina Faso;; and 3Univ Montpellier-1, France 

873� �� 

Reagin Serologies in a Longitudinal Cohort of HIV + 882� �� 

Tract during the Menstrual Cycle 

Marcel Curlin* 

Persons 

Ikwo Oboho*, K Gebo, R Moore, and K Ghanem 


1 , W Leelawiwat2 , E Dunne1 , W Chonwattana2 , P Mock2 , 

F Mueanpai2 , S Thep-Amnuay3 , S Whitehead1,2 , and J McNicholl1 1 2 CDC, Atlanta, GA, US;; Thailand Ministry of Publ Hlth-Ctrs for Disease 

Control and Prevention Collaboration, Nonthaburi;; and 3Independent Consultant 



Opportunistic Infections and Other Novel Pathogens 

874 Emmonsia hoerikwaggiana sp. nov., a Novel Dimorphic 

�� 

Immunocompromized Hosts: 

South Africa 

Chris Kenyon* 1 , K Bonorchis1 , C Corcoran2 , H Vismer3 , M Van Wyk2 , 

C Bamford1 , R Colebunders4 , A Bornman3 , M Mendelson1 , and N Govender5 1 2 Univ of Cape Town, South Africa;; Ampath Natl Reference Lab, 

Centurion, South Africa;; 3Natl Mycology Reference Lab, Bristol, UK;; 4Inst for Tropical Med, Antwerp, Belgium;; and 5 883� �� 

HIV 

Natl Inst for Communicable 

Diseases, Johannesburg, South Africa 

+ Women Using Culture Independent Methods 

Daljeet Mahal* 1 , B Chaban2 , A Albert3 , L Vicol4 , E Wagner3 , J Hill2 , 

S Hemmingsen2,5 , N Pick4 , D Money1,3 , and Vogue Study Group 

1 2 Univ of British Columbia, Vancouver, Canada;; Univ of Saskatchewan, 

Saskatoon, Canada;; 3Women�s Hlth Res Inst, Vancouver, Canada;; 4Oak Tree Clin, Vancouver, Canada;; and 5Plant Biotech Inst, Saskatoon, Canada 

884 HIV Target Cells in the Genital Mucosa in Patients with 

�� 

Elisabeth Kleppa* 1,2 , V Ramsuran3,4 , S Zulu5 , GH Karlsen6 , K Lillebo1,2 , 

M Taylor5 , M Onsrud1 , SG Gundersen7,8 , E Kjetland1,5 , and T Ndung’u5 1 2 3 Oslo Univ Hosp, Norway;; Univ of Oslo, Norway;; Cancer Inflammation 

Prgm, Frederick, MD, US;; 4Ragon Inst of MGH, MIT and Harvard Univ, 

Charlestown, MA, US;; 5Univ of KwaZulu-Natal, Durban, South Africa;; 

6 7 Aarhus Univ, Denmark;; Sorlandet Hosp, Kristiansand, Norway;; and 

8Univ of Agder, Kristiansand, Norway


885 The Impact of Valacyclovir on Systemic Immune Activation and 

�� 

� �� Women 

Tae Joon Yi* 1 , S Kumar1 , B Shannon1 , L Chieza2 , M Saunders2 , 

W Tharao2 , S Huibner1 , and R Kaul1 1 2 Univ of Toronto, Canada and �� 

�s Hands, 

Toronto, Canada 



Hepatitis C Virus Testing in Women 

886 High-risk Human Papillomavirus Testing using Real-time 

Polymerase Chain Reaction on Urine Compared to Vaginal 

�� 

V Rabier, Y-M Vandamme, Jean-Marie Chennebault*, P Fialaire, 

P Abgueguen, S Rehaiem, S Fanello, E Pichard, F Lunel-Fabiani, 

and A Ducancelle 

Univ Hosp, Angers, France 

887� �� 

Immediate Cryotherapy among HIV + Women: Western Kenya 

Orango Omenge* 1 , P Itsura1 , T Liu2 , H Mabeya1 , A Christoffersen-Deb1,3 , 

S Washington4 , and S Cu-Uvin2 1Moi Teaching and Referral Hosp/Moi Univ Sch of Med, Eldoret, Kenya;; 

2 3 Brown Univ/The Miriam Hosp, Providence, RI, US;; Univ of Toronto, 

Canada;; and 4 c Wednesday, 2:30-4 pm; Hall B2 



Family Planning: Unintended Pregnancy and Unmet 

Need 

895 Periconception HIV Risk Behavior among Men and Women 

�� 

Africa 

Lynn Matthews* 

Albert Einstein Univ, NY, US 

1 , D Bangsberg1 , C Milford2 , N Mosery2 , R Greener2 , 

A Kaida3 , C Psaros1 , S Safren1 , and J Smit2 1 2 Massachusetts Gen Hosp, Boston, US;; MatCH, Durban, South Africa;; 

and 3Simon Fraser Univ, Vancouver, Canada 

896 Predictors of Unplanned Pregnancies among Women Living 

with HIV: US 

Lisa Rahangdale* 1 , S Cohn2 , R Stewart3 , J Levison4 , G Lazenby5 , 

M Badell6 , M Nguyen6 , M Kempf7 , M Sturdevant7 , P Ellis8 , and HIV 

and OB Pregnancy Ed Study 

1 2 Univ of North Carolina at Chapel Hill, US;; Northwestern Univ Feinberg 

Sch of Med, Chicago, IL, US;; 3Univ of Texas Southwestern Med Ctr, 

Dallas, US;; 4Baylor Coll of Med, Houston, TX, US;; 5Med Univ of South 

Carolina, US;; 6Emory Univ, Atlanta, GA, US;; 7Univ of Alabama at 

Birmingham, US;; and 8Louisiana State Univ, Baton Rouge, US 

897 Trends in Contraceptive Use and Choice of Contraceptive 

�� 

�� 

Nuala McGrath* 1,2 , J Eaton3 , and M-L Newell2,4 1 2 London Sch of Hygiene and Tropical Med, UK;; Africa Ctr for Hlth and 

Population Studies, KwaZulu-Natal, South Africa;; 3Imperial Coll London, 

UK;; and 4Inst of Child Hlth, Univ Coll London, UK 



HIV Risk Factors, Prevalence, and Barriers to Care 

888 South African Women with Recent Pregnancy RarelyKnow 

Partner’s HIV Status: Implications for Interventions 

Targeting Serodiscordant Couples 

Lynn Matthews* 1 , D Bangsberg 1 , C Milford 2 , N Mosery 2 , R Greener 2 , 

A Kaida 3 , C Psaros 1 , S Safren 1 , and J Smit 2 

1 Massachusetts Gen Hosp, Boston, US;; 2 MatCH, Durban, South Africa;; 

and 3 Simon Fraser Univ, Vancouver, Canada 

889 Pregnancy Intentions and Reproductive Behaviors in HIV + 

and HIV � Women: US 

Chinenye Ugoji* 1 , H Watts 2 , M Young 3 , M Cohen 4 , R Karim 5 , 

R Wright 6 , D Cohan 7 , H Minkoff 8 , and E Golub 9 

1 Inst of Human Virology Nigeria, Abuja;; 2 Natl Inst of Child Hlth 

and Human Devt, Rockville, MD, US;; 3 Georgetown Univ Med Ctr, 

Washington, DC, US;; 4 Stroger Hosp and Rush Univ, Chicago, IL, US;; 

5 Ctr for Hlth Professions, Univ of Southern California, Los Angeles, US;; 

6 Albert Einstein Coll of Med and Montefiore Med Ctr, New York, NY, US;; 

7 Univ of California, San Francisco, US;; 8 Maimonides Med Ctr and SUNY 

Downstate, New York, NY, US;; and 9 Johns Hopkins Univ Bloomberg Sch 

of Publ Hlth, Baltimore, MD, US 

890� �� 

Susan Graham* 1,2 , J Raboud3,4 , W Jaoko2 , K Mandaliya5 , S McClelland1,2 , 

and A Bayoumi3,6 1 2 3 Univ of Washington, Seattle, US;; Univ of Nairobi, Kenya;; Univ of 

Toronto, Canada;; 4Univ Hlth Network, Toronto, Canada;; 5PathCare, Mombasa, Kenya;; and 6St Michaels Hosp, Toronto, Canada 

891� �� 

�� 

�� 

�� 

Madisa Mine* 1,2 , S Moyo2 , K Makhaola1,2 , and T Gaolathe2 1 2 Natl Hlth Lab, Gaborone, Botswana and Botswana Harvard AIDS Inst 

Partnership, Gaborone 

892 Barriers to HIV Care for Women of Color Living in the 

�� 

determination 

M Toth1 , Byrd Quinlivan* 1 , and L Messer2,3 1 2 Univ of North Carolina at Chapel Hill, US;; Portland State Univ, OR, 

US;; and 3Duke Univ, Durham, NC, US 

893� �� 

Treatment Outcomes Compared to Men: Results from a 

Multi-center Study 

Jaimie Meyer* 1,2 , A Zelenev1 , J Wickersham1 , C Williams3 , P Teixiera4 , 

and F Altice1,2 1 2 Yale Univ Sch of Med, New Haven, CT, US;; Yale Univ Sch of Publ Hlth, 

New Haven, CT, US;; 3Univ of Illinois at Chicago Sch of Publ Hlth, US;; 

and 4 894 

New York City Dept of Hlth and Mental Hygiene, NY, US 

Endogenous Reproductive Hormone Concentrations and 

HIV Infection in African Women 

�� 

* 1 , W Clarke2 , B Makanani3 , F Taulo3 , N Kumwenda1 , 

J Sun1 , S Schools2 , A Breaud2 , J Kumwenda3 , and T Taha1 900 Comparison of Tenofovir Plasma Concentrations in Postmenopausal 

vs Pre-menopausal HIV 


2 3 Johns Hopkins Univ Med Inst, Baltimore, MD, US;; and Coll of Med, 

Univ of Malawi, Blantyre 

+ Women 

Cristina Gervasoni*, P Meraviglia, S Landonio, C Impagnatiello, 

M Galli, G Rizzardini, A Riva, and D Cattaneo 

Luigi Sacco Hosp, Milan, Italy 

901� �� 

�� 

�� 

J Yan, G Soon, S Zhou, M Min, K Chan-Tack, Kimberly Struble*, 

J Murray, and D Birnkrant 

Ctr for Drug Evaluation and Res, FDA, Silver Spring, MD, US 

902� �� 

Associated with the Activation Status of Peripheral T 

�� 

Anita Parmigiani*, M Alcaide, M Fischl, and S Pahwa 




HIV Testing and ARV Drug Resistance during 

Pregnancy 

903 Timing of HIV Tests during Pregnancy in Rural Uganda and 

Risk of Undiagnosed Infection at Birth 

F Tabu1 , K MacLeod1,2 , and Mark Siedner* 3 

1 2 Mbarara Univ of Sci and Tech, Uganda;; Mersey Deanery Hosp, Liverpool, 

UK;; and 3 904 

Massachusetts Gen Hosp Ctr for Global Hlth, Boston, US 

HIV Testing among Commercially Insured Pregnant 

�� 

Allan Taylor* 1 , M Furtado1,2 , L Hall1,3 , and S Nesheim1 1 2 CDC, Atlanta, GA, US;; Dynamics Res Corp, Andover, MA, US;; 

and 3ICF Intl, Atlanta, GA, US 



898� �� 

and Unintended Pregnancy among Women Living with HIV 

�� 

Sandra McCoy* 1 , R Buzdugan 1 , L Ralph 1 , A Mushavi 2 , A Mahomva 3 , 

C Watadzaushe 4 , J Dirawo 4 , C Frances 4,5 , and N Padian 1 

1 Univ of California, Berkeley, US;; 2 Ministry of Hlth and Child Welfare, 

Harare, Zimbabwe;; 3 Elizabeth Glaser Pediatric AIDS Fndn, Harare, 

Zimbabwe;; 4 Ctr for Sexual Hlth and HIV Res, Harare, Zimbabwe;; and 

5 Univ Coll London, UK 



HIV in Peri- and Post-menopause 

899� �� 

Perimenopausal HIV + Women 

Sara Looby* 1 , H Joffe 1 , J Shifren 1 , I Corless 2 , A Rope 1 , M Pedersen 1 , 

and S Grinspoon 1 

1 Massachusetts Gen Hosp, Boston, US and 2 Massachusetts Gen Hosp Inst 

of Hlth Professions, Charlestown, US



905 High Rates of Baseline ARV Resistance among HIV + 

�� 

MD Teixeira 1 , E Santos 1 , MI Gouvea 1 , Esau Joao* 1 , N Yeganeh 2 , 

L Ceci 1 , F Lattanzi 1 , ML Cruz 1 , LC Sidi 1 , and K Nielsen-Saines 2 

1 Hosp dos Servidores do Estado, Rio de Janeiro, Brazil and 2 David Geffen 

Sch of Med, Univ of California, Los Angeles, US 

907 Is Intrapartum Prophylaxis for MTCT Still Useful 

in the HAART Era? 

Nelly Briand* 1 , J Warszawski 1,2 , A Faye 3,4 , J Le Chenadec 1 , 

C Dollfus 5 , J-P Teglas 1 , R Tubiana 6 , C Rouzioux 7 , L Mandelbrot 1,4,8 , 

S Blanche 7 , and ANRS EPF Study Group 

1 INSERM U1018, CESP, Le Kremlin-Bicetre, France;; 2 Univ Paris-Sud, 

AP-HP, Hosp Bicetre, Le Kremlin Bicetre, France;; 3 AP-HP, Hosp Robert 

Debre, Paris, France;; 4 Univ Paris 7, France;; 5 AP-HP, Hosp Trousseau, 

Paris, France;; 6 AP-HP, Hosp Pitie Salpetriere, INSERM, U943, Paris, 

France;; 7 AP-HP, Hosp Necker-Enfants Malades, Univ Paris Descartes, 

Paris, France;; and 8 AP-HP, Hosp Louis Mourier, Colombes, France 




PMTCT Implementation: Barriers and Program 

Innovations 

914 Barriers to Participation in Early Infant Diagnosis and 


Treatment of HIV: Malawi 

Elizabeth Cromwell* 


ART, Viral Suppression, and MTCT 

906� �� 

C Townsend, Laura Byrne*, C Thorne, M Cortina-Borja, 

C Peckham, and P Tookey 

Univ Coll London Inst of Child Hlth, UK 

1 , A Dow1 , Q Dube2 , D Low3 , and A Van Rie1 1 2 Univ of North Carolina at Chapel Hill, US;; Malawi-Liverpool-Wellcome 

Trust Clinical Res Prgm, Queen Elizabeth Central Hosp, Blantyre;; and 

3Univ of Washington Sch of Med, Seattle, US 

915 Adaptation of Immunization’s Reaching Every District 

Approach Improves Uptake of and Retention in PMTCT 

�� 

Lynn Kanyuuru* 1 , M Kabue1 , I Malonza1 , L Archer1 , K Curran2 , 

T Adamu3,4 , and T Jacobs5 1Jhpiego/Maternal and Child Hlth Integrated Prgm, Nairobi, Kenya;; 

2 3 Jhpiego, Baltimore, MD, US;; Jhpiego/Maternal and Child Hlth 

Integrated Prgm, Baltimore, MD, US;; 4Johns Hopkins Univ Bloomberg 

Sch of Publ Hlth, Baltimore, MD, US;; and 5USAID, Washington, DC, US 

916 Uganda’s Innovative Interventions in PMTCT Produce 

Dramatic Gains in Linkage and Retention of HIV + Pregnant 

Women and Their HIV-exposed Children 

Godfrey Esiru* 1 , J Grosz 2 , L Nabitaka 1 , and V Narayan 2 

1 Ministry of Hlth, Kampala, Uganda and 2 Clinton Hlth Access Initiative, 


+ 908� �� 

Women 

on cART and Virologically Suppressed Antenatally 

Deborah Money* 1,2,3 , J van Schalkwyk1,2,3 , N Pick1,2 , A Alimenti2 , 

T Chaworth-Musters1 , E Wagner3 , A Albert3 , E Maan2 , M Murray1,2,3 , 

K Tullock1,2 , and Oak Tree Clin Res Group 

1 2 Univ of British Columbia, Vancouver, Canada;; Oak Tree Clin, BC 

Women�s Hosp, Vancouver, Canada;; and 3Women�s Hlth Res Inst, 


909� �� 

among Women Conceiving on cART: Western Europe 

910 

Heather Bailey*, C Townsend, M Cortina-Borja, C Thorne, 

and European Collaborative Study in EuroCoord 


Differential Characteristics of HIV + �� 

�� 

�� 

Martina Badell*, A Kachikis, L Haddad, ML Nguyen, and M Lindsay 




ARV Strategies, MTCT, and HIV-free Survival 

911 Impact of the WHO’s Option B PMTCT Strategy on 

Population HIV-free Survival: A Community Survey in 

�� 

Benjamin Chi* 1,2 , N Chintu2 , P Musonda2,3 , M Gartland2 , S Mulenga2 , 

M Lembalemba4 , M Bweupe5 , E Turnbull2 , E Stringer1,2 , and J Stringer1,2 1 2 Univ of North Carolina at Chapel Hill, US;; Ctr for Infectious Disease 

Res in Zambia, Lusaka;; 3Univ of East Anglia, Norwich, UK;; 4Kafue District Hlth Mgmt Team, Zambia;; and 5Ministry of Hlth, Lusaka, Zambia 

912� �� 

�� 

Trial Using Boosted Lopinavir or Lamivudine in Africa 

Thorkild Tylleskar* 1 , N Nagot2 , C Kankasa3 , N Meda4 , J Tumwine5 , 

A Aku6 , M Mwiya3 , G Ndeezi5 , R Vallo2 , P Van de Perre2 , and ANRS 

12174 Study Group 

1 2 Univ of Bergen, Norway;; INSERM U1058 and Univ Montpellier 1, 

France;; 3Univ Teaching Hosp, Lusaka, Zambia;; 4Univ de Ouagadougou, 

Burkina Faso;; 5Makerere Univ, Kampala, Uganda;; and 6Univ of the 

Western Cape, Cape Town, South Africa 

913 ARV Management of Antenatal and Natal HIV Infection in 

�� 

of Antiretroviral Management of Antenatal and Natal HIV 

Infection Study 

Francesco Vairo* 1 , Z Chaula2 917� �� 

Antenatal Care in South Africa 

Andrea Ciaranello* 

, and AMANI Study Group 

1 2 Natl Inst for Infectious Diseases L Spallanzani, Rome, Italy and Dodoma 

Regional Referral Hosp, Tanzania 

1 , L Myer2 , S Christensen1,3 , K Kelly1 , K Daskilewicz2 , 

K Doherty1 , L-G Bekker4 , T Hou1 , K Freedberg1,5 , and R Walensky1,5,6 1 2 Massachusetts General Hosp, Boston, MA, US;; Univ of Cape Town 

Sch of Public Health and Family Medicine, Cape Town, South Africa;; 

3 4 Amherst College, Amherst, MA, US;; Univ of Cape Town Desmond Tutu 

HIV Centre, Cape Town, South Africa;; 5Harvard Univ Ctr for AIDS Res, 

Boston, MA, US;; and 6�� c Wednesday, 2:30-4 pm; Hall B2 


Pregnancy Complications among HIV + Women 

+ � 918� �� 

and HIV Pregnant Women: 

Cameroon 

Jennifer Jao* 1 , J Wisnivesky1 , R Van Dyke2 , M Geffner3 , E Nshom4 , 

D Palmer4 , P Tih4 , D LeRoith1 , E Abrams5 , and R Sperling1 1 2 Mt Sinai Sch of Med, New York, NY, US;; Tulane Univ Hlth Sci Ctr, 

New Orleans, LA, US;; 3Univ of Southern California Keck Sch of Med, 

Los Angeles, US;; 4Cameroon Baptist Convention Hlth Svcs, Bamenda;; 

and 5Intl Ctr for AIDS Care and Treatment Prgm, Columbia Univ, 


920 Vitamin D Inadequacy in HIV + Women on HAART Is 

�� 

Impairment of Uninfected Infants: Botswana 

Kathleen Powis* 1,2,3 , W Fawzi2 , L Smeaton2 , M Hughes2 , S Lockman2,3,4 , 

A Ogwu3 , S Moyo3 , J Makhema3 , M Essex2,3 , and R Shapiro5 1 2 Massachusetts Gen Hosp, Boston, US;; Harvard Sch of Publ Hlth, 

Boston, MA, US;; 3Botswana-Harvard AIDS Inst Partnership, Gaborone;; 

4 5 �� 

Beth Israel 

Deaconess Med Ctr, Boston, MA, US 



PMTCT: Maternal and Child Health Outcomes 

921 Post-ARV Outcomes among Women Who Received Triple- 

ARV Regimens from Pregnancy to Weaning as PMTCT: 

�� 

Timothy Minniear* 1,2 , S Girde3 , F Angira4 , L Mills2,4 , C Zeh2,4 , P Peters2 , 

R Masaba4 , R Lando4 , T Thomas2 , and A Taylor2 1 2 Epidemic Intelligence Svc, CDC, Atlanta, GA, US;; Div of HIV/AIDS 

Prevention, CDC, Atlanta, GA, US;; 3CDC Information Mgmt Svcs, ICF 

Intl, Atlanta, GA, US;; and 4Kenya Med Res Inst/CDC Res and Publ Hlth 

Collaboration, Kisumu 

922 Maternal ART for the Prevention of Breastfeeding 

�� 

Years after Delivery 

Marina Giuliano* 1 , M Andreotti1 , G Liotta2,3 , H Jere3 , J-B Sagno3 , 

R Amici1 , MC Marazzi4 , S Vella1 , L Palombi2,3 , and S Mancinelli2,3 1 2 Istituto Superiore di Sanita, Rome, Italy;; Univ of Tor Vergata, Rome, 

Italy;; 3DREAM Prgm, Community of S Egidio, Blantyre, Malawi;; and 

4LUMSA Univ, Rome, Italy 

923� �� 

Birth Outcomes: Data from the ARV Pregnancy Registry 

Vani Vannappagari* 1,2 , J Albano 3 , H Tilson 2 , C Gee 3 , A Gandhi 2 , 

N Koram 1 , and C Ryan 3 

1 GlaxoSmithKline, Research Triangle Park, NC, US;; 2 Univ of North 

Carolina at Chapel Hill, US;; and 3 INC Res, Raleigh, NC, US


+ 924� �� 

Women Who Received 

�� 

PMTCT 

R Masaba1 , C Zeh2 , S Girde3 , C Borkowf4 , R Ndivo1 , I Nyangau1 , 

K Achola1 , T Thomas2 , and Shirley Lee Lecher* 4 

1 2 3 Kenya Med Res Inst, Kisumu;; CDC, Kisumu, Kenya;; ICF Intl, Atlanta, 

GA, US;; and 4 932� �� 

�� 

Botswana 

R Shapiro 


1,2,3 , S Rossi4 , Anthony Ogwu* 3 , M Moss4 , J Leidner1 , 

S Lockman1,3,5 , S Moyo3 , J Makhema1,3 , M Essex1,3 , and E Capparelli4 1 2 Harvard Sch of Publ Hlth, Boston, MA, US;; Beth Israel Deaconess Med 

Ctr, Boston, MA, US;; 3Botswana-Harvard Partnership, Gaborone;; 4Univ of California, San Diego, US;; and 5�� MA, US 

925 Pregnancy Outcomes in HIV + Women with Advanced 

�� 

Giuseppina Liuzzi* 1 , C Pinnetti 1 , E Tamburrini 2 , M Ravizza 3 , 

A Vigano 4 , A degli Antoni 5 , G Guaraldi 6 , A Maccabruni 7 , M Floridia 8 , 

and Italian Group on Surveillance on ART in Pregnancy 

1 Natl Inst for Infectious Diseases Lazzaro Spallanzani, Rome, Italy;; 

2 Catholic Univ, Rome, Italy;; 3 S Paolo Hosp, Milan, Italy;; 4 Luigi Sacco 

Hosp, Univ of Milan, Italy;; 5 Azienda Ospedaliera di Parma, Italy;; 6 Univ 

of Modena and Reggio Emilia, Modena, Italy;; 7 IRCCS S Matteo, Pavia, 

Italy;; and 8 Istituto Superiore di Sanita, Rome, Italy 



Breast Feeding and Prevention of Postnatal MTCT 

927 Predictors of Early Breastfeeding Cessation among HIV + 

�� 

Anthony Ogwu* 1,2 , S Moyo 1 , D Kitch 2 , J Leidner 2 , K Powis 1,2 , 

S Lockman 1,2,3 , J Makhema 1,2 , M Pagano 2 , M Essex 1,2 , and R Shapiro 1,2,4 

1 Botswana-Harvard AIDS Inst, Gaborone;; 2 Harvard Sch of Publ Hlth, 

+ 928� �� 

Mothers Administering Longterm 

Nevirapine Syrup to Their Infants at Home: Mulago 

�� 

Joyce Namale Matovu* 1 , Z Namukwaya1 , M Mubiru1 , E Musingye1 , 

M Kyarimpa1 , A Kakande1 , S Kamya1 , P Musoke1 , M Kamya2 , 

and MG Fowler1,3 1Makerere UnivJohns Hopkins Univ Res Collaboration, Kampala, 

Uganda;; 2Mulago Mbarara Teaching Hosp Joint AIDS Prgm, Kampala, 

Uganda;; and 3Johns Hopkins Med Inst, Baltimore, MD, US 



ARV Pharmacokinetics during Pregnancy and 

Breast Feeding 

931 A Comparison of the Pharmacokinetics of Maraviroc during 

Pregnancy and Postpartum 

Angela Colbers* 1 , B Best 2 , J Wang 3 , A Stek 4 , C Hidalgo Tenori 5 , 

D Hawkins 6 , G Taylor 7 , E Capparelli 2 , D Burger 1 , M Mirochnick 8 , 

on behalf of PANNA Network and IMPAACT P1026 

1 Radboud Univ Nijmegen Med Ctr, The Netherlands;; 2 Univ of California, 

San Diego, US;; 3 Ctr for Biostatistics in AIDS Res, Harvard Sch of Publ 

Hlth, Boston, MA, US;; 4 Univ of Southern California Keck Sch of Med, Los 

Angeles, US;; 5 Hosp Univ Virgen de las Nieves Granada, Spain;; 6 Chelsea 

and Westminster Hosp, London, UK;; 7 Imperial Coll Hlthcare NHS Trust, 

London, UK;; and 8 Boston Univ Sch of Med, MA, US 

933 Exposure of Breastfed Infants to Maternal Efavirenz from 

Breast Milk 

Adeniyi Olagunju* 1,2 , A Amara 2 , J Tjia 2 , M Siccardi 2 , J Oyigboja 3 , 

O Bolaji 1 , S Khoo 2 , and A Owen 2 

1 Obafemi Awolowo Univ, Ile-Ife, Nigeria;; 2 Univ of Liverpool, UK;; 

and 3 Ctr for Clin Res, Nigeria 

926 Safety of in Utero and Neonatal ARV Exposure: Effects on 

Cognitive and Academic Outcomes in 

�� 

Molly Nozyce* 1 , Y Huo2 , P Williams2 , S Kapetanovic3 , R Hazra4 , 

S Nichols5 , S Hunter6 , K Rich6 , G Seage2 , P Sirois7 , and Pediatric 

HIV/AIDS Cohort Study 

1 2 Jacobi Med Ctr, Bronx, NY, US;; Harvard Sch of Publ Hlth, Boston, 

MA, US;; 3Natl Inst of Mental Hlth, NIH, Washington, DC, US;; 4Natl Inst 

of Child Hlth and Human Devt, NIH, Washington, DC, US;; 5Univ of 

California, San Diego, US;; 6Univ of Chicago, IL, US;; and 7 934 Effect of Seven Days Phenytoin on Pharmacokinetics of 

and Resistance to Single-dose Nevirapine for Perinatal HIV 

Prevention: A Randomized Pilot Study 

Catherine Chunda* 

Tulane Univ 

Sch of Med, New Orleans, LA, US 

1 , Q Fillekes2 , E Muro3 , M Thomason4 , 

S Aitken5 , E Kisanga3 , C Kankasa1 , D Gibb4 , S Walker4 , and D Burger2 1 2 Univ Teaching Hosp, Lusaka, Zambia;; Radboud Univ Nijmegen Med 

Ctr, The Netherlands;; 3Kilimanjaro Christian Med Coll, Moshi, Tanzania;; 

4 5 MRC Clin Trials Unit, London, UK;; and Utrecht Univ Med Ctr, The 

Netherlands 



ARV Regimens and Safety during Pregnancy 



935� �� 

and Peripartum Viral Load of Increased Lopinavir/Ritonavir 

Dose in Pregnancy 

Simone Bonafe*, J Senise, D Costa, MJ Vaz, A Castelo, 

and Nucleo de Patologias Infecciosas da Gestacao 

Federal Univ of Sao Paulo, Brazil 

Boston, MA, US;; 3 936 Incidence and Management of Adverse Events to Nevirapine 

in Pregnancy in a Resource-constrained Setting 

4 �� 

Beth 

Francesca Bisio* 

Isreal Deaconess Med Ctr, Boston, MA, US 

1 , E Schenone1 , S Grignolo1 , A Calzi1 , M Guaitolini1 , 

DR Giacobbe1 , G Masini1 , I Bitari2 , B Bruzzone3 , and C Viscoli1,3 1 2 Univ of Genoa, Italy;; Army Hosp, Pointe Noire, Republic of Congo;; 

and 3IRCSS AOU San Martino-IST, Genoa, Italy 

929� �� 

for PMTCT: Adherence and Nevirapine Exposure 

Jim Aizire* 1 , E Capparelli2 , C Herron3 , E Brown3 , A Desmond4 , 

S Eshleman5 , B Maldonado6 , K Manji7 , MG Fowler5 , M Mirochnick8 , 

and HPTN 046 Study Team 

1Makerere Univ-Johns Hopkins Univ Res Collaboration, Kampala, 

Uganda;; 2Univ of California, San Diego, US;; 3Fred Hutchinson Cancer 

Res Ctr, Seattle, WA, US;; 4CAPRISA, Nelson R Mandela Sch of Med, 

Univ of KwaZulu-Natal, Durban, South Africa;; 5Johns Hopkins Univ 

Sch of Med, Baltimore, MD, US;; 6Stanford Univ Sch of Med, CA, US;; 

7Muhimbili Univ of Hlth and Allied Sci, Dar es Salaam, Tanzania;; and 

8Boston Univ Sch of Med, MA, US 

930 Role of Intestinal Mucosal Integrity in HIV Transmission 

�� 

�� 

Athena Kourtis* 1 , C Ibegbu2 , J Wiener1 , C King1 , G Tegha3 , D Kamwendo3 , 

V Flax4 , D Kayira3 , C van der Horst4 , D Jamieson1 , and BAN Study Team 

1 2 3 CDC, Atlanta, GA, US;; Emory Univ, Atlanta, GA, US;; UNC Project, 

Lilongwe, Malawi;; and 4 c Monday, 2:30-4 pm; Hall B2 


Incidence and Prevention of PMTCT-associated 

Drug Resistance 

937� �� 

in Women Treated with Zidovudine Monotherapy for PMTCT 

Scott Olson* 


1 , N Ngo-Giang-Huong2 , I Beck3 , R Hall1 , R Bumgarner1 , 

W Deng1 , J Mullins1 , R Van Dyke4 , G Jourdain2 , and L Frenkel1,3 1 2 Univ of Washington, Seattle, US;; Inst de Recherche pour le Devt UMI 

174-PHPT, Chiang-Mai, Thailand;; 3�� and 4Tulane Univ Sch of Med, New Orleans, LA, US 

938 Effect of Short-course Maternal ARV Regimens 

after Single-dose Nevirapine on HIV-1 Transmission and 

�� 

Jane Hitti* 1 , E Halvas2 , L Zheng3 , F Taulo4 , J Kabanda5 , H Sprenger6 , 

K Klingman7 , E Chan3 , D McMahon2 , J Mellors2 , and ACTG A5207 

Protocol Team 

1 2 3 Univ of Washington, Seattle, US;; Univ of Pittsburgh, PA, US;; Harvard 

Sch of Publ Hlth, Boston, MA, US;; 4Queen Elizabeth Central Hosp, 

Blantyre, Malawi;; 5Joint Clin Res Ctr, Kampala, Uganda;; 6Frontier Sci 

Tech and Res Fndn, Amherst, NY, US;; and 7Therapeutics Res Prgm, 

DAIDS, NIH, Bethesda, MD, US 



New HIV Infections among Children in the US 

939� �� 

�� 

�� 

Steven Nesheim* 1 , L Linley 1 , S Whitmore 1 , T Kajese 2 , H Shericka 2 , 

L Fitz Harris 2 , M Lampe 1 , and A Taylor 1 

1 CDC, Atlanta, GA, US and 2 ICF Intl, Atlanta, GA, US





ART Initiation and Immune Reconstitution 

Inflammatory Syndrome among Infants and Children 

942 Low Incidence of TB and Bacille Calmette Guerin Immune 

Reconstitution Inflammatory Syndrome in South African 

Children: Results of a Prospective Cohort Study 

Annelies Van Rie* 1 , S Sawry 2 , A Richardson 1 , S DeLong 1 , 

N Mahomed 3 , D Murdoch 2 , and H Moultrie 2 

1 Univ of North Carolina at Chapel Hill, US;; 2 Wits Reproductive Hlth and 

HIV Inst, Johannesburg, South Africa;; and 3 Univ of the Witwatersrand, 


943 Dermatologic Immune Reconstitution Inflammatory 

Syndrome vs Immune Status in Children Receiving 

Treatment from a Community Outreach Program 

Anne Bagenda* 1,2 , M Mboowa 1 , and J Mbabazi 3,4 

1 Intl Hlth Sci Univ, Kampala, Uganda;; 2 Makerere Coll of Hlth Sci, 

Kampala, Uganda;; 3 Mulago Natl Referral Hosp, Kampala, Uganda;; 

and 4 Intl Hosp Kampala, Uganda 



ART Strategies and Outcomes among Children 

945 Growth among HIV + Children Receiving ART: Dar es 

�� 

Ramadhani Mwiru* 1,2 , D Spiegelman 1 , C Duggan 1,3 , G Seage 1 , H Semu 4 , 

G Chalamilla 1,2 , R Kisenge 5 , and W Fawzi 1 

1 Harvard Sch of Publ Hlth, Boston, MA, US;; 2 Mgmt and Devt for Hlth, 




Cost and Cost-effectiveness of ART and Monitoring 


940� �� 

Middle- and High-income Countries 

D Avila1 , K Patel2 , B Chi3 , K Wools-Kaloustian4 , V Leroy5 , A Sohn6 , 

C Chimbetete7 , R Hazra8 , Matthias Egger* 1,9 , and M-A Davies9 1 2 Inst of Social and Preventive Med, Univ of Bern, Switzerland;; Harvard 

Sch of Publ Hlth, Boston, MA, US;; 3Ctr for Infectious Disease Res in 

Zambia, Lusaka;; 4Indiana Univ Sch of Med, Indianapolis, US;; 5French Natl Inst for Hlth and Med Res, Univ Bordeaux;; 6TREAT Asia, Fndn for 

AIDS Res, Bangkok, Thailand;; 7Newlands Clin, Harare, Zimbabwe;; 8Natl Inst of Child Hlth and Human Devt, NIH, Bethseda, MD, US;; and 9 941 

Univ 

of Cape Town, South Africa 

Impact of Routine Early Infant Diagnosis and Early ART in 

HIV + Malawian Infants at Community Health Centers 

Anna Dow* 1 , Q Dube2 , R Heyderman2 , and A Van Rie1 1Univ of North Carolina Gillings Sch of Global Publ Hlth, Chapel Hill, 

US and 2 949 Within-trial Cost-effectiveness Analysis of Clinically-driven vs 

�� 

Malawi-Liverpool-Wellcome Trust Clinical Res Prgm, Queen 

Elizabeth Central Hosp, Blantyre 

on ART: The AntiRetroviral Research for Watoto Trial 

Paul Revill* 1 , T Mabugu2 , F Mirimo3 , K Nathoo2 , P Mugyenyi4 , 

P Musoke5,6 , P Munderi3 , D Gibb7 , S Walker1 , M Sculpher1 , 

and ARROW Study Team 

1 2 3 Univ of York, UK;; Univ of Zimbabwe, Harare;; Uganda Virus Res Inst, 

Entebbe;; 4Joint Clinical Res Ctr, Kampala, Uganda;; 5Makerere Univ, 

Kampala, Uganda;; 6Paediatric Infectious Diseases Clin, Kampala, 

Uganda;; and 7 950 

MRC Clin Trials Unit, London, UK 

Time in Care and Resource Utilization Prior to ART 

�� 

Hari Iyer* 1 , C Scott1,2 , D Bwalya1 , J Kasimba1 , K McCoy2 , 

G Meyer-Rath2,3,4 , C Moyo5 , C Bolton-Moore6,7 , B Larson2,8 , and S Rosen2,3,4 1 2 Zambia Ctr for Applied Hlth Res and Devt, Lusaka;; Ctr for Global Hlth 

and Devt, Boston Univ, MA, US;; 3Hlth Economics and Epidemiology 

Res Office, Johannesburg, South Africa;; 4Univ of the Witwatersrand, 

Johannesburg, South Africa;; 5Zambian Ministry of Hlth, Lusaka;; 6Univ of North Carolina at Chapel Hill, US;; 7Ctr for Infectious Disease Res in 

Zambia, Lusaka;; and 8Boston Univ Sch of Publ Hlth, MA, US 



HIV Drug Resistance in Children and Youth 

951 Pre-treatment Drug Resistance Mutations among HIV + 

�� 

�� 

Louise Kuhn* 1 , G Hunt 2 , K Technau 3 , A Coovadia 3 , V Black 3 , L Morris 2 , 

E Abrams 1 , and Finding Infants with HIV Disease and Evaluating 

Resistance Study Group 

1 Columbia Univ, New York, NY, US;; 2 Natl Inst of Communicable 

Diseases, Johannesburg, South Africa;; and 3 Rahima Moosa Mother and 

Child Hosp, Univ of the Witwatersrand, Johannesburg, South Africa 

944 Mortality and Long-Term Virologic Outcomes in Children 

�� 

Therapy: Panama 

D Estripeaut1 , Jonathan Mosser* 2 , M Doherty2 , W Acosta2 , H Shah2 , 

E Castano1 , K Luciani1 , J Pascale3 , R Bollinger2 , and K Page2 1 2 Hosp del Nino, Panama City, Panama;; Johns Hopkins Univ Sch of Med, 

Baltimore, MD, US;; and 3 952a�� 

�� 

1 

Inst Conmemorativo Gorgas de Estudios de la 

Salud, Panama City, Panama 

st-Line Regimen 

Kim Steegen* 1 , L Levin2 , I Ketseoglou1 , M Bronze1 , 

M Papathanasopoulos1 , S Carmona1,3 , and W Stevens1,3 1 2 Univ of the Witwatersrand, Johannesburg, South Africa;; Right to Care, 

Johannesburg, South Africa;; and 3Natl Hlth Lab Svcs, Johannesburg, 

South Africa 

952b�� 

Adolescents and Young Adults: New York City 

Christina Gagliardo* 1 , L Saiman1 , J Birnbaum2 , A Radix3 , M Foca1 , 

J Nelson1 , M Yin1 , A Brozovich1 , E West1 , and N Neu1 1 2 Columbia Univ Med Ctr, New York, NY, US;; SUNY Downstate Med Ctr, 

Brooklyn, NY, US;; and 3Callen-Lorde Community Hlth Ctr, New York, 

NY, US 

Dar es Salaam, Tanzania;; 3 4 �� 

Ministry of 

Hlth and Social Welfare, Dar es Salaam, Tanzania;; and 5 946 

Muhimbili Univ 

of Hlth and Allied Sci, Dar es Salaam, Tanzania 

Weight and Height as Predictors of Clinical Progression and 

�� 

HIV + Children: Asia 

Azar Kariminia* 1 , N Durier2 , G Jourdain3,4,5 , S Saghayam6 , T Nguyen7 , 

and D Kumarawati8 1 2 Univ New South Wales, Sydney, Australia;; TREAT Asia/amfAR-Fndn 

for AIDS Res, Bangkok, Thailand;; 3Chiang Mai Univ, Thailand;; 4Harvard Sch of Publ Hlth, Boston, MA, US;; 5Inst de Recherche pour le Devt UMI 

174, Paris, France;; 6YRG CARE, Chennai, India;; 7Children�s Hosp 2, Ho 

Chi Minh City, Vietnam;; and 8Sanglah Hosp, Bali, Indonesia 

947 Treatment Simplification in HIV + Children and Adolescents 

Talia Sainz* 1 , M Santos1 , B Jimenez2 , S Jimenez de Ory1 , J Saavedra1 , 

D Blazquez Gamero3 , JT Ramos4 , MI de Jose5 , MJ Mellado6 , 

ML Navarro1 , and Madrid Cohort of HIV-infected Children and 

Adolescents, Integrated in CORISPE 

1 2 Hosp Gregorio Maranon, Madrid, Spain;; Hosp Infanta Sofia, Madrid, 

Spain;; 3Hosp 12 de Octubre, Madrid, Spain;; 4Hosp de Getafe, Madrid, 

Spain;; 5Hosp La Paz, Madrid, Spain;; and 6Hosp Carlos III, Madrid, Spain 

948� �� 

Perinatally HIV + Children and Adolescents: US 

Lee Fairlie* 1 , B Karalius2 , K Patel2 , R Van Dyke3 , G Siberry4 , G Seage2 , A 

Agwu5 , H Mendez6 , R Hazra4 , A Wiznia7 , and PHACS Team and IMPAACT 

1Wits Reproductive Hlth Inst, Faculty of Hlth Sci, Univ of the 

Witwatersrand, South Africa;; 2Ctr for Biostatistics in AIDS Res, Harvard 

Sch of Publ Hlth, Boston, US;; 3Tulane Univ Hlth Sci Ctr, New Orleans, 

LA, US;; 4Pediatric, Adolescent and Maternal AIDS Branch, Natl Inst of 

Child Hlth and Human Devt, NIH, Bethesda, MD, US;; 5Johns Hopkins 

Univ Sch of Med, Baltimore, MD, US;; 6SUNY Downstate, Brooklyn, NY, 

US;; and 7 c Tuesday, 2:30-4 pm; Hall B2 


Co-infections among HIV-infected and -exposed 

Children 

953 Early TB Infection among HIV-1-exposed Kenyan Infants 

Lisa Cranmer* 

Jacobi Med Ctr/Family Based Svcs, Bronx, NY, US 

1,2 , M Kanyugo3 , S Jonnalagada1 , B Lohman-Payne1 , 

E Maleche-Obimbo3 , D Wamalwa3 , B Richardson1 , B Sorensen1 , 

and G John-Stewart1 1 2 Univ of Washington, Seattle, US;; �� 

and 3Univ of Nairobi, Kenya 

954 Incidence of Malaria in HIV + Children on Pediatric ART: 

�� 

�� 

A Mounkala Harouna1 , Madelaine Amorissani-Folquet* 2 , T Eboua3 , 

S Desmonde1 , E Aka4 , K Kouadio5 , B Kouakou5 , P Coffie6 , V Leroy1 , 

and IeDEA Pediatric West African Study Group 

1 2 Univ Bordeaux, ISPED, Ctr INSERM U897, France;; Univ Cocody, 

Cocody Univ Hosp, Abidjan, Cote dIvoire;; 3Yopougon Univ Hosp, Abidjan, 

Cote dIvoire;; 4CePReF-Enfant, ACONDA, Abidjan, Cote dIvoire;; 5CIRBA, Abidjan, Cote dIvoire;; and 6Ctr MTCT-plus, Abidjan, Cote dIvoire 

955 Hepatitis C in HIV + Patients: Brazil 

Denise Pacola*, M Della Negra, Y Ching Lian, W Queiroz, and C Roberio 

Inst Infectologia Emilio Ribas, Sao Paulo, Brazil 

956 Dynamics of Epstein-Barr Virus in HIV-1 + Children: Uganda 

Maria Raffaella Petrara* 1 , M Penazzato1,2 , W Massavon2 , 

S Nabachwa3 , M Nannyonga3 , A Mazza4 , K Gianesin1 , M Zanchetta5 , 

C Giaquinto1,2 , and A De Rossi1,5 1 2 3 Univ of Padova, Italy;; Tukula Fenna Project;; Nsambya Home Care, 

Kampala, Uganda;; 4Hosp of Cles, Italy;; and 5Inst Oncologico Veneto- 

IRCCS, Padova, Italy




HIV and ART-related Complications and Treatment 

in Children and Youth 

+ 959� �� 

Children in the Era of cART 

P Williams1 , M Abzug2 , Denise Jacobson* 1 , J Wang1 , R Van Dyke3 , 

R Hazra4 , K Patel1 , L DiMeglio5 , J Oleske6 , M Geffner7 , and IMPAACT 

219C and Pediatric HIV/AIDS Cohort Study Teams 

1 2 Harvard Sch of Publ Hlth, Boston, MA, US;; Univ of Colorado Sch of 

Med, Denver, US;; 3Tulane Univ Sch of Med, New Orleans, LA, US;; 4Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US;; 5Indiana Univ Sch of Med, Indianapolis, US;; 6New Jersey Med Sch, Newark, US;; 

and 7�� 960 Incidence of Lipodystrophy Syndrome in a European Cohort 

of HIV + Children and Adolescents 

N Alam 1 , M Cortina-Borja 1 , T Goetghebuer 2 , M Marczynska 3 , A Vigano 4 , 

Claire Thorne* 1 , and European Paediatric HIV and Lipodystrophy 

Study in EuroCoord 

1 Univ Coll London, UK;; 2 Ctr Hosp Univ St Pierre, Brussels, Belgium;; 

3 Med Univ of Warsaw, Poland;; and 4 Univ of Milan, Italy 

+ 961� �� 

Pediatric and 

Adolescent Patients: The Use of Speckle Tracking 

M Alvarez Fuente1 , Talia Sainz* 1 , JT Ramos Amador2 , C Medrano3 , 

D Blazquez Gamero3 , MI de Jose4 , MJ Mellado5 , ML Navarro1 , 

P Rojo Conejo1 , and MA Munoz1 1 2 Hosp Gregorio Maranon, Madrid, Spain;; Hosp de Getafe, Madrid, 

Spain;; 3Hosp 12 de Octubre, Madrid, Spain;; 4Hosp La Paz, Madrid, 

Spain;; and 5Hosp Carlos III, Madrid, Spain 

962 Hypertension in HIV + Children and Adolescents 

Sam Chatterton-Kirchmeier* 1 , R Chakraborty 2 , A Camacho-Gonzalez 2 , 

and D Batisky 2 

1 Emory Univ Sch of Med, Atlanta, GA, US and 2 Emory Univ, Atlanta, 

GA, US 



Characteristics of Youth with HIV 

957 Mortality among HIV + Children with Cancer in South 

Africa: A Pilot Linkage Study 

M Maskew1 , Julia Bohlius* 2 , C Stefan3 , A Davidson4 , N Maxwell1 , 

B Eley4 , H Prozesky5 , M Egger2 , and M-A Davies1 1 2 Univ of Cape Town, South Africa;; Inst of Social and Preventive Med, 

Univ of Bern, Switzerland;; 3Univ of Stellenbosch, South Africa;; 4Red �� 

5Tygerberg Hosp, Cape Town, South Africa 

958� �� 

and Adolescents 

P Martos1 , E Sanchez2 , A Noguera-Julian1 , J Lledo3 , A Mur3 , 

and Claudia Fortuny* 1 

1 2 Hosp Sant Joan de Deu, Univ de Barcelona, Spain;; Univ Ramon Llull, 

Barcelona, Spain;; and 3 966� �� 

or More after Perinatal HIV Infection: Agence Nationale de 

�� 

S Blanche 

Hosp del Mar, Univ Autonoma de Barcelona, Spain 

1 , D Scott-Algara2 , J Le Chenadec3 , V Avettand-Fenoel1 , 

N Bouallag3 , C Rouzioux1 , J-P Viard4 , C Dollfus5 , J Warsawski3,6 , 

and Florence Buseyne* 2 

1 2 Univ Paris Descartes, Hosp Necker, Paris, France;; Inst Pasteur, Paris, 

France;; 3INSERM U1018, Le Kremlin-Bicetre, France;; 4Hosp de l’Hotel- 

Dieu, Paris, France;; 5Hosp Trousseau, Paris, France;; and 6Univ Paris 

Sud, Le Kremlin-Bicetre, France 

+ 967� �� 

T Cell 

Diversity Decades after Perinatal HIV-1 Infection 

Christian Aguilera-Sandoval* 1 , O Yang1 , N Jojic2 , M Belzer3 , 

J Church3 , and P Krogstad1 1Geffen Sch of Med, Univ of California, Los Angeles Med Ctr, US;; 

2 3 Microsoft Inc, US;; and �� 

Southern California, Los Angeles, US 

+ 963� �� 

Children from Latin 

�� 

Development Initiative Study 

Cristina Hofer* 1 , R Harris2 , R Oliveira1 , T de Abreu1 , F Kakehasi3 , 

JH Pilotto4 , N Pavia Ruz5 , M Krauss2 , R Hazra6 , and NISDI Pediatric 

Study Group 2012 

1Inst de Puericultura e Pediatria Martagao Gesteira, Rio de Janeiro, 

Brazil;; 2Westat, Rockville, MD, US;; 3Uviv Federal de Minas Gerais, Belo 

Horizonte, Brazil;; 4Hosp Geral Nova de Iguacu, Brazil;; 5Hosp Infantil de 

Mexico Federico Gomez, Mexico City;; and 6Natl Inst of Child Hlth and 

Human Devt, NIH, Bethesda, MD, US 

964 Low Bone Mineral Density in Vertically HIV + Adolescents: 

�� 

B Jimenez1 , Talia Sainz* 2 , L Diaz2 , ML Navarro2 , MI Gonzalez-Tome3 , 

MJ Mellado4 , MI de Jose5 , P Rojo3 , JT Ramos6 , MA Munoz-Fernandez2 , 

and Madrid Cohort of HIV-infected Children and Adolescents, Integrated 

in CORISPE 

1 2 Hosp Infanta Sofia, Madrid, Spain;; Hosp Gregorio Maranon, Madrid, 

Spain;; 3Hosp 12 de Octubre, Madrid, Spain;; 4Hosp Carlos III, Madrid, 

Spain;; 5Hosp La Paz, Madrid, Spain;; and 6Hosp de Getafe, Madrid, Spain 

965 Vitamin D�� Children and Adults with HIV 

A Steenhoff1,2,3,4 , J Schall2 , B Seme1 , M Marape5 , I Tsimako1 , M Tolle5 , 

M Nnyepi4 , L Mazhani4 , Richard Rutstein* 2,3 , and V Stallings2,3 1 2 Botswana-UPenn Partnership, Gaborone;; �� 

Philadelphia, PA, US;; 3Perelman Sch of Med at the Univ of Pennsylvania, 

Philadelphia, US;; 4Univ of Botswana, Gaborone;; and 5 Session 179–Poster Abstracts 


Tenofovir in Children 

972� �� 

+ �� 

�� 

Once-daily HAART Regimen 

L Aurpibul 

Botswana-Baylor 

�� 

1 , T Narkbunnam2 , Virat Sirisanthana* 1 , O Wittawatmongkol2 , 

W Phongsamart2 , T Sudjaritruk1 , T Cressey1,3,4 , and K Chokephaibulkit2 1 2 Chiang Mai Univ, Thailand;; Mahidol Univ, Bangkok, Thailand;; 

3 4 Harvard Sch of Publ Hlth, Boston, MA, US;; and Inst de Recherche pour 

le Devt, Marseille, France 

973 Pharmacokinetics of Tenofovir in Thai Adolescents Using 

�� 

Wasana Prasitsuebsai* 1 , S Kerr1,2 , N Thammajaruk1 , A Colbers3 , 

S Keadpudsa1 , T Chuanjaroen1 , M Gorowara1 , D Burger3 , A Sohn4 , 

and J Ananworanich1,5 1HIV-NAT Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok;; 

2 3 Kirby Inst, Univ of New South Wales, Sydney, Australia;; Radboud Univ 

Nijmegen Med Ctr, The Netherlands;; 4TREAT Asia/amfAR-Fndn for AIDS 

Res, Bangkok, Thailand;; and 5SEARCH, Thai Red Cross AIDS Res Ctr, 

Bangkok 



ARV Pharmacokinetics in Children 



968� �� 

Young Adults Infected Perinatally than in Older Patients 

�� 

Nelly Briand* 1 , J-P Viard 2 , C Dollfus 3 , F Boufassa 1 , J Le Chenadec 1 , 

C Goujard 1,4 , R Seng 1 , S Blanche 5 , L Meyer 1,4,6 , J Warszawski 1,4,6 , and 

ANRS EPF, COVERTE, PRIMO, SEROCO, COPANA Study Groups 

1 INSERM U1018, CESP, Le Kremlin-Bicetre, France;; 2 AP-HP Hotel- 

Dieu, Paris, France;; 3 AP-HP, Hosp Trousseau, Paris, France;; 4 AP-HP, 

Hosp Bicetre, Paris, France;; 5 AP-HP Hosp Necker-Enfants Malades, 

Univ Paris Descartes, Paris, France;; and 6 Univ Paris-Sud, Le Kremlin- 

Bicetre, France 

969� �� 

�� 

Allison Agwu* 1 , A Neptune 2 , R Rutstein 3 , T Korthuis 4 , K Gebo 1 , 

for HIV Res Network 

1 Johns Hopkins Med Inst, Baltimore, MD, US;; 2 Howard Univ Coll of 

Med, Washington, DC, US;; 3 Children�s Hosp of Philadelphia, PA, US;; 

and 4 Oregon Hlth and Sci Univ, Portland, US 

970� �� 

Behaviorally Acquired HIV 

Sharon Nichols* 1 , J Bethel 2 , P Garvie 3 , D Patton 4 , S Thornton 2 , 

B Kapogiannis 5 , W Ren 2 , T Li 2 , H Major-Wilson 6 , S Woods 1 , 

and Adolescent Trials Network for HIV/AIDS Interventions 

1 Univ of California, San Diego, La Jolla, US;; 2 Westat, Rockville, MD, US;; 

3 Independent Consultant, Memphis, TN, US;; 4 Children�s Diagnostic and 

Treatment Ctr, Inc, Fort Lauderdale, FL, US;; 5 NIH, Bethesda, MD, US;; 

and 6 Univ of Miami, FL, US 

974 Raltegravir Pharmacokinetics and Safety in Neonates 

�� 

Diana Clarke* 1 , E Acosta 2 , M Rizk 3 , Y Bryson 4 , S Spector 5 , 

L Mofenson 6 , H Teppler 3 , C Welebob 3 , E Handelsman 7 , M Mirochnick 8 , 

and IMPAACT P1097 Study Team 

1 Boston Med Ctr, MA US;; 2 Univ of Alabama at Birmingham, US;; 3 Merck 

Res Labs, Clin Res, North Wales, PA, US;; 4 Univ of California, Los 

Angeles, US;; 5 Univ of California, San Diego, US;; 6 Natl Inst of Child Hlth 

and Human Devt, NIH, Bethesda, MD, US;; 7 NIAID, NIH, Bethesda, MD, 

US;; and 8 Boston Univ, MA, US



975a Is Nevirapine Dose Escalation Appropriate in Young African 

HIV + Children? 

Quirine Fillekes* 1 , V Mulenga2 , D Kabamba2 , C Kankasa2 , 

M Thomason3 , A Cook3 , C Chintu2 , D Gibb3 , S Walker3 , and D Burger1 1 2 Radboud Univ Nijmegen Med Ctr, The Netherlands;; Univ Teaching 

Hosp, Lusaka, Zambia;; and 3MRC Clinical Trials Unit, London, UK 

975b�� 

+ 

�� 

�� 

Sabrina Bakeera-Kitaka* 1 , Q Fillekes2 , R Keishanyu3 , N Young4 , 

A Babirye1 , C Tumusiime3 , L Kendall4 , M Lallemant5 , D Burger2 , 

and D Gibb4 1Baylor Coll of Med Children’s Fndn Uganda, Mulago Hosp, Kampala;; 

2 3 Radboud Univ Nijmegen Med Ctr, Nijmegen, The Netherlands;; Joint 

Clinical Res Ctr, Kampala, Uganda;; 4MRC Clinical Trials Unit, London, 

UK;; and 5 983 Microarray Analysis Reveals Novel Insights into Immunity 

to H1N1/09 Influenza Vaccine in HIV 

Drugs for Neglected Diseases Initiative, Geneva, Switzerland 

+ Children and 

Adolescents in the International Maternal Pediatric 

�� 

Savita Pahwa* 1 , L Trautmann2 , M Cameron2 , C Steel2 , R-P Sekaly2 , 

A Weinberg3 , C Cunningham4 , P Flynn5 , and IMPAACT P1088 Team 

1 2 Univ of Miami Miller Sch of Med, FL, US;; Vaccine and Gene Therapy 

Inst Florida, Port St Lucie, US;; 3Univ of Colorado Denver, US;; 4Duke Univ, 

Durham, NC, US;; and 5�� 984 Higher Regulatory B and T Cell Rates Are Associated with 

Decreased Immune Responses to pH1N1 Influenza Vaccine in 

HIV + Children and Youth 

Adriana Weinberg* 1 , P Muresan2 , T Fenton2 , K Richardson1 , 

T Dominguez1 , A Bloom3 , C Cunningham4 , S Spector5 , S Nachman6 , 

P Flynn7 , and IMPAACT P1088 Study Team 

1 2 Univ of Colorado Denver, Aurora, US;; Harvard Sch of Publ Hlth, 

Boston, MA, US;; 3Frontier Sci & Tech Res Fndn, Amherst, NY, US;; 4Duke Univ Med Ctr, Durham, NC, US;; 5Univ of California, San Diego, La 

Jolla, US;; 6Stony Brook Hlth Sci Ctr, NY, US;; and 7�� Hosp, Memphis, TN, US 

976 Pharmacokinetics of Lopinavir/ritonavir Dosed According to 

the WHO Pediatric Weight Band Dosing Guidelines: Interim 

�� 

Jorge Pinto* 1 , E Capparelli 2 , M Mirochnick 3 , M Warshaw 4 , B Zimmer 5 , 

J Roa 6 , B Smith 7 , C Worrell 7 , T Cressey 8 , M Martinez-Tristani 9 , 

and IMPAACT P1083 Team 

1 Univ Federal de Minas Gerais, Belo Horizonte, Brazil;; 2 Univ of 

California, San Diego, US;; 3 Boston Med Ctr, MA, US;; 4 Harvard Sch of 

Publ Hlth, Boston, MA, US;; 5 Frontier Sci & Tech Res Fndn, Buffalo, NY, 

US;; 6 Social & Scientific Systems, Silver Spring, MD, US;; 7 NIH, Bethesda, 

MD, US;; 8 Prgm for HIV Prevention and Treatment, Chiang Mai, 

Thailand;; and 9 Abbott Labs, Miami, FL, US 



Response to Pediatric Vaccines in Children and 

Youth 

981 Human Papillomavirus Vaccination in ARV-treated HIV + 

Adolescents and Young Adults Induces Strong Human 

Papillomavirus-specific Cell-mediated Immune Responses 

Daria Trabattoni* 1 , V Rainone 1 , F Penagini 2 , F Dinello 2 , F Calascibetta 1 , 

V Giacomet 2 , A Vigano 1,2 , M Clerici 1,3 , and GV Zuccotti 1,2 

1 Univ of Milan;; 2 Luigi Sacco Hosp;; and 3 Don G Gnocchi Fndn 




Preclinical Studies of Topical ARV for Prevention 

977� �� 

+ �� 

Children in the Anti- 

Retroviral Research for Watoto Trial 

Victor Musiime* 1 , P Kasirye2 , B Naidoo-James3 , P Nahirya-Ntege4 , 

T Mhute5 , L Mugarura1 , M Munjoma5 , M Spyer3 , M Thomason3 , 

S Walker3 , and ARROW Trial Team 

1 2 Joint Clinical Res Ctr, Kampala, Uganda;; Baylor-Uganda, Paediatric 

Infectious Diseases Clin, Mulago Hosp, Kampala;; 3MRC Clinical Trials 

Unit, London, UK;; 4MRC/Uganda Res Unit on AIDS, Uganda Virus Res 

Inst, Entebbe;; and 5Univ of Zimbabwe, Harare 

978 Pharmacokinetics of Darunavir 800 mg with Ritonavir 100 mg 

Once Daily in HIV + Adolescents and Young Adults 

Jennifer King* 1 , R Hazra2 , A Wiznia3 , P Jean-Philipe4 , B Graham5 , 

P Britto6 , V Carey6 , E Acosta1 , R Yogev7 , and IMPAACT P1058A Team 

1 2 Univ of Alabama at Birmingham, US;; Natl Inst of Child Hlth and 

Human Devt, NIH, Bethesda, MD, US;; 3Jacobi Med Ctr, Bronx, NY, 

US;; 4Henry M Jackson Fndn for the Advancement of Military Med, NIH, 

Bethesda, MD, US;; 5Frontier Sci & Tech, Amherst, NY, US;; 6Harvard Sch of Publ Hlth, Boston, MA, US;; and 7Children�s Memorial Hosp, 

Northwestern Univ Feinberg Sch of Med, Chicago, IL, US 

979 Methylphenidate Concentrations and Dose Requirements in 

HIV + and HIV�� Brookie Best* 1 , M Farhad2 , S Rossi1 , J Hodge3 , S Kapetanovic4 , 

E Capparelli1 , P Brouwers4 , G Siberry5 , E Smith6 , M Paul7 , 

and IMPAACT P1080 

1 2 Univ of California, San Diego, US;; Harvard Sch of Publ Hlth, Boston, 

MA, US;; 3Frontier Sci & Tech Res Fndn, Amherst, NY, US;; 4Natl Inst 

of Mental Hlth, NIH, Rockville, MD, US;; 5Natl Inst of Child Hlth and 

Human Devt, NIH, Bethesda, MD, US;; 6NIAID, NIH, Bethesda, MD, US;; 

and 7Baylor Coll of Med, Houston, TX, US 



Immune Response to Perinatal HIV 

980� �� 

Early in HIV + �� 

Andrew Prendergast* 1,2,3 , B Chasekwa1 , S Rukobo1 , T Mupfudze1,2 , 

M Govha1 , K Mutasa1 , and J Humphrey1,2 1 2 Zvitambo Project, Harare, Zimbabwe;; Johns Hopkins Univ Bloomberg Sch 

of Publ Hlth, Baltimore, MD, US;; and 3 985 Impact of Depo-Provera and Menstrual Cycle on Vaginal 

�� 

Charles Dobard*, S Sharma, R West, A Martin, N Makarova, A Taylor, 

J Mitchell, C-P Pau, and W Heneine 


986 A Novel Intravaginal Ring Design Releasing Tenofovir 

�� 

Vaginal Target Cells in Macaques to Gel Dosing 

James Smith* 

Queen Mary Univ of London, UK 

1 , R Rastogi2 , R Teller2 , P Srinivasan1 , C-P Pau1 , 

J McNicholl1 , M Hendry1 , P Mesquita3 , B Herold3 , and P Kiser2 1 2 3 CDC, Atlanta, GA, US;; Univ of Utah, Salt Lake City, US;; and Albert 

Einstein Coll of Med, Bronx, NY, US 

987 Differential Intracellular Retention of Drugs: A Tool for 

�� 

Pedro Mesquita* 1 , M Kay2 , and B Herold1 1 2 Albert Einstein Coll of Med, Bronx, NY, US and Univ of Utah, Salt Lake 

City, US 

988� �� 

Implications for HIV Prevention 

Julie Russo* 1 , L Wang1 , L Rohan1,2 , I McGowan1,2 , and C Dezzutti1,2 1 2 �� 

Univ of Pittsbugh, 

PA, US 

989� �� 

�� 

from HIV-1 Infection 

Yanille Scott* 1 , K Whaley2 , and C Dezzutti1 1 2 Univ of Pittsburgh, PA, US and Mapp Biopharmaceutical Inc, 

San Diego, CA, US 

990� �� 

Semen Exposure in Women from HIV: Prevention Trials 

�� 

Kerri Penrose* 1 , B Richardson2 , G Besson1 , B Harold3 , C Dezzutti1 , 

S Abdool Karim4 , J Mellors1 , U Parikh1 , and MTN Biomed Sci Working 

Group and HPTN 035 Protocol Team 

1 2 3 Univ of Pittsburgh, PA, US;; Univ of Washington, Seattle, US;; Albert 

Einstein Coll of Med, New York, NY, US;; and 4Ctr for the AIDS Prgm of 

Res in South Africa, Durban 



Non-human Primate Models of STI, PrEP, and 

Vaccines 

991 Co-infection with STI Chlamydia trachomatis and 

Trichomonas vaginalis�� 

Pigtail Macaques 

Tara Henning* 1 , K Butler 1 , D Hanson 1 , D Garber 1 , E Secor 1 , J Papp 1 , 

H Caldwell 2 , G Sturdevant 2 , J McNicholl 1 , and E Kersh 1 

1 CDC, Atlanta, GA, US and 2 Natl Inst of Allergy and Infectious Diseases, 

Hamilton, MT, US 

992� �� 

the Prophylactic Efficacy of Truvada in Pigtail Macaques 

Jessica Radzio* 

982� �� 

+ 

�� 

Pediatric and Adolescent Patients 

George Varghese*, S Pallikkuth, S Andreansky, I Gonzalez, and S Pahwa 


1 , K Hanley2 , J Mitchell1 , S Bachman1 , F Deyounks1 , 

W Heneine1 , and G Garcia-Lerma1 1 2 CDC, Atlanta, GA, US and Emory Univ, Atlanta, GA, US 

993 Prophylactic Efficacy of Oral Truvada against a Tenofovir- 

�� 

M-E Cong, J Mitchell, E Sweeney, S Bachman, D Hanson, W Heneine, 

and Gerardo Garcia-Lerma* 

CDC, Atlanta, GA, US


994� �� 

Protective Truvada Pre-exposure Prophylaxis Prevents SHIV 

Infection in Macaques 

Ted Ross* 1 , A Luckay2 , J McNicholl2 , G Garcia-Lerma2 , H Eugene1 , 

B Pierce1 , L Pereira3 , J Zhang2 , M Hendry2 , and J Smith2 1004 Daily Assessment of Sexual Activity and Pre-exposure 

Prophylaxis Use among Kenyan HIV Serodiscordant Couples 

Kathryn Curran* 

1 2 3 Univ of Pittsburgh, PA, US;; CDC, Atlanta, GA, US;; and ICF Intl, 


1 , N Mugo2 , A Kurth3 , K Ngure2,4 , R Heffron1 , 

C Celum1 , and J Baeten1 1 2 Univ of Washington, Seattle, US;; Kenyatta Natl Hosp, Nairobi, Kenya;; 

3 4 New York Univ, NY, US;; and Jomo Kenyatta Univ of Agriculture and 

Tech, Nairobi, Kenya 

995 Does the Intravenous Administration of the Primatized 

�� 

�� 

Brianne Kallam* 1 , F Villinger1 , A Mayne1 , D Little1 , J McNicholl2 , 

E Kersh2 , R Aubert2 , J Arthos3 , C Cicala3 , and A Ansari1 1 2 Emory Univ Sch of Med, Atlanta, GA, US;; CDC, Atlanta, GA, US;; 

and 3 1005� �� 

African HIV 

Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US 



Oral PrEP and ARV Adherence 

+ Individuals in HIV Serodiscordant Partnerships 

Andrew Mujugira* 1 , R Heffron1 , C Celum1 , N Mugo1,2 , E Nakku-Joloba3 , 

and J Baeten1 1 2 Univ of Washington, Seattle, US;; Univ of Nairobi, Kenya;; 

and 3Makerere Univ, Kampala, Uganda 

1006� �� 

Measure of ARV Medication Adherence in HIV-1 + Women 

Amie Meditz* 1 , J Predhomme1 , K Searls1 , P Caraway2 , E Gardner2 , 

J-H Zheng1 , L Bushman1 , and P Anderson1 1 2 Univ of Colorado, Anschutz Med Campus, Aurora, US and Denver Publ 

Hlth, CO, US 

996 Does Sexual Behavior Influence Adherence to Pre-exposure 

Prophylaxis? Data from a Pre-exposure Prophylaxis Trial 

among Young MSM 

Sybil Hosek* 1 , K Telander 1 , C Balthazar 1 , M Lally 2 , G Siberry 3 , 

B Kapogiannis 3 , C Wilson 4 , and Adolescent Trials Network for HIV/AIDS 

Interventions 

1 John Stroger Hosp of Cook County, Chicago, IL, US;; 2 Alpert Med Sch 

of Brown Univ, Providence, RI, US;; 3 Natl Inst of Child Hlth and Human 

Devt, NIH, Bethesda, MD, US;; and 4 Univ of Alabama at Birmingham, US 

997 Pre-exposure Prophylaxis in Young MSM: Needs and Challenges 

Linda-Gail Bekker* 1 , D Glidden 2 , S Hosek 3 , B Brown 1 , A Liu 2 , R Amico 4,5 , 

J Guanira 6 , J Lama 6 , V McMahan 7 , R Grant 2,7 , for iPrEx Study Team 

1 Desmond Tutu HIV Ctr, Univ of Cape Town, South Africa;; 2Univ of 

California, San Francisco, US;; 3 Stroger Hosp of Cook County, Chicago, 

IL, US;; 4 Ctr for Hlth, Intervention, and Prevention, Univ of Connecticut, 

Storrs, US;; 5 Applied Hlth Res, Brighton, MI, US;; 6 INMENSA, Lima, Peru;; 

and 7 Gladstone Inst of Virology and Immunology, San Francisco, CA, US 

1001 No Evidence of Sexual Risk Compensation in the iPrEx Trial 

of HIV Pre-exposure Prophylaxis 

Julia Marcus* 1,2 , K Mayer 3 , J Guanira 4 , M Casapia 5 , O Montoya 6 , 

S Chariyalertsak 7 , L-G Bekker 8 , V McMahan 1 , D Glidden 9 , R Grant 1,9 , 

and iPrEx Study Team 

1 Gladstone Inst of Virology and Immunology, San Francisco, CA, US;; 

2 Univ of California, Berkeley, US;; 3 Fenway Inst, Fenway Hlth, Boston, 

MA, US;; 4 Investigaciones Med en Salud, Lima, Peru;; 5 Assn Civil Selva 

Amazonica, Iquitos, Peru;; 6 Fndn Ecuatoriana Equidad, Guayaquil- 

Guayas, Ecuador;; 7 Res Inst for Hlth Sci, Chiang Mai Univ, Thailand;; 

8 Desmond Tutu HIV Ctr, Univ of Cape Town, South Africa;; and 9 Univ of 


1002 When to Stop Pre-exposure Prophylaxis: A Prospective 

Analysis of Discontinuation of Sexual Activity and Initiation 

of ART among HIV Serodiscordant Couples 

Jared Baeten* 1 , P Murnane 1 , N Mugo 1,2 , E Katabira 3 , R Heffron 1 , 

A Mujugira 1 , D Donnell 1,4 , C Celum 1 , and Partners PrEP Study Team 

1 Univ of Washington, Seattle, US;; 2 Kenyatta Natl Hosp, Nairobi, Kenya;; 

3 Makerere Univ, Kampala, Uganda;; and 4 Fred Hutchinson Cancer Res 

Ctr, Seattle, WA, US 

1003 Preferred Pre-exposure Prophylaxis Dosing Regimens and 

Sex Planning among Kenyan HIV-1 Serodiscordant Couples 

Renee Heffron* 1 , K Ngure 2 , N Mugo 3 , C Celum 1 , K Curran 1 , 

A Kurth 4 , and J Baeten 1 

1 Univ of Washington, Seattle, US;; 2 Jomo Kenyatta Univ of Agriculture 

and Tech, Nairobi, Kenya;; 3 Kenyatta Natl Hosp, Nairobi, Kenya;; and 

4 New York Univ, NY, US 




Implementation and Cost-effectiveness of Male 

Circumcision 



1007� �� 

a Randomized Controlled Effectiveness Study: Western 

Uganda 

Samuel Kanyago* 1,2 , D Riding 1,3 , E Mutakooha 1 , A Lopez 1 , and M Siedner 4 

1 Mbarara Univ of Sci and Tech, Uganda;; 2 Good Shepherd Hosp, Siteki, 

Swaziland;; 3 Northwest Deanery, Manchester, UK;; and 4 Massachusetts 

Gen Hosp Ctr for Global Hlth, Boston, US 

998� �� 

�� 

iPrEx 

Marc Solomon* 1 , J Lama2 , K Mulligan1 , A Liu3 , V McMahan4 , J Guanira2 , 

M Schechter5 , D Burns6 , D Glidden1 , R Grant1,4 , and iPrEx Study Team 

1 2 3 Univ of California, San Francisco, US;; INMENSA, Lima, Peru;; San 

Francisco Dept of Publ Hlth, CA, US;; 4Gladstone Inst, San Francisco, 

CA, US;; 5Praca Onze, Federal Univ of Rio de Janeiro, Brazil;; and 6NIH, Bethesda, MD, US 

999� �� 

exposure Prophylaxis and Prevention of Herpes Simplex Virus 

�� 

Connie Celum* 1 , R Morrow2 , D Donnell1,2 , T Hong1 , K Fife3 , 

E Nakku-Joloba4 , A Mujugira1 , J Baeten1 , and Partners PrEP Study Team 

1 2 Univ of Washington, Seattle, US;; Fred Hutchinson Cancer Res Ctr, 

Seattle, WA, US;; 3Indiana Univ, Indianapolis, US;; and 4Makerere Univ, 


1000 Daily Oral Pre-exposure Prophylaxis Is Highly Effective among 

�� 

Pamela Murnane* 1 , C Celum1 , E Kahle1 , D Donnell1,2 , E Bukusi1,3 , 

N Mugo1,3 , A Mujugira1 , K Thomas1 , J Baeten1 , and Partners PrEP Study 

Team 

1 2 Univ of Washington, Seattle, US;; Fred Hutchinson Cancer Res Ctr, 

Seattle, WA, US;; and 3 1008� �� 

�� 

Kipruto Chesang* 

Univ of Nairobi, Kenya 

1 , Z Mwandi1 , S Mwalili1 , P Cherutich2 , A Ochieng2 , 

P Oyaro3 , G Otieno4 , K Serrem5 , D Odera6 , and A Kim1 1 2 CDC, Ctr for Global Hlth, Nairobi, Kenya;; Natl AIDS and STD Control 

Prgm, Kenya Ministry of Publ Hlth and Sanitation, Nairobi;; 3Kenya Med 

Res Inst, Nairobi;; 4Nyanza Reproductive Hlth Society, Kisumu, Kenya;; 

5 6 Catholic Med Mission Board, Nairobi, Kenya;; and Impact Res and Devt 

Org, Kisumu, Kenya 

1009� �� 

Xiangrong Kong* 1 , A Ndyanabo2 , G Kigozi2 , F Nalugoda2 , 

D Serwadda3 , M Wawer1 , R Gray1 , and Rakai Hlth Sci Prgm 

1 2 Johns Hopkins Univ, Baltimore, MD, US;; Rakai Hlth Sci Prgm, Kalisizo, 

Uganda;; and 3Makerere Univ, Kampala, Uganda 

1010 Costs and Effectiveness of Male Circumcision Scale-up for 

the Prevention of HIV and Other Sexually Transmitted 

�� 

Seema Kacker* 1 , K Frick2 , T Quinn1,3 , R Gray2 , and A Tobian1 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; Johns Hopkins 

Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; and 3NIAID, NIH, 


1011 Uptake of Neonatal Male Circumcision as Part of HIV 

Prevention Efforts in Botswana: Maternal Motivators and 

Barriers 

Rebeca Plank* 1,2,3 , K Wirth2,3 , N Ndubuka3 , P Kebaabetswe4 , C Lesetedi5 , 

J Makhema3 , D Halperin6 , R Shapiro2,3,7 , M Mmalane3 , and S Lockman1,2,3 1 2 3 �� 

Harvard Sch of Publ Hlth;; Botswana- 

Harvard Partnership;; 4Univ of Botswana, Sch of Med;; 5Botswana Ministry of Hlth;; 6Univ of North Carolina at Chapel Hill;; and 7Beth Israel 

Deaconess Med Ctr 



Voluntary Medical Male Circumcision 

1012 Male Circumcision Decreases High Risk of Human 

�� 

�� 

Aaron Tobian* 1,2 , M-A Davis 1 , M Grabowski 1 , D Serwadda 2,3 , G Kigozi 2 , 

P Gravitt 1 , F Nalugoda 2 , M Wawer 1,2 , T Quinn 4 , and R Gray 1,2 

1 Johns Hopkins Univ, Baltimore, MD, US;; 2 Rakai Hlth Sci Prgm, Entebbe, 

Uganda;; 3 Makerere Univ, Kampala, Uganda;; and 4 NIH, Bethesda, MD, US 

1013 Voluntary Medical Male Circumcision Scale-up Expands Access 

to Sexually Transmitted Infection Screening and Management 

and HIV Testing: Tanzania 

Augustino Hellar* 1 , D Boyee 1 , K Curran 2,3 , H Mahler 1 , M Plotkin 1 , 

TA Ashengo 2,3 , M Machaku 1 , F Hezwa 1 , S Koshuma 4 , and P Luvanda 5 

1 Jhpiego, Dar es Salaam, Tanzania;; 2 Jhpiego, Baltimore, MD, US;; 3 Johns 

Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 4 Iringa 

Regional Hosp, Tanzania;; and 5 Ministry of Hlth and Social Welfare, 

Iringa Region, Tanzania



1014 Outreach Voluntary Medical Male Circumcision Sites Attract 

�� 

H Mahler1 , M Plotkin1 , F Hezwa1 , Tigistu Adamu Ashengo* 2,3 , 

K Curran2,3 , J Lija4 , S Greenberg5 , and E Njeuhmeli6 1 2 3 Jhpiego, Dar es Salaam, Tanzania;; Jhpiego, Baltimore, MD, US;; Johns 

Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; 4Ministry of Hlth and Social Welfare, Dar es Salaam, Tanzania;; 5USAID, Dar es 

Salaam, Tanzania;; and 6 1024 Longitudinal Analysis of HIV-risk Behavior Patterns and 

�� 

P Girault 

USAID, Washington, DC, US 

1 , W Wimonsate2 , Timothy Holtz* 2,3 , A Varangrat2 , 

S Chaikummao2 , W Thienkrua2 , T Chemnasri2 , W Sukwicha2 , 

R Thiebaut4 , and F van Griensven2,3,5 1 2 FHI 360 AsiaPacific Regional Office, Bangkok, Thailand;; Thailand 

Ministry of Publ HlthCDC Collaboration, Nonthaburi;; 3CDC, Atlanta, GA, 

US;; 4INSERM U897 and Inst de Sante Publ, dEpidemiologie et de Devt, 

Univ Bordeaux Segalen, France;; and 5AVRAM Corp, Miami, FL, US 

1015 HIV Prevention: Male Circumcision with a Nonsurgical 

Device—Evaluation of Training Efficacy and Usage of 

Lidocaine 5% Dermal Cream 

Vincent Mutabazi* 1 , JP Bitega 2 , LM Ngeruka 2 , S Kaplan 3 , 

T Hategekimana 4 , F Mugabo 2 , C Karema 1 , and A Binagwaho 1 

1 Ministry of Hlth, Kigali, Rwanda;; 2 Kanombe Military Hosp, Kigali, 

Rwanda;; 3 Weill Cornell Med Coll, New York, NY, US;; and 4 Kigali Univ 

Teaching Hosp, Rwanda 



The Ongoing Epidemic in MSM 

1019 Sexually Transmitted Infections Identify MSM at High Risk 

for Undiagnosed HIV and HIV Transmission and Acquisition 

Matthew Golden* 1,2 , J Dombrowksi 1,2 , R Kerani 1,2 , J Kent 2 , and J Stekler 1,2 

1 Ctr for AIDS and STD, Univ of Washington, US and 2 Publ Hlth-Seattle & 

King County, WA, US 

1020� �� 

�� 

Sarika Desai* 1 , A Nardone1 , G Hughes1 , V Delpech1 , F Burns2 , 

G Hart2 , and N Gill1 1029� �� 

�� 

Julio Montaner* 

1 2 Hlth Protection Agency, London, UK and Univ Coll London, UK 

1 , B Nosyk1 , G Colley1 , H Samji1 , R Hogg1 , 

R Gustafson2 , and M Gilbert3 1 2 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada;; Vancouver 

Coastal Hlth, Canada;; and 3BC Ctr for Disease Control, Canada 




MSM in the Developing World 

1021� �� 

�� 

Avi Hakim* 1 , J Aho2 , G Semde3 , M Diarrassouba4 , K Ehoussou4 , 

B Vuylsteke2 , C Murrill1 , M Thiam5 , T Wingate4 , and SHARM Study Group 

1 2 3 CDC, Atlanta, GA, US;; Inst of Tropical Med, Antwerp, Belgium;; Family 

Hlth Intl 360, Abidjan, Cote dIvoire;; 4CDC, Abidjan, Cote dIvoire;; and 

5Ministry of Hlth and Publ Hygiene, Abidjan, Cote dIvoire 

1022� �� 

�� 

John Aberle-Grasse* 1 , W McFarland2,3 , A El-Adas4 , S Quaye1 , K 

Atuahene4 , W Ampofo5 , R Adanu6 , S Chaturvedi2 , R Fisher2 , and E Harrison5 1 2 3 CDC, Atlanta, GA, US;; Univ of California, San Francisco, US;; San 

Francisco Dept of Publ Hlth, CA, US;; 4Ghana AIDS Commission, Accra;; 

5 6 Univ of Ghana, Noguchi Memorial Inst for Med Res, Legon;; and Univ of 

Ghana, Sch of Publ Hlth, Legon 

1023� �� 

among Male Sex Workers: Vietnam 

Donn Colby* 1,2,3 , N Trang4 , T Mai2 , T Nguyen2 , HT Lan4 , DD Thien4 , 

NA Ngoc5 , K Mayer1,3,6 , and M Mimiaga3,6,7,8 1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US;; Harvard Med Sch 

AIDS Initiative in Vietnam, Ho Chi Minh City;; 3Harvard Med Sch, 

Boston, MA, US;; 4Life Ctr, Ho Chi Minh City, Vietnam;; 5Ctr for Applied 

Res on Men and Hlth, Ho Chi Minh City, Vietnam;; 6The Fenway Inst, 

Fenway Hlth, Boston, MA, US;; 7Massachusetts Gen Hosp, Boston, US;; 



Engagement and Retention in Care 

1031a Continuum of HIV Care among Ryan White HIV/AIDS 

�� 

Rupali Doshi*, T Matthews, D Isenberg, M Matosky, J Milberg, 

F Malitz, and L Cheever 

Hlth Resources and Svc Admin, Rockville, MD, US 

1031b�� 

Engagement and ARV Use: Results from the Pilot Phase of a 

Health Department Intervention 

Julia Dombrowski* 

Harvard Sch of Publ Hlth, Boston, MA, US 

1,2 , M Fleming2 , J Simoni1 , J Hughes1 , and M Golden1,2 1 2 Univ of Washington, Seattle, US and Publ Hlth-Seattle & King County, 

WA, US 

1032a Disparities in Initiation of HAART and in Virologic 

�� 

�� 

Richard Novak* 1 , R Debes2 , J Chmiel3 , J Brooks4 , K Buchacz4 , 

and HOPS Investigators 

1 2 Univ of Illinois, Chicago, US;; Cerner Corp, Kansas City, MO, US;; 

3 4 Northwestern Univ Feinberg Sch of Med, Chicago, IL, US;; and CDC, 



1025� �� 

�� 

Warunee Thienkrua* 1 , W Chonwattana 1 , P Mock 1 , S Chaikummao 1 , 

W Wimonsate 1 , J Tongtoyai 1 , C Todd 1,2,3 , A Chitwarakorn 4 , M Curlin 1,5 , 


1 Thailand Ministry of Publ Hlth-CDC Collaboration, Nonthaburi;; 

2 FHI360 Asia Pacific Regional Office, Bangkok, Thailand;; 3 AVRAM Corp, 

Miami, FL, US;; 4 Thailand Ministry of Publ Hlth, Nonthaburi;; and 5 CDC, 


1016� �� 

�� 

Gabriela Paz-Bailey* 1 , A Smith1 , S Masciotra1 , H Pham2 , C Flynn3 , 

M Lalota4 , A Al-Tayyib5 , T Bingham6 , M Mangus7 , and M Owen1 1 2 3 CDC, Atlanta, GA, US;; ICF Intl, Atlanta, GA, US;; Maryland Dept of 

Hlth and Mental Hygiene, Baltimore, US;; 4Florida Dept of Hlth, Fort 

Lauderdale, US;; 5Denver Publ Hlth, Denver Hlth and Hosp Authority, 

CO, US;; 6Dept of Publ Hlth, Los Angeles County, CA, US;; and 7George Washington Univ, Washington, DC, US 

1017 Risk Behaviors Among HIV + Bisexual Men Receiving 

�� 

Mark Freedman* 1 , C Mattson1 , L Beer1 , P Sullivan2 , J Skarbinski1 , 

and the Med Monitoring Project 

1 2 CDC, Atlanta, GA, US and Emory Univ, Rollins Sch of Publ Hlth, 


1018 Concurrency and HIV Risk among MSM: New York City 

Hong Van Tieu* 1,2 , V Nandi1 , V Frye1 , K Stewart1 , H Oquendo1 , B Bush1 , 

M Cerda3 , D Ompad4 , D Hoover5 , B Koblin1 , and M2M Study Team 

1 2 New York Blood Ctr, NY US;; Columbia Univ Med Ctr, New York, NY, 

US;; 3Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US;; 4New York Univ, NY, US;; and 5 c Monday, 2:30-4 pm; Hall B2 



The Cascade of Care 

1026 Application of Indicators to Monitor US Department of 

Health and Human Services-funded HIV Services in the 

�� 

and Design 

Keri Althoff* 

Rutgers Univ, NJ, US 

1 , P Rebeiro1 , M Horberg2 , K Buchacz3 , K Gebo1 , 

T Sterling4 , M Kitahata5 , A Justice6 , J Brooks3 , R Moore1 , for North 

American AIDS Cohort Collaboration on Res and Design 

1 2 Johns Hopkins Univ, Baltimore, MD, US;; Kaiser Permanente Mid- 

Atlantic States, Rockville, MD, US;; 3CDC, Atlanta, GA, US;; 4Vanderbilt Univ, Nashville, TN, US;; 5Univ of Washington, Seattle, US;; and 6Yale Univ and the VA Connecticut Hlthcare System, New Haven, US 

1027� �� 

Just More Accurate Data? 

Julia Dombrowski* 1,2 , J Kent2 , S Buskin1,2 , J Stekler1,2 , E Barash2 , 

A Bennett2 , and M Golden1,2 1 2 Univ of Washington, Seattle, US and Publ Hlth-Seattle & King County, 

WA, US 

1028� �� 

Suppression among HIV + �� 

�� 

Kelly Quinn* and J Skarbinski 


1030� �� 

Strengths and Gaps 

V Supervie 1 and Dominique Costagliola* 1,2 

1 INSERM U943, UMR S943, UPMC Univ Paris 06, Paris, France and 

2 APHP, Hosp Pitie Salpetriere, Paris, France


1032b Changes in HIV Viral Load Suppression among HIV + New 

�� 

Laura Stadelmann* 1 , A Terzian 1 , 2 , M Irvine 1 , S Braunstein 1 , and 

C Shepard 1 1 New York City Dept of Hlth and Mental Hygiene, NY, US and 

2 Long Island Univ, Sch of Hlth Professions, Brooklyn, NY, US 

1033 HIV Spectrum of Engagement Cascade in a Large Integrated 

�� 

Michael Horberg* 1,2 , L Hurley 3,4 , W Towner 5 , R Gambatese 6 , D Klein 7 , 

D Antoniskis 8 , P Kadlecik 9 , D Kovach 10 , C Remmers 6 , and M Silverberg 3,4 

1 Mid-Atlantic Permanente Res Inst of Kaiser Permanente Mid-Atlantic 

States, Rockville, MD, US;; 2 HIV Initiative of Kaiser Permanente, 

Rockville, MD, US;; 3 HIV Initiative of Kaiser Permanente, Oakland, CA, 

US;; 4 Kaiser Permanente Northern California, Oakland, US;; 5 Kaiser 

Permanente Southern California, Los Angeles, US;; 6 Kaiser Permanente, 

Oakland, CA, US;; 7 Kaiser Permanente Northern California, Hayward, 

US;; 8 Kaiser Permanente Northwest, Portland, OR, US;; 9 Kaiser 

Permanente Mid-Atlantic States, Washington, DC, US;; and 10 Kaiser 

Permanente Hawaii, Honolulu, US 

1034 Impact of Recent Incarceration on HIV + Adults Receiving 

Outpatient Medical Care: US 

Muazzam Nasrullah*, J Fagan, E Frazier, F Hardnett, and J Skarbinski 


1035� �� 

US Government Agencies within the Largest HIV Cohort 

�� 

Peter Rebeiro* 1 , M Horberg2 , K Gebo1 , J Brooks3 , K Buchacz3 , 

M Silverberg4 , J Gill5 , R Moore1 , K Althoff1 , and North American AIDS 

Cohort Collaboration on Res and Design 

1 2 Johns Hopkins Univ, Baltimore, MD, US;; Kaiser Permanente Mid- 

Atlantic, Rockville, MD, US;; 3CDC, Atlanta, GA, US;; 4Kaiser Permanente 

Northern California, Oakland, US;; and 5Univ of Calgary, Canada 

1036� �� 

Defining Engagement in Care 

B Dean1 , R Debes1 , Sam Bozzette* 1,2 , K Buchacz3 , J Brooks3 , 

and HIV Outpatient Study Investigators 

1 2 Cerner Corp, Kansas City, MO, US;; Univ of California, San Diego, US;; 

and 3CDC, Atlanta, GA, US 

1037� �� 

�� 

Jacek Skarbinski*, C Furlow-Parmley, and E Frazier 


1038 ART-naïve Individuals’ Attitudes to Starting ART at High 

�� 

Transmission 

Alison Rodger* 1 , A Phillips1 , A Speakman1 , R Gilson1 , M Fisher2 , 

E Wilkins3 , J Anderson4 , S Collins5 , L Sherr1 , F Lampe1 , and ASTRA 

Study Group 

1 2 Univ Coll London, UK;; Royal Sussex County Hosp, Brighton, UK;; 

3 4 North Manchester Gen Hosp, UK;; Homerton Univ Hosp, London, UK;; 

and 5HIV iBase, London, UK 

1039� �� 

�� 

Lise Cuzin* 1 , C Allavena2 , P Pugliese3 , D Rey4 , B Hoen5 , I Poizot-Martin6 , 

A Cabie7 , Y Yazdanpanah8 , and Dat’AIDS Study Group 

1 2 3 CHU Toulouse, France;; CHU Nantes, France;; CHU Nice, France;; 

4 5 6 CHU Strasbourg, France;; CHU Besancon, France;; Hosp Ste 

Marguerite, Marseille, France;; 7CHU Fort de France;; and 8 1045a Continued Declines in AIDS and Non-AIDS-related 

Mortality with Persistently Higher Mortality among Blacks 

�� 

Frank Palella* 

Hosp Bichat, 

Paris, France 

1 , K Buchacz2 , R Debes3 , R Baker3 , C Armon3 , J Brooks2 , 

and HOPS Investigators 

1 2 Northwestern Univ, Chicago, IL, US;; CDC, Atlanta, GA, US;; 

and 3Cerner Corp, Vienna, VA, US 

1045b Is HIV Development Assistance Reducing Child Mortality in 

�� 

Eran Bendavid* and J Bhattacharya 

Stanford Univ, CA, US 

1046 Predictors of Mortality in a South African Military Cohort 

Initiated on Randomized cART 

Judith Dlamini* 1,2 , L Kondlo1 , G Louwagie2 , L Dzikiti2 , S Emery3 , 

and Phidisa II Study Group 

1 2 Project Phidisa, Pretoria, South Africa;; Univ of Pretoria, South Africa;; 

and 3Univ of New South Wales, Sydney, Australia 

1047 Viremia Copy-years as a Predictive Marker in HIV-1 + 

�� 

Catherine Chirouze* 1 , V Journot2 , V Le Moing3 , L Bernard4 , A Taieb5 , 

C Katlama6 , G Chene5 , C Leport7 , F Raffi8 , B Hoen1 , and ANRS CO 08 

Aproco Copilote Study Group 

1 2 3 Univ Hosp, Besancon, France;; INSERM U897, Bordeaux, France;; Univ 

Hosp, Montpellier, France;; 4Univ Hosp, Tours, France;; 5INSERM U897, 

Univ Bordeaux Segalen, Bordeaux, France;; 6INSERM U943, Univ Pierre 

et Marie Curie, Paris, France;; 7UMR 738 INSERM, Paris Diderot Univ, 

France;; and 8Univ Hosp, Nantes, France 

1048 Cardiovascular-related Deaths in HIV + �� 

�� 

�� 

Sandrine Henard* 1 , C Roussillon2,3 , F Bonnet3,4 , A Taieb2,3 , P Cacoub5 , 

D Salmon6 , E Rosenthal7 , P Morlat3,4 , G Chene2,3,4 , and T May1 1 2 Ctr Hosp et Univ, Nancy, France;; INSERM U897, Bordeaux, France;; 

3 4 5 Univ Bordeaux, France;; CHU de Bordeaux, France;; Hosp La Pitie- 

Salpetriere, Univ Paris 6, France;; 6Hosp Cochin, Univ Paris 5, France;; 

and 7Hosp LArchet, Nice, France 



Disease Progression, Morbidity, and Mortality 

1041 The Incidence and Risk of AIDS-defining Illnesses at Current 

� �� or Higher 

Amanda Mocroft and COHERE in EuroCOORD 


1042 Risk of Non-AIDS-defining Events amongst HIV + Patients 

Not Yet on ART 

Ard van Sighem* 1 , A Kesselring 1 , L Gras 1 , J Prins 2 , E Hassink 3 , 

R Kauffmann 4 , C Richter 5 , P Reiss 2 , F de Wolf 1,6 , and ATHENA Natl 

Observational Cohort 

1 Stichting HIV Monitoring Fndn, Amsterdam, The Netherlands;; 

2 Academic Med Ctr, Univ of Amsterdam, The Netherlands;; 3 Soa Aids 

Nederland, Amsterdam, The Netherlands;; 4 HAGA Hosp, The Hague, The 

Netherlands;; 5 Rijnstate Hosp, Arnhem, The Netherlands;; and 6 Imperial 

Coll Sch of Med, London, UK 

1043 Rate and Predictors of Non-AIDS Events in a Cohort of Elite 

and Viremic Controllers 

C Lucero, B Torres, A Leon, M Calvo, L Leal, I Perez, M Plana, 

J Mallolas, J Gatell, and Felipe Garcia* 

Hosp Clin, Univ of Barcelona, Spain 

1044� �� 

Increased Mortality for Most Causes of Death 

G Sturm1 , M Sarcletti1 , S Gogl1 , A Rieger2 , M Geit3 , A Steuer4 , B Haas5 , 

N Taylor6 , Robert Zangerle* 1 , and AHIVCOS Group 

1 2 3 Innsbruck Med Univ, Austria;; Vienna Med Univ, Austria;; Gen Hosp 

Linz, Austria;; 4Otto Wagner Hosp Vienna, Austria;; 5Gen Hosp Graz West, 

Austria;; and 6Paracelsus Univ Salzburg, Austria 

1040a A Decline in Community Viral Load in Cape Town and 

�� 

Sergio Carmona* 1,2 , B Macleod3,4 , N Cassim1 , S Nene2 , G Sherman1,2 , 

and W Stevens1,2 1 2 Natl Hlth Lab Svc, Johannesburg, South Africa;; Univ of the 

Witwatersrand, Johannesburg, South Africa;; 3Right to Care, 

Johannesburg, South Africa;; and 4Boston Univ, MA, US 

1040b �� 

Representative Sample of HIV + Adults: Swaziland HIV 

Incidence Measurement Survey 

Charles Azih* 1 , N Bock2 , D Donnell3 , G Bicego2 , V Okello1 , 

P Ehrenkranz2 , and R Nkambule1 1049� �� 

�� 

�� 

* 

1 2 Ministry of Hlth, Mbabane, Swaziland;; CDC, Atlanta, GA, US;; and 

3Statistical Ctr for HIV/AIDS Res and Prevention and the Vaccine and 

Infectious Disease Inst, Fred Hutchinson Cancer Res Ctr, Seattle, WA, US 

1 , E Foca2 , F Maggiolo3 , A Scalzini4 , N Ladisa5 , 

S Lo Caputo6 , F Castelli2 , L Sighinolfi7 , P Nasta2 , 

and S Di Giambenedetto1 1 2 3 Catholic Univ of Sacred Heart, Italy;; Univ of Brescia, Italy;; Ospedali 

Riuniti, Bergamo, Italy;; 4Spedali Civili di Brescia, Italy;; 5Policlinico di Bari, Italy;; 6S Maria Annunziata Hosp, Florence, Italy;; and 7S Anna 

Hosp, Ferrara, Italy 

1050� �� 

Disease in HIV + and HIV�� Men: Multi-center AIDS Cohort 

Study 

Jennifer Price* 1 , W Post2 , E Seaberg3 , M Budoff4 , L Kingsley5 , 

F Palella6 , M Witt4 , and C Thio2 1 2 Univ of California, San Francisco, US;; Johns Hopkins Univ Sch of Med, 

Baltimore, MD, US;; 3Johns Hopkins Univ Bloomberg Sch of Publ Hlth, 

Baltimore, MD, US;; 4Los Angeles Biomed Res Inst at Harbor-UCLA Med 

Ctr, US;; 5Univ of Pittsburgh Sch of Publ Hlth, PA, US;; and 6Northwestern Univ Feinberg Sch of Med, Chicago, IL, US 



1051� �� 

�� 

Attenuation Parameter in HIV Infection 

Juan Macias* 1 , J Gonzalez 2 , C Tural 3 , E Ortega 4 , F Pulido 5 , R Rubio 5 , 

C Cifuentes 1 , C de Alvaro 6 , A Burgos 6 , J Pineda 1 , and ESTAMPA Study 

Group 

1 Hosp Univ de Valme, Seville, Spain;; 2 Hosp Univ La Paz, Madrid, Spain;; 

3 Hosp Univ Germans Trias i Pujol, Badalona, Spain;; 4 Hosp Gen Univ de 

Valencia, Spain;; 5 Hosp Univ 12 de Octubre, Madrid, Spain;; and 6 Abbott 

Labs, Madrid, Spain



1052� �� 

Associated with Survival in Treatment-näive Individuals with 

HIV Infection 

Hans Hartling* 1 , LW Thorner1 , C Erikstrup2 , R Zinyama3,4 , 

P Kallestrup5 , EG Gomo4 , S Nielsen1 , and H Ullum1 1 2 Rigshospitalet, Copenhagen, Denmark;; Aarhus Univ Hosp, Skejby 

Sygehus, Denmark;; 3Ministry of Hlth and Child Welfare, Harare, 

Zimbabwe;; 4Univ of Zimbabwe, Harare;; and 5 1062 Randomized Comparison of Universal or Targeted HIV 

Screening in the Emergency Department 

Michael Lyons*, C Lindsell, A Ruffner, B Wayne, K Hart, M Sperling, 

A Trott, and C Fichtenbaum 

Univ of Cincinnati, OH, US 

Aarhus Univ, Denmark 

1063 Outcomes from a Routine Screening Program for HIV 

�� 

Aggressive Routine Testing 

Thomas Giordano* 1,2 , S Pasalar2 , M Arya1 , C Flash1 , J Davila1 , 

N Miertschin2 , K Malone2 , and S Hoxhaj1 1 2 Baylor Coll of Med, Houston, TX, US and Harris County Hosp District, 




Estimating Incidence 

1053 Use of a Multi-assay Algorithm for Cross-sectional HIV 

�� 

�� 

Oliver Laeyendecker* 1,2 , L Wang3 , J Hughes4 , V Cummings2 , 

E Piwowar-Manning2 , D Wheeler5 , S Griffith6 , K Mayer7 , B Koblin8 , 

S Eshleman2 , and HPTN 061 Study Team 

1 2 NIAID, NIH, Bethesda, MD, US;; Johns Hopkins Univ Sch of Med, 

Baltimore, MD, US;; 3Statistical Ctr for HIV/AIDS Res and Prevention, 

Seattle, WA, US;; 4Univ of Washington, Seattle, US;; 5Loyola Univ 

Chicago, IL, US;; 6FHI 360, Research Triangle Park, NC, US;; 7Harvard Med Sch, Boston, MA, US;; and 8New York Blood Ctr, NY, US 

1054� �� 

�� 

�� 

Andrea Hauser* 1 , S Masciotra2 , S Fiedler1 , C Santos-Hoevener1 , 

K Meixenberger1 , S Somogyi1 , B Bartmeyer1 , N Bannert1 , M Owen2 , 

and C Kuecherer1 1064 Replacing Clinic Testing with Home-use Tests May Increase 

HIV Transmission among Seattle MSM: Evidence from a 

Mathematical Model 

David Katz* 

1 2 Robert Koch-Inst, Berlin, Germany and CDC, Atlanta, GA, US 

1055 Performance of Dried Blood Spots with a Modified Genetic 

�� 

Identifying Recent HIV Infections 

Silvina Masciotra*, X Wei, W Luo, A Smith, I Miles, C Sionean, 

G Paz-Bailey, J Johnson, and M Owen 


1 , S Cassels1 , and J Stekler1,2 1 2 Univ of Washington, Seattle, US and Publ Hlth-Seattle & King County, 

WA, US 

1065 Characteristics and Testing Uptake of Heterosexual Couples 

�� 

Referral: South Africa and Uganda 

Heidi van Rooyen* 1 , R Barnabas2,3 , E Tumwesigye4 , H Humphries1 , 

H Tumwebaze4 , P Joseph1 , M Krows2 , P Murnane2 , J Baeten2 , and C Celum2,3 1 2 Human Sci Res Council, Sweetwaters, South Africa;; Univ of 

Washington, Seattle, US;; 3Fred Hutchinson Cancer Res Ctr, Seattle, WA, 

US;; and 4Integrated Community Based Initiatives, Kabwohe, Uganda 

1066 An Integrated Youth Center Model Improves HIV Testing in 

�� 

Samantha Black*, M Wallace, K Middelkoop, D Robbertze, T Bennie, 

R Wood, and L-G Bekker 

Desmond Tutu HIV Ctr, Univ of Cape Town, South Africa 

1067� �� 

�� 

�� 

F Khalid1 , M Kibona2 , A Khatib1 , A Leidich3 , A Othman1 , 

Irene Benech* 4 , M Dahoma5 , C Mullen3 , E Kim4 , and G Arthur6 1 2 Zanzibar AIDS Control Prgm, Ministry of Hlth, Tanzania;; CDC, Dar es 

Salaam, Tanzania;; 3Global Hlth Sci, Univ of California, San Francisco, 

US;; 4CDC, Atlanta, GA, US;; 5Directorate of Preventive Svcs and Hlth Ed, 

Ministry of Hlth, Zanzibar, Tanzania;; and 6CTS Global USA assigned to 

Div of Global HIV/AIDS, CDC, Dar es Salaam, Tanzania 

1056 The Performance of Candidate Assays to Detect Recent 

HIV Infection for Cross-sectional Incidence Estimation: An 

�� 

Reshma Kassanjee* 1,2 , G Murphy 3 , M Busch 4 , C Pilcher 5 , E McKinney 3 , 

S Keating 4 , S Facente 5 , J MacArthur 4 , and A Welte 2 

1 Univ of the Witwatersrand, Johannesburg, South Africa;; 2 South African 

Ctr for Epidemiological Modelling and Analysis, Stellenbosch;; 3 Hlth 

Protection Agency, London, UK;; 4 Blood Systems Res Inst, San Francisco, 

CA, US;; and 5 Univ of California, San Francisco, US 

1057 Characterization of Immune Response in Ugandan Women 

�� 

�� 

Andrew Longosz* 1 , C Morrison2 , P-L Chen2 , E Arts3 , I Nankya3 , 

R Salata3 , V Franco4 , T Quinn1,4 , S Eshleman4 , and O Laeyendecker1,4 1 2 NIAID, NIH, Baltimore, MD, US;; Clinical Sci, FHI 360, Durham, 

NC, US;; 3Case Western Reserve Univ, Cleveland, OH, US;; and 4Johns Hopkins Univ Sch of Med, Baltimore, MD, US 

1058 Estimating HIV Incidence in Rural Western Kenya: 

�� 

Clement Zeh* 1 , A Kim2 , S Inzaule3 , A Morwabe3 , P Amornkul4 , 

M Owen4 , L Mills1 , and B Parekh4 1 2 3 CDC, Kisumu, Kenya;; CDC, Nairobi, Kenya;; Kenya Med Res Inst/CDC 

Res and Publ Hlth Collaboration, Kisumu;; and 4CDC, Atlanta, GA, US 



New Testing Strategies 

1059� �� 

�� 

Florence Momplaisir*, B Fetzer, M Harhay, and J Long 

Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US 

1060� �� 

HIV with Limited Healthcare Access 

Silvia Amesty* 1,2 , V Nandi3 , M Sutton4 , L Willis4 , P Weidle4 , and C Fuller2 1Ctr for Family and Community Med, Coll of Physicians and Surgeons, 

Columbia Univ, New York, NY, US;; 2Mailman Sch of Publ Hlth, Columbia 

Univ, New York, NY, US;; 3Lindsley F Kimball Res Inst, New York Blood 

Ctr, NY, US;; and 4CDC, Atlanta, GA, US 

1061� �� 

Rapid HIV Testing in a High-volume Jail and a High-volume 

�� 

Anne Spaulding* 1 , L Reid2 , C Bowden1 , B Copeland3 , R Macgowan2 , 

A Margolis2 , R Shresta2 , G Mustaafaa1 , K Heilpern1 , and B Shah1 1 2 Emory Univ Rollins Sch of Publ Hlth, Atlanta, GA, US;; CDC, Atlanta, 

GA, US;; and 3 1068 Patterns of HIV Retesting among Clients of Voluntary HIV 

�� 

�� 

Cari Courtenay-Quirk* 

Emory Univ Sch of Med, Atlanta, GA, US 

1 , K Grabbe1 , A Baughman1 , G Djomand1 , 

and B Pederson2 1 2 CDC, Atlanta, GA, US and Population Svcs Intl, Maseru, Lesotho 



Biological and Behavioral Transmission Risks 

1069 HIV Transmission Risk Behavior in a Cohort of HIV + 

Treatment-nïave Men and Women: US 

Raphael Landovitz* 1 , T Tran2 , S Cohn3 , I Ofotokun4 , J Lennox4 , 

J Currier1 , and H Ribaudo2 1 2 UCLA Ctr for Clinical AIDS Res and Ed, US;; Harvard Sch of Publ Hlth, 

Boston, MA, US;; 3Northwestern Univ Feinberg Sch of Med, Chicago, IL, 

US;; and 4Emory Univ Sch of Med, Atlanta, GA, US 

1070� �� 

�� 

�� 

Thomas Peterman* 1 , D Newman1 , L Maddox2 , K Schmitt2,3 , and S Shiver2 1 2 CDC, Atlanta, GA, US;; Florida Dept of Hlth, Div of Disease Control 

and Hlth Protection, Tallahassee, US;; and 3Florida State Univ Coll of 

Nursing, Tallahassee, US 

1071 Correlates of Asymptomatic Gonococcal and Chlamydial 

Infections among US Military Men Infected with HIV 

R Carpenter1 , Oliver Refugio* 2 , K O’Brien2 , N Adams1 , M Bavaro1 , 

M Johnson1 , R Maves1 , J Sklar1 , H Groff1 , and N Crum1,2 1 2 Naval Med Ctr, San Diego, CA, US and San Diego State Univ, CA, US 

1072 Incidence of Acute Sexually Transmitted Infections among 

HIV Diagnosed Individuals Attending Sexual Health Clinics: 

�� 

Sarika Desai*, V Delpech, L Peters, and G Hughes 

Hlth Protection Agency, London, UK 

1073� �� 

Sexually Transmitted Infections among HIV + Men 

Nimish Patel* 1 , M Nasiri1 , S Kwon2 , C Miller2 , L-A McNutt3 , and D Fish2 1 2 Albany Coll of Pharmacy and Hlth Sci, NY, US;; Albany Med Coll, NY, 

US;; and 3Univ at Albany, State Univ of New York, Sch of Publ Hlth, 

Rensselaer, US 

68 � 20th Conference on Retroviruses and Opportunistic Infections


1074� �� 

�� 

�� 

Alexandra Oster*, M Sternberg, S Nebenzahl, D Broz, F Xu, S Hariri, 

I Miles, and G Paz-Bailey 


1075 A Socioenvironmental Exploration of Community-level Social 

�� 

Leigh Willis* 1 , J Opoku2 , R Wiegand1 , A Murray1 , Y Jia2 , K Elmore1 , 

T West2 , G Pappas2 , and M Sutton1 1 2 CDC, Atlanta, GA, US and District of Columbia Dept of Hlth, HIV/ 

AIDS, Hepatitis, STD, and TB Admin, US 

1076� �� 

risk Transmission Behavior among HIV + �� 

Data from CNICS 

Richard Haubrich* 1 , S Jain1 , C Perez-Heydrich2 , C Hurt2 , S Morris1 , 

S Sun1 , S Napravnik2 , H Crane3 , M Emch2 , J Eron2 , and CNICS 040 Study 

Team 

1 2 Univ of California, San Diego, US;; Univ of North Carolina at Chapel 

Hill, US;; and 3Univ of Washington, Seattle, US 

1077� �� 

prevalence Kenyan Population: Lessons for Intervention 

Trials and Programmatic Strategies 

Rennatus Mdodo* 1 , D Gust1 , F Otieno2 , E McLellan-Lemal1 , R Chen1 , 

C LeBaron1 , F Hardnett1 , C Zeh1,2 , T Samandari1 , and L Mills1,2 1 2 CDC, Atlanta, GA, US and Kenya Med Res Inst/CDC Res and Publ Hlth 

Collaboration, Kisumu 

1078 Determinants of Couple Sexual Concurrency among 

�� 

Zachary Kwena* 1 , I Mwanzo2 , E Bukusi1 , L Achiro1 , and C Shisanya2 1085 Decline in HIV 

1 2 Kenya Med Res Inst, Nairobi and Kenyatta Univ, Nairobi, Kenya 

+ �� 

�� 

�� 

Spana Motsisi* 1 , P Loeto2 , M Boima1 , K Molosiwa1 , L Manthe1 , 

MG Alwano2 , and A Voetsch2 1Tebelopele Voluntary Counseling and Testing Ctrs, Gaborone, Botswana 

and 2CDC, Gaborone, Botswana 

1086 HIV Control in West Africa: The End of the Tunnel? Zero 

�� 

�� 

Isidore Traore* 1 , N Meda1,2 , N Hema1 , I Konate2 , D Drabo1 , F Some1 , 

R Some1 , P Mayaud3 , P Van De Perre4 , and N Nagot4 1 2 Univ of Ouagadougou, Burkina Faso;; Ctr Muraz, Bobo-Dioulasso, 

Burkina Faso;; 3London Sch of Hygiene and Tropical Med, UK;; and 4Univ of Montpellier 1 and INSERM U1058, France 

1087� �� 

Risk Reduction Strategies among HIV-1 Serodiscordant 

Couples: Kenya 

Kenneth Ngure* 1,2 , R Heffron2 , N Mugo2,3 , C Celum2 , K Curran2 , 

A Kurth4 , and J Baeten2 1 2 Jomo Kenyatta Univ of Agriculture and Tech, Nairobi, Kenya;; Univ of 

Washington, Seattle, US;; 3Kenyatta Natl Hosp, Nairobi, Kenya;; and 4New York Univ, NY, US 

1088� �� 

Rural Southwestern Uganda 

Annet Kembabazi* 1 , F Bajunirwe1 , J Martin2 , C Muzoora1 , P Hunt2 , 

J Haberer3 , D Bangsberg3,4 , and M Siedner3 1 2 Mbarara Univ of Sci and Tech, Uganda;; Univ of California, San 

Francsico, US;; 3Massachusetts Gen Hosp Ctr for Global Hlth, Boston, 

US;; and 4Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US 



Performance and Innovation in ART Programs in RLS 

1079 Shedding of HIV and Human Herpesviruses in the Semen of 

Effectively Treated HIV + Men 

Sara Gianella Weibel* 1 , D Smith 1,2 , M Vargas 1 , S Little 1 , D Richman 1,2 , 

E Daar 3 , M Dube 4 , C Ginocchio 5 , R Haubrich 4 , and S Morris 1 

1 Univ of California, San Diego, US;; 2 VA San Diego Hlthcare System, CA, 

US;; 3 Los Angeles Biomed Res Inst at Harbor-UCLA Med Ctr, Torrance, 

CA, US;; 4 Univ of Southern California Keck Sch of Med, Los Angeles, US;; 

and 5 Hofstra North Shore-LIJ Sch of Med, Hempstead, NY, US 

nd 1080� �� 

-line 

Lopinavir/ritonavir Monotherapy 

T Bunupuradah1 , C Bowonwattanuwong2 , S Jirajariyavej3 , W Munsakul4 , 

V Klinbuayaem5 , J Sophonphan1 , A Mahanontharit1 , B Hirschel6 , 

K Ruxrungtham1,7 , Jintanat Ananworanich* 1,7,8 , and HIV STAR Study 

1 2 HIV-NAT, Thai Red Cross AIDS Res Ctr, Bangkok;; Chonburi Hosp, 



Reducing Risk 

1082 “No one’s at home and they won’t pick up the phone”: Using 

the Internet and SMS to Enhance Partner Services: North 

Carolina 

Lisa Hightow-Weidman* 1 , S Beagle 1 , J Embry 1 , E Pike 1 , J Kuruc 1 , 

P Leone 1,2 , E Foust 2 , and C Gay 1 

1 Univ of North Carolina at Chapel Hill, US and 2 North Carolina DHHS, 

Communicable Disease Branch, Raleigh, US 

1083 Impact of Language Barriers on HIV Serodisclosure and 

Risk Behaviors among MSM during International Travel 

Hong-Ha Truong* 1,2 , T Kellogg 3 , Y-H Chen 3 , M Grasso 3 , T Robertson 3 , 

A Curotto 1 , W McFarland 1,3 , R Grant 1,2 , O Reznick 1 , and W Steward 1 

1 Univ of California, San Francisco, US;; 2 Gladstone Inst of Virology and 

Immunology, San Francisco, CA, US;; and 3 San Francisco Dept of Publ 

Hlth, CA, US 

1084 The Effect of HIV Counseling and Testing on HIV Acquisition 

among South African Youth: A Protective Association 

Nora Rosenberg* 1,2 , D Westreich 3 , T Barnighausen 2,4 , W Miller 1 , 

F Behets 1 , S Maman 1 , M-L Newell 2 , and A Pettifor 1 

1 Univ of North Carolina at Chapel Hill, US;; 2 Africa Ctr for Hlth and 

Population Studies, Mtubatuba, South Africa;; 3 Duke Univ, Durham, NC, 

US;; and 4 Harvard Univ, Boston, MA, US 



1089� �� 

ART among Asian HIV + Patients 

Sasisopin Kiertiburanakul* 1 , D Boettiger 2 , M Po Lee 3 , S Omar 4 , 

J Tanuma 5 , O Tek Ng 6 , N Durier 7 , S Sungkanuparph 1 , and TREAT Asia 

HIV Observational Databases and TREAT Asia Studies to Evaluate 

Resistance 

1 Faculty of Med Ramathibodi Hosp, Mahidol Univ;; 2 The Kirby Inst, Univ 

of New South Wales, Australia;; 3 Queen Elizabeth Hosp, Hong Kong, 

China;; 4 Univ of Malaya, Malaysia;; 5 Natl Ctr for Global Hlth and Med, 

Japan;; 6 Tan Tock Seng Hosp, Singapore;; and 7 TREAT Asia, amfAR–Fndn 

for AIDS Res, Thailand 

Thailand;; 3Taksin Hosp, Bangkok, Thailand;; 4Faculty of Med, Univ of 

Bangkok Metropolitan Admin, Thailand;; 5Sanpatong Hosp, Chiang Mai, 

Thailand;; 6Geneva Univ, Switzerland;; 7Faculty of Med, Chulalongkorn 

Univ, Bangkok, Thailand;; and 8 1090� �� 

�� 

SEARCH, Thai Red Cross AIDS Res Ctr, 

�� 

Bangkok 

Eugene Mutimura* 

1081� �� 

Associated with Semen HIV-1 Shedding 

Jennifer Hoffman*, D Elashoff, D Anisman-Posner, K Tanner, 

C Sugar, J Elliott, GC Baldwin, P Anton, O Yang, and R Hoffman 

UCLA Med Ctr, US 

1 , D Addison1 , K Anastos2 , D Hoover3 , JC Dusingize4 , 

Q Shi5 , D Duggan6 , B Karenzi7 , I Izimukwiye8 , D Nash1 , and Central 

African Intl Epidemiologic Database to Evaluate AIDS Study Group 

1 2 CUNY Sch of Publ Hlth Hunter Coll, US;; Albert Einstein Coll of Med 

and Montefiore Med Ctr, New York, NY, US;; 3State Univ of New Jersey, 

New Brunswick, US;; 4Women�s Equity in Access to Care and Treatment, 

Kigali, Rwanda;; 5Sch of Hlth Sci, New York Med Coll, NY, US;; 6Stevens Inst of Tech, Hoboken, NY, US;; 7Rwanda Military Hosp Kigali;; and 

8Masaka District Hosp Kigali, Rwanda 

1091� �� 

�� 

Nuala McGrath* 1,2 , R Lessells 1,2 , and M-L Newell 2,3 

1 London Sch of Hygiene and Tropical Med, UK;; 2 Africa Ctr for Hlth and 

Population Studies, KwaZulu-Natal, South Africa;; and 3 Inst of Child Hlth, 


1092 The Effect of a Maturing ARV Program on Early Mortality 

�� 

South Africa 

Kennedy Otwombe*, T Tutu-Gxashe, L Mohapi, G Gray, and F Laher 

Perinatal HIV Res Unit, Univ of the Witwatersrand, Johannesburg, South 

Africa 

1093 The Survival Benefits of ART: South Africa 

M April 1,2 , R Wood 3 , B Berkowitz 4 , D Paltiel 5 , X Anglaret 6,7 , E Losina 8,9,10 , 

K Freedberg 4,8,10,11 , and Rochelle Walensky* 4,9,10 

1 San Antonio Uniformed Svcs Hlth Ed Consortium, TX, US;; 2 Harvard Med 

Sch, Boston, MA, US;; 3 Univ of Cape Town, South Africa;; 4 Massachusetts 

Gen Hosp, Boston, US;; 5 Yale Sch of Publ Hlth, New Haven, CT, US;; 

6 Univ Bordeaux, INSERM U897, France;; 7 Prgm PAC-CI/ANRS Res Site, 

Abidjan, Côte d’Ivoire;; 8 Boston Univ, MA, US;; 9 Brigham and Women�s 

Hosp, Boston, MA, US;; 10 Ctr for AIDS Res, Harvard Univ, Boston, MA, 

US;; and 11 Harvard Sch of Publ Hlth, Boston, MA, US 

1094 Long-term Outcomes of 1 st �� 

Fred Sarfo* 1 , A Kasim 2 , G Bedu-Ado 1 , R Phillips 1 , M Booth 2 , 

and D Chadwick 3 

1 Komfo Anokye Teaching Hosp, Kumasi, Ghana;; 2 Durham Univ, Stockton 

on Tees, UK;; and 3 James Cook Univ Hosp, Middlesbrough, UK



1095� �� 

Initiation: Rwandan Adults 

Kathryn Anastos* 1 , Q Shi2 , JC Dusingize3 , E Mutimura3 , D Duggan4 , 

B Karenzi5 , I Izimukwiye6 , D Nash7 , D Smith4 , and D Hoover8 1Albert Einstein Coll of Med and Montefiore Med Ctr, Bronx, NY, US;; 

2 3 Sch of Hlth Sci, New York Med Coll, Valhalla, US;; Women�s Equity in 

Access to Care and Treatment, Kigali, Rwanda;; 4Stevens Inst of Tech, 

Hoboken, NY, US;; 5Rwanda Military Hosp, Kigali;; 6Masaka District 

Hosp Kigali, Rwanda;; 7CUNY Sch of Publ Hlth Hunter Coll, NY, US;; 

and 8Rutgers, the State Univ of New Jersey, New Brunswick, US 

1096� �� 

�� 

South Africa 

Ingrid Bassett* 1 , S Regan1 , H Mbonambi2 , J Blossom3 , S Bogan3 , 

R Walensky1,4 , B Mhlongo2 , H Thulare2 , K Freedberg1 , and E Losina1,4 1 2 Massachusetts Gen Hosp, Boston, US;; Ithembalabantu People�s Hope 

Clin/AIDS Hlthcare Fndn, Durban, South Africa;; 3Harvard Univ Ctr for 

Geographic Analysis, Cambridge, MA, US;; and 4Brigham and Women�s 

Hosp, Boston, MA, US 

1097� �� 

�� 

Ingrid Bassett* 1,2 , D Govindasamy3 , A Erlwanger1 , E Hyle1 , N van Schaik3 , 

F Noubary1 , R Wood3 , E Losina1,4,5 , L-G Bekker3 , and K Freedberg1,2,6 1 2 Massachusetts Gen Hosp, Boston, US;; Harvard Univ Ctr for AIDS 

Res, Boston, MA, US;; 3Univ of Cape Town, South Africa;; 4Brigham and 

Women�s Hosp, Boston, MA, US;; 5Boston Univ Sch of Publ Hlth, MA, US;; 

and 6Harvard Sch of Publ Hlth, Boston, MA, US 

1098� �� 

Treatment Outcomes amongst HIV + �� 

South Africa 

Alana Brennan* 1,2 , M Maskew2 , I Sanne2,3,4 , and M Fox1,2,5 1 2 Ctr for Global Hlth and Devt, Boston Univ, MA, US;; Hlth Economics 

and Epidemiology Res Office, Dept of Internal Med, Sch of Clin Med, 

Faculty of Hlth Sci, Univ of the Witwatersrand, Johannesburg, South 

Africa;; 3Right to Care, Johannesburg, South Africa;; 4Clin HIV Res Unit, 

Dept of Internal Med, Sch of Clin Med, Faculty of Hlth Sci, Univ of the 

Witwatersrand, Johannesburg, South Africa;; and 5Boston Univ Sch of 

Publ Hlth, MA, US 

1099� �� 

Insecurity and HIV Treatment Outcomes: Rural Uganda 

Sheri Weiser* 1,2 , K Palar3 , E Frongillo4 , A Tsai5 , E Kumbakumba6 , 

N Grede7 , P Hunt1,2 , K Ragland1,2 , J Martin2 , and D Bangsberg5,6,8 1 2 San Francisco Gen Hosp, CA, US;; Univ of California, San Francisco, 

US;; 3Univ of California, Los Angeles, US;; 4Arnold Sch of Publ Hlth, 

Univ of South Carolina, Columbia, US;; 5Massachusetts Gen Hosp Ctr 

for Global Hlth, Boston, US;; 6 1104 Retention in Care up to ART Initiation within a Decentralized 

�� 

Clinic Visit 

Melanie Plazy* 

Mbarara Univ of Sci and Tech, Uganda;; 

7 8 United Nations World Food Prgm, Rome, Italy;; and Ragon Inst of MGH, 

MIT, and Harvard, Boston, MA, US 

1,2 , R Dray-Spira3 , J Orne-Gliemann1,2 , F Dabis1,2 , 

and M-L Newell4 1 2 Univ Bordeaux, ISPED, INSERM U897, France;; ISPED, INSERM 

U897, Bordeaux, France;; 3Epidemiology of Occupational and Social 

Determinants of Hlth-Ctr for Res in Epidemiology and Population 

Hlth, INSERM U1018, Villejuif, France;; and 4Africa Ctr for Hlth and 

Population Studies, Univ of KwaZulu-Natal, South Africa 

1105 Co-enrollment of HIV + �� 

with Improved Outcomes for Women on ART: A Cohort Study 

Landon Myer* 1 , J Duong2 , Y Zhang2 , E Abrams3 , R Carter3 , 

and MTCT-Plus Initiative 

1 2 Univ of Cape Town, South Africa;; Mailman Sch of Publ Hlth, Columbia 

Univ, New York, US;; and 3Intl Ctr for AIDS Care and Treatment Prgms, 

Mailman Sch of Publ Hlth, Columbia Univ, New York, NY, US 

1106� �� 

Barriers to Retention among HIV + Patients on ART: East 

Africa 

Elvin Geng* 1 , T Odeny2 , L Rita3 , A Nakiwogga-Muwanga4 , M Bwana5 , 

E Bukusi6 , G Somi3 , P Braitstein7 , C Yiannoutsos7 , J Martin1 , 

and East Africa Intl Epidemiologic Databases to Evaluate AIDS 

1 2 Univ of California, San Francisco, US;; Family AIDS Care and Ed Svcs, 

Kisumu, Kenya;; 3Natl AIDS Control Prgm, Dar es Salaam, Tanzania;; 

4 5 Infectious Disease Inst, Kampala, Uganda;; Mbarara Univ of Sci 

and Tech, Uganda;; 6Kenya Med Res Inst, Nairobi;; and 7Indiana Univ, 

Indianapolis, US 

1107 Real-time HIV ART Adherence Monitoring Predicts Loss 

�� 

Uganda 

Jessica Haberer* 1,2 , C Muzoora3 , P Hunt4 , J Martin4 , M Siedner1,2 , 

and D Bangsberg1,2,3 1 2 Massachusetts Gen Hosp, Boston, US;; Harvard Med Sch, Boston, MA, 

US;; 3Mbarara Univ of Sci and Tech, Uganda;; and 4Univ of California, 




Virologic Failure, 2nd- and 3rd-line Therapy in RLS 

st 1108� �� 

-line 

�� 

Vincent Marconi* 1,2,3 , B Johnson2 , J Hampton4 , B Wu2 , M Gordon5,6 , 

S John4 , C Ordonez4 , R Murphy7 , D Kuritzkes8,9 , H Sunpath4 , and 

South Africa Resistance Cohort Study 

1 2 Emory Univ Sch of Med, Atlanta, GA, US;; Emory Univ Rollins Sch of 

Publ Hlth, Atlanta, GA, US;; 3Atlanta VAMC, GA, US;; 4McCord Hosp, 

Durban, South Africa;; 5Doris Duke Med Res Inst, Durban, South Africa;; 

6 7 Univ of KwaZulu-Natal, Durban, South Africa;; Albert Einstein Med Sch, 

Bronx, NY, US;; 8�� and 9Harvard Med Sch, Boston, MA, US 

1100 Does ART Attenuate the Stigma of HIV? Evidence from a 

Cohort Study in Rural Uganda 

Alexander Tsai* 1 , D Bangsberg 1 , M Bwana 2 , J Haberer 1 , E Frongillo 3 , 

C Muzoora 2 , E Kumbakumba 2 , P Hunt 4 , J Martin 4 , and S Weiser 4 

1 Massachusetts Gen Hosp, Boston, US;; 2 Mbarara Univ of Sci and Tech, 

Uganda;; 3 Univ of South Carolina, Columbia, US;; and 4 Univ of California, 





Adherence and Retention in RLS 

1101 Validating Measures of Distance to HIV Clinic in Rural 

Uganda and Its Impact on Clinic Attendance 

Mark Siedner* 1 , A Lankowski 1 , A Tsai 1,2 , C Muzoora 3 , P Hunt 4 , 

J Martin 4 , J Haberer 1 , and D Bangsberg 1,5 

1 Massachusetts Gen Hosp Ctr for Global Hlth, Boston, US;; 

2 Massachusetts Gen Hosp, Boston, US;; 3 Mbarara Univ of Sci and Tech, 

Uganda;; 4 Univ of California, San Francisco, US;; and 5 Ragon Inst of 

MGH, MIT, and Harvard Med Sch, Boston, US 

1102 Site and Program Determinants of Patient Retention in HIV 

Care: Nigeria 

Chinenye Ugoji* 1 , R Ake-Uzoigwe 1 , MY Ladele 1 , C Akolo 1 , G Mendy 1 , 

P Dakum 1 , M Charurat 2 , D Onotu 3 , O Nwanyanwu 3 , and W Blattner 2 

1 Inst of Human Virology Nigeria, Abuja;; 2 Inst of Human Virology, 

Univ of Maryland, Baltimore, US;; and 3 Ctr for Disease Control, Nigeria 

1103 Attrition through Multiple Stages of HIV Care in South 

Africa: A Challenge for Test-and-Treat 

Matthew Fox* 1,2,3 and K Shearer 3 

1 Ctr for Global Hlth and Devt, Boston Univ, MA, US;; 2 Boston Univ Sch of 

Publ Hlth, MA, US;; and 3 Hlth Economics and Epidemiology Res Office, 



+ nd 1109� �� 

�� -line 

�� 

Vu Thao* 1 , V Quang2 , M Wolbers1 , N Anh1 , N Chinh2 , C Shikuma3 , 

J Day1 , J Farrar1 , S Dunstan1 , and T Le1,3 1 2 Oxford Univ Clin Res Unit, Ho Chi Minh City, Vietnam;; Hosp for 

Tropical Diseases, Ho Chi Minh City, Vietnam;; and 3Hawaii Ctr for 

AIDS, Univ of Hawaii at Manoa, Honolulu, US 

1110� �� 

Associated with Elevated Mortality among HIV + Patients 

Treated in Africa 

Maya Petersen* 1 , L Tran 1 , E Geng 2 , S Deeks 2 , S Reynolds 3 , A Kambugu 4 , 

R Wood 5 , D Bangsberg 6 , C Yiannoutsos 7 , and J Martin 2 

1 Univ of California, Berkeley, US;; 2 Univ of California, San Francisco, 

US;; 3 Rakai Hlth Sci Prgm, Entebbe, Uganda;; 4 Infectious Diseases Inst, 

Makerere, Uganda;; 5 Univ of Cape Town, South Africa;; 6 Harvard Med 

Sch, Boston, MA, US;; and 7 Indiana Univ Sch of Med, Indianapolis, US 

1111� �� 

Strategies on Mortality in HIV + African Adults on ART 

D Ford 1 , J Robins 2 , M Petersen 3 , D Gibb 1 , C Gilks 4 , P Mugyenyi 5 , 

H Grosskurth 6 , J Hakim 7 , A Babiker 1 , Sarah Walker* 1 , and DART Trial 

Team 

1 MRC Clin Trials Unit, London, UK;; 2 Harvard Sch of Publ Hlth, Harvard 

Univ, Boston, MA, US;; 3 Univ of California, Berkeley, US;; 4 Imperial 

Coll London, UK;; 5 Joint Clin Res Ctr, Kampala, Uganda;; 6 MRC/UVRI 

Uganda Res Unit on AIDS, Entebbe;; and 7 Univ of Zimbabwe, Harare 

1112� �� 

1 st -line NNRTI-containing ART in Resource-limited Settings: 

�� 

�� 

Nagalingeswaran Kumarasamy* 1 , E Aga 2 , H Ribaudo 2 , C Wallis 3 , 

D Katzenstein 4 , W Stevens 5 , M Norton 6 , K Klingman 7 , and J Bartlett 8 

1 YRG CARE Med Ctr, Chennai, India;; 2 Statistical Data Analysis Ctr, 

Harvard Univ, Boston, MA, US;; 3 Lancet Labs, Johanesburg, South Africa;; 

4 Stanford Univ, CA, US;; 5 Univ of the Witwatersrand, Johannesburg, South 

Africa;; 6 Abbott, IL, US;; 7 DAIDS, NIAID, NIH, Bethesda, MD, US;; and 

8 Duke Univ Med Ctr, NC, US


nd 1113� �� 

-line ART after Stavudine 

�� 

Gilles Wandeler* 1,2 , F Gerber1 , J Rohr3 , C Chimbetete4 , C Orrell5 , 

H Prozesky6 , A Boulle7 , C Hoffmann8 , B Chi9 , M Egger1 , 

and IeDEA-Southern Africa 

1 2 3 Univ of Bern, Switzerland;; Univ Hosp Bern, Switzerland;; Boston 

Univ Ctr for Global Hlth and Devt, MA, US;; 4Newlands Clin, Harare, 

Zimbabwe;; 5Desmond Tutu HIV Ctr, Inst of Infectious Disease and 

Molecular Med, Univ of Cape Town, South Africa;; 6Univ of Stellenbosch 

and Tygerberg Academic Hosp, Cape Town, South Africa;; 7Khayelitsha ART Prgm, Medecins Sans Frontieres, Cape Town, South Africa;; 8Aurum Inst for Hlth Res, Johannesburg, South Africa;; and 9Ctr for Infectious 

Disease Res in Zambia, Lusaka 

1114 High Rates of Re-suppression among Patients with Viral 

nd �� -line ART: Nigeria 

Holly Rawizza* 1 , B Chaplin2 , S Meloni2 , O Agbaji3 , W Gashau4 , 

P Okonkwo5 , P Kanki2 , and APIN PEPFAR Team 

1 2 �� 

Harvard Sch of Publ 

Hlth, Boston, MA, US;; 3Jos Univ Teaching Hosp, Nigeria;; 4Univ of 

Maiduguri Teaching Hosp, Nigeria;; and 5AIDS Prevention Initiative 

Nigeria, Abuja 

rd 1115� �� 

-line 

�� 

�� 

Eric Ouattara* 1,2 , E Ross3 , Y Yazdanpanah4 , A Wong3 , E Losina3,5,6 , 

R Walensky3,6 , D Paltiel7 , S Eholie1,8 , K Freedberg3,6 , and X Anglaret1,2 1 2 Prgm PAC-CI/ANRS Res Site, Abidjan, Cote dIvoire;; Univ Bordeaux, 

INSERM U897, France;; 3Massachusetts Gen Hosp, Boston, US;; 4Ctr Hosp Univ Bichat Claude-Bernard, Paris, France;; 5 Brigham and 

6 �� 

Harvard Univ Ctr for AIDS Res, 

Harvard Med Sch, Harvard Sch of Publ Hlth, and Boston Univ Sch of 

Publ Hlth, MA, US;; 7Yale Sch of Med, New Haven, CT, US;; and 8Ctr Hosp Univ de Treichville, Abidjan, Cote dIvoire 

1116 Benefits of Early ART Initiation Outweigh Risk of 

�� 

East African Settings 

Brooke Nichols* 1 , K Sigaloff 2,3 , C Kityo 4 , K Mandaliya 5 , R Hamers 2,3 , 

S Bertagnolio 6 , M Jordan 7 , C Boucher 1 , T Rinke de Wit 2,3 , 

and D van de Vijver 1 

1 Erasmus Med Ctr, Rotterdam, The Netherlands;; 2 PharmAccess Fndn, 

Amsterdam, The Netherlands;; 3 Amsterdam Inst for Global Hlth and Devt, 

The Netherlands;; 4 Joint Clinical Res Ctr, Kampala, Uganda;; 5 Coast 

Province Gen Hosp, Intl Ctr for Reproductive Hlth, Mombasa, Kenya;; 

6 WHO, Geneva, Switzerland;; and 7 Tufts Univ Sch of Med, Boston, MA, US 


Poster Listings

Building B Georgia World Congress Center 

Level Three 

Breakout Rms B308 

B313 

Overflow Rms B310 

B311 

Level Two 

Media Ctr B202 

Speaker Svcs/Poster Drop-off B208 

CROI Headquarters B211 

Level One 

Breakout Rm Hall B1 

Poster Hall Hall B2 

CyberCafe Hall B2 

First Aid 

Level Five 

Breakout Rms Ballroom 1-2 

Ballroom 3-4 

Level Four 

Breakout Rms B402 

B406 

Overflow Rms B403 

B404 

Registration Lobby 

Message Center Lobby 

Coat Check Lobby 

Street Entrance to Bldg B 

Registration 

Message Ctr 

Terrace 

Restaurant 

Escalators 

Up to 

Ballroom 

Level Five 

Coat 

Check 

B308 

B202 

Media 

Ctr 

Escalators 

Elevators 

B310 

Overflow 

for B308 

285 International Blvd NW, Atlanta, GA 30313 

CROI Message Center � 404-222-5800 

Ballroom 

1-2 

Hall B1 

General Session 

Speaker Svcs/ 

Poster Drop-off 

+ 

B402 

Escalators Escalators Elevators Escalators 

B311 

Overflow 

for B313 B313 

Elevators Elevators 

Escalators 

Escalators 

B208 

Escalators 

B211 

HQ 

Escalators Escalators 

CyberCafe 

Elevators 

Ballroom 

3-4 

Elevators 

Escalators 

Down to 

Level Four 

Hall B2 

Poster Hall 

Coffee 

breaks 

B403 B404 

Overflow 

for B402 

Overflow 

for B406 

B406 

Escalators 

Elevators 

Escalators

POSTER SESSIONS 

Poster Hall open from 7 am to 7 pm; all posters will be available for viewing for the duration of the conference 

�� 

53. HIV Persistence, Reservoirs, and Viremic Control 

55. Envelope/Entry/Tropism/Transmission 

58. Assembly–Putting It All Together 

59. Restriction Factors: Old and New 

64. HIV Compartments 

67. HIV Infection Models 

71. Immune Restoration 

73. Immune Activation/Function in HIV Infection 

74. Immune Activation, T Cell Homeostasis, and Therapy 

75. Mucosal Factors in HIV Transmission and Infection 

77. HIV Compartmentalization and Evolution on Therapy 

84. Progressive Multifocal Leukoencephalopathy and Other 

Central Nervous System Infections 

85. Central Nervous System Penetration, ART Intensification, 

and Cerebrospinal Fluid Escape 

86. ART, Neurocognitive Outcomes, and New Central 

Nervous System-targeted Therapies 

87. Central Nervous System Viral Evolution and 


95. Mining Sequence Data to Understand Transmission and 

Disease 

96. Transmission Clusters 

98. Within-patient Diversity Compartmentalization, Dual 

Infection, and Recombination 

100. ARV Pharmacogenetics: Metabolism, Drug Interactions, 

and Response 

101. ARV Drug Exposure, Safety, and Efficacy 

105. New ARV Agents 

106. Randomized Trials of ART: A Potpourri 

118. Hepatic Injury and Fibrosis 

119. Laboratory Assessment and Imaging of Hepatic Injury 

120. Hepatitis E Virus 

121. Hepatitis B Virus 

128. HIV-associated Malignancies: Miscellaneous 

130. Cardiovascular Disease: Predicting Risk and Monitoring 

Outcomes 

131. Endothelial Dysfunction in HIV Infection 

132. Vascular Imaging and Subclinical Atherosclerosis 

141. Diabetes, Metabolic Syndrome, and Vitamin D Deficiency 

143. Bone Loss: Risk Factors and Pathogenesis 

144. ART and Bone Disease 

150. Cryptococcal Infections 

151. Herpes Zoster 

152. Cytomegalovirus–Host Pathogen Interactions 

153. Syphilis: Not Gone, Not Forgotten 

154. Opportunistic Infections and Other Novel Pathogens 

155. Vaccines: TB, Pneumococcus, and Influenza 

156. HIV Shedding and Impact of Infection on Immune Cells in 

Women 

161. HIV Testing and ARV Drug Resistance during Pregnancy 

162. ART, Viral Suppression, and MTCT 

170. Incidence and Prevention of PMTCT-associated Drug 

Resistance 

171. New HIV Infections among Children in the US 

172. ART Initiation and Immune Reconstitution Inflammatory 

Syndrome among Infants and Children 

173. ART Strategies and Outcomes among Children 

174. Cost and Cost-effectiveness of ART and Monitoring 


178. Characteristics of Youth with HIV 

180. ARV Pharmacokinetics in Children 

183. Preclinical Studies of Topical ARV for Prevention 

187. Voluntary Medical Male Circumcision 

190. The Cascade of Care 

191. Engagement and Retention in Care 

197. Performance and Innovation in ART Programs in RLS 

56. Transcription/Reverse and Forward, Splicing/Replication 

60. Restriction Factors: APOBEC and Others 

62. Shutting the Door on HIV Entry 

63. Transmitted/Founder Viruses 

66. Markers of HIV Disease Progression 

69. CD8 T Cells in HIV Infection 

70. Killer T Cells 

78. Viral DNA Dynamics 

79. Infected Cell Dynamics on Therapy 

80. What Is Latency and What Can We Do about It? 

82. Novel Vaccine Strategies 

88. Neuropathogenesis Mechanisms 

89. Central Nervous System Inflammation and Biomarkers 

of HIV-associated Neurocognitive Disorders 

90. Aging and Neurocognitive Function in HIV Infection 

94. Simian Viral Reservoirs 

97. HIV Subtypes: Epidemiology and Disease Progression 

99. New Approaches to ARV Drug Delivery 

102. ARV Pharmacokinetics: New Assays, Drugs, and Special 

Populations 

110. Tropism Testing/Maraviroc Resistance 

111. HIV Drug Resistance: Trends and Emergence 

112. Detecting and Interpreting HIV Drug Resistance 

113. Innovation in Measuring Viral Nucleic Acids 

114. Transmitted Drug Resistance 

115. Drug Resistance Mutational Pathways and Subtype 

Associations 

116. Advances in Sequencing and Analysis 

117. Detecting HIV Infection 

122. Hepatitis C Virus Treatment Today and Tomorrow 

123. Hepatitis C Virus Resistance and Virology 

124. Innate Immunity and Hepatitis C Virus 

126. Hepatic Failure and Transplantation 

127. Emergence and Persistence of HPV-associated 


133. Statin Use and HIV: How Sweet Is It? 

134. Dyslipidemia: Risks, Pathogenesis, and Treatment 

135. Risk Prediction, Risk Factors, Biomarkers, and Outcomes 

137. Inflammatory Biomarkers, Microparticles, and Clinical 


138. ART Effects: Monocyte and T Cell Activation 

147. TB Screening Strategies: Diagnostics New and Old and 

Latent TB Treatment 

149. Mechanisms of Immune Reconstitution 

157. Hepatitis C Virus Testing in Women 

163. ARV Strategies, MTCT, and HIV-free Survival 

164. PMTCT Implementation: Barriers and Program 

Innovations 

167. Breast Feeding and Prevention of Postnatal MTCT 

168. ARV Pharmacokinetics during Pregnancy and Breast 

Feeding 

169. ARV Regimens and Safety during Pregnancy 

175. HIV Drug Resistance in Children and Youth 

176. Co-infections among HIV-infected and -exposed Children 

184. Non-human Primate Models of STI, PrEP, and Vaccines 

186. Implementation and Cost-effectiveness of Male 

Circumcision 

188. The Ongoing Epidemic in MSM 

193. Estimating Incidence 

194. New Testing Strategies 

198. Adherence and Retention in RLS 

54. ART, Complications, and TB 

57. Accessory Proteins/Gag 

61. Macrophage–HIV Interactions: Cell Biology and 

Treatment 

65. HIV Genotypes and Phenotypes 

68. HIV and Monocytes, Macrophages, and Dendritic Cells 

72. Microbial Translocation 

76. Neutralizing Antibodies and How to Stimulate Them 

81. Mechanism of HIV Latency and Reactivation 

83. Gene and Adoptive Immunotherapy 

91. NeuroAIDS Clinical Studies 

92. Neuroimaging Studies 

93. Human Genomics 

103. Compartment Penetration of ARV 

104. ARV Drug Interactions 

107. ART: Too Early or Too Late? Or Better Late than Never! 

108. ART: Host and Viral Determinants of Outcome 

109. ART: Care and Adherence 

125. Hepatitis C Virus Epidemiology and Clinical Outcomes 

129. HIV-associated Malignancies: Lymphoma 

136. Microbial Translocation Measurement and Associations 

139. ART Effects: Gene Expression and Cellular Function 

140. Frailty: From Mice to Men and Women 

142. Renal Disease: Diagnosis, Predictors, and Drugs 

145. TB: Incidence, Risk Factors, and Outcomes 

146. TB Diagnostics 

148. The “ART” of TB Treatment 

158. HIV Risk Factors, Prevalence, and Barriers to Care 

159. Family Planning: Unintended Pregnancy and Unmet Need 

160. HIV in Peri- and Post-menopause 

165. Pregnancy Complications among HIV + Women 

166. PMTCT: Maternal and Child Health Outcomes 

177. HIV and ART-related Complications and Treatment in 


179. Tenofovir in Children 

181. Immune Response to Perinatal HIV 

182. Response to Pediatric Vaccines in Children and Youth 

185. Oral PrEP and ARV Adherence 

189. MSM in the Developing World 

192. Disease Progression, Morbidity, and Mortality 

195. Biological and Behavioral Transmission Risks 

196. Reducing Risk 

199. Virologic Failure, 2 nd - and 3 rd -line Therapy in RLS

CR I 2O13 Program at-a-Glance 

DAY HALL B2 TIME/TYPE B402 B406 B308 B313 Ballroom 3-4 Ballroom 1-2 Hall B1 TIME/TYPE DAY 

SUNDAY 3/3/13 

MONDAY 3/4/13 

TUESDAY 3/5/13 

WEDNESDAY 3/6/13 

Poster 

Set-up 

7 am-7 pm 

Posters 

Open 

7 am-7 pm 

Posters 

Open 

7 am-7 pm 

Posters 

Open 

7 am-6 pm 

Poster 

Removal 

6-9 pm 

9 am-1:30 pm 

Workshop 

2:30-4:30 pm 

Workshop 

5-7 pm 

Opening 

1. New Investigators and 

Trainees Workshop 

9 am-1:30 pm 

Workshop 

2. Frontiers in Lab Sci 3. Clinical Trials Design 2:30-4:30 pm 

Workshop 

4. 18 th Bernard Fields 

Lecture and 7 th 

N’Galy-Mann Lecture 

7-10 pm 7-10 pm 

Welcome Reception 

8:30-9 am 

Plenary 

9-9:30 am 

Plenary 

10 am-12 n 

Oral Abstracts 

1:30-2:30 pm 

Themed 

Discussion 

2:30-4 pm 


4-6 pm 

Symposia + Oral 

Abstracts 

8:30-9 am 

Plenary 

9-9:30 am 

Plenary 

10 am-12 n 


1:30-2:30 pm 

Themed 

Discussion 

2:30-4 pm 


4-6 pm 

Symposia 

8:30-9 am 

Plenary 

9-9:30 am 

Plenary 

10 am-12 n 


1:30-2:30 pm 

Themed 

Discussion 

2:30-4 pm 


4-6 pm 

Symposium 

11. Simian Viral 

Reservoirs 

27. Mining Sequence 

Data to Understand 

Transmission and 

Disease 

10-11:45 am 

39. New Discoveries in 

Vaccines and Gene 

Therapy 

44. Aging and 

Neurocognitive 

Function in HIV 

Infection 

10-11:30 am 

7. Neurocognitive 

Disorders: New 

Developments and 

Therapies 

12. Tenofovir in Children 13. New Approaches to 

ARV Drug Delivery 

17. Is Something 

Bugging You? 

23. HIV/SIV–Host 

Interaction 

28. Restriction Factors: 

Old and New 

33. HIV–Host Cell 

Interactions 

40. Virology: From the 

Outside In 

45. Transmitted/ 

Founder Viruses 

50. Progress in 

Deciphering HIV 

Protective Immunity 

29. MSM in the 

Developing World 

46. Emergence and 

Persistence of 

HPV-associated 

Malignancies in 

the ART Era 

14. Implementation and 

Cost-effectiveness 

of Male Circumcision 

30. Family Planning: 

Unintended 

Pregnancy and 

Unmet Need 

47. Mechanisms 

of Immune 

Reconstitution 

10 am-12:15 pm 

8. HIV Prevention: 

ARV, Counselling, 

Contraception, and 

Condoms 

15. What Is Latency and 

What Can We Do 

about It? 

10 am-12:15 pm 

9. Advances in Hepatitis 

Therapy 

16. Statin Use and HIV: 

How Sweet Is It? 

18. Preventing HIV/AIDS Oral Abstracts Session 

in the US: Can We Do 19. Cardiovascular 

Better? 

Disease and Other 

Non-AIDS Events: 

Epidemiology and 

Pathogenesis 

10 am-12:15 pm 

24. MTCT and HIV 

Treatment in Children 

31. The Cascade 

of Care 

34. Reproductive 

Hormones and HIV 

25. North and South: 

Epidemiology and 

Engagement in Care 

32. Cardiovascular 

Disease: Predicting 

Risk and Monitoring 

Outcomes 

35. When Worlds 

Collide–Adolescents 

and HIV 

10-11 am 

10 am-12:15 pm 

41. HIV-associated 43. Advances in ARV 

Malignancies 

and Anti-Hepatitis C 

11 am-12:15 pm 

42. TB and Cryptococcal 

Meningitis 

Virus Therapy 

48. Adherence and 

Retention in RLS 

51. HIV Testing and 

Monitoring the 

Epidemic: New Tools 

for Patients and 

Populations 

49. Inflammatory 

Biomarkers, 

Microparticles, 

and Clinical 


5. HIV-1 Eradication 

Strategies: Design, 

Assessment, and 

Clinical Consequences 

6. Reality Check: Is the 

End of AIDS in Sight? 

10 am-12:15 pm 

10. Is There Hope for 

HIV Eradication? 

20. New Frontiers in 

Hepatitis C Virus 

Treatment 

21. The Global MSM 

HIV Epidemic: 

Time to Act 

22. Evolution of the 

Host–Virus 

Interaction: A Guide 

to the Development 

of Novel 

Therapeutics? 

10 am-12:15 pm 

26. ART: New Agents 

and New Insights 

36. Opportunities 

and Threats to 

ART Success 

37. Incorporating New 

Drugs into Regimens 

that Will Change the 

TB Treatment 

Paradigm: The 

Magic Mountain 

Meets Table 

Mountain 

38. Treatment with 

Gene-modified 

Hematopoietic Stem 

Cells May 

Definitively Abolish 

HIV-1 Infection 

5-7 pm 

Opening 

8:30-9 am 

Plenary 

9-9:30 am 

Plenary 

10 am-12 n 


1:30-2:30 pm 

Themed 

Discussion 

2:30-4 pm 


4-6 pm 

Symposia + Oral 

Abstracts 

8:30-9 am 

Plenary 

9-9:30 am 

Plenary 

10 am-12 n 


1:30-2:30 pm 

Themed 

Discussion 

2:30-4 pm 


4-6 pm 

Symposia 

8:30-9 am 

Plenary 

9-9:30 am 

Plenary 

10 am-12 n 


1:30-2:30 pm 

Themed 

Discussion 

2:30-4 pm 


52. TB on the Verge 4-6 pm 

Symposium 

SUNDAY 3/3/13 

MONDAY 3/4/13 

TUESDAY 3/5/13 

WEDNESDAY 3/6/13

croi-2013-pocket-program

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?